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ABSTRACT
In all eukaryotic organisms, from yeast to mammals, progression through the cell cycle 
is ultimately regulated by the actions of a group of highly conserved serine/threonine protein 
kinases named the cyclin dependent kinases (CDKs). CDK activity is controlled by the 
association of CDK subunits with regulatory protein subunits named cyclins to form active 
CDK-cyclin complexes. The trypanosomatids represent one of the earliest known divergent 
branches of the eukaryotic phylogenetic tree. At the start of this project several putative CDK 
and cyclin homologues had been described in Trypanosoma brucei, tbCRKl-3 and tbCYCl. 
During the project tbCRK2 and tbCYCl were analysed and a new CRK (tbCRK4) isolated.
The function of the tbCRK2 protein and the ibCRK.2 gene was investigated using 
biochemical and molecular genetic approaches. Use of anti-CRK2 antisera showed that 
tbCRK2 is expressed in both proliferative and nonproliferative life cycle stages of T. brucei. 
Attempts to create null mutants at the tbCRK2 locus repeatedly failed, with the wild-type allele 
preserved in all transgenic lines generated. Ectopic expression of a cloned copy of tbCRK2 did 
not allow deletion of wild-type alleles, although the cloned copy of tbCRK2 was demonstrated 
to generate abnormally high cellular levels of tbCRK2. These results may suggest that tbCRK2 
is an essential gene in the procyclic form of the parasite; however, control experiments are 
needed to verify this.
The tbCYCl protein was previously reported to be a mitotic-type cyclin in T. brucei. 
Biochemical and molecular genetic approaches were taken to investigate tbCYCl function. A 
specific anti-CYC 1 antiserum was generated, which demonstrated that in T. brucei strain STIB 
247 tbCYCl is expressed in the short stumpy bloodstream and procyclic forms, but not in the 
long slender bloodstream form, suggesting a function in differentiation rather than cell cycle 
control per se. No significant tbCYCl-associated kinase activity was found in procyclic 
extracts. In addition, no association of tbCYCl with any of the known T. brucei CRKs or with
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the yeast protein pl3 or the leishmanial protein p l2  was found in procyclic extracts. 
These data suggests that tbCYCl does not fulfil the function of a mitotic-type cyclin. Attempts 
to generate null mutants for the tbCYCl locus failed, which may provide preliminary evidence 
that tbCYCl serves an essential function in the procyclic form. However, further experiments 
are required to clarify this.
A full-length genomic clone of the tbCRK4 gene was isolated and demonstrated to be 
homologous to the Crithidia fasciculata cfCRK gene. Computer analysis revealed the presence 
of two large, highly hydrophilic insert domains between the conserved kinase catalysis domains 
VIb and VII, and X and XI. Specific anti-CRK4 antisera were generated and used to 
demonstrate that in strain STIB 247, tbCRK4 is expressed in the short stumpy bloodstream and
procyclic forms, but not in the long bloodstream form. No tbCRK4-associated kinase activity 
was detected from procyclic extracts, and no interactions with the yeast protein p l3 sucl or the 
leishmanial protein p l2 CKS1 was found from procyclic extracts.
This study has provided evidence that mechanisms of cell cycle control in 
trypanosomatids may be based upon the functional CDK-cyclin paradigm observed in higher 
eukaryotes yet have diverged to serve the parasite’s unique biology. If sufficient divergence in 
terms of biochemical function between trypanosome CRKs and cyclins and the CDKs and 
cyclin of mammals could be demonstrated, they would provide a tempting drug target.
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NOTE ON GENETIC NOMENCLATURE
The new standard for genetic nomenclature as applied to trypanosomatid parasites has 
been revised recently (Clayton et al., 1998). The nomenclature used in this thesis shall broadly 
follow those guidelines. The basic principles are as follows, using the CRK3 gene as an 
example. Wild-type alleles are italicised in upper case, with lower case prefix denoting species 
e.g. CRK3, tbCRK3 denoting the T. brucei gene, lmmCRK3 denoting the Leishmania mexicana 
gene. Multiple related but non-identical genes are distinguished by non-hyphenated letters or 
numbers e.g. PKCa, PKCS, THT1, THT2\ RNA products have the exact same designations. 
Protein products have the same designations but are not italicised (I have not used italicisation 
for the species prefix with protein products).
Gene replacements are indicated with a double colon. For example, replacement of one 
allele of tbCRK3 with a bleomycin marker BLE is denoted by Acrk3::BLE/CRK3. Insertional 
inactivations are indicated by a circumflex (A) e.g. *crk3::BLE for the insertional inactivation 
of BLE to one allele of tbCRK3.
Properly, the system of genetic nomenclature differs between the two species of yeast 
mentioned in this thesis. Schizosaccharomyces pombe genes are italicised in lower case with a 
plus sign for wild-type allele, and a minus sign for an inactive mutant allele or deleted wild- 
type allele e.g. cdc2+, cdc2~. Protein products are lower case but non-italicised. Saccharomyces 
cerevisiae genes are italicised in upper case for wild-type alleles and lower case for mutant 
alleles e.g. CDC28 and cdc28, except for dominant mutants which are italicised in upper case 
e.g. DAF1-1.
However, in the interests of continuity I have applied the trypanosomatid system to the 
yeast genes: This is not the consensually accepted nomenclature for yeast genes. However, as 
the sections on S. pombe and S. cerevisiae cell cycle are separate, confusion should be 
minimised. Outwith these sections (chapter 1.2.1 and 1.2.2) if a yeast gene or protein is 
mentioned, species is specified. It should be noted that although the CDC system of naming 
yeast genes is used for both S. pombe and S. cerevisiae, the two do not correspond i.e. the same 
number of CDC gene between the two species designates a completely different gene. For 
genes homologous between the two species that are designated by different numbers/names, the 
relationship has been emphasised in the text to clarify the relationship and avoid confusion.
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CHAPTER 1: INTRODUCTION
1.1: General biology of African trypanosomes
Protozoa were once regarded as a phylum within the kingdom Anamilia, although it is 
now believed that this classification is not a natural one and that it contains members that could 
be classified as animals, plants or fungi. Accordingly, the concept of Protozoa as a taxon has 
been abandoned and the term is applied to animal-like members of the kingdom Protista. From a 
historical perspective classification of such single-celled organisms has been problematic, based 
upon a wide and complex range of features such as morphology, cell ultrastructure, variations in 
life cycle, and increasingly on biochemical and molecular differences. There continues to be 
arguments about the relationship between various taxonomic groups within the kingdom 
Protista, many of which will doubtless be clarified by advances in molecular systematics and 
increased genetic information (Coombs et al., 1998). The protozoa have traditionally been 
divided into four groups, based on mode of locomotion: The flagellates, which move by the use 
of one or more flagella, the amoeba, which move by pseudopodia, the ciliates, moving by the co­
ordinated beating of hundred of cilia, and the sporozoans, which lack any obvious form of 
locomotion (Sleigh, 1989). Within the flagellates group, phylum Kinetoplastida includes order 
Trypanosomatida: Leishmania and Trypanosoma species (Cox, 1992, 1993).
The trypanosomatids are characterised by the presence of the kinetoplast, a unique 
organelle that is an integral part of the mitochondrion and which contains DNA in the form of 
maxicircles and minicircles. The kinetoplast is located near the base of the flagellum, the exact 
location of which changes with respect to the rest of the cell in different life cycle stages and is 
associated with changes in the mitochondrial system. The life cycle of T. b. brucei has been 
described (Vickerman, 1985). The cycle is complex, with alternating proliferative and cell cycle 
arrested forms (Fig. 1.1), and as the host environments of mammals and tsetse flies are very 
different the patterns of gene expression between forms vary. The cell cycle arrested short 
stumpy form is ingested when a tsetse fly takes a bloodmeal from an infected mammal (Glossina 
species; T. b. brucei is transmitted by many Glossina species, T. b. rhodesiense mainly by the G. 
morsitans group, T. b. rhodesiense by G. palpalis and G. tachinoides). The stumpy form enters 
the midgut and transforms to the procyclic, which is a proliferative form that establishes the 
infection in the fly. The tsetse itself has a lectin defence mechanism (Maudlin and Welbum, 
1987); susceptibility to trypanosome infection is maternally inherited and associated with the 
presence of a rickettsia-like symbiont in the midgut cells (Maudlin and Ellis, 1985). The 
symbiont produces a chitinase activity that releases D+ glucosamine, which may interfere with 
lectin binding, and the chitinase itself may render the peritrophic membrane (PTM) more
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penetrable. The procyclic form penetrates the PTM, reaches the ectoperitrophic space and 
migrates to the proventriculus, where it differentiates to the elongate cell cycle arrested 
mesocyclic form. Mesocyclics retraverse the PTM and migrate via the oesophagus, proboscis 
lumen and hypopharynx to the salivary glands (Vickerman et al., 1988). Here, they differentiate 
to the proliferative epimastigote form, which attaches to the epithelia and gland cell microvilli 
via branched outgrowths of the flagellum. Differentiation to the cell cycle arrested metacyclic 
form is accompanied by regression of the flagellar outgrowths, although attachment is retained 
until cell cycle arrest and acquisition of the VSG coat, leading to detachment as the mature, cell 
cycle arrest metacyclic (Vickerman et al., 1988). Determination of the VSG expressed appears 
to occur at the last division of the nascent metacyclic (Tetley et a l, 1987). The part of the cycle 
in the fly takes 3-5 weeks, and in many cases the infection aborts, with only a small percentage 
of tsetse flies eventually producing metacyclics. Metacyclics are injected to the mammalian 
vascular system upon tsetse feeding, where they differentiate to the proliferative long slender 
bloodstream form. Parasitaemia increases until differentiation to the cell cycle arrested stumpy 
form occurs. This differentiation step is thought to be initiated by a low molecular weight 
molecule, stumpy inducing factor (SIF; Vassella et al., 1997); stumpy form cells are ingested by 
the tsetse again and the cycle returns to the start.
The basic metabolism of the parasite is therefore quite distinctive between the forms in 
the two hosts and there is a requirement for rapid switching between these modes when 
transmission between species occurs. In addition, metabolic processes may vary between 
different forms of the parasite within the same host, for example between the proliferative 
procyclic form in the tsetse midgut and the mature metacyclic form, preadapted for transmission 
to a mammal, in the salivary glands. One of the most striking examples of this is the difference 
in energy metabolism between the long slender bloodstream form and the procyclic form.
In the long slender bloodstream form the mitochondrion has a regressed form, 
morphologically appearing as a simple tube with the components of the TCA (tricarboxylic 
acid) cycle missing, and energy generation being achieved by the process of ‘aerobic 
glycolysis’. The mitochondrion interacts with an organelle called the glycosome (Clayton and 
Michels, 1996): Glucose is imported to the cell from the mammalian bloodstream by specific 
glucose transporters (Barrett et al., 1998) and then enters the glycosome. Here it is metabolised 
to 1,3-diphosphoglycerate and glycerol-3-phosphate, the former of which leaves the glycosome 
and enters the cytosol where it is converted to pyruvate, the latter of which is transported to the 
mitochondrion where it is oxidised to dihydroxyacetone phosphate. This then re-enters the 
glycosome where its electrons are transferred by glycerophosphate oxidase to oxygen; it is 
unclear whether this step is coupled to the synthesis of ATP but the net effect is to ensure 
continual reoxidation of NADH. This rapid oxidation of glucose and production of ATP is 
inefficient, generating only two moles of ATP per mole of glucose utilised, but this is irrelevant
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given the high availability of glucose from the host’s bloodstream and therefore inefficiency is 
compensated for by the high throughput of glucose carbon (Cox, 1993).
As the parasite differentiates through the intermediate form to the cell cycle arrested 
short stumpy form the mitochondrion becomes more complex, developing branches and cristae. 
It gains the functions of acetate and succinate production from pyruvate, fumarate reductase is 
present and so are the enzymes of the TCA cycle although the cycle itself does not function 
normally. The glycosome gains phosphoenolpyruvate carboxykinase and malate dehydrogenase 
activity, the latter assuming the role of NADH reoxidation as glycolytic activity wanes (Durieux 
et al., 1991; Priest and Hadjuk, 1994). These changes are geared towards preadapting the 
parasite for survival in the insect host. The short stumpy form arrives in the tsetse fly midgut, a 
highly oxidising environment, and subsequently transforms to a procyclic trypomastigote and 
migrates via the insect’s haemolymph to the salivary glands. Glucose ingested in the bloodmeal 
is very rapidly oxidised in the midgut and the muscles powering the insects' wings rely on 
oxidation of amino acids, chiefly proline, as the energy source. Consequently, the parasite must 
adapt quickly to an amino acid based energy generation. In transforming to the procyclic form 
the partially developed mitochondrion branches further and acquires large numbers of cristae 
and a fully functional TCA cycle, and is therefore able to at least partially oxidise the proline 
and other amino acids that it takes up from the insect’s haemolymph. In both life cycle stages - 
indeed in all life cycle stages of T. b. brucei - although the specific metabolic pathways may 
differ they are regulated in general in the same manner as in other organisms, responding to the 
adenylate energy charge and the redox state, enzymes showing allosteric regulation, metabolic 
paths subject to both feedback and feedforward control and to product inhibition.
1.2.1: Fission yeast cell cycle
The eukaryotic cell cycle is a complex and highly ordered process by which a cell 
replicates its DNA and ensures proper segregation of replicated DNA between its daughter cells. 
The cell cycle is divided into four phases; S-phase, in which the DNA content of the cell 
doubles, mitosis (M phase) in which DNA is segregated between the forming daughter cells, and 
two gap phases that separate these other phases, called G1 and G2. The normal progression is 
therefore that a newly formed daughter cell passes through G l, growing and preparing for S 
phase in which chromosomes are replicated. Following S phase, the cell moves through G2 prior 
to entry to M phase and the formation of two new daughter cells. Understanding of the metazoan 
cell cycle has to a large extent been underpinned by the deconstruction of the cell cycle of two 
species of yeast, providing a template of eukaryotic cell cycle control that could then be used as 
a model for elucidating mechanisms of cell cycle control in mammalian cells. The species of
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genetically tractable, easily cultured yeast used in these cell cycle analyses are fission yeast, 
Schizosaccharomyces pombe, and budding yeast, Saccharomyces cerevisiae. These yeasts are 
ideal tools for the dissection of cell cycle control as they have small genomes, only 4-5 times 
larger than the genome of E. coli, are easily cultured and have short mean generation times, 
allowing rapid isolation of mutants altered in the normal cell cycle. Both propagate with stable 
haploid genomes, although both may conjugate and subsequently either sporulate, undergoing 
meiosis to produce daughter cells with new haploid genomic arrangements, or propagate as a 
diploid (Forsburg and Nurse, 1991). Both tend to mate in response to the stress of nutrient 
limitation.
Schizosaccharomyces pombe is a rod-shaped single-celled organism of constant 
diameter that grows by extension of the cell ends and which divides by septation and medial 
binary fission. Microtubule reorganisation and formation of the mitotic spindle occur in M 
phase, as in other eukaryotic cells (Hagan and Hyams, 1988), but in contrast - and in common 
with Saccharomyces cerevisiae - the nuclear envelope remains intact. The emergent daughter 
cells are already big enough to support DNA replication in rapidly growing 
Schizosaccharomyces pombe', therefore S phase commences before cytokinesis is complete, with 
a correspondingly short G l. Cell cycle regulation is chiefly at the Gl/S transition where cell size 
and nutritional status are monitored, thus if nutrient limitations are a factor Gl is extended 
before the decision to enter S phase is taken (Nasmyth 1979; Nasmyth et al., 1979). The 
decision point for a cell to replicate its DNA and complete mitosis is called START, defined as 
the point in Gl in which the cell becomes committed to the cell cycle. Schizosaccharomyces 
pombe grows mitotically until nutrients are limiting when one of two alternate paths is followed. 
The cells can arrest in Gl or G2 (reviewed by Costello et al., 1986), although they do not enter a 
state analogous to the GO state of mammalian cells, or they can conjugate to form a diploid 
which then sporulates and undergoes meiosis to produce haploid daughter cells. The diploid 
state of S. pombe is highly unstable, although it can be maintained by culturing in rich media.
Delineation of the mechanisms of cell cycle control in fission yeast has largely been 
reliant on isolation of temperature-sensitive mutants. These are clones which display normal 
growth and division at the permissive temperature of 25°C but which display an abnormal 
phenotype with respect to the cell cycle when shifted to the restrictive temperature of 37°C. The 
first such identified were highly elongated mutants relative to the normal cell shape, therefore 
cell cycle progression had been blocked but cell growth was unaffected, which could be 
confirmed by analysis of the DNA content of the mutants. The genes that produced the mutant 
phenotypes could then be isolated by screening of genomic or cDNA libraries for plasmids 
containing S. pombe DNA that could rescue the phenotype. Genes isolated in this manner were 
termed CDC genes, for cell division cycle, and by this method 26 separate CDC mutants were 
characterised (Hartwell, 1978).
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One gene isolated by this approach, and subsequently to be shown to be a key regulator 
of cell cycle progression, was the CDC2 gene. Absence of CDC2 function leads to cell cycle 
arrest at both the Gl/S and G2/M transitions, revealing a role for this gene at both decision 
points (Nurse and Bisset, 1981). Analysis of the gene sequence proved it to be a serine/threonine 
protein kinase, although it did not fall into any of the existing kinase families. It is now known 
that CDC2 is a member of a distinct family of serine/threonine kinases, called the cyclin 
dependent kinase (CDK) family. CDKs depend on binding to proteins called cyclins for 
activation and direction of function; cyclins were initially isolated in biochemical analyses of 
protein oscillation through the cell cycle in sea urchin embryos (Evans et al., 1983). One protein 
was identified which was present only at very low levels in G l and S phase, but which showed 
an increase in abundance through G2 that peaked at M phase. The protein was rapidly destroyed 
after M phase was underway, and began its gradual accumulation after M phase as daughter 
cells re-entered Gl (Evans et al., 1983). In S. pombe, a gene was isolated that fulfilled this 
cyclin function. The previously identified CDC 13 gene was discovered to have three 
temperature-sensitive alleles that acted as suppressors of a cold-sensitive CDC2 allele (Nurse et 
al., 1976; Nasmyth and Nurse, 1981); in addition, overexpression of CDC2 could rescue a 
CDC13 temperature-sensitive allele. Deletion of CDC13 leads to an M phase bypass, with 
multiple rounds of S phase with no intervening M phase (Hayles et al., 1994; Fisher and Nurse, 
1996). The temperature-sensitive allele mentioned above, CDC13-117 (a conditional point 
mutant) arrests cells at the restrictive temperature with a mixed G2/M phenotype in which the 
chromosomes are condensed with an interphase array of microtubules (Nurse et al., 1976; 
Nasmyth and Nurse, 1981; Hagan et al., 1988), indicating functions for CDC 13 within M phase. 
Binding of CDC 13 to CDC2 and subsequent destruction of CDC 13 at anaphase are therefore the 
key regulatory events (Moreno et al., 1989). CDC2-CDC13 binding is stochiometric, but it is 
not just the ratio of CDC2 to CDC13 subunits that regulate binding; phosphorylation of Thrl67 
(a residue conserved in an equivalent position in all CDKs) is necessary for cyclin binding 
(Ducommun et al., 1991). Phosphorylation of Thrl67 is performed by CAK (CDC2-activating 
kinase). CAK has been purified from Xenopus laevis oocytes and found to be the previously 
identified p40MO15 protein (Fesquet et al., 1993; Poon et al., 1993). Furthermore, a 
dephosphorylation event is necessary subsequent to cyclin binding for activity of the complex. 
The phosphorylated Tyrl5 residue of CDC2 that inhibits CDC2-cyclin complexes (Lee et al., 
1988; Gould and Nurse, 1989) is dephosphorylated by the CDC25 protein phosphatase. CDC25 
mRNA and protein levels increase through the cell cycle (Ducommun et al., 1990), peaking at 
G2, and dephosphorylation of Tyrl5 occurs just before M phase, activating the complex 
(Draetta and Beach, 1988; Morla et al., 1989; Millar et al., 1991) and driving the cell into 
mitosis. A mutation in CDC25 leads to a G2 arrest (Nurse et al., 1976) with an elongated 
phenotype; overexpression of CDC25 drives the cell prematurely into M phase (Fantes, 1979;
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Russell and Nurse, 1986) thus CDC25 acts as a dosage-dependent inducer of mitosis. It 
therefore defines a rate-limiting step in G2/M transition.
Further genetic analysis for rate-limiting genes identified mutants in which the cells 
moved through the cell cycle with a reduced size, with a truncated or ‘wee’ phenotype. The wee 
phenotype maps to two loci, the CDC2 gene itself and WEE1, a gene that sequence analysis 
predicts to be a serine/threonine kinase. WEE1 was isolated by complementation of a strain with 
the wee phenotype (Russell and Nurse, 1987a). While a mutation in WEE1 gives the phenotype 
of cell division at reduced size, overexpression of WEE1 results in abnormally elongated cells; 
therefore WEE1 acts as a dosage-dependent inhibitor of mitosis (Russell and Nurse, 1987a) and 
is directly opposite in effect to CDC25. Although by sequence analysis WEE1 is predicted to be 
a serine/threonine kinase, it has been demonstrated to inhibit CDC2 by phosphorylating Tyrl5 
(McGowan and Russell, 1993). Cells with a WEE1 mutation are too small to pass START after 
M phase and therefore have an extended Gl. Overexpression of an allele of WEE1 with a 
mutation suppresses the elongated, G2 arrested phenotype of a CDC25ts mutant and restores 
growth (Fantes, 1979; Russell and Nurse, 1986). Evidence that the effect of the genes is additive 
comes from overexpression of CDC25 in a WEE1-deficient background that leads to an 
acceleration of mitosis to such a degree that the cells attempt to divide at too small a size 
(mitotic catastrophe). Additional evidence supporting the view of a bifurcated upstream control 
of CDC2 ending in the antagonistic effects of CDC25 and WEE1 comes from the wee 
phenotype that maps to CDC2. These mutants fall into two classes and map to different portions 
of the CDC2 protein (Nurse and Thuriaux, 1980; Carr et al., 1989); cells that are independent of 
WEE1 function and cells that are independent of CDC25 function. A regulator of WEE 1 
activity, NIM1, was isolated (Russell and Nurse, 1987b) and later shown to be allelic with a 
gene called CDR1, which is involved in cell size and nutritional control. NIM1/CDR1 acts to 
inhibit WEE1 activity and thus has a net inducing effect on CDC2 activity. Another protein that 
interacts with CDC2-CDC13 is the SUC1 protein, the gene of which was isolated as a 
suppressor of CDC2ts (Hayles et al., 1986). Deletion of SUC1 leads to mitotic bypass with 
multiple rounds of S phase (Hayles et al., 1994; Fisher and Nurse, 1996); however, as the 
CDC2ts mutants rescued by SUC1 also arrest at G2/M, SUC1 is also implicated in mitosis. The 
function of SUC1 is not yet clear, although there is genetic evidence of a direct interaction with 
CDC2 (Moreno et al., 1989) and biochemical evidence of strong association between SUC1 and 
CDC2 homologues from a number of species (Hindley et al., 1987; Dunphy et al., 1988; Arion 
et al., 1988).
Evidence has been accumulating that the RUM1 gene product is an important control 
factor in the fission yeast cell cycle. RUM1 null mutants cannot delay entry to S phase and 
cannot institute a G l block, and so consequently are sterile (Moreno and Nurse, 1994). 
Overexpression of RUM1 gives a phenotype similar to a CDC13 null (Moreno and Nurse, 1994;
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Hayles et al., 1994). Four cyclins in total have been demonstrated to complex with CDC2 - 
PUC1, CIG1, CIG2 and CDC13 (Fisher and Nurse, 1995). CDC2-CIG2 activity peaks at 
START (in parallel with the peak of CIG2 expression) implicating it in control of the traverse of 
START (Obara-Ishihara and Okayama, 1994; Martm-Castellanos et al., 1996; Mondesert et al., 
1996). CDC13 is the mitotic cyclin (Booher et al., 1989; Moreno et al., 1989). CIG1 may have a 
role in the Gl/S transition as a CDC13-CIG2 double null can traverse S phase but a triple null 
CDC13-CIG2-CIG1 cannot (Fisher and Nurse, 1996; Mondesert et al., 1996). The role of PUC1 
in the cell cycle is not yet clear (Forsburg and Nurse, 1991, 1994). RUM1 inhibits CDC2- 
CDC13 and CDC2-CIG2 activity in vivo during G l, and also promotes the turnover of CDC13 
(Correa-Bordes and Nurse, 1995; Martm-Castellanos et al., 1996; Correa-Bordes et al., 1997). 
Transient CDC2 inhibition during Gl may be important in setting the minimum cell size to pass 
START and therefore timing START as well as preventing premature entry to M phase (Labib 
and Moreno, 1996; Martm-Castellanos et al., 1996). The expression of RUM1 oscillates, with 
RUM1 present from anaphase to the end of G l, mirroring the period of mitotic cyclin 
degradation (Amon et al,. 1994; Brandeis and Hunt, 1996). Not all CDC13 is destroyed at the 
end of M phase (Benito et al., 1998) therefore there is a requirement for CDC2-CDC13 
inhibition and CDC13 destruction in G l, which RUM1 mediates. The peak of CDC2-CIG1 
activity at Gl/S may therefore act to relieve CDC2-CDC13 and CDC2-CIG2 repression by 
RUM1 (Benito et al., 1998).
A general schedule of cell cycle progression is shown (Fig. 1.2). As the cell leaves M 
phase and enters G l, RUM1 inhibits the remaining CDC2-CDC13 and promotes CDC13 
turnover, thus preventing entry to M phase from pre-START G l or premature entry to S phase. 
Levels of CIG2 and CDC13 rise and the abundance of the CDC2-CIG2 and CDC2-CDC13 
complexes increase, held inactive by RUM1 until the minimum size to pass START is achieved. 
Once a certain level of CDC2-CIG2 is achieved, RUM1 inhibition is bypassed and the active 
complex drives the cell past START. As RUM1 function is lost, CDC2-CDC13 activity 
becomes inhibited by phosphorylation on Tyrl5 by the WEE1 kinase. CDC2-CIG2 may or may 
not have functions once START has been passed. As the cells leave S phase the position within 
the cell cycle is monitored by rising levels of CDC25 and the presence of (inactive) CDC2- 
CDC13 complex. Inhibition of CDC2-CDC13 is relieved by inhibition of WEE 1 kinase by the 
NIM1/CDR1 kinase, in response to cell size and nutritional status, and peaking levels of CDC25 
in late G2 cells activates the CDC2-CDC13 complex by dephosphorylation of Tyrl5, driving the 
cell into M phase. CIG1 expression peaks at M phase and the CDC2-CIG1 complex is active 
within the progression of M phase, with CDC13 being rapidly destroyed at anaphase as a 
necessity for completion of and exit from M phase. Given that gene functions at START can be 
temporally mapped, the decision to enter S phase is not a simple bimodal switch. The 'switch' of 
Gl/S appears to have functions beyond START and likewise, the CDC2-CDC13 complex that
controls entry to M phase appears to have functions beyond passing the restriction point. As is 
only reasonable, the nutritional status of the cell influences cell cycle progression by impinging 
ultimately on the effectors of cell cycle control mentioned.
1.2.2: Budding yeast cell cycle
Budding yeast, Saccharomyces cerevisiae, unlike fission yeast is stable as both a 
haploid and a diploid. The bud initiates in late G l and grows throughout the rest of the cycle, 
although it does not grow as big as the mother cell. For division, the nucleus migrates to the bud 
neck but as with Schizosaccharomyces pombe, the nuclear membrane stays intact. In contrast to 
fission yeast there is no chromosome condensation, and due to the unique nature of division, 
there are certain requirements to be met; for example, the spindle poles must replicate early. 
Similarly, the interphase microtubule array must reconfigure to the mitotic nuclear spindle early. 
Consequently, Saccharomyces cerevisiae undergoes much of the cell cycle with cytological 
markers indicative of G2/M and there is no clear division between S phase, G2 and M phase.
The point at which M phase can be said to have initiated has been a point of contention (Nurse, 
1985). Cell cycle regulation appears to occur mainly in G l, where cell size and nutritional status 
are monitored; if nutrition is limiting, G l is consequently extended. Bud growth, DNA 
replication and spindle reorganisation initiate simultaneously but are genetically distinct 
processes, and therefore represent three parallel paths co-ordinated with respect to the cell cycle 
(Pringle and Hartwell, 1981). A Saccharomyces cerevisiae cell in G l has three possible fates: 
Firstly, if nutrients are not limiting, in can enter S/G2/M and divide. Secondly, under conditions 
of nutrient limitation it can enter a stationary state which is metabolically quiescent, and which 
exhibits a lag period before re-entry to G l after being introduced to a rich medium (Pringle and 
Hartwell, 1981). Thirdly, an alternative response to nutrient limitation is for haploids to mate; 
peptide hormones arrest the two haploid cells synchronously in G l, the cells fuse and continue 
to propagate as a diploid, or under conditions of starvation sporulates. Saccharomyces 
cerevisiae mates easily and can switch mating types, maximising the chances of diploid 
formation (Thomer, 1981).
As in the case of Schizosaccharomyces pombe, CDC mutants were isolated throughout 
the cell cycle under the criteria of cell cycle arrest without blocking of cell growth (Hartwell 
1974, 1978; Pringle 1978). Such mutants were identified visually, for example by arrest with 
uniform bud phenotype, or with a visual mitotic defect. As with Schizosaccharomyces pombe, 
mutants isolated were conditional and thus suppressor analysis allowed the identification of 
other cell cycle regulatory genes.
Several genes were identified in Saccharomyces cerevisiae whose function mapped to
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Gl/S. The linchpin gene isolated was CDC28, lesions in which resulted in a cell cycle block at 
Gl/S (Hartwell et al., 1973; Reed, 1980) but certain allelic mutations arrested in G2 (Piggot et 
al., 1982; Reed and Wittenberg, 1990), thus implicating CDC28 as having functions in both 
Gl/S and G2/M. Analysis of the coding sequence showed CDC28 to be a homologue of 
Schizosaccharomyces pombe CDC2, a serine/threonine kinase, and complementation studies 
demonstrated functional equivalence (Beach et al., 1982; Booher and Beach, 1986). CDC28 was 
demonstrated to have kinase activity (Reed et al., 1985) but that it was inactive as a monomer 
(Wittenberg and Reed, 1988). Analysis of the CDC28ts mutants demonstrated that arrest was 
most often in G l; suppressor analysis identified three more regulatory genes. The first of these, 
the CKS1 gene, was isolated as a high copy suppressor of some CDC28ts alleles, although it was 
not able to completely bypass the requirement for CDC28 function (Hadwiger et al., 1989a). 
Deletion of CKS1 is lethal, resulting in a nonbudded phenotype and arrest is therefore in G l 
prior to START. Sequence analysis of the coding sequence revealed CKS1 to be homologous to 
the Schizosaccharomyces pombe SUC1 gene. The other two genes, termed CLN1 and CLN2, 
were also identified as high copy suppressors of CDC28ts mutants, but like CKS1 they could not 
bypass the requirement for CDC28 function (Hadwiger et al., 1989b). Sequence analysis 
revealed that neither had homology to the A and B type family of cyclins from metazoan cells, 
and they therefore appeared to form a distinct cyclin subgroup. A third member of this 
subgroup, the CLN3 gene, was isolated independently on two separate occasions as dominant 
mutant alleles: The WHI1-1 gene (Nash et al., 1988), which accelerated cells through Gl with a 
reduced cell size, and as the DAF1-1 gene (Cross, 1988) which resulted in cells insensitive to a- 
factor mating signal-induced Gl arrest. Both of these dominant mutant alleles were shown to be 
truncations in the gene that was renamed CLN3 (Nash et al., 1988; Cross, 1988). Deletion of one 
or even two of the CLN genes is not lethal, although cells exhibit an increase in cell size and an 
extended Gl. However, deletion of all three is lethal and leads to arrest in G l, therefore the 
functions of these three genes are redundant (Nasmyth, 1993).
START in budding yeast is generally defined as the period when spindle pole body 
duplication, budding and DNA replication all initiate (Nasmyth, 1993). CDC28 function 
mapping to START requires CLN 1-3, as not only does deletion of all three lead to a G l arrest 
(Nasmyth, 1993) but ectopic overexpression of CLN 1-3 results in acceleration through START 
(Futcher, 1996). The temporal expression pattern of the three genes differs: CLN3 transcript and 
protein are present throughout the cell cycle but protein levels rise in early G l (Tyres et al.,
1993; Mclnemy et al., 1997). This is a result of a translational control element in the 5’ 
untranslated region (UTR; Polymenis and Schmidt, 1997) responsive to the RAS-cAMP 
signalling pathway (Hall et al., 1998). Thus under conditions of slow growth CLN3 expression 
is repressed (Gallego et al., 1997) providing a direct coupling of cell growth with the cell cycle. 
By contrast, the expression of CLN1 and CLN2 are cell cycle regulated with a peak in protein
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levels and CDC28-associated kinase activity in late G l (Tyres et al., 1993). CLN transcription 
and entry to S phase are regulated by the SBF and MBF transactivators, which form a program 
of ST ART-dependent gene activation (Breeden, 1995). CDC28-CLN3 activates SBF at START, 
inducing expression of CLN1 and CLN2 (Tyres et al., 1993). SBF is a substrate for CDC28- 
CLN1/2, thus forming a positive feedback loop. MBF is activated near S phase and induces the 
expression of CLB5 and CLB6, as well as other genes involved in DNA replication (Breeden,
1995). Generally speaking, CLNs are though to function by permitting CLB expression and 
activity at the correct point in the cell cycle (Nasmyth, 1996).
Negative control of CDC28-CLN complexes is regulated by the SIC1 gene product, 
which inhibits CDC28-CLN complexes (Schwob et al., 1994; Schneider et al., 1996). SIC1 
destruction by the ubiquitin proteolytic machinery is regulated by CDC28-CLN (Schneider et 
al., 1996), therefore once CDC28-CLN activity rises above a threshold, CDC28-CLN 
phosphorylation of SIC1 occurs, initiating its destruction. As with CDC2 in fission yeast, 
CDC28 binding to cyclins is positively regulated by phosphorylation on the conserved Thrl61 
residue (Thrl67), and this event is performed by the CAK1/CIV1 kinase. Oddly, this CDK- 
related kinase is active as a monomer and has never been demonstrated to bind a cyclin partner 
(Kaldis et a l, 1996; Thuret et al., 1996; Espinoza et al., 1996). CDC28 differs from CDC2, 
however, in that strains harbouring an altered CDC28 allele such that CDC28 could not be 
phosphorylated on the Tyr equivalent of fission yeast Tyrl5 could grow and divide normally 
(Sorger and Murray, 1992; Amon et al., 1992). This has been confirmed by studies on strains 
lacking the budding yeast WEE1 homologue SWE1 (Booher et al., 1993); budding yeast lacking 
SWE1 function can still divide normally and delay entry to M phase in response to DNA 
damage. The reason for budding yeast possessing an operative WEE1-CDC25 homologous 
system, SWE1-MIH1 (Russell et al., 1989) is therefore unclear and has been the subject of 
speculation (Dunphy, 1994).
Six B-type cyclins have been identified in S. cerevisiae, CLB 1-6, which are involved in 
the promotion of S phase and M phase (reviewed by Nasmyth, 1996). CLB5 and CLB6 are 
expressed in late G l (Breeden, 1995). Both are required for S phase entry. Deletion of CLB5 
and CLB6 impairs S phase entry but does not affect START (Epstein and Cross, 1992; Kuhne 
and Linder, 1993; Schwob and Nasmyth, 1993), presumably due to degeneracy of function on 
the part of CLB 1-4. CLB3 and CLB4 are expressed during S phase while CLB1 and CLB2 are 
expressed in G2 (Fitch et al., 1992). The degeneracy of the CLB proteins makes defining precise 
in vivo functions problematic. The temporal pattern of expression would suggest that CLB3 and 
CLB4 function in S phase progression, and that CLB1 and CLB2 function at M phase. Deletion 
of CLB 1-4 does not inhibit DNA replication but cells do not form bipolar mitotic spindles and 
arrest in G2 (Fitch et al., 1992; Amon et al., 1993), suggesting that CLB3/4 are not needed for 
DNA synthesis but more specifically for correct spindle formation and function. Deletion of
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CLB1 and CLB2 is lethal, leading to a cell cycle arrest with a fully formed mitotic spindle. A 
triple deletion of CLB1, CLB2 and CLB3 leads to cells arrested with an immature spindle 
(Surana et al., 1991; Fitch et al., 1992; Richardson et al., 1992), supporting the theory that 
CLB3/4 function during early spindle formation. However, a double CLB3/4 deletion is viable 
and shows no obvious phenotype (Schwob and Nasmyth, 1993). With this type of analysis it is 
therefore difficult to determine if CLBs have overlapping functions or only display degeneracy 
of function in the absence of other CLBs.
Other CDK-cyclin pairs are involved in G l progression in Saccharomyces cerevisiae. 
The CDK PH085, which has 51% identity to CDC28, can bind multiple cyclins including PCL1 
and PCL2 (Measday, 1997). PH085-PCL1/2 complexes have potential roles in G l progression 
as deletion of PCL1 and PCL2 in a CLN1/CLN2 null results in a Gl arrest (Espinoza et al.,
1994; Measday et al., 1994), and thus PH085 is essential if there is no CDC28 activity present. 
PH085-PCL1 has been demonstrated to phosphorylate SIC1 in vitro (Sanchez-Diaz et al., 1998; 
Nishizawa et al., 1998). SIC1 phosphorylation leads to its rapid degradation, which is a 
requirement for relief of CDC28-CLN1/2 repression and DNA synthesis to occur (Nishizawa et 
a l, 1998). Cyclin PCL9 expression peaks in late M phase/early G l, and deletion causes bud 
formation defects (Tennyson et al., 1998). A general schematic of budding yeast cell cycle 
control is shown (Fig. 1.3).
The first activity identified for PH085 was in complex with the PHO80 cyclin, in 
regulation of S. cerevisiae phosphate metabolism. In conditions of limited phosphate 
availability, the PH02 and PH04 transcription factors binds DNA and activate the transcription 
of genes involved in phosphate metabolism, for example the PH05 gene which encodes an acid 
phosphatase (Jayaraman et al., 1994). In conditions of high phosphate availability, PH04 cannot 
bind DNA due to phosphorylation by the PHO85-PHO80 complex. In addition, there is control 
of the PHO85-PHO80 complex by binding to the PH081 gene product, which inhibits the 
complex. PH081 can bind PHO85-PHO80 during conditions of both high and low phosphate 
availability, but is only inhibitory under conditions where phosphate is low, therefore PH081 
activity is regulated post-translationally (Schneider et al., 1994; Hirst et al., 1994). PH085 may 
also be involved in the control of other cellular activities that are not directly concerned with the 
regulation of cell cycle progression. For example, PH085 is involved in glycogen metabolism 
(Timblin et al., 1996) in complex with the PCL8 and PCL10 cyclins (Huang et a l, 1996), 
regulating glycogen biosynthesis by phosphorylation of the glycogen synthetase GSY2 (Huang 
et al., 1998). PHO85-PCL8/10 negatively regulates GSY2, and as would be expected a double 
PCL1/2 deletion accumulates glycogen due to deregulation of PH085-PCL1/2 control (Huang et 
al., 1998). The functions of the PH085 cyclins PCL5, PCL6, PCL7 and CLG1 are currently 
unknown. Three further CDK-cyclin pairs have been identified. KIN28-CCL1 is the CDK-cyclin 
component of the basal transcription factor TFDH, and SRB10-SRB11 forms part of the RNA
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polymerase II (RNA pol II) holoenzyme complex (Liao et al., 1995; Valay et al., 1995). Both 
display RNA pol II C-terminal domain (CTD) kinase activity and are therefore presumably 
involved in transcriptional regulation. A third RNA pol II CTD activity has been found to 
consist of the divergent CDK-cyclin pair CTK1-CTK2, in association with a third protein, 
CTK3, that has no homology to any known protein (Sterner et al., 1995).
1.3: Metazoan cell cycle
The metazoan cell cycle follows the same schedule as the yeast cell cycle: G l, S phase, 
G2 and M phase. G l, S phase and G2 are often collectively called interphase. M phase is 
described as a series of subphases: Prophase is the first subphase, in which chromatin condenses 
and the mitotic spindle forms. It is followed by prometaphase, where the nuclear membrane 
fragments; metaphase, when the spindle fibres align chromosomes along the middle of the cell; 
anaphase, when paired chromosomes are separated to opposite poles of the cell; and telophase, 
when the nuclear envelope reforms around the daughter nuclei and the mitotic spindle disperses. 
Telophase is followed by cytokinesis, division of the cell to form two autonomous daughter 
cells.
Early progress in delineating the molecular mechanisms underpinning the metazoan cell 
cycle came from experiments using nuclear transplantation to challenge nuclei from one 
position in the cell cycle with factors present in the cytoplasm of cells at another part of the cell 
cycle (Prescott, 1976). These determined that entry to S phase is controlled by a trans-acting 
cytoplasmic signal which is not present in pre-S phase Gl cells ( ‘S phase promoting factor’).
The second fundamental control process discovered was the inhibition of successive rounds of S 
phase, in that a G2 nucleus transplanted to an S phase cytoplasm will not undergo another S 
phase (Heichman and Roberts, 1994). Further, that an interphase nucleus challenged with M 
phase cytoplasm will attempt to segregate its DNA, thus being promoted by a trans-acting 
cytoplasmic signal that was termed maturation promoting factor (MPF; also known as M phase 
promoting factor). A histone HI kinase activity that peaked at M phase was identified and 
partially purified (Arion et a l, 1988), and subsequently demonstrated to correlate to MPF 
(Labbe et al., 1989). MPF contained the metazoan equivalent of fission yeast CDC2; human 
CDC2 (later renamed CDK1 for cyclin dependent kinase 1) had been isolated by 
complementation of a fission yeast CDC2ts mutant (Lee and Nurse, 1987). MPF was 
demonstrated to be a multiprotein complex, with a 62 kDa protein, subsequently identified as 
cyclin B (Pines and Hunter, 1989) coprecipitating with the 34 kDa CDK1 from G2 but not Gl 
HeLa cells (Draetta and Beach, 1988). Cyclins were first identified in sea urchin oocytes as 
proteins that showed an oscillating pattern of expression, synthesised during interphase and
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destroyed at M phase (Evans et al., 1983). Purification of MPF to homogeneity confirmed that 
MPF consisted of a complex formed of a 1:1 stochiometric association of CDK1 and cyclin B 
(Labbe et al., 1989). The binding of CDK1-cyclin B to SUC1, the M phase associated histone 
HI kinase activity, and the periodic nature of cyclin B expression suggested that the 
mechanisms of cell cycle control in multicellular eukaryotes might essentially be the same as 
those observed in yeast, not least because of the remarkable degree of evolutionary conservation 
between CDC2 and CDK1.
To date, there have been nine genes isolated and classified as CDKs in humans, 
although not all are directly involved in cell cycle control (reviewed by Pines, 1995; Gao and 
Zelenka, 1997). The CDK proteins associate with members of the cyclin family, of which a 
number have so far been identified in humans: Cyclin A (Henglein et al., 1994), cyclins B l, B2 
and B3 (Gallant and Nigg, 1994), cyclin C (Lew et al., 1991), cyclins D l, D2 and D3 (Xiong et 
al., 1991; Motokura et al., 1992), cyclin E (Koff et al., 1991), cyclin F (Bai et al., 1994), cyclins 
Gl and G2 (Tamura et al., 1993; Home et al., 1996), cyclin H (Makela et al., 1994; Fisher and 
Morgan, 1994), cyclin I (Nakamura et al., 1995), cyclin K (Edwards et al., 1998) and cyclin T 
(Wei et al., 1998). The known patterns of interaction of these CDKs and cyclins are shown in 
table 1. CDK partners have not yet been identified for cyclin F, cyclin I or cyclin K, although 
cyclin K appears to be associated with RNA pol II C-terminal domain (CTD) kinase activity 
(Edwards et al., 1998) and cyclin G is implicated in p53-mediated DNA damage arrest (Home et 
al., 1996; Reimer et al., 1999).
Studies on the function of CDK1 showed an immediate difference between metazoans 
and yeast. In yeast, CDC2/CDC28 has functions at both Gl/S and G2/M transitions. Evidence 
from metazoan cells suggested that CDK1 functioned only at G2/M (or at least, had a critical 
function only at G2/M). A Xenopus laevis oocyte extract depleted of CDK1 will carry out DNA 
replication but will not enter M phase (Fang and Newport, 1991). A temperature sensitive 
CDK1 mutant has been shown to traverse S phase but not pass G2/M at the restrictive 
temperature (Hamaguchi et al., 1992). The association of CDK1 with the A and B cyclins (often 
dubbed ‘mitotic cyclins’) has been further investigated, and the kind of degeneracy displayed by 
the yeast CLN and CLB cyclins is not mirrored in metazoans. For example, transgenic mice 
homozygous for either cyclin B l or B2 dysfunction have shown that cyclin B l but not B2 is 
essential for viability (Brandeis et al., 1998). The subcellular localisation of the B-type cyclins 
differs: B 1 is located in the cytoplasm at interphase and moves to the nucleus at M phase (Ohi 
and Gould, 1999). Cyclin B2 is always located at the Golgi, presumably having a function in 
complex with CDK1 in Golgi fragmentation during M phase, and cyclin B3 is always located in 
the nucleus (Ohi and Gould, 1999). The synthesis of the B cyclins begins in G l and they must 
accumulate above a threshold level to be able to promote mitosis (Murray and Kirschner, 1989; 
Solomon et al., 1990). Threshold is defined as the point beyond which no further protein
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synthesis is required for MPF to induce mitosis. Cyclin B starts to associate with CDK1 in late S 
phase. Binding of cyclin B promotes phosphorylation of Thrl61 by the CDK1 activating kinase 
(CAK) but the complex is held inactive due to phosphorylation of Thrl4 and Tyrl5 (Pines,
1993; King et al., 1994; Pines, 1995). Phosphorylation of Thrl4 is carried out by MYT1 
(Booher et al., 1997; Liu et al., 1997). Although MYT1 also appears able to phosphorylate 
Tyrl5, the major Tyrl5 phosphorylating kinase is WEE1, which phosphorylates exclusively on 
this residue (McGowan and Russell, 1993). MYT1 and WEE1 become heavily phosphorylated 
once the cell enters M phase, a change concomitant with their inactivation (McGowan and 
Russell, 1995; Mueller et al., 1995a,b; Booher et al., 1997). In parallel, the dual-specificity 
CDC25 phosphatase, held inactive until then by dephosphorylation becomes phosphorylated and 
active (Izumi et al., 1992; Izumi and Mailer, 1993; Kumagai and Dunphy, 1992, 1996). Active 
CDC25 dephosphorylates CDK1 on Thrl4 and Tyrl5 (Gautier et al., 1991; Kumagai and 
Dunphy, 1991, 1992) and, released from inhibition, the CDK 1-cyclin B complex drives the cell 
into M phase. Active CDK 1-cyclin B can phosphorylate CDC25 (Hoffmann et al., 1993; 
Dunphy, 1994), forming a positive feedback loop that results in rapid activation of the complex 
and entry to M phase. During metaphase, ubiquitin-mediated proteolytic machinery is activated 
that quickly destroys cyclin B prior to anaphase and thus inactivates CDK1 (King et al., 1994). 
However, cyclin B destruction and CDK1 inactivation is not necessary for anaphase as in cells 
with ectopically expressed mutant forms of cyclin B that are ultrastable, chromatid separation 
occurs normally and the cells arrest in telophase (Holloway et al., 1993); however, activation of 
the machinery is required for completion of cytokinesis. Thus as the cell leaves M phase, CDK1 
is once more an inactive monomer, and cyclin B accumulation begins anew. Active CDK1- 
cyclin A is also required for entry to M phase.
The CDK2 gene was isolated by complementation of an S. cerevisiae CDC28ts mutant 
(Elledge and Spottswood, 1991); only CDK1, CDK2 and CDK3 can rescue budding yeast 
CDC28ts mutants (Meyerson et al., 1992). The CDK2 gene is 66% identical to CDK1, the 
highest homology to CDK1 of all the CDK family (Elledge et al., 1991). The involvement of 
CDK2 in the cell cycle has been demonstrated by expression of a dominant negative allele, 
which resulted in a G l cell cycle arrest (Van den Heuvel and Harlow, 1993). Biochemical 
evidence for a Gl/S involvement came from studies on depletion of CDK2 from Xenopus laevis 
oocyte extracts, which could undergo M phase but not enter S phase (Fang and Newport, 1991). 
As regards cyclin binding, CDK2 has been shown to be significantly associated with both cyclin 
E and cyclin A. Cyclin E is expressed during Gl/S and forms a complex with CDK2 near the 
‘restriction’ (R) point at which a cell commits to S phase; the activity of the complex is maximal 
at this point and declines as cyclin E is rapidly destroyed as S phase is entered (Lew et al., 1991; 
Dulic et al., 1992; Koff et al., 1992). Overexpression of cyclin E causes accelerated progression 
through Gl and entry to S phase (Ohtsubo and Roberts, 1993), suggesting that premature CDK2
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activation mediates this effect. Cyclin A is expressed at the start of S phase (Pines and Hunter 
1990; Tsai et al., 1991). CDK2 and cyclin A form a complex which is required for S phase 
progression (Girard et al., 1991; Elledge et al., 1992; Rosenblatt et al., 1992) and 
overexpression of cyclin A causes premature entry to S phase (Rosenberg et al., 1995). The 
CDK2-cyclin E and CDK2-cyclin A complexes are both associated with the retinoblastoma 
protein (pRB) and members of the E2F family of transactivators (Mudryj et al., 1991; Devoto et 
al., 1992; Lees et al., 1992; Pagano et al., 1992).
CDK3 is something of a mystery, as it has not been demonstrated to associate with a 
cyclin. It has been classified as a CDK on the basis of high homology to CDK1 and CDK2 and 
also the fact that it can complement a CDC28ts mutant (Meyerson et al., 1992) although it 
cannot complement a CDC2ts mutant. A CDK3 dominant negative mutant showed a G l block 
that was specifically released by wild-type CDK3 but not CDK2, implying an essential function 
in Gl/S progression distinct from CDK2 function (Van den Heuvel and Harlow, 1993). Despite 
the fact that purified recombinant CDK3 can complex with cyclins A and E in vitro and shows 
kinase activity toward the retinoblastoma protein (pRB), no cyclin partner has been identified 
for CDK3 in vivo (Harper et al., 1995; Connel-Crowley et al., 1997). The temporal activity of 
CDK3 has been mapped (Braun et al., 1998). CDK3 activity is absent in GO and early G l, peaks 
in mid G l and declines during G2; comparative mapping with cyclin D- and cyclin E-associated 
kinase activity showed that they map before and after the appearance and peak of CDK3 
activity, respectively (Braun et al., 1998). As CDK3 protein levels do not fluctuate throughout 
the cell cycle, the data suggests that CDK3 activity is controlled by as yet unidentified partner 
molecule(s), although as CDK3 activity overlaps temporally with the cell-cycle fluctuation of 
cyclin E-associated kinase activity a role for cyclin E in CDK3 function cannot be ruled out 
(Braun et al., 1998).
The CDK4 gene was originally isolated in a general screen for serine/threonine kinases 
(Hanks, 1987; Matsushime et al, 1992) and is most closely related to the CDK6 gene (Meyerson 
et al., 1992), with approximately 70% identity between them at the amino acid level. CDK2, 
CDK4, CDK5 and CDK6 have all been demonstrated to bind the D-type cyclins, but the major 
partners for cyclins Dl-3 are CDK4 and CDK6 (Matsushime et al., 1992; Xiong et al., 1992; 
Bates et al., 1994; Meyerson and Harlow, 1994). Expression of the D-type cyclins does not 
oscillate to any significant degree during the cell cycle, but their cellular levels are absolutely 
dependent on the presence of growth factors, peaking at the Gl/S boundary, and they are rapidly 
degraded upon the withdrawal of mitogens (reviewed by Sherr, 1994). Studies with transgenic 
mice have demonstrated that cyclins Dl-3 are for the most part functionally redundant but that 
each has tissue-specific functions (Sicinski et al., 1995). The primary function for CDK4-cyclin 
D (and possibly CDK6-cyclin D) is phosphorylation of pRB (Matsushime et al., 1994; Kato et 
al., 1993). Given the temporal expression and activity of cyclins Dl-3, E and A, the general
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model of Gl/S progression is that mitogenic signals stabilise cyclins Dl-3 in the G0-G1 
transition (Sherr, 1994). Cyclins Dl-3 complex with CDK4/6 to form active kinase complexes 
which hyperphosphorylate pRB at about the Gl/S transition, releasing E2F. E2F induces cyclin 
E expression, which maintains pRB phosphorylation in complex with CDK2 as the D-type 
cyclins are destroyed and CDK4/6 inactivated. Later induction of cyclin A directs CDK2 
activity through S phase as cyclin E is destroyed.
The CDK5 gene was isolated by library screening for CDK1 -related sequences 
(Meyerson et al., 1992) and independently as a histone HI kinase activity from bovine brain 
tissue (Lew et al., 1995). It has been demonstrated to be expressed in many different 
differentiated tissues but is only found to be active in the brain, apparently due to the highly 
restricted expression of its regulatory partner p35, and two further partners derived from p35 by 
proteolysis, p25 and p23 (Lew et al., 1995). Although CDK5 is highly homologous to other 
members of the CDK family, the primary sequence of p35 is unrelated to that of the members of 
the cyclin family. Substrates of CDK5-p35 include the microtubule-associated protein TAU and 
neuron-specific intermediate filaments, suggesting a role in regulation of neurite outgrowth 
(Lew et al., 1995). This is supported by cotransfection of neurons by CDK5 and p35, which 
results in longer neurite outgrowth, and expression of dominant negative CDK5 or antisense 
p35, which results in fewer and shorter neurite outgrowth (Nicolic et al., 1996). A homozygous 
deletion of CDK5 in mice causes a lethal phenotype with central nervous system abnormalities 
(Oshima et al., 1996; Gilmore et al., 1998). The in vivo association of CDK5 with other proteins 
has been demonstrated in bovine brain, where three forms appear to exist: monomeric CDK5, 
CDK5-p35, which is inactive, and CDK5-p25, which is highly active (Lee et al., 1996). 
Interestingly, gel filtration chromatography indicated CDK5-p35 was part of a large (670 kDa) 
macromolecular complex (Lee et al., 1996). CDK5 has also been demonstrated to associate with 
cyclin D2 (Guidato et al., 1998) although the functional significance of this interaction is not yet 
clear, and it has been suggested that CDK5 may have a role in the control of muscle 
differentiation and patterning (Philpott et al., 1997).
The function of CDK7 is not yet clear. The CDC activating kinase (CAK) activity that 
phosphorylates Thrl61 of CDK1 was found to be a complex of CDK7 (Fesquet et al., 1993; 
Poon et al., 1993) and cyclin H (Fisher and Morgan, 1994; Makela et al., 1994). As almost all 
CDKs require phosphorylation on the conserved Thrl61 equivalent for activity (Nigg, 1995) it 
was surprising that CAK was itself a CDK-cyclin pair. CDK7-cyclin H were demonstrated to be 
associated with a protein called Menage a trois (MAT1) that appears to act as an assembly 
factor (Tassan et al., 1995a), and CDK7-cyclin H-MAT1 was shown to be a component of the 
basal transcription complex TFIIH (Roy et al., 1995). The Saccharomyces cerevisiae CAK is a 
monomer called CAK1/CIV1 (Espinoza et al., 1996; Kaldis et al., 1996), therefore it was 
unclear as to whether or not CDK7 had a dual function as a component of TF11H and as a CAK.
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CDK7 has been isolated from cell extracts in different forms (Yankulov and Bentley, 1997) and 
while CDK7-cyclin H-MAT1 has a strong preference for CDK2 as a substrate, as a component 
of TFIIH it does not possess CAK activity (Rossignol et al., 1997). Furthermore, 
phosphorylation of CDK7 is necessary for cyclin H binding in the absence of MAT1, but 
phosphorylation is not necessary for binding in the presence of MAT1 (Martinez et al., 1997). 
Current evidence leans towards the dual function of CDK7 as a component of CAK that can be 
recruited to function as a modulator of transcriptional activity by association with TFIIH 
(Harper and Elledge, 1998).
The CDK8 gene was isolated by PCR and subsequent library screening (Tassan et al., 
1995b). Cyclin C was identified through its ability to rescue S. cerevisiae CLN mutants (LaHue 
et al., 1991; Leopold and O’Farrel, 1991; Lew et al., 1991) and was therefore initially assumed 
to play a role in Gl progression, although no direct involvement in G l progression could be 
demonstrated. CDK8 was demonstrated to associate with cyclin C by coprecipitation, and 
appeared to be structurally related to the yeast protein pair SRB10-SRB11, which forms part of 
the RNA pol II complex in S. cerevisiae (Tassan et al., 1995; Liao et al., 1995). CDK8-cyclin C 
has also been shown to associate with RNA pol II in vivo and to possess RNA pol II CTD kinase 
activity in vitro (Rickert et al., 1996). CDK8-cyclin C is therefore the second CDK-cyclin pair 
demonstrated to be involved in transcriptional control.
The most recently identified member of the CDK family, CDK9, was also isolated by 
the approach of PCR and library screening (Grana et al., 1994). Although CDK9 was 
demonstrated to have kinase activity as a monomer, overexpression of CDK9 does not result in 
an increase in cellular CDK9-associated activity (Garriga et al., 1996a). In addition, it was 
demonstrated by gel filtration to associate with multimeric protein complexes of approximately 
670 kDa and in smaller complexes (Garriga et al., 1996a) and to be capable of phosphorylating 
pRB (Garriga et al., 1996b; De Luca et al., 1997). It is expressed at higher levels in 
differentiating tissue and levels are highest in terminally differentiated tissue (Bagella et al., 
1998). CDK9 is a required component of the transcriptional elongation factor P-TEFb, which 
has RNA pol II CTD kinase activity (Marshall et al., 1996; Yang et al., 1996; Mancebo et al., 
1997; Yang et al., 1997). A novel cyclin most closely related to cyclin C was identified, named 
cyclin T, which associates in complex with CDK9 and is required as part of the P-TEFb 
complex for RNA pol II CTD activity (Wei et al., 1998). It is therefore possible that CDK9 
functions in transcriptional control of differentiation.
Thus the cyclins and their CDK partners described represent functional pairings that 
have diverged further from the CDK1 paradigm, and some of which have evolved to regulate 
aspects of cellular biology that are only marginally related to cell cycle control. CDK-cyclin 
functional pairing is a powerful, flexible system that can adapt to serve as regulators and 
integration points for different systems.
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From the delineation of the expression and pairings of the CDKs and cyclins described, 
a basic picture of metazoan cell cycle has emerged (Fig. 1.4). Newly formed daughter cells leave 
M phase with inactive CDK1 and no A or B cyclins, as the proteolytic machinery is still active: 
This activity ensures that CDK 1-cyclin B cannot accumulate in G l and the cell prematurely 
enter M phase from Gl. As the cell nears the restriction point, the D cyclins are synthesised and 
- in some manner not yet understood, whether directly or indirectly - turn off the proteolytic 
machinery, thus allowing gradual accumulation of the B cyclins through late G l and S phase. In 
this manner, analogous to the situation in budding yeast where CLB 1 and CLB2 stability 
depends on the CLNs, so the stability of cyclins A and B depend on Gl cyclins. The D cyclins 
complex with CDK4 and CDK6, CDK4-cyclin D (and possibly CDK6-cyclin D) 
hyperphosphorylates pRB, which releases E2F1-3; these form heterodimers with members of the 
DP transactivator family (of which there are three documented members), and the resulting 
complexes induce the expression of genes required for DNA synthesis, including cyclin E. 
Newly synthesised cyclin E complexes with CDK2, which is synthesised in G l, and the 
complex maintains pRB in a hyperphosphorylated state. The D cyclins are then destroyed, thus 
limiting their span of influence to a narrow window that begins just before R and ends at the 
Gl/S transition (Weinberg, 1995). CDK2-cyclin E maintains the induction of genes required in 
S phase via pRB/E2F until the Gl/S boundary is passed, when cyclin E is rapidly destroyed via 
the ubiquitin-proteasome pathway due to phosphorylation by CDK2. Cyclin A, synthesised in 
late G l, then complexes with CDK2 and functions throughout S phase. CDK2-cyclin A 
negatively regulates the E2F transactivators as the cell traverses and prepares to leave S phase. 
As the cell leaves S phase CDK1 becomes associated with the B cyclins, which promotes 
phosphorylation on Thrl61 by CDK7-cyclin H. The mitotic complexes are held inactive by 
phosphorylation on Thrl4 by MYT1 and Tyrl5 by WEE1 until late G2 when CDC25 activity 
rises due to increased phosphorylation, and it dephosphorylates both these residues, activating 
the CDK 1-cyclin B complexes which drive the cells through the G2/M transition. CDK 1-cyclin 
B functions until the condensed chromosomes are aligned on the metaphase plate, when the 
proteolytic machinery that has already destroyed cyclin A destroys cyclin B and renders CDK1 
inactive. Anaphase proceeds, followed by cytokinesis, and the two new daughter cells re-enter 
G l.
Two other families of significant players in the regulation of cell cycle progression have 
been isolated, the cyclin dependent kinase inhibitor (CKI) proteins. The first family comprises 
three members: p21Cipl (Harper et al., 1993; Xiong et al., 1993), p27Kipl (Toyoshima and Hunter,
1994), and p57Kip2 (Lee et al., 1995). The CIP/KIP family act as specific inhibitors of CDK2 
complexes and as positive regulators of CDK4/6 complexes (reviewed by Johnson and Walker, 
1999; Sherr and Roberts, 1999). There are four members of the second family of CKIs: p i6 ^ ^  
(Serrano et al., 1993), p l5 INK4b (Hannon and Beach, 1994), p l S ^ 40 (Guan et al., 1994), and
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plQiNK4d et ai ? 1 9 9 5 ). INK4 proteins function to induce cell cycle arrest in a
retinoblastoma protein-dependent manner, by inhibition of CDK4/6 activity. INK4 inhibition of 
CDK4/6 releases p21/p27, which inhibit CDK2 complexes, thereby preventing a bypass of 
CDK4 function in control of the retinoblastoma protein-mediated control of E2F transactivation 
of S phase (Sherr and Roberts, 1999).
1.4: Cell signalling in trypanosomes
In many metazoan organisms the methods by which a cell receives extracellular signals, 
transduces them across the plasma membrane, integrates and transmits that information to the 
correct effector mechanisms, and the manner in which these webs of signalling pathways 
communicate with each other have been extensively studied. While the picture is far from 
complete in most paths of signalling, a great deal of information has been garnered. The same 
cannot be said of trypanosomatids; ten years ago it was not known whether the same kinds of 
mechanisms for signal transduction and intracellular signalling existed in trypanosomes. Over 
the course of the last ten years fragmentary evidence has accumulated that trypanosomes possess 
many of the same types of signalling mechanisms as metazoan organisms. However, as might be 
expected evolutionary divergence as well as the trypanosomes’ unique biology means that such 
paths, when finally elucidated, may well throw up unexpected surprises. What is known about 
signalling mechanisms in trypanosomes is discussed below.
1) Cell surface receptors: The only receptor that to date has been characterised to a 
molecular level is the transferrin receptor. Transferrin was identified as an essential component 
of culture medium for the bloodstream form of T. brucei, and a transferrin-binding species 
identified (Schell et al., 1991). This was discovered to be the product of the expression site 
associated gene number 6 (ESAG6). There are approximately 20 telomeric sites for the 
expression of variant surface glycoprotein genes; each site has a number of other genes 
associated with it, which are homologous between expression sites. Further analysis revealed 
that the functional receptor was a heterodimer of ESAG6 and ESAG7, attached to the plasma 
membrane by a glycosylphosphatidylinositol (GPI) anchor, located at the C-terminal of ESAG6 
(Salmon et al., 1994; Steverding et al., 1994; Ligtenberg et al., 1994). Furthermore, although the 
receptor is located in the flagellar pocket the majority is found in the lumen of the pocket, 
suggesting that the receptor may be released to bind transferrin and then re-intemalised, 
although the mechanisms involved are unclear (Salmon et al., 1994; Steverding et al., 1994).
The two genes that encode the components of the transferrin receptor are not identical between 
different expression sites (ESs) thus an in situ switch between which ES is active results in the
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expression of transferrin receptors with different affinities for transferrin from any particular 
host (Steverding et al., 1995; Borst et al., 1996; Bitter et al., 1998). A striking example is a 
single amino acid substitution that accounts for a 10-fold difference in the affinity of the 
receptor for the same transferrin molecule (Salmon et al., 1997). Furthermore, the same receptor 
isoform has large differences in affinity for transferrins from different mammalian species, and 
trypanosomes appear to undergo in situ ES switching until an optimal isoform is expressed for 
the particular mammalian transferrin (Borst et al., 1996).
Host epidermal growth factor has also been demonstrated to influence trypanosome 
growth (Hide et al., 1989) although a receptor remains to be identified. Low density lipoprotein 
(LDL) influences trypanosome growth (Coppens et al., 1988) and although it is clear that 
trypanosomes possess an LDL receptor (Coppens et al., 1991) the gene has not yet been 
identified. The best candidate appears to be a protein of approximately 145 kDa with high 
antigenic similarity to the host LDL receptor (Bastin et al., 1994). Other host-derived molecules 
that have been demonstrated to influence trypanosome growth but for which specific receptors 
have not yet been isolated include interferon y (INFy; Olssen et al., 1993), and tumour necrosis 
factor a  (TNFa; Lucas et al., 1993). These two may be considered to be antagonistic growth 
regulators, as INFy stimulates proliferation (Olssen et al., 1993) whereas TNFa, secreted from 
macrophages under stimulation by trypanosome-secreted factors (Tachado and Schofield, 1994), 
has a lytic effect. The effect of TNFa appears to be dependent on differential sensitivity of 
trypanosomes during parasitaemia, as TNFa exerts a lytic effect only during late parasitaemia 
(high parasite density).
Adenylate cyclase activity has been identified in trypanosomes, at least some of which 
is stage-regulated (Rolin et al., 1990). Four adenylate cyclase genes have also been identified in 
T. brucei, one of which is contained in the polycistronic transcription units of the VSG genes 
(Paindavoine et al., 1992) and is termed ESAG4. The ESAG4 protein is predicted to be located 
on the flagellum (Paindavoine et al., 1992) and is expressed only in the bloodstream form of the 
parasite. Genes related to ESAG4, termed GRES AGs, have been found to be expressed in both 
bloodstream and procyclic forms of T. brucei (GRESAG4.1, 4.2 and 4.3; Alexandre et al., 1990); 
comparison over the receptor domain of these molecules gives three groups: ESAG4,
GRESAG4.1 and GRESAG4.2/4.3. Analysis of the genomic organisation of the GRESAG genes 
has shown that GRESAG4.3 is a single copy gene, whereas GRESAG4.1 exists as a multigene 
family of at least 9 members all located on a 3 Mb chromosome (Alexandre et al., 1996). Within 
the GRESAG4.1 family three of the genes clustered in a tandem array while the others were 
scattered over a 300 kb region. This distribution was reflected in sequence comparisons, which 
showed the tandemly arranged genes to have greatest identity between themselves, with the 
scattered copies showing more divergence (Alexandre et al., 1996). At least several of the 
GRESAG4.1 genes are transcribed in both bloodstream and procyclic forms. Control of
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adenylate cyclase activity is cryptic; there is no evidence of G-protein involvement (Pays et al.,
1997) although the putative receptor-like structure of the trypanosome adenylate cyclases is 
quite different from that of mammalian cyclases, and may suggest activation is via 
homodimerisation following ligand binding. Activation by peptide binding to the extracellular 
domain has not been demonstrated, although tsetse fly proventricular extracts can induce 
activation (Van den Abbeele et al., 1995). There is a correlation of activation with calcium 
mobilisation in the bloodstream form (Rolin et al., 1990), although this may be coincident as the 
release of VSG is calcium-linked, and indeed all treatments that release VSG result in adenylate 
cyclase activity (Voorheis et al., 1981, 1982). Experiments with protein kinase C inhibitors 
suggests a role in both VSG release and adenylate cyclase activation, as the processes occur 
concomitantly, although evidence shows that they are not obligatorily coupled (Rolin et al.,
1996).
2) Putative cell surface receptors: Aside from those discussed above a number of cell- 
surface proteins have been identified, by the combined techniques of surface labelling and 
cloning (Pays and Nolan, 1998). The suggested function of a number of these has been as 
structural proteins, possibly associated with VSG or PARP, depending on the life cycle stage. 
Other surface proteins have been identified but are as yet not sufficiently characterised for 
putative functions to be ascribed, particularly in view of the fact that those isolated by cloning 
have not been found to have significant homology with any known genes (Nolan et al., 1997; 
Jackson et al., 1993). Those identified by techniques like catalysed surface radioiodination 
(Gardiner et al., 1983; Jackson and Voorheis, 1990) have not been characterised or the genes 
isolated.
3) G-proteins: To date, there has been no proof of the existence of functional 
heterotrimeric G-proteins in T. brucei. Putative a  and (3 subunits have been identified (Coulter 
and Hide, 1995; Lips and Pays, unpublished) that are preferentially expressed in the 
bloodstream and procyclic form, respectively. There is evidence for both stimulatory and 
inhibitory G-proteins in T. cruzi (Coso et al., 1992; Oz et al., 1994; Eisenschlos et al., 1986) but 
not T. brucei. Control of adenylate cyclase activity, described above, does not appear to be G- 
protein coupled in T. cruzi as agents known to perturb G-protein responsive cyclases do not 
affect trypanosomal adenylate cyclase activity (Torruella et al., 1986; Eisenschlos et al., 1986). 
Of the small guanine nucleotide-exchange factor proteins, a homologue of the nuclear Ran 
family has been described in T. brucei (Field et al., 1995). Three homologues of the Rab family 
of small GTPases that are involved in endocytosis have been isolated in T. brucei (Field et al.,
1998).
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4) Protein kinases: Protein kinases in eukaryotes form a large superfamily, defined as 
enzymes that use the y-phosphate of ATP or GTP to form phosphate monoesters on 
serine/threonine residues (alcohol groups) or tyrosine residues (phenolic groups). They are 
related in possessing 11 homologous kinase catalysis domains which consist in total of 
approximately 250-300 amino acids (Hanks, 1991). Phylogenetic analysis based only on the 
homologous kinase catalysis domains broadly classified kinases into four groups, which can 
then be further subdivided into families, based on homology of non-kinase catalysis domains, 
substrate specificities and modes of regulation (Hanks and Hunter, 1995). The four groups are:
1) The ACG group, which includes the cyclic-nucleotide-dependent family, the protein kinase C 
family and the (3-adrenergic family; 2) The CaMK group, which includes the families of protein 
kinases regulated by calcium and/or calmodulin; 3) The GMGC group, which includes the 
mitogen activated protein (MAP) kinase family, the cyclin dependent kinase (CDK) family and 
CDK-related kinases; 4) The ‘conventional’ protein tyrosine kinase (PTK) group, including the 
SRC family and the various families of peptide hormone receptor tyrosine kinases (RTKs).
Protein kinases that fall outwith these four groups can usually be classified as defined 
families in terms of being clearly related to each other by structure/function. It has proven 
difficult to define broader generalisations that could be used to group these kinases into a larger 
category (Hanks and Hunter, 1995). One notable type of kinase that falls outwith the four 
groups are those that display dual specificity i.e. are capable of phosphorylating both 
serine/threonine and tyrosine residues (Lindberg et al., 1992), hence the designation of the 
‘conventional’ tyrosine kinases above. Dual-specificity kinases are not closely related to the 
conventional PTKs and map throughout the protein kinase phylogenetic tree (Lindberg et al.,
1992). The completion of the Saccharomyces cerevisiae genome sequencing project has 
revealed that budding yeast has 113 kinase genes, corresponding to about 2% of the total 
number of genes. Although many of the genes discovered fall within the conventional four 
kinase groups - including cAMP-dependent kinases, Ca2+-calmodulin protein kinases, MAPKs 
and CDKs - there are no conventional protein tyrosine kinases (Hunter and Plowman, 1997). 
However, there are dual-specificity kinases and tyrosine phosphatases, as well as some kinases 
unique to budding yeast (Hunter and Plowman, 1997). The ubiquity of phosphorylation 
networks in eukaryotes from yeast to mammals strongly suggests that such networks should 
exist in trypanosomes, with a comparable percentage of the genes of T. brucei encoding protein 
kinases. Furthermore, the kinases involved could be identified as phosphorylation differences 
and differential kinase activities between life cycle stages or at different points in the cell cycle.
Difficulties in achieving good synchronisation of cultured T. brucei (chapter 1.5) has 
led investigators to concentrate on observable changes between life cycle stages. 
Phosphorylation differences have been observed in proteins between the long slender and short 
stumpy bloodstream forms (Aboagye-Kwarteng et al., 1991). Phosphorylation on tyrosine
22
residues has also been demonstrated (Parsons et al., 1991). Multiple proteins phosphorylated on 
tyrosine were detected both in the bloodstream and procyclic forms, and the patterns of 
phosphotyrosine proteins varied during the life cycle. As regards analysis of the differential 
kinase activities between life cycle stages, multiple kinase species have been detected by use of 
renaturation kinase assays (Parsons et al., 1993); phosphoamino acid analysis revealed that the 
phosphorylated residues were serine and threonine, with no phosphotyrosine. However, it 
should be noted that phosphotyrosine species were previously noted to be of very low cellular 
abundance (Parsons et al., 1991) and difficult to detect by radiolabelling.
Monoclonal antibodies raised against purified phosphotyrosine proteins has allowed the 
characterisation of two phosphotyrosine proteins, of 44 kDa and 46 kDa, that are 
phosphorylated on serine and tyrosine (Parsons et al., 1994). Transformation from the 
bloodstream to the procyclic form was accompanied by increased tyrosine phosphorylation of 
both proteins. Fractionation of trypanosome lysates by isoelectric focussing has also been used 
to characterise autophosphorylating kinases (Hide et al., 1994). This approach detected a family 
of 60 kDa and 90 kDa serine/threonine protein kinases in bloodstream form lysates; the 60 kDa 
family was capable of utilising both ATP and GTP whereas the 90 kDa family could only use 
GTP. Despite the uniformity of molecular weight the isoelectric points within the families 
varied, suggesting that they represented two sets of isoenzymes (Hide et al., 1994). A protein 
kinase C activity has also been identified in bloodstream form T. brucei (Keith et al., 1990).
Due to the difficulties of obtaining synchronous populations of any particular 
proliferative stage of T. brucei, the focus has necessarily been of the differential kinase 
activities and phosphorylation profiles between life cycle stages. However, a cell cycle 
regulated serine/threonine protein kinase activity has been reported (Gale et al., 1994). An 89 
kDa protein, named SPK89, previously identified to have activity only in proliferative forms 
(Parsons et al., 1993) was demonstrated to be specifically induced when stationary-phase 
procyclics were simulated to re-enter the cell cycle. SPK89 activity mapped predominantly to S 
phase with some residual activity in G2 (Gale et al., 1994).
Complementary to the biochemical methods is the approach of using degenerate primers 
to fish for genes. Using degenerate primers to conserved kinase catalysis domains, seven distinct 
kinase fragments were amplified from cDNA, two of which showed differential accumulation of 
transcript between life cycle stages (Hua and Wang, 1994). The full-length gene of fragment 
TbPK-Al was isolated and renamed KFR1, as it showed significant homology to the S. 
cerevisiae kinases KSS1 and FUS3, and the KFR protein was present at twice the abundance in 
the long slender bloodstream form as compared to the procyclic form (Hua and Wang, 1994).
By analogy with KSS1/FUS3 function in yeast, KFR1 may be implicated in a MAP kinase-like 
pathway in T. brucei. Another of the fragments isolated was used to isolate a full-length gene 
with significant homology to the Drosophila kinase POLO (Graham et al., 1997), named tbPLK,
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which is expressed in both bloodstream and procyclic forms. This appears to be a member of the 
POLO-hke kinase (PLK) family, hence the name; the PLKs have been implicated in mitotic 
control. A slightly different PCR-based approach is to use degenerate oligonucleotides with 
genomic DNA, isolate the whole gene and then investigate the relative transcript/protein 
presence between life cycle stages. By this approach, two protein kinase genes named NRKA 
and NRKB have been isolated, both of which are constitutively expressed through the life cycle 
(Gale and Parsons, 1993). NRKA and NRKB show homology to the NEKHNIMA subfamily over 
the catalysis domains but are probably not functional homologues as there is no homology over 
the non-catalytic regions.
Other kinase genes cloned from T. brucei include three genes related to protein kinase A 
(PKA); the genes appear to code for PKA catalytic subunits, and have been named tbPKAa, 
tbPKAfi and tbPKAy (Boshart and Mottram, 1997). TbPKAy is expressed constitutively, 
whereas the other two are expressed to higher levels in the bloodstream forms. A protein kinase 
C (PKC) activity has been defined biochemically in T. brucei (Keith et al., 1990) and a putative 
PKC gene cloned. The gene encodes a protein predicted to be 97 kDa and to have greatest 
homology to the unconventional PKCi (Selbie et al., 1993) and PKCX (Akimoto et al., 1994) 
isoforms. In addition, a number of genes related to the CDK gene family have been isolated and 
partially characterised (see chapter 1.5). Although tyrosine protein kinase activity has been well 
documented in T. brucei (see above) as yet no tyrosine kinase gene has been isolated.
5) Protein phosphatases: Reversible phosphorylation of proteins is an important 
mechanism in the cellular control of phosphorylated proteins, as at any time the balance of 
activity of any particular phosphorylated protein will depend on the balance between the relative 
activities of kinases and phosphatases that act upon that protein. There are four types of 
serine/threonine phosphatase identified from a number of species (Cohen, 1989). Based on 
sequence comparisons, types 1, 2A and 2B are members of the same gene family, whereas type 
2C is unrelated (Cohen, 1989). Tyrosine phosphatases are of receptor/transmembrane form 
(types I-V) with some non-membrane associated forms. Protein phosphatase activity has been 
documented in T. brucei (Walter and Opperdoes, 1982) and three phosphatase catalytic subunits 
have been isolated by PCR from a T. b. rhodesiense cDNA library (Erondu and Donelson,
1991). Two of the genes coded for closely related type 1 subunits, named TPP1A and TPP2A, 
the third coded for a type 2A subunit, named TPP2 (Erondu and Donelson, 1991). TPP1A and 
TPP2A have 66% and 40% amino acid identity, respectively, to mammalian phosphatase 1 and 
2A, while TPP2 has 39% and 55% amino acid identity to mammalian phosphatase 1 and 2A.
The in vivo functions of these phosphatases was indicated by treatment of procyclic-stage cells 
with okadaic acid, a specific inhibitor of type 1 and 2A phosphatases (Das et al., 1994), in 
which co-ordination of nuclear and kinetoplast cytokinesis was disrupted. A life cycle stage-
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regulated protein tyrosine phosphatase activity has been partially characterised (Bakalara et a l, 
1995a) and there is evidence for multiple protein tyrosine phosphatase activities in T. brucei 
(Bakalara et al., 1995b).
Although the evidence is fragmentary, it is clear that the basic mechanisms underlying 
signal transduction in higher eukaryotes are present in trypanosomes. The cryptic nature of some 
of these mechanisms may in time be revealed to be specific biological adaptions evolved to deal 
with the parasite’s unique biology and life cycle. The greatest success in the field of 
trypanosome signal transduction has been in the characterisation and cloning of kinase genes, 
while information on processes such as cAMP and calcium signalling remain elusive, as does 
the isolation of specific cell-surface receptors. The significant aberrations to date are the failure 
to clone a tyrosine kinase gene, despite the fact that tyrosine phosphorylation and 
dephosphorylation have been demonstrated to occur in T. brucei (Parsons et al., 1991, 1994; 
Bakalara et a l, 1995a,b) and the puzzling lack of functional G-proteins. While good progress is 
being made in identifying components of the T. brucei signalling machinery, to date not one 
single path has been mapped.
1.5: Cell cycle and differentiation in trypanosomes
The complete life cycle of T. brucei has been described (chapter 1.1). One of the 
most notable features is the alternation of proliferative and non-proliferative cell cycle forms, 
with much interest directed to the degree of coupling between progression through the cell cycle 
and differentiation processes (Matthews and Gull, 1994a,b, 1997). The study of the cell cycle in 
the proliferative life cycle stages, and of the interplay between the cell cycle and differentiation, 
has been hampered by the lack of a suitable method of inducing cell cycle arrest to achieve 
synchronous populations of life cycle stages tractable to in vitro culture. Hydroxyurea treatment 
is a suitable method for many cell types, but has been demonstrated to be unsuitable for T. 
brucei (Brun, 1980; Mutomba and Wang, 1996). Treatment with aphidicolin, an inhibitor of 
DNA polymerase, is often a useful method of introducing a Gl/S block in mammalian cells, but 
it has also been demonstrated to be unsuitable for synchronisation for T. brucei (Mutomba and 
Wang, 1996). Other chemicals have been reported to interfere with normal cell cycle 
progression in T. brucei: Okadaic acid, a highly specific, reversible inhibitor of the protein 
phosphatases PP1 and PP2A in mammalian cells (Cohen et al, 1990) was tested on procyclic 
form T. brucei (Das et al., 1994). Treatment with okadaic acid produced cells defective in 
organellar genome segregation and cytokinesis, but not M phase, resulting in multinucleate 
cells. Neither nuclear or kDNA synthesis appeared to inhibited, suggesting that okadaic acid
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acts to inhibit cytokinesis and kinetoplast division without inhibiting DNA replication (Das et 
al., 1994). The adenosine analogue (S)-9-(-3-hydroxy-2-phosphonylmethoxypropyl)adenine 
((S)-HPMPA) was tested on the T. b. brucei and T. b. rhodesiense bloodstream form (Kaminsky 
et al., 1998). As trypanosomes are incapable of purine synthesis de novo, the expected effect 
would be an inhibition of DNA synthesis and a resulting block of cells at Gl/S and in S phase. 
This is what was observed, although the effect was specific to the nucleus and kDNA synthesis 
was not affected. However, synchronisation was not possible as the lag phase to recovery was 
too long and when cells undergoing cytokinesis were detected the populations were 
desynchronised (Kaminsky et al., 1998). The CDK inhibitor flavopiridol introduces both a G l/S 
block and a G2/M block in procyclic T. b. brucei (Hassan, 1999). Partial synchrony can be 
achieved by arresting procyclic-stage cells by growing to stationary phase before inoculating to 
fresh medium (Gale et al., 1994) or by removal of fatty acid-free BSA or low-density 
lipoprotein from the culture medium (Morgan et al., 1993, 1996), but it is difficult to achieve 
acceptable reproducibility by these methods. However, by analysis of single cells and by 
methods involving mathematical analysis, it has been possible to develop a detailed picture of 
cell cycle progression in T. brucei procyclics and consequently a good range of cytological and 
morphological markers (Sherwin and Gull, 1989; Woodward and Gull, 1990; Robinson and 
Gull; 1991; Matthews and Gull, 1994b). Ten distinct morphological stages within the complete 
cell cycle of the procyclic have been described (Sherwin and Gull, 1989), allowing the exact 
positioning of any particular cell within the cell cycle. The temporal ordering of major events is 
as follows and is shown (Fig. 1.5).
1) Probasal body elongation
2) Initiation of a new flagellum by the posterior basal body
3) Generation of two new probasal bodies
4) Extension of the new flagellum, emergence from the flagellar pocket and
consequent initiation and extension of the new paraflagellar rod
5) Kinetoplast division
6) Separation of kinetoplasts by basal body segregation
7) Nuclear mitosis
8) Cytokinesis
The exact timing of stages of the events above (occurring within a cell cycle typically 
lasting 8.5 hours) have been described as points within an idealised unit cell cycle, a useful 
concept (Sherwin and Gull, 1989). Flagellar growth, DNA replication and basal body replication 
appear to be highly co-ordinated, with a very high level of spatial ordering. This would be 
expected in a highly elongate cell with a strict requirement for correct segregation of a number
26
of single organelles, the nucleus, kinetoplast, mitochondrion and flagellum (Sherwin and Gull, 
1989; Turner, 1992).
Determination of how the classical picture of four cell cycle phases - G l, M, G2, S - 
maps around the observance of these morphological events has been investigated (Woodward 
and Gull, 1990), in particular with reference to kinetoplast DNA replication ( ‘S k ’ ) and nuclear 
DNA replication ( ‘S n ’). By monitoring 5-bromo-2-deoxyuridine (BRDU) incorporation to DNA  
with use of a specific monoclonal antibody, and use of a monoclonal antibody that recognised 
the basal bodies, three periods were defined: Period C, defined as cytokinesis for the nuclear 
cycle including post-M phase and cleavage; period D, defined as the period when kinetoplast 
division is occurring (demonstrated to be achieved by basal body movement: Robinson and 
Gull, 1991); and period A, defined as the period of time when the predivision cell contains two 
kinetoplasts. Determination of these periods was important as the period between completion of 
DNA replication and cell division is more complex in T. brucei than in most cells (Woodward 
and Gull, 1990). The timings of these periods are shown expressed as points in an idealised unit 
cell cycle (Fig. 1.6).
0 0.4 0.58 0.8 0.88 1.0
______________________ I
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Fig. 1.6: Relative temporal order of events in the DNA cycles of T. brucei
The timing of events of the nuclear and kinetoplast cycles, expressed as points within an 
idealised unit cell cycle. N - nuclear cycle; K - kinetoplast cycle; S - period of DNA replication; 
M - nuclear mitosis; D - kinetoplast division; C - cytokinesis period for the nuclear cycle 
(including post-M phase and cleavage); A - period of time in which the predivision cell contains 
two kinetoplasts.
SN is longer than SK by approximately 30 mins, although this may simply reflect the 
proportionally lesser quantity of kDNA to replicate. However, G2K is entered about 45 mins 
before G2N, therefore the replicative phases overlap, showing a non-co-ordinate start and finish 
to the two S phases. The termination of SK before Sn argues for intra-organelle control of S 
phase i.e. SK can terminate in a cellular environment where SN continues, leading to a ‘licensing 
factor’ theory (Blow and Laskey, 1988). In this, the hypothetical factor is associated with DNA 
until it is displaced by replication, marking DNA as replicated and thus preventing more than 
one S phase per cell cycle. Period D represents the portion of the overall cell cycle in which the 
kinetoplast has an elongated, bilobed appearance. Periods C and A are lengthy, representing the
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time required for the post-M phase nuclei and kinetoplasts to migrate to the appropriate 
positions for division. Interestingly, the relative positions of D and M vary according to species. 
For example, for Crithidia luciliae M occurs before D (Van Assel and Steinert, 1971). This may 
be a function of morphology as unlike the highly elongate T. brucei, Crithidia cells are more 
rounded and the nuclei, kinetoplasts and basal bodies assume a bilateral symmetry soon after 
organelle duplication. By contrast, in T. brucei the post-duplicative arrangement is more 
tandem, requiring extensive reorganisation to produce bilateral symmetry (Woodward and Gull, 
1990). The close temporal association of DNA replication and basal body replication as well as 
precise organelle spatial positioning suggests a point where synchrony of organelle cycling 
might be achieved (Woodward and Gull, 1990; Matthews and Gull, 1994a,b; Robinson et al.,
1995).
Given the nature of the parasite’s periodic cell cycle arrest and proliferation, and the 
fact that two of these arrested forms - the short stumpy and the metacyclic - are the infective 
forms that facilitate transmission between vectors and which begin differentiation to the next 
life cycle stage immediately after transmission, the next logical question is: To what extent, if 
any, is there interplay between the cell cycle and differentiation? Most studies have dealt with 
the differentiation most tractable to study, that from the short stumpy form to the procyclic 
form. This differentiation - often referred to as transformation - is coincident with re-entry to the 
cell cycle and progression through one full turn of the cell cycle, although the two processes can 
be uncoupled (Matthews and Gull, 1994b). The two most obvious markers for the 
transformation is the loss of the VSG coat which characterises the mammalian bloodstream 
forms and the appearance of the procyclic-specific procyclin protein, or PARP (procyclic acidic 
repetitive protein), as the dominant coat protein (Roditi et al., 1989; Ziegelbauer et al., 1993). 
Analysis of VSG loss and PARP appearance in the transformation of bloodstream to procyclic 
forms supported the hypothesis that there is a window in the cell cycle in Gl (or possibly GO) 
where the parasite is responsive to the differential trigger(s) that induce differentiation to the 
procyclic form, and that stumpy form cells are arrested in that window whereas slender form 
cells are not (Matthews and Gull, 1994a,b). Therefore the general picture is of the appearance of 
a mechanism that tends to arrest cells in the G l/0 window as the parasitaemia progresses, 
leading to cell cycle arrested cells that undergo morphological and gene expression changes. 
Transfer to the tsetse fly and exposure to induction factor(s) releases the cell cycle arrest and 
cells re-enter the cell cycle and concomitantly complete the differentiation to the procyclic form. 
The nature of the induction factor(s) in vivo are not understood. The commitment to 
differentiation has also been examined (Matthews and Gull, 1994b). This provided evidence that 
between 0-4 hours post-induction an irreversible commitment to differentiation is made. Drug 
treatment showed that DNA synthesis could be halted but procyclic-specific marker proteins 
still appeared; therefore cell cycle progression and differentiation are coincident processes that
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can be uncoupled, at least after the induction of differentiation (Matthew and Gull, 1994b).
Analysis of the relative importance of the two factors in the in vitro transformation from 
stumpy to procyclic form - temperature shift and the presence of c/s-aconitate - has been 
addressed (Matthews and Gull, 1997). The presence of cfs-aconitate was essential for the 
triggering of all the differentiation changes - both antigenic markers like VSG loss and PARP 
appearance, as well as morphological changes - and was independent of the temperature. By 
contrast, re-entry to a proliferative cell cycle could only be triggered by the combined action of 
c/s-aconitate and shift from 37°Cto 27°C (Matthews and Gull, 1997). The mechanism of 
temperature sensitivity is unknown, but this data provided evidence that in the absence of 
artificial drug treatment differentiation and cell cycle re-entry and progression are separable 
pathways, which are nevertheless in vivo precisely coincident processes controlled by cellular 
commitment in parallel, by unknown factor(s) and temperature shift (Matthews and Gull, 1997; 
Matthews, 1999).
The mechanism of induction of long slender bloodstream to stumpy form transformation 
has been studied in detail (Vassella and Boshart, 1996; Vassella et al., 1997). The pleomorphic 
long slender bloodstream form, above a certain density, exhibits cell cycle arrest and transforms 
to the stumpy form (Vassella and Boshart, 1996). It was demonstrated that this was not due to 
the depletion of essential culture medium factor(s) or to cell-cell contact signalling, but to a 
stumpy inducing factor (SIF) that was accumulating in the medium, that was heat-stable and 
time-stable (Vassella et al., 1997). Slender cells arrested by SIF have 1 nucleus and 1 
kinetoplast, by cytometry were demonstrated to be in Gl (or GO), and differentiated 
synchronously to the procyclic form with the same kinetics as stumpy cells purified from whole 
blood. The cell cycle arrest appears to precede the phenotypic changes. The monomorphic strain 
MITat 1.2 did not respond to SIF, although conditioned medium from MITat 1.2 culture could 
transform pleomorphic strains, therefore suggesting the existence of a specific signalling 
pathway that couples density sensing to differentiation. Use of cAMP agonists and 
phosphodiesterase inhibitors demonstrated the involvement of the cAMP signalling pathway 
(Vassella et al., 1997). At present it is not known whether SIF is a single or multifactor signal, a 
specifically synthesised pheromone-like factor or a catabolite. T. brucei is known to contain a 
family of unconventional adenylate cyclases (Alexandre et al., 1990; Painavoine et al., 1992; 
Alexandre et al., 1996) therefore the scenario of SIF as a specific ligand for an adenylate 
cyclase, activating a cAMP pulse that initiates cell cycle arrest, is plausible. Unfortunately, little 
is known about the downstream effectors of cAMP signalling in trypanosomatids, although in 
the development of the stumpy form immediate effects downstream of the cAMP pulse are 
probably mediated by protein kinase A. Analysis of stage-regulated and differentiation-enriched 
transcripts in the transformation from the stumpy to the procyclic form has isolated two 
previously identified early transcripts - PARP and histone H2B - and two novel transcripts
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(Matthews and Gull, 1998). One encoded a protein with similarity to the Leishmania major 
protein LACK (Leishmania activated protein kinase C receptor; Mougneau et al., 1995; Julia et 
al., 1996), the other encoded a protein with significant homology to the polypeptide sequence 
derived from purification of the Crithidia fas ciculata cytochrome c oxidase complex (Matthews 
and Gull, 1998). Rapid downregulation of VSG and upregulation of PARP has previously been 
characterised (Pays et al., 1993) as has the temporal expression of histone H2B (Ersfield et al.,
1996).
The detailed definition of progression of T. brucei through the cell cycle, at least in the 
procyclic form, and identification of good morphological and cytological markers, means that 
study of how cell cycle and life cycle interplay will be greatly facilitated. The definition of 
nuclear and kinetoplast cycles with at least some degree of co-ordination and some evidence of 
intra-organelle control raises interesting questions about the molecular mechanisms 
underpinning cell cycle progression. The existence of the cell cycle arrested stages and the 
demonstration that in the stumpy to procyclic transformation, cell cycle and differentiation can 
be uncoupled, raises questions about the tsetse to mammal transition. How are the nuclear and 
kinetoplast cycles co-ordinated and how does the cell achieve intra-organelle control? Does the 
proventricular to metacyclic differentiation also depend on a specific induction factor, and can 
cell cycle be decoupled from differentiation in this case? What are the signalling pathway(s) 
involved in a cAMP-mediated cell cycle arrest, and what are the effectors that change patterns 
of gene expression and produce phenotypic changes? The unique biology of the African 
trypanosome suggests that the answers to this question may be as unexpected as they are 
interesting.
While little is known about the signalling pathways involved in cell cycle control and 
differentiation in T. brucei, an increasing number of genes homologous to the genes that 
underpin cell cycle control in higher eukaryotes are being isolated from trypanosomatids. The 
first CDK gene isolated from a kinetoplastid was the cfCRK gene from Crithidia fasciculata 
(Brown et al., 1992). This encoded a CDC2-like kinase that contained insertions of 66 and 79 
amino acids between kinase catalysis domains VIb and VII, and X and XI, respectively; these 
insertions had not been found in CDC2-related genes from any other organism. A number of 
these CDC2-related kinase (CRK) genes have been isolated by PCR from T. brucei and 
Leishmania mexicana. The ImmCRKl gene was isolated during an unrelated experiment in 
screening for proteinases (Mottram et al., 1993). The ImmCRKl gene encoded a 34 kDa protein 
containing residues at homologous positions to those residues known to be critical in the 
regulation of CDKs, such as the Tyrl5 and Thrl61 residues (Pines, 1995). In addition, it 
contained all eleven required kinase catalysis domains and also possessed a modified PSTAIR 
box, containing only one amino acid substitution compared to human CDK1 (Mottram et al., 
1993; Mottram, 1994). LmmCRKl was demonstrated to possess histone HI kinase activity,
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showing stage-specific regulation: The kinase was active in promastigotes, whether in 
logarithmic growth or stationary phase, but not active in the proliferative amastigote stage, 
suggesting a role in differentiation rather than cell cycle progression (Mottram et al., 1993). It 
was unable to complement an Schizosaccharomyces pombe CDC2 temperature-sensitive mutant. 
As the protein was detected to equivalent levels in all three life cycle stages, the evidence 
pointed to post-translational regulation of activity, consistent with the control of CDK activity 
observed in higher eukaryotes (Solomon et al., 1993; Mottram et al., 1993; Pines, 1993, 1995; 
Morgan, 1995). LmmCRKl is essential, as judged from chromosome plasticity resulting from 
targeted gene disruption to generate null mutants (Mottram et al., 1996). The tbCRKl gene was 
isolated by library screening, using a fragment produced by PCR from a T. brucei cDNA library 
using degenerate primers. TbCRKl was found to have 73% identity to ImmCRKl (Mottram and 
Glasssmith, 1995). The tbCRKl protein possess the required kinase catalysis domains and 
residues involved in phosphorylation, and also has a degenerate PSTAIR box, with 2 amino acid 
substitutions. Ectopic expression of tbCRKl from an episomal vector can at least to some degree 
fill in the function of ImmCRKl, as the leishmanial gene can be deleted in this case (Mottram et 
al., 1996). Promastigotes null for ImmCRKl with tbCRKl expressed episomally grow with 
normal kinetics as compared to wild-type, although when induced to transform to amastigotes 
growth kinetics do not match that of wild-type promastigotes transformed to amastigotes 
(Mottram et al., 1996). The inference is that tbCRKl will perform a homologous function in 
trypanosomes and that it will also be an essential gene.
The lmmCRK3 gene was also isolated by the approach of library screening following 
amplification of a gene fragment by PCR from cDNA. The lmmCRK3 protein has six amino 
acid substitutions in the PSTAIR box as compared to human CDK1, and is expressed throughout 
the life cycle (Grant et al., 1998). Relative transcript abundance between life cycle stages for 
promastigote:metacyclic:amastigote is 5:1:1, although this does not accurately reflect protein 
abundance and kinase activity; lmmCRK3 histone HI kinase activity is highest in promastigotes, 
high in amastigotes and very low in the cell cycle arrested metacyclics (Grant et al., 1998). This 
corresponded well to the previously documented histone HI activity profile of SUC-binding 
CDC2-related kinase (SBCRK; Mottram et al., 1993). SBCRK was defined as a kinase activity
Q i  r p i  p t / p i
that bound the S. pombe protein p l3  .A  leishmanial homologue of SUC1, p l2  , was 
isolated (Mottram and Grant, 1996) that showed 70% identity to human CKS1 and 44% identity 
to S. pombe SUC1. The lmmCKSl protein was shown to bind a strong histone HI kinase activity 
from promastigotes and amastigotes but not metacyclics, mirroring the profile of SBCRK and 
lmmCRK3 (Mottram and Grant, 1996; Grant et al., 1998). Depletion of ImmCRKl did not 
change this lmmCKSl-associated activity, indicating that it was not responsible for SBCRK 
(Mottram and Grant, 1996). Depletion of lmmCRK3 lowered the lmmCKSl-associated SBCRK 
activity by over 50%, indicating that lmmCRK3 is the major kinase subunit of SBCRK (Grant et
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al., 1998). As SBCRK is active in the proliferative stages of Leishmania but not the 
nonproliferative, the data suggests that lmmCRK3 is a good candidate for a functional 
CDK1/CDC2 homologue. Deletion of lmmCRK3 gave similar results to attempted deletion of 
ImmCRKl, showing it to be an essential gene, as would be expected (Hassan, 1999). The 
tbCRK3 gene was isolated in the same manner as lmmCRK3, by PCR and library screening 
(Mottram and Glasssmith, 1995). It encodes a kinase with 78% identity to lmmCRK3, and like 
lmmCRK3 it contains 6 amino acid substitutions in the PSTAIR box and was unable to 
complement a yeast mutant (Mottram, 1994; Grant et al, 1998). Targeted deletion of tbCRK3 
generated a very small population of cells that appeared to be severely compromised in their 
ability to faithfully segregate organelles during cytokinesis (Glasssmith, 1997). Spindle 
formation was badly affected, with uneven distribution of nuclei and kinetoplasts leading to a 
variety of daughter cell types i.e. 2k In, lk  2n, 2k 2n, in addition to anuclear cells lk  On (termed 
‘zoids’).
Library screening at low stringency with the ImmCRKl gene isolated the tbCRK2 gene 
(Mottram and Glasssmith, 1995). In common with the expanding family of CRK genes, tbCRK2 
also encoded a kinase with the conserved features mentioned above, although the PSTAIR box 
contained four substitutions. It also possessed an N-terminal extension of 41 amino acids as 
compared to tbCRKl, human CDK1 and CDK2. The tbCRKl gene was found to be unable to 
complement an S. pombe CDC2 mutant (Mottram, 1994). A fifth member of the family, 
tbCRK5, was isolated as part of the EST sequencing project and shows highest identity to a 
mammalian meiosis-specific kinase (Van Hellemond and Mottram, unpublished). The function 
of tbCRK5 is unknown, although it is not localised to the nucleus but apparently associated with 
elements of the cytoskeleton.
In addition to CDK homologues, three cyclin homologues have been isolated from T. 
brucei. The CYC1 gene was isolated by PCR using degenerate primers (Affranchino et al.,
1993) and described as a mitotic-type cyclin. However, other data has suggested a role in the 
transformation from the short stumpy bloodstream to procyclic form (Hua et al., 1997). Two 
further cyclins, CYC2 and CYC3, were isolated through complementation of a Saccharomyces 
cerevisiae G1 cyclin mutant by a T. brucei cDNA library (Van Hellemond et al., 1999). Putative 
cyclins have not been isolated from any other trypanosomatid to date, although the T. cruzi 
CRK1 (which is homologous to ImmCRKl and tbCRKl) has been demonstrated to bind 
mammalian cyclins A, D3 and E in vivo when expressed in COS-7 cells (Gomez et al., 1998). 
CYC2 has been demonstrated to have a functional association with tbCRK3 (Van Hellemond et 
al., 1999), the first evidence of a functional CRK-cyclin pair in trypanosomatids.
As the trypanosomatid equivalent of CDKs, the CRKs are likely to represent the 
endpoint of signalling pathways, at least as far as cell cycle control is concerned. In addition, 
they may represent integration points for cross-talk between the cell cycle and differentiation
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events concerned with life cycle progression. In this study molecular genetics and biochemistry 
were used to attempt to analyse the function of CRK2 and to further analyse the function of 
CYC1. In addition, in this study the isolation and partial characterisation of a novel trypanosome 
CRK, CRK4, is reported; tbCRK4 has a high degree of sequence identity to the C. fasciculata 
CRK gene.
1.6: Molecular genetic analysis
The life cycle stages of T. brucei that are amenable to molecular genetic analysis are 
diploid. African trypanosomes are the only kinetoplastid in which sexual genetic exchange has 
been demonstrated to take place (Tait, 1990), and that appears to occur at low frequency during 
passage through the tsetse fly. The molecular karyotyping of different strains is in progress; the 
characterisation of chromosomes through increasing abundance of syntenic molecular markers 
(Melville et al., 1998) is providing information on the genomic arrangement of T. brucei. 
Characterisation of kinetoplastid chromosomes recently took a step forward with the complete 
sequencing of the Leishmania major Friedlin chromosome 1 (Myler et al., 1999), which showed 
an unusual and highly distinctive distribution of protein coding genes; the first 29 genes were all 
located on one DNA strand, and the following 50 genes were located on the other strand. This is 
consistent with the polycistronic arrangement seen in smaller regions (Swindle and Tait, 1996) 
but is the first known case of a head-to-head polycistron arrangement that spans an entire 
chromosome with absolute strand polarity. It will be interesting to see if this is a general feature 
of Leishmania, and whether other kinetoplastids - T. brucei included - also display this type of 
gene organisation.
As the life cycle stages of T. brucei that can be cultured are diploid, the well-established 
reverse genetic approach of studying gene function by targeted gene disruption is a feasible tool. 
Stable transfection of trypanosomes with the neomycin phosphotransferase (NEO) gene into the 
tandem tubulin locus was demonstrated to yield G418 resistant clones (ten Asbroek et al.,
1990). Transfection was more efficient with linearised DNA than with circular constructs, with 
longer regions of the tubulin locus in the targeting construct, and appeared to occur by 
homologous recombination (ten Asbroek et al., 1990). Other data supported this (Lee and Van 
der Ploeg, 1990; ten Asbroek et al., 1993). In trypanosomes episomal constructs are not well 
maintained and there appears to be a strong preference for integration (ten Asbroek et al., 1993) 
although later studies generated more stable autonomously replicating episomes (Patnaik et al., 
1993; Patnaik, 1997) in which it was shown that episomes were only maintained if they 
contained transcriptional promoters. Analysis of targeted gene disruption (Eid and Sollner- 
Webb, 1991a,b) confirmed that gene replacement occurs by homologous recombination, and
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that recombination was initiated by a crossover event between the linearised end of the 
transfecting DNA and a homologous region in the host genome. There are, however, problems 
with this straightforward approach resulting from the general plasticity of parasite genomes. It 
has been demonstrated in Leishmania that preservation of essential genes often occurs by the 
formation of genomic tetraploids, or aneuploids that are trisomic for the locus in question (Cruz 
et al., 1993). In addition, relatively large chunks of chromosomes can apparently be translocated 
into other chromosomes (Dumas et al., 1997). There is relatively little data on similar processes 
in trypanosomes. A number of genes suitable for use as selectable markers have been described, 
most of which were first used as selectable markers in Leishmania. Those used in these studies 
are the hygromycin phosphotransferase (.HYG) gene, which confers resistance to the antibiotic 
hygromycin B (Lee and Van der Ploeg, 1991), the bleomycin (BLE) gene that confers resistance 
to the DNA-binding aminoglycoside phleomycin (Souza et al., 1994), the puromycin 
acetyltransferase (PAC) gene which confers resistance to the glycopeptide puromycin 
(Freedman and Beverley, 1993), and the streptathricin acetyltransferase (SAT) gene that confers 
resistance to the antibiotic nourseothricin (Joshi et al., 1995).
There are no easily manipulated and maintained episomal constructs for use of ectopic 
gene expression in T. brucei, as there is in Leishmania (LeBowitz et al., 1990; Kelly et al.,
1992). However, systems utilising stable transfection via homologous recombination, with 
inducible expression of the subject gene and resistance marker allowing ectopic expression and 
selection, have began to address this issue in T. brucei (Wirtz and Clayton, 1995). The pHD 
vector series initially consisted of a modified PARP promoter that contained the operator region 
of the E. coli tetracycline resistance operon along with the appropriate 5’ and 3’ processing 
elements, linked to a copy of the BLE gene. The second component of the system was a T. 
brucei cell line that contained a constitutively expressed copy of the tetracycline repressor 
protein gene integrated into the a/|3-tubulin gene array (Wirtz and Clayton, 1995). Following 
cloning of the subject gene into the pHD vector, transfection was followed by selection in the 
presence of phleomycin and tetracycline; the tetracycline bound the repressor protein, releasing 
repression of the modified promoter and allowing transcription of the subject gene and the BLE 
gene, with the phleomycin then selecting for stable recombinants. However, this system does 
not allow for the expression of toxic gene products. A later series of vectors (Biebinger et al.,
1997) corrected this fault by decoupling the control of expression of the resistance marker 
(rendering expression constitutive) from the inducible expression of the subject gene. In 
addition, the selectable marker was changed from BLE, which operates in a stochiometric 
binding fashion, to HYG, which operates enzymatically, thus helping to reduce background 
(Biebinger et al., 1997). This system therefore provides an ideal tool for the expression of 
modified dominant negative alleles, and for overexpression of native alleles. In addition, 
expression of epitope-tagged dominant negative or wild type alleles may aid in elucidation of
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gene function (example: Mottram et al., 1996; Grant et al., 1998). In parallel with a detailed 
description of the trypanosome cell cycle, an increase in the cytological and morphological 
markers available, and progress in the understanding of differentiation processes in 
trypanosomes and how these are linked to cell cycle progression (section 1.5), such systems will 
allow for greater dissection of the precise roles of trypanosome CRK and cyclin genes, 
particularly in cases where targeted deletion cannot produce a null genotype/phenotype.
The aims of this project were an investigation of the mechanisms of cell cycle control in 
T. brucei, specifically:
1) Analysis of tbCRK2 gene function in procyclic-stage cells by targeted gene 
disruption.
2) Biochemical characterisation of tbCRK2 through the use of specific antibodies and 
the tetracycline inducible expression system.
3) Analysis of the tbCYCl gene function in procyclic-stage cells by targeted gene 
disruption.
4) Biochemical characterisation of tbCYCl through the use of specific antibodies.
5) Isolation and characterisation of the tbCRK4 gene and tbCRK4 protein.
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Fig. 1.1: Life cycle of T. brucei
The complete life cycle of T. brucei. Metacyclics are injected to the vascular system of a 
mammal (a), differentiate to the long slender form and divide by binary fission (b), then 
transform via the intermediate form (C) to the stumpy form (d) which are ingested by the tsetse 
during a bloodmeal. In the tsetse midgut the parasite divides as the procyclic form, transforms to 
the nonproliferative proventricular mesocyclic (e) and then migrates to the salivary glands.
Here, the epimastigote form is assumed (f) and further division occurs before transformation to 
the mature, mammalian-infective metacyclic form (g). Taken from Cox, 1983.
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Fig. 1.2: Schematic of the Schizosaccharomyces pombe cell cycle 
RUM1 inhibits any CDC2-CDC13 still present after cytokinesis, and continues to inhibit 
CDC2-CDC13 complexes as they form, as CDC 13 levels rise throughout G l. CIG2 
levels rise, and forming CDC2-CIG2 complexes are inhibited by RUM1. At a threshold point 
near START, CDC2-CIG2 acts to inhibit RUM1; the cell passes START and progresses through 
S phase, with CDC2-CDC13 held inactive by WEE1 Tyrl5 phosphorylation. In late G2 the 
CDC25 phosphatase is activated, and in turn activates CDC2-CDC13, while WEE1 is 
inactivated. CDC2-CIG2 may have functions in S phase. CDC2-CIG1 has as yet undefined 
functions in M phase.
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Fig. 1.3: Schematic of the Saccharomyces cerevisiae cell cycle
Near the end of M phase the CLB1/2 cyclins are destroyed and the inhibitory protein SIC1 and 
the cyclin PCL9 are induced by SWI5. CDC28-PCL9 is greatest at the M-GO transition. Growth 
signals induce CLN3 expression but SIC1 inhibit the activity the CDC28-CLN3 complexes that 
form. After a threshold has been reached, CDC28-CLN3 induce CLN1/2 via SBF, and CDC28- 
CLN1-3 initiates SIC1 destruction. PH085-PCL1/2 may also do this. Later in G1 CLN is 
downregulated and CDC28-CLN1/2 induce CLB5/6 via MBF. CDC28-CLB5/6 mediate entry to 
S phase, and as CLB5/6 expression wanes, CLB3/4 rises and CDC28-CLB3/4 moves the cell 
through S phase. CLB1/2 in induced in G2, and active CDC28-CLB1/2 drives the cell into M 
phase. CLB1/2 destruction at the end of M phase resets the cell cycle. CDC28 is phosphorylated 
on Thrl67 by CAK1/CIV1 for activity regardless of cyclin partner.
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Table 1: Mammalian CDKs and cyclins.
Cyclin Associated CDK Function
A CDK1, CDK2 S-phase entry and progression, M phase
Bl-3 CDK1 M phase entry and exit
C CDK8 Transcriptional regulation, Gl-S transition
Dl-3 CDK4,CDK6 Gl-S transition
E CDK2 Gl-S transition
F ? Unknown
D2 CDK5 DNA damage response?
H CDK7 CDK activation and transcriptional 
regulation
I ? Unknown
K CDK9 Transcriptional regulation?
Tl-3 CDK9 Transcriptional regulation
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Fig. 1.4: Schematic of the metazoan cell cycle
Cells in early G1 have no mitotic-type cyclins, hence CDK1 is inactive. Upon mitogenic 
stimulation, cyclin D is upregulated, binds CDK4/6 and drives the cell past the restriction point 
via pRB/E2F-mediated induction of late G1 and S phase genes, including cyclin E and cyclin A. 
As the restriction point is passed cyclin D is destroyed, providing rapid feedback to limit the 
influence of CDK4/6-cyclin D. CDK2-cyclin E complexes form and participate in a positive 
feedback loop to maintain pRB inactivity and hence E2F function. CDK3 is active at the Gl-S 
transition. Cyclin E is destroyed as the cell enters S phase, and CDK2 instead complexes with 
cyclin A, which is synthesised in late G l. CDK2-cyclin A negatively regulates the activity of 
E2F. Rising levels of cyclin B mean the CDKl-cyclin B complexes begin to form at the end of S 
phase and in G2, and CDK7-cyclin H phosphorylates Thrl61, but the complex is held inactive 
by Thrl4 phosphorylation by MYT1 and Tyrl5 phosphorylation by WEE1. The CDC25 
phosphatase is held inactive during much of G2, possibly by the action of phosphatase PP1. In 
late G2 both MYT1 and WEE1 become hyperphosphorylated and inactivated. PP1 activity falls 
in parallel with a sharp increase of phosphorylation of CDC25, and the active CDC25 
dephosphorylates CDKl-cyclin A/B complexes on Thrl4 and Tyrl5, activating the complexes 
and driving the cell into M phase. Cyclin A and, later, cyclin B are destroyed during M phase, 
and both newly formed daughter cells re-enter Gl with inactive CDK1.
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Fig. 1.5: Schematic representation of the T. brucei cell cycle
Diagram of the morphological changes occurring in the cytoskeleton of procyclic form T. 
brucei. The stage I cell is newly formed. In the stage II cell probasal body extension has 
occurred, and in the stage HI cell two new probasal bodies have formed and elongation of the 
daughter flagellum has begun. In the stage IV cell the daughter flagellum has emerged from the 
flagellar pocket, and in the next stage the basal bodies begin to move apart before the daughter 
flagellum is full-length. Mitosis has initiated in the stage VI cell, and by stage VIIM  phase has 
progressed to the point where the nucleus is elongate. M phase is complete in the stage VIE cell; 
one nucleus lies between the two basal bodies, the other anterior to both basal bodies. In the 
stage IX cell the cleavage furrow has initiated and by the final defined stage, X, fission is almost 
complete, with the two daughter cells lying opposed to each other and joined only by their 
extreme posterior regions. Taken from Sherwin and Gull, 1989.
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CHAPTER 2: MATERIALS AND METHODS
2.1 General materials and methods
2.1.1: Growth and handling of parasites
T. b. brucei Swiss Tropical Institute of Biology strain 247 (STIB 247) was used 
throughout, except where specifically stated otherwise. For the CRK2 expression experiments 
the strains used were transgenic clonal isolates derived from Antat 1.1 ( ‘360’ cell line) and 
STEB 427 Mitat 1 ( ‘449’ cell line), for the pHD430 and pHD675 vector work, respectively.
Procyclic form STIB 247 were grown in SDM-79 medium (GibcoBRL) supplemented 
with 10% foetal bovine serum (GibcoBRL) at 27°C (Brun and Schonenberger, 1979). 
Subpassage was typically done by inoculating fresh medium to a cell density of 5x 105 cells 
ml'1. Antibiotics used for the selection of transgenic procyclics were as follows, used at the 
final concentrations in culture: Hygromycin (Sigma) at 50 pg ml'1, phleomycin at 20 pg m l1, 
nourseothricin (W. Werner, HKI Jena) at 50 pg ml'1, puromycin (Sigma) at 10 pg ml'1. 
Tetracycline HC1 (Sigma) used for the induction of expression of cloned genes from the pHD 
constructs (Wirtz and Clayton, 1995; Biebinger et al., 1997) was used at various concentrations 
ranging from 0.2 ng ml'1 to 10 ng ml'1. Antibiotics were kept at 4°C once made in solution and 
were discarded after one month.
Harvesting of the procyclic form was done by centrifugation at 600g for 10 min at room 
temperature. Culture medium was aspirated and the cell pellet resuspended in an equivalent 
volume of lx  phosphate buffered saline (PBS) pH 7.2. Subsequently, the cells were spun as 
before and the PBS decanted. For some applications the PBS wash was repeated to ensure 
lower contamination of protein from the culture medium.
Purification of bloodstream form parasites was performed according to the protocol of 
Lanham, 1968, 1970. Following test bleeds and cell counts, to calculate the parasitaemia and 
thus determine whether cell type was predominantly of the long slender bloodstream form or 
enriched in the short stumpy bloodstream form, the mice were killed and exsanguinated. Whole 
blood was spun at 300g for 12 min at 4°C, and the serum was discarded. The trypanosome 
pellet, sitting on top of the erythrocytes, was then carefully resuspended in 2-3 ml of phosphate 
saline glucose buffer (PSG) pH 8.05, so as to disturb the erythrocytes as little as possible. The 
resuspended trypanosomes were transferred to a fresh tube and applied to a pre-prepared 
column of lOx bed volume of the sample of DE52 anion exchange resin, pre-equilibrated with 
PSG pH 8.05. The column was washed with PSG pH 8.05 until the eluate ran cloudy with 
eluted trypanosomes, which was collected. Samples were removed for cell counts and slides,
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and the eluted cells were spun at 500g for 12 min at 4°C. Following aspiration of the buffer, cell 
pellets were resuspended in 2-3 ml of PSG and aliquoted to eppendorfs; these were spun briefly 
at maximum speed in a bench microfuge to pellet the cells, and following aspiration of 
supernatant the pellets were kept at -80°C until use.
Cell counts were performed in an improved Neubauer chamber.
Cryopreservation of procyclics was as follows: A small culture, typically 10 ml, was 
grown to midlog phase, approximately 6x 106 cells ml'1. Cells were spun at 600g for 10 min at 
room temperature and the supernatant aspirated. The cell pellet was resuspended to 6x 107 cells 
ml'1 in complete SDM-79 with 5% DMSO. 500 pi aliquots were transferred to 1 ml cryotubes 
(Nunc) and the tubes were wrapped in cotton wool, placed in a polystyrene box and kept at - 
80°C overnight. The next day the tubes were transferred to liquid nitrogen long-term storage.
On removal from liquid nitrogen tubes were allowed to thaw at room temperature before the 
contents were transferred to 4.5 ml complete SDM-79 medium with appropriate antibiotics, 
prewarmed to 27°C.
2.1.2: Transfection and cloning of procyclics
Transfection of procyclic form T. b. brucei STIB 247 was carried out as described by 
Sherman, 1991. Cells were grown to 6x 106 cells ml'1 and harvesting by centrifugation at 300g 
for 20 min at room temperature. Cell pellets were resuspended to 6x 107 cells ml'1 in 
Zimmermans post fusion medium (ZPFM) and spun as before. Supernatant was aspirated and 
the pellets again resuspended to 6x 107 cells ml'1 in ZPFM. 500 pi aliquots of resuspended cells 
were dispensed to 0.4 cm cuvettes (BioRad) and 5-50 pg plasmid DNA added and mixed in by 
gentle swirling. Each cuvette was then pulsed twice at 1.5 kV, 25 pF, in a Gene Pulser 
(BioRad) before being immediately removed to 4.5 ml complete SDM-79, prewarmed to 27°C. 
Transfection cultures were then incubated at 27°C for 6-12 hours to allow the cells to recover 
from electroporation before appropriate antibiotics were added and the cultures diluted to 10 
ml, and cloned if so required.
Cloning of procyclic form cells was done by the semisolid plate method (Carruthers 
and Cross, 1992). Conditioned medium was made by growing wild-type STIB 247 procyclics to 
approximately lx 107 cells ml'1 before centrifugation at 900g for 10 min to pellet the cells. The 
supernatant was decanted and centrifuged twice more as previously. The final supernatant was 
decanted and frozen at -70°C for several weeks, or kept at 4°C for 1-3 days, until required. A 
lOx suspension of low melting point type VII agarose (Sigma) was prepared and autoclaved, 
and then remelted by incubation in a 50°C waterbath. SDM-79 medium containing 20% FBS, 
20% conditioned medium and 7.5 pg ml'1 haemin was prepared, filter sterilised, temperature
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equilibrated in the same waterbath and added to the agarose. Final agarose concentration was 
0.65%. After addition of appropriate antibiotics and thorough mixing 20 ml aliquots were 
poured into 9 cm Petri dishes. Plates were left to solidify for 1 hour and were dried in the TCR 
flow hood for exactly 1 hour before being spread with 100 pi of a suspension of transfected 
cells or control cells. Plates were incubated standing upright at 27°C until colonies started to 
appear (approximately 2 weeks). Colonies were lifted to 1 ml prewarmed complete SDM-79 
medium, with appropriate antibiotics, using a sterile cell scraper.
2.2 Molecular materials and methods
2.2.1: E. coli strains
E. coli strain XL 1-Blue (Stratagene) was used throughout for cloning, growth and 
general maintenance of plasmid DNA. For AFIXII work E. coli strain LE392 (Stratagene) was 
used. For the expression of recombinant histidine-tagged proteins E. coli strain M15[pREP4] 
(Qiagen) was used. For the expression of recombinant GST fusion protein the protease- 
deficient E. coli strain BL21 (Pharmacia Biotech) was used.
For short-term maintenance bacteria containing plasmid DNA were streaked to LB 
plates with appropriate antibiotics. Following overnight incubation at 37°C plates were kept at 
4°C for up to one month, with individual colonies being picked with sterile picks to liquid LB 
medium as required.
For long-term maintenance individual colonies of bacteria containing plasmid DNA 
were inoculated to 3 ml LB with appropriate antibiotics and incubated at 37°C overnight with 
shaking at 200-250 rpm in a rotary shaker incubator. Approximately 16 hours later 1 ml of each 
culture was mixed with 1 ml of sterile LB containing 40% glycerol and 2% peptone, and this 
stabilate kept at -80°C. To safeguard plasmid maintenance, small-scale plasmid ‘minipreps’ 
were also made and kept at -20°C.
Bacteria were cultivated in LB broth with appropriate antibiotics in a rotary 37°C 
incubator; good aeration was ensured by not exceeding 20% of the flask volume with culture. 
Except in the case of cultures for plasmid minipreps, generally a small saturated overnight 
culture was used to inoculate a larger culture the next day, typically at a ratio of 1:100. This 
was the method used for midiprep cultures, and cultures for recombinant protein expression.
2.2.2: Plasmid isolation
Isolation of plasmid DNA from bacteria was effected using a variety of commercially 
available plasmid preparation kits. Small scale plasmid preparations - ‘minipreps’ - were done
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using the WIZARD miniprep kit (Promega) or the Tip20 kit (Qiagen). Briefly, cell pellets were 
resuspended in TRIS buffer containing EDTA and RNaseA. Alkaline lysis of the bacteria was 
effected by addition of an NaOH solution containing SDS, followed by neutralisation with an 
acidic solution of potassium acetate to precipitate chromosomal DNA and cellular debris. The 
lysate was cleared by centrifugation and plasmid DNA specifically bound to proprietary resins. 
The bound DNA was washed in a medium salt-alcohol buffer that elutes contaminating RNA 
and traces of proteins, and the plasmid DNA was then eluted in a small volume of 10 mM TRIS 
pH 8.0 (WIZARD kit) or with a high salt-alcohol buffer (Tip20 kit). Plasmid DNA eluted from 
the Qiagen tips was then desalted and precipitated by isopropanol precipitation, washed with 
70% ethanol, air-dried and resuspended in a small volume of 10 mM TRIS pH 8.0. 
Spectroscopic analysis was used in conjunction with electrophoresis of small aliquots of 
purified plasmid DNA on 1% TAE agarose gels to estimate DNA concentration.
Medium-scale plasmid preparations - ‘midipreps’ - were done using the Tip 100 kit 
(Qiagen). The methodology is exactly the same as for minipreps, only scaled up.
2.2.3: Restriction digestion and ligation of plasmid
Restriction endonuclease digestion of plasmid DNA was typically carried out using 0.2- 
0.6 pg DNA in a total reaction volume of 20 p.1 at 37°C, except in specific cases where there 
was a requirement for incubation at a different temperature for maximal activity of the specific 
restriction endonuclease. Restriction enzymes and buffers used were obtained from either 
GibcoBRL or New England Biolabs. Where possible, combination digests using two enzymes 
were carried out simultaneously using a buffer compatible to both enzymes. In cases where this 
was not possible digestion was carried out using one enzyme and the buffer conditions then 
changed to suit the second enzyme, for example by raising the salt concentration. When buffer 
incompatibility precluded this, digestion with the first enzyme was followed by 
electrophoresing the cut DNA on an agarose gel and extraction of the DNA with the QIAquick 
Gel Extraction kit (Qiagen), then digestion with the second enzyme.
In restriction digests of large (100 |Lig) amounts of DNA intended for transfection, the 
extent of digestion was followed over time by electrophoresing small aliquots on TAE agarose 
gels. Once digestion was complete, the DNA was purified by two extractions with 
phenol:chloroform equilibrated by saturation with TRIS EDTA buffer (TE) pH 8.0 and one 
extraction with chloroform, followed by ethanol precipitation. The pellet was washed twice 
with large volumes of 70% ethanol. After brief drying under vacuum (approximately 5 min) 
DNA pellets were resuspended to 2 mg ml'1 in sterile distilled water preheated to 65°C, 
aliquoted and stored at -20°C until use.
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Ligation reactions were performed using either the Amersham ligation kit or New 
England Biolabs T4 ligase and buffer. In both cases ligation reactions and conditions were 
according to the manufacturer’s protocol, typically using a molar ratio of cut plasmid:insert 
fragment of 1:3, where possible. Reaction volume was typically 20 pi. The New England 
Biolabs system was far more frequently used, in which case 400 units of T4 ligase (for 
cohesive-end ligations) or 2 000 units of T4 ligase (for blunt-end ligations) were added to a 20 
pi ligation reaction containing various concentrations of cut plasmid and insert fragment, and 
reaction buffer at lx final concentration. Reactions were left to proceed overnight at 16°C in an 
insulated waterbucket.
2.2.4: Transformation of E. coli
Transformation of plasmid DNA or ligation reactions was done using either competent 
XL 1-Blue cells prepared by the calcium chloride method (Sambrook et al, 1989), 
electrocompetent XLI-Blue cells, or commercially available competent XLl-Blue cells 
(Stratagene). Calcium chloride competent cells were prepared by growing a fresh culture of 
XLl-Blue E. coli to an optical density at 600 nm of 0.6 before harvesting by centrifugation at 6 
000# for 10 min at 4°C. Cell pellets were resuspended in ice-cold 50 mM CaCl2 to one-tenth the 
volume of the original culture and incubated on ice for 20 min. The cells were collected by 
centrifugation as previously, the resuspension and incubation step repeated, the cells collected 
again by centrifugation as previously and resuspended in 2 ml ice-cold 50 mM CaCl2 per 50 ml 
original culture. An equivalent volume of LB with 40% glycerol and 2% peptone was 
thoroughly mixed in, 50 pi aliquots dispensed to eppendorfs and cells frozen quickly at -80°C. 
For use, aliquots were thawed on ice, transferred to sterile 15 ml Falcon tubes, and appropriate 
amounts of plasmid DNA or ligation reactions mixed in by gentle swirling, followed by a 25 
min incubation on ice. Transformation reactions were then placed in a 42°C waterbath with a 40 
second heat-shock window and a further 3 min incubation on ice before the addition of 0.5-3.0 
ml of LB and incubation at 37°C in a rotary shaker for 1 hour to recover. Transformed cells 
were plated on predried LB plates at 100 pi per plate, with appropriate antibiotics added to the 
LB when pouring the plates and IPTG/X-gal where appropriate [2% X-gal with 40 mM IPTG] 
prespread on the plates once predried, and incubated, inverted, at 37°C overnight.
2.2.5: DNA gel electrophoresis
Agarose gel electrophoresis was carried out using agarose from GibcoBRL or SeaKem 
with TRIS acetate buffer (TAE), except in the case of gels to be used for Southern blotting, in 
which case TRIS borate buffer (TBE) was used. Stock solutions of 50X TAE and 50x TBE 
were prepared, autoclaved and dilutions of these used in casting agarose gels and preparing
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electrophoresis buffers. Typical agarose concentration gels was 1%, although for resolution of 
smaller DNA fragments (500 bp and less) 2% agarose gels were used and for Southern blotting 
0.8% TBE agarose gels were used. The molecular weight marker used was the 1 kb ladder 
(GibcoBRL) at a concentration of 0.5 pg per lane.
DNA in agarose gels was visualised by the addition of ethidium bromide to the gel mix 
and the electrophoresis buffer at a concentration of 0.5-2.0 pg ml'1. Visualisation was by 
exposure to UV light using a transilluminator (Appligene) and images were recorded using a 
gel documentation system (Appligene).
DNA was extracted from agarose gels by using either SpinX minicolumns (Costar) or a 
Gel Extraction kit (Qiagen). In the former, the gel chip was added to the column, frozen briefly 
(30 min) at -70°C, thawed for 15 min at 37°C and then centrifuged in a bench microfuge to elute 
the DNA. Problems with this method include recovered DNA being relatively dilute and thus 
requiring subsequent precipitation, and agarose carry-through, which can inhibit subsequent 
enzymatic reactions. For these reasons the Qiagen kit was adopted for most purposes. DNA 
fragments were excised from the agarose gel with a scalpel, transferred to eppendorfs and 
weighed, then 3 volumes of dissolution buffer added and eppendorfs incubated at 50°C for 10 
min to dissolve the agarose chip. DNA was bound to a resin and debris cleared by 
centrifugation, contaminating RNA and protein traces removed by washing with a salt-ethanol 
buffer and the DNA eluted by addition of a small volume of 10 mM TRIS pH 8.5. For 
downstream applications of ligation or probe labelling, the DNA was eluted with sterile 
distilled water preheated to 65°C, and kept at -20°C until use.
2.2.6: DNA sequencing
Manual DNA sequencing was carried out using the USB Sequenase 2.0 kit according to 
the manufacturer’s instructions (Amersham). Reactions were run on wedge gels using glycerol 
tolerant buffer to prevent distortions. Typically, the gel was cast the night before use and then 
pre-run at 65 watts (approximately 2500 V) for 30 min prior to sample loading. Samples were 
heated to 80°C immediately before loading at 3 pi per lane, and once loaded were 
electrophoresed at the same voltage until the dye-front had come off the end of the gel. Once 
the run was complete gels were soaked in several changes of fixing solution [5% acetic acid, 
15% methanol] to remove the urea, backed onto 3 mm Whatmann filter paper and dried in a 
slab dryer (BioRad) at 80°C for approximately an hour and a half. They were then exposed to 
autoradiography film (DuPont) by direct exposure in a hypercassette (Amersham) for twelve 
hours to seven days, depending on signal strength. This method of sequencing was used 
initially, until automatic cycle sequencing became available. However, for obtaining sequence 
very close (10-50 bp) to the primer site, this was still the method of choice, as cycle sequencing
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does not provide good resolution in this range. The use of a manganese modification to the 
Sequenase kit allows good results in this range.
Automatic DNA cycle sequencing was carried out using the Perkin-Elmer Amplitaq FS 
kit according to the manufacturer’s instructions. 400 ng of template DNA and 3.2 pmol of 
primer were used per reaction, and reactions were performed in an Appligene GeneAmp 2400 
machine, cycles programmed according to the manufacturer’s instructions. DNA for this 
purpose was always prepared using the Qiagen Tip20 kit, as this was generally agreed by all 
operators to give the optimal results, with the DNA eluted from the resin with distilled water.
Data analysis was performed using 373 Sequence Analysis Software on an Apple Mac 
computer. Once the sequence trace had been examined and ambiguities removed manually the 
appropriate section of good data was selected, and exported to UNIX, to be manipulated by 
GCG packages.
2.2.7: Isolation of genomic DNA and Southern blotting
Isolation of genomic DNA from STIB 247 procyclics was performed using the Nucleon 
II kit (Scotlab) which utilises a silica suspension for purification of DNA. lx 107 procyclic cells 
were lysed by resuspension in 2 ml Nucleon buffer B and treated with 0.75 pg ml"1 RNaseA at 
37°C for 30 min, and then deproteinised by treatment with 1 M sodium perchlorate. Following 
extraction with chloroform precooled to -20°C the silica suspension was added and the mixture 
centrifuged at 1400g for 3 min at 4°C. The aqueous, DNA-containing upper phase was then 
removed and any residual silica suspension collected by centrifugation at 1300g for 1 minute. 
The supernatant was removed and DNA was precipitated by addition of 2x volumes of 100% 
ethanol at -20°C. DNA was removed by hooking it with a heat-sealed pasteur pipette, rinsed in 
a large excess of 70% ethanol and briefly air-dried. The DNA pellet was then redissolved in 50 
pi of 10 mM TRIS pH 8.0 to give an approximate final concentration of 1 mg ml'1, and stored at 
4°C.
Southern blotting was performed by the capillary method as described (Sambrook et al, 
1989). Briefly, digested samples were electrophoresed on 0.8% TBE agarose gels, either for 
several hours at 70-90 V or overnight at 25 V, in both cases until the dye-front had migrated 
approximately three-quarters of the way down the gel. Gels were stained by incubation in lx 
TBE buffer with 1 pg ml"1 ethidium bromide at room temperature for 25 min, DNA visualised 
on a gel documentation system (Appligene) and a visual image taken, and gels rinsed in a large 
excess of distilled water for 10 min. Gels were then incubated in several changes of denaturing 
buffer for 45 min with gentle agitation and then several changes of neutralisation buffer for 45 
min with gentle agitation. After neutralisation, DNA was transferred to Hybond-N supported 
nitrocellulose (Amersham) by capillary action using lOx SSC as the transfer buffer. Following
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overnight transfer membranes were air-dried and fixed by exposure to UV light. Filters were 
pre-hybridised at 65°C in prehybridisation buffer for 4 hours. The prehybridisation solution was 
then decanted and the radioactive probe added in 5 ml of fresh prehybridisation solution and 
incubated at 65°C overnight. The probe was decanted the next morning and the membrane 
washed at 65°C with shaking for 2x 10 min in 2x SSC with 0.1% SDS, then for 3x 15 min in 
O.lx SSC with 0.1% SDS. The membrane was then exposed to Renaissance autoradiography 
film (DuPont) in a hypercassette (Amersham).
Probes for Southern blotting were prepared by gel purifying the particular DNA 
fragment from TAE agarose gels using the Qiagen Gel Purification kit and eluting the DNA in 
distilled water. 25 ng of purified DNA was labelled to high specific activity using the Prime-It 
II kit (Stratagene) with 3000 Ci mmof1 32P-dCTP, according to the kit protocol. Briefly, purified 
DNA was mixed with random oligonucleotide primers, heated to 100°C for 5 min and allowed 
to cool to room temperature to promote annealing of the random primers to the DNA fragment. 
Reaction buffer, radiolabelled dCTP and 5 units of Exo(-) Klenow enzyme were added, the 
reaction incubated at 37°C for 10 min to allow extension, and the reaction stopped. Labelled 
probe was then purified from unincorporated nucleotide on a NucTrap column (Stratagene) 
using a beta shield device (Stratagene) according to the manufacturer’s instructions. Purified 
probes were stored in eppendorfs, and sealed in lead pots at -20°C until use.
2.2.8: Isolation and manipulation of RNA
Standard precautions were taken when isolating and manipulating RNA: All tips were 
specially autoclaved for this purpose and used only for RNA work and all solutions, where 
possible, were treated with 0.1% DEPC.
Isolation of total RNA from procyclics was performed using the Total RNA Midi kit 
(Qiagen), according to kit instructions with one exception: Trypanosomes are smaller by 
volume than mammalian and other higher eukaryotic cells, and thus proportionally more cells 
per prep must be used to obtain the same quantity of RNA. Accordingly, ten times as many 
cells were used per midiprep as recommended by the manufacturers for mammalian cells. 
Briefly, cells were lysed and genomic DNA sheared in a highly denaturing buffer that generated 
an RNase-free environment and stabilised RNA; many proteins were then removed by salt 
precipitation. RNA was collected by rapid precipitation, resuspended, and RNA bound to a 
resin that only binds nucleic acids. The resin was then washed with a medium salt buffer that 
specifically elutes DNA but leaves RNA bound. RNA was eluted with a high salt wash, 
collected by isopropanol precipitation, washed with large volumes of 70% ethanol, and 
resuspended in a small volume of RNase-free water. RNA was stored at -80°C until use.
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Isolation of poly[A]+ RNA was done using the Oligotex Direct mRNA kit (Qiagen); 
again, ten times as many cells per prep was used as recommended in the kit manual. The kit 
exploits the fact that eukaryotic mRNA species end in a homopolymer of 20-250 adenosine 
nucleotides. Cells were lysed and homogenised using a QIAshredder, diluted with Dilution 
buffer and centrifuged to remove cellular debris and protein. The supernatant was removed to a 
fresh eppendorf and Oligotex suspension added, allowing the poly[A] transcript tails to 
hybridise to oligo[dT] primers which were coupled to latex microparticles. Following washing 
to remove nonbound material poly[A]+ RNA was eluted in 5 mM RNase-free TRIS pH 7.5 
preheated to 70°C. Poly[A]+ RNA was stored at -80°C until use.
First-strand cDNA synthesis was carried out as follows: Eppendorfs were labelled 
either plus (+) or minus (-). Each received 5 pig of total RNA or 1 pig of poly [A] + RNA, 60 
pmol oligo[dT] or oligo[dT]-Anchor primer, and DEPC-treated distilled water to 12.5 pil. Tubes 
were incubated at 65°C for 10 min to denature the RNA, then chilled on ice to allow annealing. 
Following a brief spin, each tube received First Strand Buffer (GibcoBRL) to lx final 
concentration, 50 mM DTT, 1 mM dNTPs and 0.5 pil of RNasin (GibcoBRL). Incubation at 
42°C for 2 min was followed by addition of 25 units of Molony Murine Leukaemia Virus (M- 
MLV) reverse transcriptase (GibcoBRL) to the (+) tube and 1 pil of DEPC-treated distilled 
water to the (-) tube. Incubation at 42°C for 30 min allowed first-strand synthesis to occur, and 
the reactions were stopped by the addition of 480 pil TE pH 8.0 to each tube and heating at 65°C 
for 10 min. First-strand cDNA was stored at 4°C.
RNA for Northern blots were run on lx MOPS/0.7 M formaldehyde gels according to 
the protocol supplied with the instructions for Hybond-N membrane (Amersham). Agarose gel 
strength was 1.5%, and no ethidium bromide was used as it can inhibit RNA transfer to the 
membrane. Following electrophoresis, the gel was rinsed for 15 min in RNase-free water and 
then in lOx SSC. RNA was transferred to Hybond-N membrane by capillary blotting as for 
Southern blots, using lOx SSC as the transfer buffer. Once transferred, membranes were 
partially dried, UV fixed and stained with methylene blue to visualise the RNA. Following 
destaining the membranes were then treated as for Southern blots. The RNA molecular weight 
markers used was an RNA ladder (New England Biolabs).
2.2.9: PCR reactions
PCR reactions were carried out using two different enzymes: Taq (Thermus aquaticus 
DNA polymerase, Promega and Applied Biosystems) and the high-fidelity Pfu (Pyrococcus 
furiosus DNA polymerase, Stratagene), the latter only being used in a few cases where fidelity 
was of greater importance than the enzyme’s processivity or the abundance of the end-product.
52
PCR using plasmid DNA was performed in 10 pi reactions with 1 pi of an appropriate dilution 
of plasmid (typically, approximately 200-300 pg DNA per reaction) in thin-walled 200 jllI PCR 
tubes. The other components of the reactions were 50 pg of each primer, 0.4 units of Taq DNA 
polymerase and 0.9 pi of 11.1 x PCR mix. Reactions were carried out in a Perkin-Elmer 
GeneAmp 2400 machine. Reactions involving amplification of very GC-rich regions of DNA 
were facilitated by addition of DMSO to a final concentration of 5% in the reaction mix; 
DMSO inhibits Taq to approximately 50%, therefore double the usual amount of Taq per 
reaction was used in these cases. Extension times were based on an assumption of 30 seconds 
per kilobase, and annealing temperatures based on the thermal Tm values of the primers 
involved. For reactions using the high-fidelity but slow-procession polymerase Pfu extension 
times were doubled. PCR reaction end-point products were electrophoresed on 1% TAE 
agarose gels.
Screening by PCR of bacterial colonies, principally used to screen bacteria transformed 
with ligated plasmid, was performed as follows: Single colonies were picked off plates using a 
sterile pick and scraped off into 200 |nl thin-walled PCR tubes. The picks were then transferred 
to 3 ml LB with appropriate antibiotics and set to grow in a rotary 37°C incubator. Meanwhile, 
PCR reactions were set up as normal in the tubes containing the cell scrapes but with no added 
DNA. A prehold of 4 min at 94°C was sufficient to lyse the cells, with the annealing 
temperature based on the thermal Tm of the primers and an extension time based on the length 
of the target region to be amplified. Once complete, reactions were electrophoresed on TAE 
agarose gels and based on the results of this, LB cultures were either discarded or left to grow 
up overnight for plasmid DNA preps.
PCR reactions with genomic DNA were performed as described for plasmid PCR 
reactions; PCR reactions using first-strand cDNA were performed as described for plasmid 
PCR reactions, except that double the volume of template (2 pi) was used per 10 pi reaction.
2.2.10: Screening A.FIX1I library
A XFIXH genomic library was used to screen for the CRK4 gene, to isolate a clone or 
clones representing the full open reading frame. The bacterial host used for the phage was 
LE392, which was prepared by picking a single colony from an LB plate and inoculating 20 ml 
LB medium containing 10 mM maltose and 10 mM M gS04. This was grown at 37°C with 
shaking (225 rpm) until the optical density of the culture at 600 nm was between 0.5-1.0. Cells 
were harvested at 2000g for 20 min at 4°C, then resuspended in sterile 10 mM MgS04 to an 
optical density at 600 nm of 0.5. Cells prepared this way were stored at 4°C and used in under 3 
days. For 2.FIXII plating on petri dishes, 100 pi of prepared LE392 were mixed with 100 pi of
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sterile phage buffer containing AJF1XII and incubated for 20 min at 37°C to allow adsorption of 
phage to the cells. After this each cell-phage mix was inoculated to 3.5 ml BBL top agarose at 
48°C, mixed by gentle inversion, and poured onto predried BBL bottom agarose plates. Plates 
were incubated at 37°C, inverted, overnight or until plaques appeared and lysis was complete.
Phage lifts for Southern blotting from plates or petri dishes was performed by laying a 
clean sheet of Hybond-N on the surface of the top agarose for 1-2 min, using needles to mark 
orientation on the membrane and plate. The membrane was then carefully lifted off, submersed 
DNA side up for 5 min in denaturing solution, DNA side up for 5 min in neutralising solution, 
and then rinsed briefly in 2x SSC before being air-dried and UV fixed. The rest of the 
procedure was as for a standard Southern blot. Agar plugs were removed to 1 ml phage buffer, 
incubated at 37°C for 2-4 hours, one drop of chloroform added and the phage solution stored at 
4°C.
APTXII clones were grown for the isolation of phage DNA by the liquid culture method 
as described in the Promega kit manual. Briefly, 500 pi of an overnight LE392 culture was 
mixed with 10-20 pi of agar plug eluate and incubated at 37°C for 20 min. This was then 
inoculated to 100 ml prewarmed LB with 10 mM MgSC>4 and grown at 37°C in a rotary 
incubator for 6 hours. Cell lysis was not clear at this point, so 500 jllI chloroform was added and 
the culture left to shake for a further 15 min. The lysate was then centrifuged at 8 000# for 10 
min at 4°C to pellet cellular debris. The supernatant was removed to a fresh tube and phage 
DNA purified using the Magic Lambda Preps DNA Purification System (Promega). Phage 
DNA was eluted in a small volume of 10 mM TRIS pH 8.0.
2.3 Biochemical materials and methods
2.3.1: Protein gels and Western blotting
SDS-PAGE gels were cast and run according to the method of Lammeli (Lammeli, 
1970) as adapted for the BioRad Mini-Protean system. Typically, resolving gel acrylamide 
concentration was 12.5 %, but for better resolution of some closely migrating proteins a 
resolving gel acrylamide concentration 7.5 % strength was used. SDS-PAGE running buffer 
(SPRB) was made as a lOx stock and used at lx concentration. Usually, gels were run at 130 V 
at room temperature until the dye-front had just migrated off the bottom of the resolving gel. 
Loading buffer for protein samples was either four times sample buffer (FSB) or three times 
sample buffer (TSB, New England Biolabs). Gels were stained with Coomassie blue stain and 
destained with either fast destain or slow destain. Gels were dried in a slab gel drier (BioRad)
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or an EasyBreeze apparatus (Hoeffer). Silver staining was carried out using commercially 
available kits from either Sigma or BioRad, according to the manufacturer’s instructions. 
Molecular weight markers used were Kaleidoscope coloured markers (Amersham), low-range 
Rainbow coloured markers (BioRad) and both prestained and non-prestained Low Range 
markers (New England Biolabs).
Western blotting of gels was carried out under a variety of conditions, as requirements 
for good results vary between different antisera. The typical protocol used was as follows: Gel 
blotting was done in a wet-blot tank (BioRad) at 250 mA for 2 hours at 4°C, or at 25 mA 
overnight at 4°C, in Towbin transfer buffer (Towbin et al., 1979). Transfer was to either 
Hybond-N supported nitrocellulose membrane (Amersham) or to PVDF membrane (DuPont). 
Because PVDF has a higher specific capacity for protein binding and generally resulted in 
lower backgrounds, this was usually the membrane of choice. Following transfer, membranes 
were briefly stained with Ponceau S to check for the transfer of proteins, destained with 5% 
acetic acid, and lanes demarcated with a soft lead pencil; non-prestained markers were also 
marked at this point with a soft lead pencil. After staining and destaining, PVDF membranes 
were re wetted by briefly submerging in 100% methanol and then rinsing in TRIS-buffered 
saline with Tween-20 (TBST) buffer. Blocking of nonspecific binding sites for 
immunoglobulins on the filters was performed by incubation of the membranes for 1 hour at 
4°C in blotto with 0.05 % sodium azide. Binding of primary antiserum to target proteins was 
carried out using varying titres of monoclonal antibody or polyclonal antiserum in blotto with 
0.05 % sodium azide at 4°C for 2-4 hours. Following this, membranes were washed for 6x 5 
min in large (200-300 ml) volumes of lx TBST on a rotary shaking platform at room 
temperature, and then incubated with secondary HRP-conjugated antibody in blotto, either anti­
rabbit antiserum or anti-mouse antiserum (both from Promega). Following incubation of 
membranes with secondary antibody, they were washed as previously in lx TBST. Blots were 
developed by incubation of the membrane in ECL reagents (Amersham) or SuperSignal 
Substrate system (Pierce). As the Pierce system is very powerful optimal exposure was often 
achieved by diluting the active solution mix 1:10 in distilled water before incubation of 
membrane
2.3.2: Preparation of protein samples
Small-scale (mini) crude whole cell E. coli lysates were prepared by resuspending cell 
pellets in an appropriate volume of lysis solution (LS) and adding either one-third or one- 
quarter volume of TSB or FSB, respectively. The suspension was then needled 5-6 times 
through progressively smaller needles: 21G, 23G and 25G, the suspension transferred to a fresh 
eppendorf and boiled at 100°C for five min.
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Soluble (S-14) and insoluble protein fractions were made by spinning whole cell 
lysates at maximum speed in a bench microfuge for 10-20 min at 4°C. The soluble protein 
fraction was aspirated and transferred to a fresh eppendorf, insoluble protein was resuspended 
in fresh LS. For larger-scale soluble protein lysate preparation cell pellets were resuspended in 
a phosphate- or TRIS-based saline buffer and sonicated using a microtip. Lysates were 
centrifuged at 10 OOOg for 20 min at 4°C to pellet cellular debris, the supernatant aspirated and 
processed as appropriate.
Crude whole cell lysates of T. brucei were prepared by taking harvested, washed cells 
(see chapter 2.1.1), resuspending the cell pellet to approximately 5x 108 cells ml'1 in LS plus 
protease inhibitors (LSI) and incubating on ice for 20 min. An appropriate volume of sample 
buffer was then added, either TSB or FSB, and the lysate was processed as for E. coli whole 
cell lysates. S-14 protein fractions were made as described for E. coli lysates. S-100 lysates 
were made by performing the lysis step and then centrifuging at 100 OOOg for 45 min at 4°C in a 
Beckman ultracentrifuge. The supernatant was aspirated and was used for 
immunoprecipitations, selections and kinase assays. Estimation of protein concentration was 
performed using the Biorad DC Protein Microassay kit, with a set of immunoglobulin standards 
as reference.
2.3.3: Expression of fusion proteins in E. coli
The systems used for the production of recombinant fusion protein in E. coli were the 
QiaExpress system (Qiagen) and the GST Gene Fusion system (Pharmacia Biotech).
The pQE32 vector was chosen for expression of the CYC1 gene; this vector adds an N- 
terminal hexahistidine tag, and includes an ATG start as well as all-frame stop codons. The 
pQE60 vector was used in the generation of histidine-tagged CRK2, used to create the pHD675- 
CRK2His construct (pGL234), as the vector’s polylinker allowed for easy tag insertion and 
subsequent subcloning, and for the expression of full-length CRK2.
The pQE32-CYCl construct (pGL107) was transformed to M15[pREP4] E. coli, and a 
series of pilot expression experiments carried out. A small-scale native purification was 
performed as per the manufacturer’s instructions: 2x 1.5 ml LB was inoculated with 500 pi of 
an overnight saturated culture of M15[pREP4]pGL107. The cultures were grown for 30 min at 
37°C before addition of IPTG to a final concentration of 2 mM to one of the cultures, and 
grown for a further 2 hours before harvesting. The cell pellets were resuspended in SB, 
incubated with 1 mg ml'1 lysozyme for 30 min, put through 5 freeze/thaw cycles in dry 
ice/ethanol and a 100°C heating block. The supernatant from an S-14 spin was added to 50 pi of 
a 50% slurry of Ni-NTA resin (prewashed in SB) and incubated for 30 min at 4°C with gentle
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agitation. Brief centrifugation collected the resin, the supernatant was aspirated and bound 
protein eluted by the addition of SB containing 200 mM imidazole.
A subcellular localisation check was performed for CYClHis by inoculating 100 ml LB 
at 1:100 with an overnight saturated culture of M15[pREP4]pGL107 and growing to an OD at 
600 nm of 0.8. After harvesting, cell pellets were processed by the protocol described by the 
manufacturer (Qiagen) to give soluble, insoluble and periplasmic shock protein fractions.
Pilot denaturing purification of CYClHis was performed by inoculation of 2 L of LB 
with 10 ml of a saturated overnight culture of M15[pREP4]pGL107. When cell density had 
reached an OD at 600 nm of 0.8, IPTG was added to 1 mM and the culture grown for a further 
2 hours before harvesting as two equivalent aliquots. One cell pellet was resuspended in 5 ml 
QLAexpress buffer A, the other resuspended in 5 ml QIAexpress buffer B. The resuspended 
cells were sonicated and the supernatants from a centrifugation at 4 000# for 10 min at 4°C 
were loaded to 2 ml bed volume columns of Ni-NTA resin that had been pre-equilibrated in 
buffer A or buffer B, as appropriate. The columns were washed and CYClHis eluted as shown:
Column 1. Washed with buffer A, buffer C and eluted by the protonation 
method (buffers D, E and F).
Column 2. Washed with buffer B, buffer C and eluted by the protonation 
method (buffers D, E and F).
Column 3. Washed with buffer A, buffer C and eluted with imidazole 
(buffer C with 300 mM imidazole).
Column 4. Washed with buffer B, buffer C and eluted with imidazole 
(buffer C with 300 mM imidazole).
From the pilot denaturing purification above, a denaturing protocol with elution of 
CYClHis by protonation was chosen to produce milligram quantities of recombinant protein. 
M15[pREP4]pGL107 were grown, induced with 2 mM IPTG for 3 hours and harvested as 
described.. The cell pellet was resuspended in 5 ml of QIAexpress buffer A, sonicated, 
centrifuged at 2 OOOg for 10 min at 4°C, and the supernatant applied to a 4 ml bed volume Ni- 
NTA column previously equilibrated in buffer A. The resin was washed with 15 column 
volumes of buffer B, then with 15 column volumes of buffer C. The elution program was 5x 3 
ml buffer D, 5x 3 ml buffer E and 6x 3 ml buffer F. Samples of each eluate fraction were 
analysed on Lammeli gels and by spectroscopic measurement at 280 nm, to ensure that the bulk 
of the CYClHis had eluted in the first two F eluate fractions. The protein-containing fractions 
were pooled and dialysed against 2.5 L of dialysis buffer over 2 days with three changes of 
buffer. Following dialysis, precipitated CYClHis was collected by centrifugation at 4 OOOg for 
10 min at 4°C, the supernatant aspirated and the protein pellet resuspended in 1 ml of dialysis
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buffer, sonicated briefly to break up precipitated protein aggregates with a microtip. Purified 
CYClHis was then dispensed as 50 pi aliquots to eppendorfs and stored at -20°C until required.
The pQE60-CRK2 construct (pGL217) was transformed to M15[pREP4] E. coli and a 
pilot induction of CRK2His was performed as described by the manufacturer (Qiagen). Pilot 
time-course induction and pilot denaturing purification was carried out as described by the 
manufacturer (Qiagen).
The pGEX-5X-2 vector was chosen for expression of a fragment of the CRK4 gene, as 
this vector preserved the reading frame of the GST-CRK4 fusion. pGL134 was transformed to 
competent BL21 cells and a small-scale pilot time-course expression was carried out by 
inoculating LB at 1:100 using a saturated overnight culture of BL21pGL134 and growing to an 
OD of 0.8 at 600 nm before induction with 2 mM IPTG. Cultures were then grown for 4 hours 
with samples withdrawn hourly, and crude whole cell lysates made as described in chapter 
2.3.2. A solubility check was carried out on an induced cell pellet as described in chapter 3.2.6.
Small-scale pilot induction and purification was performed by induction of 
BL21pGL134 with 2 mM IPTG. Cells were harvested, resuspended in SB and sonicated, and 
centrifuged. The S-14 supernatant was added to a 50% slurry of Glutathione-Sepharose 4B 
(GS4B) resin and incubated for 10 min at room temperature with gentle agitation. Meanwhile 
the cellular debris (insoluble protein) was resuspended in QIAexpress buffer B/TSB, syringed 
to resuspend and heated to 100°C for 5 min. The resin was collected by brief centrifugation, the 
supernatant aspirated, added to TSB and heated to 100°C for 5 min (soluble nonbound protein). 
The resin was washed with lx PBS pH 7.2 and bound protein eluted by the addition of 
Glutathione Elution Buffer (GEB) and incubation at room temperature for 5 min. The resin was 
collected by brief centrifugation, the elute aspirated and added to TSB, and heated to 100°C for 
5 min (soluble bound protein).
Induction and purification of milligram quantities of GST-CRK4 was done by the 
column method as described in the manufacturer’s kit instructions. 4x 500 ml LB were each 
inoculated at 1:100 with a saturated overnight culture of BL21pGL134, grown to an OD at 600 
nm of 0.8, induced by the addition of 0.5 mM final concentration IPTG and grown for 4 hours. 
Cells were harvested by centrifugation at 7 500g for 10 min at 4°C. Cell pellets were 
resuspended in a total of 100 ml lx PBS pH 7.2 and sonicated, TritonX-100 was added to 1% 
and the lysate was centrifuged at 12 000g for 10 min at 4°C. The supernatant was applied to a 2 
ml bed volume column of GS4B. The resin was washed with lx PBS pH 7.2 until the protein 
content of the flow-through was negligible, and bound GST-CRK4 was eluted with 3x 3 ml 
GEB, each time incubating for 10 min at room temperature with gentle agitation. Eluate 
fractions were dialysed overnight at 4°C against 2 L lx  PBS pH 7.2. Purified GST-CRK4 was 
dispensed as small aliquots to eppendorfs and stored at -20°C until required.
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2.3.4: Generation of antisera and purification of antibodies
The general schedule of immunisation of New Zealand white rabbits with purified 
recombinant protein was as described in Harlow and Lane (1988). Initially, a preimmune test 
bleed of several millilitres was taken before a subcutaneous injection with 200 pg of protein 
homogenised in an equivalent volume of complete Freund’s reagent. Between four and six 
week after primary immunisation, secondary immunisation was performed using 200 pg of 
protein in incomplete Freund’s reagent, in the same range of volume. An immune test bleed was 
taken approximately one week after this secondary immunisation. Two weeks after secondary 
immunisation a programme of booster immunisations began, each administered two weeks 
apart and with a test bleed being taken prior to each boost. For booster immunisation only 20 
pg protein in incomplete Freund’s reagent was required. The animal was exsanguinated and the 
antiserum stored at -20°C until use directly in experiments, or until antibody purification.
Once a specific response was detected with a particular antiserum on Western blots, the 
antiserum was partially purified by selecting specifically for the IgG fraction, using affinity 
purification with the immobilised recombinant bacterial protein A/G kit (Pierce) as described 
by the manufacturers. Sodium azide added to 0.03% and gelatin to a final concentration of 
0.1%, to stabilise the antibodies, and the purified antibodies stored at 4°C.
Antisera raised using GST fusion proteins will contain a strong anti-GST response, and 
this can cause problems in immunoprecipitations and Western blots due to cross-reactivity to 
endogenous GST-like proteins in the protein samples under study. Consequently, anti-GST 
antibodies were removed from the anti-CRK4 antiserum used in such applications by using 
prepacked immobilised GST columns (Pierce) as described by the manufacturers. An aminolink 
immobilised GST-CRK4 column was made to further increase the specificity of the anti-CRK4 
antibodies by specifically purifying only those antibodies that bind the CRK4 portion of the 
fusion protein. An immobilised column was made as per the manufacturer’s instructions 
(Pierce). Freshly purified GST-CRK4 was made and the concentration was calculated using the 
Biorad DC protein microassay system; subsequently 10 mg of GST-CRK4 was used to couple a 
2 ml bed volume column of aminolink gel. The GST-CRK4 sample was diluted 1:3 in 0.1 M 
sodium phosphate pH 7.0. After equilibration of the column with 0.1 M sodium phosphate pH
7.0 the GST-CRK4 sample was added to the column with 200 pi of reductant solution, and the 
reaction incubated at room temperature for 6 hours with gentle agitation. Subsequently the 
column was drained and washed with 5 ml 0.1 M sodium phosphate pH 7.0, the flow-through 
being collected and dialysed overnight against an excess of lx PBS pH 7.2 for protein 
concentration determination. Any remaining active sites on the gel were blocked by washing 
the column with 4 ml of 1.0 M TRIS pH 7.4 and then incubating the gel with 2 ml 1.0 M TRIS 
pH 7.4 and 40 pi of reductant solution for 30 min at room temperature with gentle agitation.
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Finally, the column was drained, washed with 1.0 M NaCl and then lx PBS pH 7.2 with 0.05% 
sodium azide, and stored under lx PBS pH 7.2 with 0.05% sodium azide at 4°C. A BioRad DC 
protein assay of the dialysed column flow-through and wash fraction showed a coupling 
efficiency of approximately 98%.
Specific purification of anti-CRK4 antibodies was carried out using aliquots of antisera 
which had been processed to remove all anti-GST antibodies, as described above. Following 
pre-equilibration of the GST-CRK4 aminolink column with lx PBS pH 7.2 the partially 
purified antiserum diluted 1:3 with lx  PBS pH 7.2, applied to the column and the column 
incubated for 90 min at room temperature with gentle agitation. The column was then drained 
and washed with 5x 5 ml lx  PBS pH 7.2. Bound antibodies were eluted by application of 8x 1 
ml of Immunopure IgG Elution buffer (Pierce) and then 8x 1 ml of 100 mM glycine pH 2.8. 
Eluate was collected as 1 ml fractions in eppendorfs (containing 50 pi 1 M TRIS pH 9.5 for the 
glycine elutant fractions, to neutralise them immediately) and spectroscopic measurement at 
280 nm used to identify the fractions containing the majority of the eluted anti-CRK4 
antibodies. These fractions were pooled and dialysed overnight at 4°C against a large excess of 
30 mM sodium borate pH 7.2. After dialysis, 0.1% gelatin and 0.05% sodium azide was added 
to stabilise the antibodies.
Polyclonal antisera raised against peptide-carrier protein antigens were affinity 
purified, after protein A/G purification, on immobilised peptide columns. The peptides used 
had been generated with C-terminal cysteine residues for sulfhydryl coupling to carrier 
proteins, therefore they were coupled to a solid support matrix for antibody purification using 
the Sulfolink Immobilisation kit (Pierce) as described by the manufacturer. Affinity purification 
was carried out by loading an aliquot of the antiserum, diluted 1:1 with Immunopure Gentle 
Ag/Ab Binding buffer on a peptide column pre-equilibrated with the same buffer and 
incubating at room temperature for 60 min on a rolling platform. The column was drained and 
washed with 20 bed volumes of the same buffer, and antibody was eluted with 8 ml of Elution 
buffer followed by 8 ml of 100 mM glycine pH 2.8. 0.5 ml fractions were collected in 
eppendorfs. In the case of the glycine wash fractions the eppendorfs contained 50 pi 500 mM 
TRIS pH 8.5, to immediately neutralise the eluate fractions. Spectroscopic analysis was carried 
out to determine the fraction containing the bulk of the eluted antibodies; these were pooled and 
dialysed at 4°C overnight against a large excess of 30 mM sodium borate buffer. Sodium azide 
added to 0.05% and the antibodies kept at 4°C.
2.3.5: Immunoprecipitation-linked kinase assays and Western blots
Immunoprecipitation was carried out using the same basic protocol: An S-100 soluble 
protein lysate was incubated of aliquots of the lysate for 2-4 hours at 4°C with either polyclonal
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antiserum or monoclonal antibodies. For controls antiserum/antibodies that had been 
preblocked by preincubation with a saturating amount of peptide or purified recombinant 
protein overnight at 4°C were also performed. Minicolumns containing small aliquots of 
Sepharose-protein A beads (50-80 pi of a 50% slurry) were prepared by washing the bead 
slurry with LS and then preblocking the beads with 250 pi of 10 mg ml'1 BSA in LSI for 2 
hours, to block nonspecific binding sites. The antibody-lysate mixes were then added to the 
columns and left to bind for 1-3 hours at 4°C with agitation. Subsequently, columns were 
drained and washed extensively with LS, high salt lysis solution (HSLS) and then either kinase 
assay buffer (KAB) or 50 mM MOPS pH 7.2 buffer with 200 mM NaCl, depending on whether 
the beads were to be used in kinase assays or Western blots.
Immunoprecipitation-linked kinase assays were performed by resuspending Sepharose- 
protein A beads, incubated with antibody-lysate samples, in KAB and transferring to 
eppendorfs. After a brief spin in a bench microfuge to pellet the beads the KAB was aspirated 
and 20 pi of kinase assay mix (KAM)was added, making sure the beads were well resuspended. 
After incubation at 30°C for 20 min the reactions were stopped by addition of 20 pi of TSB or 
FSB and heating to 100°C for 5 min. The beads were centrifuged briefly before 20 pi aliquots 
of samples were electrophoresed on 12.5% Lammeli gels. Gels were stained with Coomassie 
blue, dried in a slab dryer (BioRad) and exposed with phosphorescent markers to 
autoradiography film (DuPont) in hypercassettes (Amersham) for 12-72 hours.
Immunoprecipitation-linked Western blots were performed by preparing beads and 
purifying antibody-lysate mixes as described above, and resuspending the beads in 50 mM 
MOPS pH 7.2 with 200 mM NaCl. After aliquoting to eppendorfs and brief centrifugation to 
collect the beads and aspirating the supernatant, beads were resuspended in an appropriate 
volume of a 1:1 mix of 50 mM MOPS pH 7.2/200 mM NaCl and TSB or FSB, and heated to 
100°C for 5 min before samples were electrophoresed on 12.5% Lammeli gels. This method 
was only useful when the primary antibody or antiserum in the Western blot was from a 
different species of animal from that used in the immunoprecipitation.
2.3.6: Nickel-agarose selection of protein
Selection of CRK proteins from trypanosome S-100 lysates with p l2CKS1 and p l3sucl 
aminolinked beads was performed as described by Mottram and Grant (1996). An S-100 lysate 
was prepared. Minicolumns containing 40 pi of a 50% slurry of p l2CKS1, p l3 sucl and control 
beads were prepared by washing the bead aliquots with 5 ml LS, adding 250 pi of 10 mg ml'1 
BSA in LSI and incubating for 120 min at 4°C with agitation. Subsequently, 100 pi of S-100 
lysate per column was added and the columns incubated for 120 min at 4°C with agitation. The
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columns were drained, washed with 5 ml lysis solution with glycerol (LSG), 5 ml HSLS and 5 
ml LS. Bead aliquots were resuspended in 1 ml 50 mM MOPS pH 7.2, transferred to 
eppendorfs, collected by brief centrifugation, resuspended in 66 pi 50 mM MOPS pH 7.2/33 pi 
TSB and heated to 100°C for 5 min. 15 pi aliquots were electrophoresed on 12.5% Lammeli 
gels for Western blotting.
Ni-NTA selection of CRK2His was performed by growing 10 ml cultures of the 
nonclonal procyclic population WUMP 1163 to midlog in the presence of tetracycline 
hydrochloride. S-100 lysates were prepared. 80 pi aliquots of Ni-NTA resin were dispensed to 
minicolumns and washed with 5 ml LSG with inhibitors (LSG). 200 pi of S-100 lysate was 
added per column, and the columns incubated at 4°C for 60 min with agitation. Columns were 
drained, washed with 5 ml LSG, 5 ml HSLS and then either 5 ml LS without 1% TritonX-100 
(LS-T), if the intended use was for stained Lammeli gels or Western blotting, or with 5 ml 
KAB, if the intended use was for kinase assays. For the former, bead aliquots were resuspended 
in 1 ml LS-T, transferred to eppendorfs, collected by brief centrifugation, resuspended in 100 
ml of a 2:1 mix of LS-T and TSB, and heated to 100°C for 5 min. For kinase assays, bead 
aliquots were resuspended in 1 ml KAB, transferred to eppendorfs and collected by brief 
centrifugation. Bead aliquots were resuspended in 20 pi KAM, incubated at 30°C for 20 min 
and the reaction stopped by addition of 20 pi TSB. 20 pi aliquots of reactions were 
electrophoresed on 12.5% Lammeli gels, the gels were dried and exposed with phosphorescent 
markers to autoradiography film. In most cases, regardless of the final application, samples of 
S-100 (induced or not with tetracycline) lysates and columns flow-through (nonbound soluble 
protein) were taken to confirm induction of CRK2His and binding to the resin.
2.4 Buffers and solutions
PBS: 100 mM sodium phosphate pH 7.2
200 mM NaCl
ZPFM: 132 mM NaCl
8 mM KC1
8 mM Na2H P04.anhydrous
1.5 mM KH2P 0 4.anhydrous
1.5 mM magnesium acetate 
0.9 mM calcium acetate
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50x TAE:
5Ox TBE:
PSG:
TE:
Nucleon buffer B:
Denaturing Buffer:
Neutralising buffer:
lOx SSC:
2 M TRIS
2 M sodium acetate trihydrate 
50 mM EDTA pH 8.0 
Adjusted to pH 7.2 with HC1
2 M TRIS pH 7.2 
2 M boric acid 
50 mM EDTA pH 8.0 
Adjusted to pH 7.2 with HC1
60 mM Na2H P04. anhydrous 
4 mM NaH2P 0 4.2H20  
45 mM NaCl 
55 mM D[+] glucose 
Adjusted to pH 8.05 with NaOH
10 mM TRIS 
1 mM EDTA pH 8.0 
Adjusted to pH 8.0 with HC1
400 mM TRIS 
60 mM EDTA pH 8.0 
150 mM NaCl 
1% SDS
Adjusted to pH 8.0 with HC1
0.5 M NaOH
1.5 M NaCl
1.0 M TRIS pH 7.5
1.5 M NaCl
1.5 M NaCl
1.5 M trisodium citrate pH 7.0
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Prehvbridisation buffer: 6x SSC
lOx Denhardt’s solution 
0.1% SDS
0.1% sodium pyrophosphate 
100 pg ml'1 salmon sperm DNA
Denhardt’s solution: 5% Ficoll 400
5% polyvinylpyrrolidine (PVP) 
10 mg ml’1 BSA fraction V
ll .lx P C R  mix: 495 mM TRIS pH 8.8 
123 mM (NH4)2S 04 
50 mM MgCl2 
0.5% 2-mercaptoethanol 
50 pM EDTA pH 8.0
11.1 mM each dNTP
1.25 mg ml'1 BSA
Phage Buffer: 100 mM NaCl 
50 mM TRIS pH 7.5 
10 mM M gS04 
0.01% gelatin
lOx SPRB: 250 mM TRIS pH 8.3 
1.92 M glycine 
1% SDS
FSB: 200 mM TRIS pH 6.8 
400 mM 2-mercaptoethanol 
8% SDS 
40% glycerol
A few crystals of bromophenol blue
Coomassie stain: 0.5% Coomassie Brilliant Blue R-250 
30% methanol 
10% acetic acid
Fast destain:
Slow destain:
Towbin transfer buffer:
lxT B ST:
Blotto:
LS:
LSI:
Aminolink reductant: 
HSLS:
45% methanol 
10% acetic acid
10% methanol 
5% acetic acid
25 mM TRIS pH 8.3 
93 mM glycine 
20% methanol
20 mM TRIS pH 7.6 
300 mM NaCl 
0.00005% Tween-20
5% nonfat dried milk in lx TBST 
10% horse serum
50 mM MOPS pH 7.2 
100 mM NaCl 
1 mM EDTA pH 8.0 
Im M EG TA  pH 8.0 
1 mM sodium orthovanadate 
10 mM NaF 
1% TritonX-100
Same as LS with the following protease inhibitors: 
100 mg ml-1 leupeptin 
5 mg ml-1 pepstatin A 
500 mg ml-1 Pefabloc SC
1.25 mM 1,10-phenanthroline
1.0 M sodium cyanoborohydride in 10 mM NaOH
Same as LS but with 500 mM NaCl
LSG: Same as LS but with 10% glycerol 
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LSGI: Same as LSG but with protease inhibitors as in LSI
QIAexpress buffer A:
QIAexpress buffer B:
QIAexpress buffer C: 
QIAexpress buffer D: 
QIAexpress buffer E: 
QIAexpress buffer F:
SB:
GEB:
KAB:
KAM (10 reactions):
6 M guanidine hydrochloride 
0.1 M NaH2P 0 4 
0.01 M TRIS
Adjusted to pH 8.0 with NaOH
8 M urea 
0.1 M NaH2P 0 4 
0.01 M TRIS
Adjusted to pH 8.0 with NaOH
Same as buffer B but pH 6.3
Same as buffer B but pH 5.9
Same as buffer B but pH 4.5
6 M guanidine hydrochloride 
0.1 M acetic acid
50 mM sodium phosphate pH 7.8 
300 mM NaCl
10 mM reduced glutathione in 50 mM TRIS pH 8.0
50 mM MOPS pH 7.2 
20 mM MgS04 
10 mM EGTA 
2 mM DTT
186 nl KAB 
8 pi 100 mM dATP 
5 pi 10 mg ml'1 protein substrate 
1 pi Y32p-dATP
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CHAPTER 3: ISOLATION AND ANALYSIS OF tbCRK4
3.1: Introduction
Kinetoplastid CRK genes fall into four distinct classes, based on sequence analysis and 
comparisons between examples from different organisms. CRK1 has been isolated from both 
Trypanosoma and Leishmania species; ImmCRKl is expressed in the proliferative promastigote 
and amastigote forms, although it only displays histone HI kinase activity in the promastigote 
form (Mottram et al., 1993). CRK3 has also been isolated from both organisms, and is a strong 
contender for a functional CDC2 homologue as it correlates with SUC-binding CRK kinase 
(SBCRK) activity (Grant et al., 1998). CRK2 has only been isolated to date from T. b. brucei, 
and has a distinct N-terminal extension sequence of 41 amino acids as compared to other CDKs 
(Mottram and Smith, 1995). Phylogenetic analysis clearly shows that these genes bear no greater 
homology between themselves than to CDK genes from other eukaryotes, thus forming three 
classes (Mottram and Smith, 1995).
The first CRK to be isolated was detected using a PCR-based approach with degenerate 
primers. Lisa Brown and Dan Ray (UCLA) amplified and isolated a gene fragment from 
Crithidia fasciculata (Brown et a l, 1992) which had significant homology to CDK genes from 
other eukaryotes. Isolation and analysis of the full-length cfCRK gene revealed it to be novel 
member of the CDK-like family. While cfCRK possessed the usual features of this kinase 
subfamily it had in addition two large insert sequences, of 66 and 79 amino acids, located 
between kinase catalysis domains VIb and VII and domains X and XI, respectively (Fig. 3.10). 
Multiple alignment of kinase catalysis domains I-VIb and VII-X with the same domains from 
CDC2 homologues from human, zea mays, drosophilia melanogaster and budding yeast CDC28 
showed a high level of conservation. Kinase catalysis domain XI, in comparison with domain XI 
from CDC2/CDC28 from the aforementioned organisms, showed less conservation, consistent 
with what has been observed for CDC2 homologues. Overall, cfCRK was most similar to mouse 
CDC2, with 47% identity and 67% similarity. In the PSTAIRE motif cfCRK had four amino 
acid substitutions as compared to human CDK1. Human CLK1 is a serine/threonine protein 
kinase more distantly related to CDK1 than the rest of the CDK family; it contains an insert 
domain between kinase catalysis domains X and XI, therefore corresponding to the second 
insert domain of cfCRK. However, there was no significant similarity between the insert in 
CLK1 and the inserts in cfCRK. FASTA searches of the GenBank database using the sequences 
of the two insert domains of cfCRK did not find any alignments of significance. Southern 
blotting revealed that cfCRK was a single copy gene, and Northern blotting using total RNA and 
poly[A]+ RNA, probed with a fragment of the gene covering the majority of the kinase domains,
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detected a 3.8 kb polyadenylated transcript. Northern blotting using total RNA and poly[A]+ 
RNA, using a fragment produced by PCR amplification of the first insert domain only, also 
detected a polyadenylated 3.8 kb transcript. The size of the transcript was larger than expected, 
as the coding sequence of the transcript was approximately 1.4 kb. Although no trypanosome 
gene has been found to contain introns, the presence of two inserts in cfCRK which otherwise 
has a high degree of sequence identity with CDC2-related genes, suggested that the inserts could 
represent introns. The Northern blot data repudiated this. A 60 amino acid cfCRK peptide was 
expressed as a fusion protein with glutathione-S-transferase and used to raise a polyclonal rabbit 
antiserum. Western blotting with this anti-cfCRK antiserum detected a protein of the predicted 
size (53 kDa) in C. fasciculata whole cell extracts. In addition, the anti-cfCRK antiserum 
detected a protein of 48 kDa in C. fasciculata whole cell extracts that cross-reacted to an 
antiserum raised to the 16-residue PSTAIR motif of CDC2, suggesting that C. fasciculata may 
contain a protein with a more highly conserved PSTAIR motif. Further PCR-based experiments 
resulted in the isolation of a further three C. fasciculata kinase gene fragments, all of which 
clearly belonged to this new category of CRK genes, based on sequence comparisons and the 
presence of insert domains (Lisa Brown, pers. comm.). Interestingly, there was no significant 
homology between the two insert domains of cfCRK, renamed CRK4 as CRK1-3 had been 
described previously (Mottram, 1994), and the two insert domains of the other three cloned gene 
fragments.
A trypanosome homologue of cfCRK was identified by Dr. Noel Murphy (ILRAD, 
Nairobi) as a partial gene fragment clone during a search for CDC2-related kinases using PCR 
with degenerate primers. This fragment encoded kinase catalysis domains I-VIb and a first insert 
domain, and by sequence analysis was clearly a CRK; the presence of the insert fitted it into the 
CRK4 subclass. Dr. Murphy provided the sequence of the PCR fragment with the aim of 
isolating the full-length gene.
3.2 Results 
3.2.1: Isolation of CRK4 fragments by PCR
Initially, a PCR-based approach was undertaken to attempt to isolate clones representing 
full-length CRK4. Oligonucleotides OL355 and OL356 were designed as gene-specific primers 
to amplify a gene-internal fragment (Fig. 3.1). To amplify the 5’ end of the gene the 39 base-pair 
splice leader (SL) sequence was exploited, with a primer corresponding to the SL sequence 
being used in conjunction with an internal antisense primer OL356; all trypanosome pre- 
mRNAs are trans-spliced to a small leader RNA (Agabian, 1990; Perry and Agabian, 1991). To
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amplify the 3’ end of the gene the poly[A] tail of the 3’ end of the transcript was exploited.
Total RNA was isolated from T. b. brucei STEB 247 procyclics using the Qiagen Total RNA kit 
as described (chapter 2.2.8) and first-strand cDNA synthesis was performed (chapter 2.2.8) 
using the poly [dT]-anchor primer.
To isolate the gene-internal fragment, predicted from known sequence to be 760 bp (N. 
Murphy, unpublished) a number of PCR reactions were performed at differing annealing 
temperatures using primers OL355 and OL356, with a dominant fragment of approximately 760 
bp expected to persist at higher annealing temperatures (Fig. 3.2). At 37°C annealing four main 
fragments were seen, with the dominant one at approximately the correct size (lane 2); at 42°C 
annealing the three subsidiary fragments were much fainter (lane 4), and at 48°C they were no 
longer present, leaving only the 760 bp fragment (lane 6). This fragment was excised, gel 
purified and cloned to pTAG vector (pGL138). Automatic sequencing using the AmpliTaq kit 
(Perkin-Elmer) and the vector-specific primers pTAG5’ and pTAG3’ showed the fragment to 
have identical sequence to CRK4. Completion of full-strand sequence of this fragment with the 
pTAG vector primers and the C/?AT4-specific primers shown (Fig. 3.1) showed it to be the 
expected 760 bp fragment from CRK4, with no base substitutions as compared to Dr. Murphy’s 
sequence.
To isolate the 5’ end of CRK4 an annealing temperature range set of reactions were 
done with OL356 and the SL primer on a Robocycler machine (Stratagene). 12 identical 
reactions across a range from 42-62°C were performed, thus providing an approximate annealing 
temperature difference of 1.7°C between reactions (reactions 1-7, Fig. 3.3). Because of the loss 
of specificity due to using the non-transcript-specific SL primer it was expected that more 
nonspecific fragments would be observed, particularly at the lower end of the temperature 
range, but that far fewer dominant fragments would persist at the high end of the temperature 
range. At the higher temperatures a number of fragments was detected, the major fragment of 
0.5 kb. A PCR reaction at an annealing temperature of 60°C was performed to purify this 
fragment for cloning; however, after the reaction was electrophoresed on a 1% TAE gel and 
visualised, fragments that had not previously been detected were observed at approximately 0.85 
kb and 1.0 kb (not shown). The predicted size of the amplification product was a minimum of 
0.9 kb. The 0.5 kb, 0.85 kb and 1.0 kb fragments were cloned into pTAG vector. Preliminary 
sequencing of pTAG/1.0 kb (pGL139) using the pTAG vector primers showed CRK4 sequence, 
and consequently the 0.85 kb and 0.5 kb subcloned fragments were not sequenced. Completion 
of full-strand sequence of the pGL139 insert using the pTAG vector primers and the CRK4- 
specific primers shown (Fig. 3.1) covering that region, gave the 5’ gene sequence and showed 
the splice site.
To isolate the 3’ end of CRK4 primer OL355 was used with the complementary anchor 
primer. A number of reactions were performed, differing only in the annealing temperature
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used; only two fragments persisted above moderate annealing temperatures of 50-55°C, at 
approximately 1.0 and 1.4 kb (Fig. 3.4, lane 2). A calculation of the minimum amplification 
product size for the 3’ end of the gene, required to encode the remaining kinase catalysis 
domains without a second insert domain, was approximately 1.3-1.4 kb. Consequently, only the
1.4 kb fragment was cloned to the pTAG vector. Sequencing using the vector-specific primers 
pTAG5’ and pTAG3’ showed a poly[dT] sequence and also gave an upstream sequence that was 
identified as the triosephosphate isomerase gene. The triosephosphate isomerase transcript is an 
abundant mRNA and is therefore one of the most highly represented components of an 
expression library. OL355 corresponds to the ATP-binding pocket of CRK4, which may explain 
the erroneous amplification of the triosephosphate isomerase cDNA. As the 3’ end of the CRK4 
gene could not be isolated by PCR methods it was decided to isolate the gene from a genomic 
A,phage library.
3.2.2: Isolation of CRK4 by library screening
To attempt to isolate clones derived from genomic DNA for comparison to those 
isolated by PCR, and to obtain the 3’ end of CRK4, a AFIXII T. b. brucei genomic library was 
screened. Sau3Al partial digestion of T. brucei DNA and digestion of the phage with Xhol to 
remove the stuffer fragment were used to construct the library. Both the digested phage and 
partially digested parasite DNA were subjected to a partial fill-in reaction to generate 
compatible cohesive ends, ligated and packaged. After establishing the titre a primary screen 
was carried out as described (chapter 2.2.10) with a low stringency hybridisation temperature of 
50°C. The rationale for the low stringency screen was that given the evidence of a multiple 
CRK4 gene family in C. fasciculata, it was extrapolated that such a family may also be present 
in T. brucei, hence a lower hybridisation temperature increased chances of detecting other 
homologues of tbCRK4. The insert from pGL138 was used as the probe in all rounds of phage 
screening; this fragment contains the first insert domain, and so was likely to confer added 
specificity to the probe for the CRK4.
The primary screen yielded only three clear but weakly hybridising plaques. The three 
primary plaques were titred and put through a second round of screening. Each gave 
approximately 15% positive plaques per plate. Six hybridising plaques were lifted from each of 
these secondary screens. Two secondary plaques representing each primary plaque were then 
chosen for tertiary screening. A single unique plaque from the tertiary screen was picked for 
further analysis
The three clones were labelled LA, HA and IILA; phage DNA was purified as described 
(chapter 2.2.10) for these clones and an initial analysis was carried out by performing restriction
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endonuclease digestion. The enzymes used were Notl, Sail, Sad  and Xbal, all chosen on the 
basis of site representation within the phage’s polylinker. These sites sit outside the Xhol site in 
the phage’s polylinker that was used in the generation of the library, and in addition none of 
them cut within the known sequence of CRK4. Hincll was also used; this cuts within the phage 
and also several times within the known sequence of CRK4, however as a frequent cutter it was 
used to provide a multiple fragment pattern to compare the three clones. Therefore, restriction 
digestion (except in the case of H indi) was expected to produce the phage arms of 
approximately 23 and 9 kb, with a pattern of fragments representing the fragments generated 
from the genomic inserts. The fragment pattern produced from this initial restriction digestion 
(Fig. 3.5) clearly showed clones IA and HA to have similar but not identical inserts; the notable 
differences between the two were in the Sail digest, where HA. showed an additional two 
fragments at approximately 1.8 and 3.2 kb (HA, lane 3) that were not seen with LA (LA, lane 3). 
In the Xbal digestion IA (lane 5) produced a single small fragment of 1 kb, whilst HA (lane 5) 
produced a 1.2 kb fragment. Clone HIA produced a completely different pattern of fragments. 
For clones IA and HA, there were few fragments produced from Xbal (lanes 5) and Sad  (lanes 
4), and none visible from Notl (lanes 2). The pattern of fragments in the H indi digestions 
seemed identical between clones IA and HA (lanes 6). For clone HIA, H indi sites were again 
frequent (lane 6) and there was a 1.1 kb fragment produced from Notl (lane 2). In contrast to LA 
and HA, Xbal and Sad  each generated two large molecular weight fragments for HIA (lanes 4 
and 5), and Sail generated only one or two non-phage-arm fragments, with a small fragment at 
about 1.1 kb (lane 3). Therefore clones IA and HA represented similar genomic fragments, while 
clone IILA was completely different.
Southern blotting was performed using the same restriction enzymes on purified DNA 
of the three phage clones; the probe used was again the insert from pGL138 (Fig. 3.6). For 
clones LA and LLA only very large molecular weight hybridising fragments were detected with 
Notl, Sad  and Xbal (lanes 1, lanes 3, lanes 4), indicating that CRK4 resides on a large DNA 
fragment. The CRK4 probe hybridised to a 2.5 kb Sail fragment for both clones (lanes 2), and a 
0.5 kb H indi fragment (lanes 5). The pattern of hybridising fragments was identical for clones 
IA and HA, supporting the view from the initial restrictions that these clones represent 
overlapping genomic fragments. Clone HIA gave a totally different pattern of hybridising 
fragments; the Notl digest produced a single fragment of about 1.1 kb (lane 1). Sail and Sad  
produced large molecular weight single fragments (lanes 2 and 3), and Xbal gave a single 
fragment at around 5 kb (lane 4). Interestingly, the H indi restriction gave the same-sized 
hybridising fragment at approximately 0.4 kb (lane 5) as seen for clones IA and HA, and also 
gave a very weakly hybridising fragment at an even smaller size.
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3.2.3: Subcloning and sequencing of CRK4
Subclones representing the entire CRK4 gene, with some flanking sequence, were 
cloned from the X DNA. To obtain the 5’ end of the gene plus some 5’ flanking sequence, both 
clones IA and IIA were digested with Sail and the hybridising 2.5 kb fragment cloned to the Sail 
site in pBluescript. PCR using the T3 and T7 vector primers was performed to identify colonies 
that carried inserts of the correct size. For each X clone, two independent 2.5 kb Sail subclones 
were isolated and DNA prepared for sequencing. To obtain the 3’ end of the gene and possibly 
some 3’ flank sequence, clone IIIA was digested with Notl and the hybridising 1.1 kb fragment 
cloned to the Notl site of pBluescript. Screening and selection resulted in two positive 1.1 kb 
Notl subclones being isolated. DNA was prepared from each subclone for sequencing.
Prior to sequencing of the six subclones, a restriction digestion was performed to check 
that subcloned fragments would excise properly with the relevant enzymes; in addition, Hincll 
and Sau3Al were also tested on all subclones, to provide a fragment pattern indicative of unique 
clones. The restriction patterns for subclones HA/1 and HA/2 were identical, but between the IA 
subclones there were clear differences in pattern with the H indi and Sau3Al digests; subclone 
LA/1 was clearly identical to both HA subclones, while subclone LA/2 was quite different from 
these three (data not shown). Subclones HLA/1 and HLA/2 produced identical fragment patterns 
(not shown). A Southern blot of the six subclones digested with Sail and Notl, as appropriate, 
and using the insert from pGL138 as a probe was carried out to determine which of the 2.5 kb 
subclones contained the predicted CRK4 sequence; the 1.1 kb subclones were also tested for 
hybridisation. The autoradiograph showed hybridisation to both LHA Notl 1.1 kb fragments but 
hybridisation only to subclone IA/2 Sail 2.5 kb fragment, therefore subclones LA/1, LLA/1 and 
HA/2 represented erroneous nonhybridising sequences, whilst subclones IA/2, IHA/1 and ILIA/2 
contained CRK4 sequence (data not shown).
Sequencing using the vector’s T3 and T7 primers was performed on the 3 positive 
CRK4 subclone plasmids, IA/2, IHA/1 and LHA/2. The results of preliminary sequencing 
confirmed the restriction analysis: subclone IA/2 was identified as CRK4 sequence with the T3 
primer; this showed antisense sequence from the Sau3Al site at position 560 (relative to the A 
of ATG start) towards the 5’ end of the gene. Therefore this subclone (pGLl 19) represented the 
5’ end of the gene and approximately 2 kb of upstream flank sequence. IHA/1 and IHA/2 
subclones (pGL140 and pGL141,) both gave identical sequence with the T3 primer. The 
sequence obtained was again antisense, this time from kinase catalysis domain X towards the 
Sau3Al site involved in the generation of the library. At this point it could not be determined if 
the 2.5 kb Sail fragment from IA/2 and the HLA 1.1 kb Notl fragments were contiguous 
sequence.
Southern blotting of XFIXH clone IHA DNA digested with a range and combinations of
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enzymes was carried out, to identify a hybridising fragment larger than the 1.1 kb Notl 
subcloned fragment, and so to isolate a subclone that represented the complete 3’ end of the 
gene plus some 3’ flanking sequence (Fig. 3.7). Only three of the restrictions identified a 
hybridising fragment that was a suitable size for subcloning: The Ncol digest had a fragment at 
approximately 2.2 kb (lane 6). As CRK4 has an Ncol site at position 578 (relative to A of ATG 
start) a 2.2 kb fragment would be predicted to contain the end of the gene plus approximately
1.4 kb of 3’ flank sequence. The Xbal-Xmnl digest also showed a 2.2 kb fragment (lane 1), by 
contrast the Sacl-Kpnl digest showed a hybridising fragment at approximately 1.6 kb (lane 2), 
both of which would be predicted to contain less 3’ flank than the 2.2 kb Ncol fragment. It was 
decided to subclone the Sacl-Kpnl fragment as although this fragment represented less 3’ flank 
sequence, the restriction sites involved were judged more convenient for use in subcloning. 
Inspection of clone IILA DNA digested with Sacl-Kpnl and electrophoresed on TAE midigels 
revealed that there were three fragments relatively close together; one fragment just over 1.5 kb, 
and a very close doublet at about 1.6 kb. Since it was impossible to tell from the Southern blot 
data which of these fragments was the one that hybridised with the CRK4 probe, all three were 
cloned to pBluescript. PCR using primers OL348 and OL356 were used to screen for positives, 
with an expected amplification product of approximately 450 bp. The results showed that the 
slightly larger of the two fragments at 1.6 kb was the fragment that hybridised to the CRK4 
probe. This fragment was cloned into pBluescript, to give pGL218.
3.2.4: Analysis of CRK4 sequence
Prior to complete sequencing of the three subclones, a Southern blot of STIB 247 
genomic DNA digested with a variety of restriction enzymes was carried out, and probed with 
the insert from pGL138 (Fig. 3.8). Only high molecular weight hybridising fragments were 
observed except in the case of HindUl (lane 5) which showed a hybridising fragment at 
approximately 1.6 kb, and Hindi, (lane 4) which gave a hybridising fragment of approximately 
0.4 kb. Following complete double-stranded sequencing of the gene and flanking sequences 
from subclones pGL119 (IA/2 Sail 2.5 kb), pGL140 (IDA/1 Notl 1.1 kb), pGL218 (IDA Sacl- 
Kpnl 1.6 kb), the Southern blot data were corroborated. The sequence of the PCR-generated 
fragment in pGL138 overlapped pGL119 and pGL140, thus proving that they represented 
contiguous sequences. The complete sequence of CRK4 with flanking sequences, primers and 
relevant restriction sites is shown (Fig. 3.9). From the region covered by the probe (insert from 
pGL138) the 0.4 kb H indi fragment detected on the Southern blot (Fig. 3.8) represents the 
fragment of 0.35 kb generated by cleavage at the H indi sites at positions 763 and 413 (relative 
to the A of ATG start). The 1.6 kb HindUl fragment detected represents the fragment of 1.59 kb
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generated by the cleavage at the HindUl sites at positions 1623 and 783 (relative to the A of 
ATG start). As shown in the earlier schematic (Fig. 3.1), tbCRK4 is the same as cfCRK in 
possessing two large insert domains, between kinase catalysis domains VIb and VII, and 
domains X and XI. Multiple alignment of tbCRK4 and cfCRK primary sequence with tbCRKs 
1-3 and S. cerevisiae CDC28 shows that for both CRK4s the Insert Domains 1 and 2 are almost 
exactly the same size between cfCRK and tbCRK4 (Fig. 3.10). Multiple alignment was done 
using ClustalW at EBI (http://www2.ebi.ac.uk/clustalw/). All the kinase catalysis domains 
present in CRK 1-3 are present in tbCRK4, including the conserved threonine and tyrosine 
residues (for tbCRK4, Thrl7 and Tyrl8) at the ATP binding pocket, the conserved threonine 
161 equivalent (for tbCRK4 and cfCRK this residue is a serine, at positions Ser231 and Ser230, 
respectively). The PSTAIRE box equivalent is present, through degenerate, with five 
substitutions (GAPPSTAIREIALLKV) as compared to human CDK1 (EGVPSTAIREISLLKE). 
The DSEI box equivalent is also present although highly degenerate with four substitutions 
(GNTDVDQ) as compared to human CDK1 (GDSEIDQ). There is another conserved residue at 
position 425 - a serine residue - that is also a serine at the equivalent position in tbCRK3 and 
CDC28, and a threonine in tbCRKl, tbCRK2 and cfCRK. The striking feature is that there is no 
significant homology between the insert domains for the two genes. BLAST searches for the 
insert domains only of tbCRK4 failed to produce any significant matches for any of the 
databases used (data not shown). Further differences were predicted for the two proteins using 
tools local to the ExPasy server (http://www.expasy.ch/tools/). The cfCRK protein was 
predicted to have a molecular weight of 53.5 kDa and a pi of 6.4, whereas tbCRK4 was 
predicted to be slightly smaller -as expected - at about 51.4 kDa, with a pi of 8.5.
Similarities between tbCRK4 and cfCRK are revealed by other analysis, however. 
Hydropathy plotting using the ProtScale tool at the ExPasy server with the method of Hopp & 
Wood (Fig. 3.11) shows that Insert Domain 1 for both proteins is predicted to be largely 
hydrophilic (tbCRK4 upper panel, residues 140-210; cfCRK lower panel, residues 143-210). 
Insert Domain 2 for both is less uniformly hydrophilic (tbCRK4, residues 312-390; cfCRK, 
residues 311-390) but both contain a highly hydrophilic sequence of residues, for tbCRK4 from 
about amino acids 310-350 and for cfCRK from about amino acids 305-325.
3.2.5: Production of recombinant GST-CRK4
The GST Fusion system (Pharmacia Biotech) was used for the production of 
recombinant GST-CRK4 fusion protein, to raise a specific anti-CRK4 antiserum, for use in 
Western blotting and immunoprecipitations. This system involved the large immunogenic GST 
tag, which could be problematic to remove if removal of the tag was necessary. However, GST
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is soluble and may help less soluble peptides to produce soluble protein as a fusion.
The segment of CRK4 used was a Hindl-HaeUI fragment of 244 bp, representing 
almost exactly the first insert domain with virtually no kinase domain sequence (see Fig. 3.1). 
The rationale was that as this insert domain does not have significant homology to any protein 
sequence in the SwissProt database, it would be less likely to raise antibodies that could cross- 
react to other endogenous trypanosome proteins. The GST tag is 26 kDa, so the predicted size of 
the GST-CRK4 fusion protein was approximately 36 kDa.
Plasmid pGL138 was digested sequentially with Hincll and HaelU, as the buffers for the 
enzymes are not compatible. The reaction was electrophoresed on a 1% TAE midigel, the 244 
bp fragment excised, gel purified and cloned into the Smal site of pGEX-5X-2. Transformants 
were screened by Southern blotting: Colony streaks were lifted to supported nitrocellulose filter 
and probed with the insert from pGL138. Eight positives were detected and further screened by 
PCR. Two clones containing the insert fragment in the correct orientation were detected; one of 
the clones was chosen, and DNA was prepared for restriction and sequencing. Restriction 
analysis and PCR reactions confirmed that this clone, pGL134 (Fig. 3.12) contained the insert 
fragment in the correct orientation. Sequencing of the 5’ ligation join using primer OL350 was 
performed using a manual kit (USB) with the manganese modification, rather than automatic 
sequencing, as the ligation join was less than 50 bp from the primer. The sequence obtained 
showed that the insert fragment had integrated in the correct orientation and with the reading 
frame preserved. Consequently, pGL134 was transformed to the protease-deficient E. coli strain 
BL21 for pilot expression and purification of GST-CRK4.
A 20 ml culture in LB with 100 pg ml'1 ampicillin was inoculated at 1:100 with a 
saturated overnight culture of BL21pGL134, and grown to an optical density of 0.8 at 600 nm. 
An uninduced control sample was taken, and IPTG added to a final concentration of 2 mM. 
Induced samples were then removed hourly, up to four hours. The remainder of the 4-hour 
induced culture (10 mis) was centrifuged at 10 OOOg for 10 minutes at 4°C, the medium decanted 
and the cell pellet frozen at -20°C. Crude whole cells lysates were prepared from the uninduced 
and induced samples (described in chapter 2.3.2), electrophoresed on a 12.5% Lammeli gel, 
stained with Coomassie blue and dried down (Fig. 3.13). The Lammeli gel clearly showed the 
induction of two proteins (lanes 3-6), although at 30 kDa and 44 kDa neither matched the 
predicted size of 36 kDa for recombinant GST-CRK4.
A solubility check was performed (Fig. 3.14) using the frozen cell pellet from the pilot 
expression experiment (above). The cell pellet was thawed, resuspended in sonication buffer 
and was incubated on ice for 30 minutes following addition of lysozyme to 1 mg m l1. 
Subsequently, they were put through 6 freeze/thaw cycles in dry ice/ethanol and a 100°C heating 
block and then spun at maximum speed in a bench microfuge for 20 minutes. The supernatant 
was aspirated and the cellular debris resuspended in 1 ml sonication buffer by syringing through
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a G25 needle. 400 pi of FSB was added to the supernatant (soluble protein) and the cellular 
debris (insoluble protein), the samples heated to 100°C for 5 minutes and aliquots 
electrophoresed on a 12.5% Lammeli gel, the gel stained with Coomassie blue and dried. The 
same two proteins previously noted, of 30 kDa and 44 kDa, were observed in the soluble protein 
lysate (lane 3) but not in the insoluble protein lysate (lane 2). However, the insoluble protein 
sample was very dilute.
A small-scale native purification for GST-CRK4 was performed as described (chapter 
2.3.3), and samples of insoluble protein, soluble nonbound protein and eluate protein 
electrophoresed on a 12.5 % Lammeli gel and visualised by Coomassie staining (data not 
shown). A 44 kDa protein but not a 30 kDa protein was detected in the insoluble protein sample; 
the 30 kDa protein showed in the soluble nonbound protein samples although the 44 kDa protein 
did not, but it was present with very little apparent contamination in the eluate protein sample. 
The 30 kDa protein did not show in the eluate samples. The presence of the 44 kDa protein in 
the insoluble (cellular debris) sample was likely a result of large over-expression of the 
recombinant protein, either allowing some soluble recombinant protein to be brought down in 
the pellet or representing some recombinant protein forming inclusion bodies. There was a 
disparity of 8 kDa between the predicted size of GST-CRK4 (36 kDa) and the 44 kDa protein 
selected by the GS4B resin. The isoelectric point (p/) of the CRK4 peptide was predicted to be 
4.4, therefore it was possible that the molecular weight disparity was a result of retardation on 
the Lammeli gel due to the CRK4 peptide’s acidity.
Based on the pilot assays, it was decided to use the GST system for a moderate-scale 
induction and purification of GST-CRK4. 4x 500 ml LB were each inoculated at 1:100 with a 
saturated overnight culture of BL21pGL134, grown to an OD at 600 nm of 0.8, induced by the 
addition of 0.5 mM final concentration IPTG and grown for a further 4 hours. Cells were 
harvested by centrifugation at 7 500g for 10 minutes at 4°C, cell pellets resuspended in a total of 
100 ml lx PBS pH 7.2 and lysed by sonication. The lysate was centrifuged at 12 OOOg for 10 
minutes at 4°C to clear the cellular debris, the supernatant aspirated and applied to a GS4B resin 
column. The column was washed with lx  PBS pH 7.2 until the protein content of the flow­
through was negligible as judged by absorbance at 280 nm, and bound GST-CRK4 was eluted 
with 3x 3 ml glutathione elution buffer. Eluate fractions were dialysed overnight against 2 000 
ml lx PBS pH 7.2. Samples of the dialysed eluate fractions were electrophoresed on a Lammeli 
gel to determine which fraction contained the bulk of the GST-CRK4 protein, along with 
samples of the crude soluble lysate, column flow-through and first wash fraction (Fig. 3.15).
The column appeared to be overloaded as the induced 44 kDa protein was detected in the flow­
through (lane 3) as well as the wash (lane 4). However, by far the majority of GST-CRK4 was 
in the first eluate fraction (lane 5), with a lesser amount in the second eluate fraction (lane 6). A 
number of other proteins were detected in each eluate fraction, all of which were below 40 kDa
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and may have been degradation products. Samples of the first and second eluate fractions were 
bound separately to an excess of GS4B resin, washed thoroughly, eluted and electrophoresed on 
a Lammeli gel (not shown). The profile of proteins remained the same, indicating that all the 
smaller proteins were specifically binding the resin. The concentration of protein in the first 
eluate fraction was assessed using the Biorad DC protein assay kit, and found to have a GST- 
CRK4 concentration of 3 mg ml'1. 200 pg of the first eluate fraction was used in the primary 
immunisation of two New Zealand rabbits, essentially as described in chapter 2.3.4. The antisera 
from the two rabbits were labelled anti-CRK4/A and anti-CRK4/B on receival. The purified 
GST-CRK4 protein in eluate fractions 1 and 2 were dispensed to eppendorfs as 100 pi aliquots 
and stored at -20°C.
3.2.6: Western blotting with anti-CRK4 antibodies
After exsanguination of both animals, test blots with both antisera showed that anti- 
CRK4/B gave more promising results (data not shown), therefore it was an aliquot of this 
antiserum that was purified by the two-step affinity purification. This involved one purification 
step on an immobilised GST column to remove anti-GST antibodies, and a second purification 
step on an aminolinked GST-CRK4 column to specifically purify only anti-CRK4 antibodies 
(for details see chapter 2.3.4). After the first step, removal of anti-GST antibodies, the flow­
through fraction was tested against protein lysates of STIB 247 long slender bloodstream, short 
stumpy bloodstream and procyclic lysates, and also against TREU 869 long slender bloodstream 
lysates (Fig. 3.16). A doublet at 46-48 kDa was detected very weakly in the soluble protein 
lysate of all three STIB 247 life cycle stages (lanes 1, 3, and 5) that was competed with purified 
GST-CRK4 fusion protein (lanes 9, 11 and 13). Although intensity of signal varied both proteins 
were also present to lesser degrees in the insoluble protein lysates (lanes 2, 4, and 6). The larger 
of this doublet was present in both soluble and insoluble lysates of TREU 869 (lanes 7 and 8), 
although the smaller protein was not. Proteins of 55-60 kDa were detected at in the STIB 247 
long slender bloodstream form soluble and insoluble lysates (lanes 1 and 2) that were competed 
with fusion protein. A protein of 32 kDa, not competed with purified GST-CRK4 fusion protein, 
was detected in the soluble lysate of all three STIB 247 life cycle stages (lanes 1, 3 and 5) and 
also in the short stumpy insoluble protein lysate (lane 4). This protein was also detected in both 
the soluble and insoluble lysates of the TREU 869 long slender bloodstream form.
Following the second purification step of specific purification of anti-CRK4 antibodies 
and dialysis of protein-containing pools, a Western was performed with these antibodies using 
fresh S-100 soluble protein lysates were made from all three STIB 247 life cycle stages; from 
freshly-harvested procyclics at midlog, and from freshly purified long slender bloodstream and
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short stumpy bloodstream form. The lysates were electrophoresed on Lammeli gels, transblotted 
and probed with the purified anti-CRK4 antibodies (Fig. 3.17). Two proteins were observed in 
the procyclic lysate (lane 3), the 53 kDa protein being specifically competed by preblocking of 
the antibodies with a saturating quantity of fusion protein (lane 6), indicating the specificity of 
the reaction. The 53 kDa protein was also present in the short stumpy bloodstream form (lane 2), 
although the signal was far weaker, and was competed with fusion protein (lane 5). The 53 kDa 
protein was absent from the long slender bloodstream form (lane 1). There was also a slightly 
smaller protein, detected with weak intensity, present in the long slender bloodstream and short 
stumpy bloodstream form lysates (lanes 1 and 2) that appeared to be specifically blocked (lanes 
4 and 5), and a slightly larger protein of weak intensity in the short stumpy bloodstream form 
lysate (lane 2) that was not competed with fusion protein (lane 5). A modified Western protocol 
was followed (Fig. 3.18) with the blocking step carried out at room temperature for 8 hours and 
the blot incubated with primary antibodies at a lower concentration and overnight at 4°C. This 
resulted in disappearance of all but the 53 kDa protein detected in procyclics (lanes 2 and 4) and 
more weakly in the short stumpy bloodstream form (lanes 1 and 3); for both lysates this protein 
was competed with fusion protein (lanes 5-8). The conclusion would therefore be that the 
purified anti-CRK4/B antibodies specifically detects CRK4 in soluble fraction protein lysates of 
STIB 247 short stumpy bloodstream and procyclic form, but not in soluble lysates of the long 
slender bloodstream form. Quantitatively, CRK4 abundance would appear to be low in the short 
stumpy bloodstream form, raised to a higher level in procyclics, and that the protein is not 
present in the long slender bloodstream form. The apparent size of the protein correlates well 
with the size of approximately 51-52 kDa as predicted from the gene sequence.
3.2.7: Selections using recombinant p l2  and p l3
To establish that CRK4 has one property of a CDK, that of binding to the small cofactor 
protein p i3, from yeast, or p i2, from Leishmania mexicana, procyclic S-100 soluble protein 
lysates were selected with beads cross-linked by amino linkage to either recombinant p l2CKS1, 
p l3 sucl or to TRIS (control beads). Selection was carried out as described in chapter 2.3.6. 
Protein eluted from the beads was electrophoresed on 12.5% Lammeli gels, transblotted and 
probed with the purified anti-CRK4/B antibodies (Fig. 3.19, upper panel). Two proteins of 
approximately 60 and 66 kDa were found to bind p l2  (lane 2) and p l3  (lane 3) but also control 
beads (lane 1). The cross-reaction with the antibodies was strong, and appeared to be partially 
abrogated by preblocking the antibodies with fusion protein (lanes 4-6). This result could be 
repeated with several attempts at this experiment. In no case was a protein detected at the 
predicted size of 53 kDa, although in some of the blots the resolution was sufficiently low that
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any signal from CRK4 could have been swamped by the signal from the two nonspecific 
proteins. To attempt to resolve this, lower percentage acrylamide Lammeli gels, with a resolving 
section of 7.5%, were run to achieve greater separation of proteins in this region. When probed 
with the purified anti-CRK4/B antibodies (Fig 3.19, lower panel) the same two nonspecific 
proteins were detected (lanes 7-9), although there appeared to be less blocking with fusion 
protein than previously observed (lanes 10-12). The 53 kDa CRK4 was never detected, 
suggesting that CRK4 does not bind either p l2  or p i3. Although internal positive controls were 
not performed, the same bead preparations were routinely being used by other researchers with 
the expected results, and it was therefore assumed that lack of CRK4 binding was not due to the 
beads.
3.2.8: Immunoprecipitation using purified anti-CRK4 antibodies
The purified anti-CRK4/B antibodies were used to immunoprecipitate CRK4 from S- 
100 soluble fraction protein lysates of STIB 247 procyclics, and linked to kinase assays, to try to 
demonstrate a CRK4-associated kinase activity. As Western blots had shown that the candidate 
polypeptide was present at greatest quantity in procyclic form soluble extracts, procyclic S-100 
soluble lysates were incubated with either preimmune serum, purified anti-CRK4/B antibodies 
or purified anti-CRK4/B antibodies preblocked with a saturating amount of recombinant fusion 
protein, and kinase assays performed. Antibody-CRK4 complexes were bound to Sepharose- 
protein A beads, washed extensively to remove all other soluble proteins and resuspended in a 
kinase assay mix, containing Y32p-dATP and a substrate protein at a concentration of 5 pg ml'1 
(for full details see chapter 2.3.5). The pilot assay used phosvitin as a substrate (Fig. 3.20) as 
phosvitin has been demonstrated to be a substrate for CDK phosphorylation. A stronger kinase 
activity was detected with the preimmune serum (lane 1) than the anti-CRK4/B antibodies (lane 
2) or the anti-CRK4/B antibodies preblocked with purified GST-CRK4 fusion protein (lane 3).
It is always difficult to predict a good substrate for kinases, but as phosvitin had been used to 
assay the kinase activity of other CDC2-related kinases it was chosen as a possible substrate for 
CRK4; however, the result of the pilot kinase assay suggested that phosvitin may simply not be 
a substrate for CRK4. Further attempts were carried out with a range of substrates, including 
phosvitin, a-casein, p-casein, protamine and a histone mix. No specific kinase activity was 
obtained with any of these substrates (Fig. 3.21). As no significant difference between the anti- 
CRK4 antibodies and the antibodies preblocked with recombinant protein was found, with the 
exception of a small difference for a-casein (lanes 3 and 4), and in the case of protamine (lane 
2), which showed a stronger signal with the preblocked antibodies (lane 9) it would appear that 
there is no kinase activity associated with CRK4 precipitated from STIB 247 procyclics.
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3.2.9: Northern blotting and RT-PCR
To corroborate the findings from Western blotting that CRK4 is expressed mainly in 
procyclics and to obtain a rough quantitation of transcript presence between life cycle stages, 
poly [A]+ RNA was prepared from STIB 247 long slender bloodstream, short stumpy 
bloodstream and procyclic forms, and a Northern blot performed (see chapter 2.2.8). Following 
RNA transfer from the gel to supported nitrocellulose membrane by capillary blotting, the 
membrane was stained with methylene blue and probed with the insert from pGL138. No 
transcript was detected in any of the life cycle stages, even after 14 days exposure of the filter to 
autoradiography film. However, as no mRNA was observed on methylene blue staining, and a 
re-probe of the filter with the insert from pGL130 did not detect the CRK2 transcript, it is 
possible that the RNA was degraded.
To check the integrity of the RNA preps, first-strand cDNA was made from the 
poly[A]+ RNA preps for all three life cycle stages using an oligo[dT] primer. In addition, 
control reactions were performed, identical to the first-strand synthesis reactions with the 
exception that the control reactions did not include reverse transcriptase (for details see chapter 
2.2.8). PCR was then carried out with the first-strand cDNA reactions, labelled (+), and the 
control reactions, labelled (-). Initially, the primer combination OL355 and OL356 was used, to 
amplify a 760 bp fragment; these reactions worked but the end-point products were of very low 
abundance, therefore visualisation was poor. Consequently a nested approach was taken, using 
the first round primer combination OL355 and OL90 to amplify a 945 bp fragment, with the 
second round combination of OL348 and OL356, to amplify a 437 bp fragment, or OL348 and 
OL350, to amplify a 144 bp fragment. Aliquots of the control (-) samples were treated with 
RNaseA, labelled (-/-) as an additional negative control. A set of reactions using the 
aforementioned primers gave odd results; the expected amplification fragments were seen for 
the (+) reactions, but the exact same reactions were also seen for the (-) reactions (data not 
shown). Only the (-/-) reactions showed no amplification products. As it is not possible to 
amplify by PCR from mRNA, no conclusions could be drawn from these experiments.
3.3: Discussion
The PCR-based approach to isolation of the CRK4 gene was only partially successful. 
The gene specific primers amplified a product of the predicted molecular weight (Fig. 3.2); 
cloning and sequencing of this 760 bp fragment showed it to be CRK4, with no base 
substitutions as compared to the partial sequence of Dr. Murphy (unpublished). The utilisation 
of the mini-exon 39 bp splice leader sequence along with one of the gene specific primers
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(OL355) gave a less specific reaction (Fig 3.3), with several species persisting to high annealing 
temperatures. The three major fragments of 0.5 kb, 0.85 kb and 1.0 kb were cloned. Initial 
sequencing of the cloned 1.0 kb fragment showed CRK4 sequence; further sequencing showed it 
to be the expected amplification product representing the 5’ end of the gene, and indicated the 
acceptor site for trans-splicing to the 39 bp splice leader sequence (Fig. 3.1). Attempts to 
amplify the 3’ end of CRK4 using primer OL355 and the complimentary anchor primer gave two 
amplification products that persisted to reasonable annealing temperatures, of 1.0 kb and 1.4 kb. 
Based on calculations of the minimum amplification product size required to encode all the 
remaining required kinase catalysis domains without a second insert domain, only the 1.4 kb 
fragment was cloned and sequenced. Preliminary sequencing showed this to be a fragment of the 
triosephosphate isomerase gene; the triosephosphate isomerase mRNA is an abundant transcript 
and therefore forms one of the most highly represented species in an expression library. As 
previously mentioned primer OL355 corresponds to the ATP-binding pocket of CRK4, covering 
the sequence that encodes the amino acid sequence LGEGTYG. This is a consensus sequence 
that is conserved across proteins that bind ATP, therefore OL355 provided less specificity for 
CRK4 than was initially believed and partnered with the complementary anchor primer that 
annealed all first-strand cDNAs, the erroneous amplification of a fragment of the 
triosephosphate isomerase gene is perhaps not as surprising as initially thought.
The library screen was carried out to obtain the 3’ end of CRK4, also allowing a direct 
comparison of genomic and transcript-derived sequences. In addition this enabled isolation and 
sequencing of the CRK4 flanking sequences, required for future work to develop targeted gene 
disruption constructs. The insert from pGL138 was used to screen the APEXD T. b. brucei 
genomic library; this fragment covers kinase domains I to IX, and the first insert domain. A 
hybridising temperature of 50°C was employed, lower than would normally be used. Given the 
existence of a subfamily of CRK4 genes in C. fasciculata it was hypothesised that there may be 
a similar subfamily in T. brucei, hence a lower hybridisation temperature would increase the 
likelihood of detection of CRK4 homologues. The primary screen yielded only three hybridising 
plaques; secondary and tertiary screens isolated these three clones. The initial restriction 
analysis (Fig 3.5) and Southern blotting (Fig 3.6) showed that clones LA and HA were similar 
whereas clone IDA was quite different. There were differences notable in the restriction patterns 
of clones IA and DA with Sail, and a slight difference in the size of the one noticeable fragment 
produced with Notl, therefore leading to the supposition that clones LA and DA represented 
overlapping sequences. The Southern blot (Fig 3.6) showed exactly the same pattern of 
hybridising fragments for clones IA and ELA, showing that these clones likely represented phage 
inserts covering a Sau3Al site internal to CRK4 to sequence outwith the gene. Clone DIA gave a 
different pattern of hybridising fragments, although LA, DA and IDA all gave a small molecular 
weight hybridising fragment of about 0.4 kb with Hincll. There were two Hincll sites within the
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known sequence of CRK4, at positions 11 and 413 (relative to the A of ATG start) which would 
give the 0.4 kb fragment observed for clones LA and IIA (Fig. 3.1). As clone IIIA gave a 
different pattern of restriction fragments and hybridising fragments the assumption was that 
there was a Hincll site approximately 200 bp into the phage arm sequence that gave a 0.4 kb 
fragment representing 200 bp of CRK4 sequence and 200 bp of phage sequence that was 
detected by the probe. At this point, due to the presence of two Sau3Al sites in the region of the 
gene covered by the pGL138 insert probe at positions 266 and 561 it was not possible to tell if 
clone IIIA insert sequence was contiguous with the insert sequence of clones LA and HA.
From the Southern blots the 2.5 kb Sail hybridising fragment was subcloned from 
clones IA and IIA, and the 1.1 kb Notl fragment was subcloned from clone IIIA. Restriction 
analysis and Southern blotting of the chosen subclones showed that three of the four subclones 
of IA and LLA were identical but did not hybridise the probe, with the one distinct subclone 
(IA/2, pGLl 19) producing a different restriction pattern and hybridising the probe. Both ILLA/1 
and IILA/2 hybridised the probe and were identical by restriction analysis. Preliminary 
sequencing of pGLl 19 showed antisense CRK4 5’ sequence from the Sau3Al site at position 
560 toward the 5’ end of the gene; therefore the pGLl 19 insert represented the 5’ end of the 
gene and approximately 2 kb of 5’ flanking sequence. Preliminary sequencing of pGL140 
showed antisense CRK4 3’ sequence from kinase catalysis domain X. As this subclone 
represented little if any 3’ flanking sequence, further Southern blots were done to identify larger 
hybridising fragments from clone EUA; the 1.6 kb Sacl-Kpnl fragment was identified (Fig. 3.7) 
and subcloned (pGL218).
Complete sequencing of the pGL140 insert and partial sequencing of the pGL218 and 
the pGLl 19 inserts gave the complete double-strand sequence of CRK4, showing that the 
pG Ll40 insert and both the pGL218 and pGLl 19 inserts represented contiguous CRK4 
sequence with the Sau3Al site at position 560 the site dividing the two types of subclone. The 
sequence from pGLl38 (the PCR product obtained from OL355 and OL356) overlapped this 
Sau3Al site, proving that the two types of lambda subclones represented contiguous sequence. 
The complete ORF for CRK4, translated into peptide sequence, showed the presence of a 
second Insert Domain at an equivalent position to the cfCRK Insert Domain 2, and of 
approximately the same size. Multiple alignment of tbCRK4with tbCRKl-3, cfCRK and CDC28 
showed that tbCRK4 possessed all the kinase catalysis domains as well as the CDK/CRK- 
specific features - a PSTAIRE and DSEI box (although both to some degree degenerate) as well 
as the conserved serine/threonine and tyrosine residues at equivalent positions as compared to 
CDK1 (not shown) and CDC28 (although the serine and threonine residues appear to be fairly 
interchangeable at these conserved points between CRKs). BLAST database matching searches 
using just the insert domain sequences from tbCRK4 did not find any significant matches, and 
there was little homology between tbCRK4 and cfCRK for Insert Domain 1 or Insert Domain 2.
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However, hydropathy plotting of the two CRK4 proteins showed that both insert domains were 
hydrophilic, with a striking similarity in Insert Domain 2 showing as a highly hydrophilic spike 
on the plot. It is tempting to speculate that the insert domains - despite a lack of primary 
sequence homology - may adopt similar secondary structures and have relevant and homologous 
biological function.
The Pharmacia Biotech GST system was used to try and express a fragment of CRK4 to 
produce recombinant protein. This system involves a large (26 kDa) highly immunogenic tag 
which could prove problematic to remove, should that have been necessary, but which would 
help to both stabilise the CRK4 portion of the recombinant protein and solubilise it. Purification 
of glutathione-S-transferase tagged protein is carried out under native conditions, hence GST- 
CRK4 would have to be soluble within the bacteria for this system to be feasible.
The section of CRK4 chosen to be cloned to the expression vectors was a HincU-HaeUl 
fragment of 244 bp that represented almost exactly the first insert domain with virtually no 
kinase domain sequence (Fig. 3.1). The rationale was that as this insert was not present in the 
other known CRK genes nor did database matching produce any significant matches, using it to 
produce recombinant protein and raise antisera would increase the chance of obtaining an 
antiserum specific for CRK4. The vector pGEX-5X-2 was chosen to engineer a fusion protein 
with the CRK4 portion C-terminal to the GST protein (pGL134; Fig. 3.12).
Pilot inductions with the expression construct pGL134 in E. coli strain BL21 (Fig. 3.13) 
showed two induced proteins of 30 kDa and 44 kDa. Comparing soluble and insoluble protein 
fractions of induced cultures showed that both the 30 kDa and the 44 kDa proteins in the pilot 
expression of GST-CRK4 were located in the soluble protein fraction (Fig. 3.14). A small-scale 
native purification was performed for GST-CRK4; the 44 kDa protein was seen in the insoluble 
protein fraction but not in the soluble nonbound protein fraction, although the 30 kDa was 
observed in the latter and therefore did not bind the immobilised glutathione matrix. The 44 kDa 
protein was also present with very little apparent contaminating protein in the eluate fraction. 
The assumption was therefore that the 44 kDa protein was GST-CRK4, and that the presence of 
some of this in the insoluble protein fraction was likely due to large over-expression of the 
recombinant protein thus either allowing some to be brought down with the cellular debris or 
representing some recombinant protein forming inclusion bodies. The predicted size of GST- 
CRK4 was 36 kDa, 26 kDa from the GST protein and 10 kDa from the CRK4 segment, hence 
there was a disparity of about 8 kDa between the predicted size and the observed size of the 
induced, purified protein. An examination of the isoelectric point of the CRK4 segment 
predicted a pi of 4.4. Highly acidic proteins, the exemplar being histones, are known to migrate 
anomalously on SDS-PAGE gels therefore it was possible that the low isoelectric point of the 
CRK4 segment of GST-CRK4 was causing the recombinant protein to be retarded on Lammeli 
gels, hence the molecular weight disparity of 8 kDa.
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The GST system was then used to express and purify large quantities of GST-CRK4, 
which was used in the immunisation of two rabbits, by the schedule described in chapter 2.3.4. 
Preliminary Western blotting using the first bleed antisera showed both to be detecting many 
proteins, although most of them could not be competed with fusion protein (data not shown). 
The multiplicity of proteins observed could have been the result of a number of factors: The 
antisera were nonpurified, and as such contained large quantities of IgM and other serum 
proteins. Also, the GST system uses the glutathione-S-transferase gene from Schistosoma 
japonicum', anti-GST antibodies in the resulting polyclonal antisera can cause problems in 
immunological analysis due to cross-reactivity to endogenous GST-like proteins in the protein 
samples under study. Accordingly, following the exsanguination bleed of both rabbits and 
preliminary Western blots to determine which of the two gave lower background (data not 
shown) the anti-CRK4/B antiserum was purified in a two-step process. Anti-GST antibodies 
were removed from an aliquot of the antiserum by specific adsorption to an immobilised GST 
column. The column flow-through was tested in a Western blot using lysates of STIB 247 
procyclic, long slender bloodstream and short stumpy bloodstream forms, and lysates of the 
TREU 869 long slender bloodstream form (Fig. 3.16). Many of the proteins previously observed 
that were not competed with fusion protein were absent. Specific proteins that could be 
competed with purified GST-CRK4 fusion protein were detected at 46 kDa and 48 kDa in both 
the soluble and insoluble protein lysates for all three STIB 247 life cycle stages, although these 
signals were very weak with the exception of the 48 kDa protein in the STIB 247 short stumpy 
bloodstream and long slender bloodstream form soluble lysates. In addition, there was a larger 
molecular weight protein detected in both STIB 247 long slender bloodstream form soluble and 
insoluble lysates that were competed with fusion protein. At this juncture the 3’ end of CRK4 
had not been isolated, so there was no definite predicted size for the protein. A rough calculation 
of the size that would be added to the known peptide sequence in order to represent the 
remaining kinase catalysis domains suggested that in the absence of a very large second insert 
domain, CRK4 was most likely either the 46 kDa or the 48 kDa protein.
The GST column flow-through was then affinity purified on an immobilised Sepharose- 
GST-CRK4 aminolink column, and the purified anti-CRK4 antibodies tested in a Western blot 
with fresh soluble lysates made of STIB 247 procyclic, short stumpy bloodstream and long 
slender bloodstream forms, to attempt to clarify exactly what the antiserum was detecting (Fig. 
3.17). This gave much clearer results, with one protein at approximately 54 kDa detected in the 
procyclic lysate that was competed with purified GST-CRK4 fusion protein. This protein was 
also present in the short stumpy bloodstream form lysate at lower intensity, but was absent from 
the long slender bloodstream form lysate. There were in addition faint proteins just above and 
below this dominant protein, but modification of the blotting protocol lead detection of only the 
54 kDa protein (Fig. 3.18). The size of this protein corresponds well to the predicted size from
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the complete open reading frame of the gene of approximately 51-52 kDa. The conclusion 
therefore is that CRK4 is expressed to a low degree in the short stumpy bloodstream form and to 
a high degree in the procyclic form, but that it is not expressed in the long slender bloodstream 
form. Control of expression and activity could therefore be at the level of transcriptional control, 
mRNA translation (or mRNA stability) or post-translational modification.
The purified anti-CRK4/B antiserum was also used in immunoprecipitations linked to 
kinase assays, to attempt to demonstrate a functional kinase activity for CRK4 in procyclic form 
soluble extracts (Fig. 3.20). However, use of a range of substrates failed to show any significant 
activity that could be competed by fusion protein (Fig. 3.21). As the antiserum was raised to a 
soluble GST fusion protein containing a CRK4-specific section of 83 amino acids it would be 
expected that the CRK4 portion have secondary structure and possibly some tertiary structure. A 
hydropathy plot of the first insert domain showed it to be highly hydrophilic (Fig. 3.11) and 
therefore possibly forming a discrete domain structure exposed to the cytosol. The GST-CRK4 
fusion could thus reasonably have been expected to have conformational epitopes, leading to a 
polyclonal antiserum that would perhaps be poorer at recognising denatured CRK4 in the 
context of a Western blot, but better at recognising native CRK4 in the context of an 
immunoprecipitation. The failure to demonstrate a CRK4-linked kinase activity from procyclic 
form extracts could have several explanations. Firstly, that although soluble the CRK4 portion 
of the GST-CRK4 fusion protein, outwith the context of the rest of CRK4, did not fold properly 
and that antibodies in the resulting antiserum were largely directed to linear peptide sequence 
and spurious conformational epitopes, giving specific detection on a Western blot but failing to 
recognise the native protein. Secondly, it is possible that the insert domains of CRK4 confer 
some novel functional interaction with other protein(s) or other cytosolic molecules that 
physically exclude the binding of antibodies to the domain, whether by stearically blocking 
antibodies or by causing conformational change of the insert domain. This possibility is 
intriguing, given previous speculation about the function of these domains, but beyond the fact 
that hydropathy plots show both to be highly hydrophilic, little could be extrapolated as 
database search matching found no homology to any other eukaryotic peptide sequences, nor 
any structural motif similarities. A third possibility is that CRK4 has been immunoprecipitated 
but that it is not active in the procyclic form of the parasite; this would appear to be counter­
intuitive, as it is expressed at greatest abundance in this form, but it is possible that it is active at 
the transition between the short stumpy bloodstream form and the procyclic form, and is present 
though not active in cultured procyclics. Alternatively, it is possible that CRK4 activity is 
required in the proventricular mesocyclic or the epimastigote forms, and is held as an inactive 
complex until then. As it is difficult to predict protein substrates for kinases, the possibility that 
precipitated CRK4 from procyclic extracts is active but not against any of the substrates tested 
cannot be ruled out.
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Selection with recombinant p l2CKS1 and p l3sucl from procyclic form soluble protein 
extracts were run on Lammeli gels, transblotted to PVDF membrane and probed with the 
purified anti-CRK4/B antiserum, to determine which of the recombinant proteins CRK4 bound. 
Previous work has shown that T. b. brucei CRK1, CRK2 and CRK3 all bind p i2, and that CRK3 
binds p l3  weakly (Van Hellemond and Mottram, unpublished), therefore the same was expected 
to be observed for CRK4. However, repeated attempts at selection showed that CRK4 from 
procyclics does not bind either p l2  or pl3 (Fig. 3.19). There are several possible reasons for 
this. As speculated, CRK4 may be held inactive as part of a complex in the procyclic form, 
precluding binding to p i2. Alternatively, CRK4 may simply not bind pl2; the insert domains 
may confer novel biological function upon CRK4 such that it does not interact with p l2  (or the 
as yet undiscovered T. brucei equivalent). Given the failure to demonstrate a kinase activity and 
the fact that CRK4 does not appear to bind p i2, demonstration of binding a cyclin-like protein 
would seem to be necessary to classify this as a functional CDK homologue. The position of 
trypanosomes as one of the earliest divergents form the eukaryotic tree should be borne in mind, 
as CRK4 could represent divergence from a ‘proto-CDK’ to a CDK-like protein that has novel 
biological functions, possibly not related to control of the cell cycle.
To corroborate the Western blot results, that in STIB 247 CRK4 is not expressed in the 
long slender bloodstream form, expressed to low levels in the short stumpy bloodstream form 
and expressed to higher levels in the procyclic form, Northern blotting was performed on 
poly[A]+ RNA isolated from STEB 247 procyclic, long slender and short stumpy bloodstream 
forms. No transcript was detected when the membrane was probed with the insert from pGL138. 
As there was some doubt about transcript integrity, first-strand cDNA was synthesised; 
however, the results from this had to be discounted as the negative control gave positive results. 
Successful Northern blotting, or quantitative PCR, could delineate the question of differential 
transcription rates between the life cycle stages and whether control at the level of RNA 
stability or translation is a major point of control of expression. Control of CRK4 activity by 
post-translation modification has not been shown as functional kinase activity has not been 
demonstrated.
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Fig. 3.1: The T. brucei CRK4 gene
A) Schematic diagram of the CRK4 gene showing the primers used to obtain full-strand 
sequence for the open reading frame (ORF) and the flanking sequences. The splice leader 
addition site is also shown (SL) and the two insert domains. B) Schematic diagram of the CRK4 
gene showing the relevant restriction sites. The Sau3Al site at position 1309 (560 relative to the 
A of ATG start) is the site relevant to the two contiguous lambda subclones. The Hincll site at 
1163 and the HaeIII site at 1407 (414 and 658, respectively, relative to the A of ATG start) 
were the sites used for excision of Insert Domain 1 for the recombinant protein work.
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Fig. 3.2: PCR from first-strand cDNA to amplify a CRK4 gene fragment
PCR was performed on first-strand cDNA of T. b. brucei STIB 247, using 2 pi of cDNA in a 
reaction volume of 10 pi with 50 ng each of primers OL355 and OL356. Conditions were the 
same between reactions with only the annealing temperature altered; the end-point products 
were electrophoresed on 1.0% agarose gels and visualised by staining with 0.5 pg ml"1 ethidium 
bromide.
Lanes 1, 3, 5. 1 kb ladder markers (GibcoBRL)
Lane 2. 37°C annealing 
Lane 4. 42°C annealing 
Lane 6. 48°C annealing
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Fig. 3.3: PCR from first-strand cDNA to amplify the 5’ end of CRK4
PCR was performed on first-strand cDNA of T. b. brucei STIB 247, using 2 pi of cDNA in a 
reaction volume of 10 pi with 50 ng each of primer OL356 and the splice leader (SL) primer. 
Identical reactions were run on a Robocycler machine (Stratagene) with an annealing 
temperature range of 42°C-62°C (12 reactions). The end-point products were electrophoresed 
on a 0.8% agarose gel and visualised by staining with 0.5 pg m l1 o f ethidium bromide. The 
range was run from left to right (lane 2 represents 56.4°C annealing, lane 6 represents 62.0°C 
annealing; the remaining reactions are not shown). Lane 7 is the 500 bp SAT gene amplified by 
SAT5' and SAT3' primers at 42°C; lane 8 is the 760 bp CRK4 product amplified with OL355 
and OL356 primers at 48°C annealing. Markers (lane 1) were the 1 kb ladder markers 
(GibcoBRL).
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Fig. 3.4: PCR from first-strand cDNA to amplify the 3’ end of CRK4
PCR was performed on first-strand cDNA of T. b. brucei STIB 247 that had been synthesised 
using an anchor-[dT] primer, using 2 pi o f cDNA in a reaction volume of 10 pi with 50 ng each 
of primer OL355 and the complementary anchor sequence primer. The annealing temperature 
was 52°C. The amplified fragments o f 1.0 kb and 1.4 kb are marked.
Lane 1. 1 kb ladder markers (GibcoBRL)
Lane 2. PCR reaction end-point products
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Fig. 3.5: Restriction digestion of purified AFIXII clones DNA
Approximately 1 jig of purified A.FIXII clones IA, IIA and IIIA DNA was digested with 
restriction enzyme at 37°C for 2 hours and then electrophoresed on a 1.0% agarose gel. DNA  
was visualised by staining the gel with 0.5 jig m l1 ethidium bromide.
Lanes 1. 1 kb ladder markers (GibcoBRL)
Lanes 2. Notl 
Lanes 3. Sal I 
Lanes 4. Sacl 
Lanes 5. Xbal 
Lanes 6. Hincll
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Fig. 3.6: Southern blot of AFIXII clones DNA
Approximately 1 pg o f purified XFIXII clones IA, IIA and IIIA DNA was digested with 
restriction enzyme at 37°C for 2 hours and then electrophoresed on a 0.8% TBE agarose gel. 
DNA was transferred to a nitrocellulose membrane by the capillary method and fixed by UV 
illumination. The filter was prehybridised at 65°C for 4 hours and probed with the insert from 
pG L l38. The sizes of the useful hybridising fragments are annotated. The markers were the 1 
kb ladder (GibcoBRL).
Lanes 1. Notl 
Lanes 2. Sal I 
Lanes 3. SacI 
Lanes 4. Xbal 
Lanes 5. Hincll
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Fig. 3.7: Southern blot of A.FIXII clone IIIA
Purified A.FIXII clone IIIA DNA (1 pg) was digested with restriction enzymes at 37°C for 2
hours and then electrophoresed on a 0.8% TBE agarose gel. DNA was transferred to a
nitrocellulose membrane by the capillary method and fixed by UV illumination. The filter was
prehybridised at 65°C for 4 hours and probed with the insert from pGLl38. The sizes of the
useful hybridising fragments are annotated. The markers were the 1 kb ladder (GibcoBRL).
Lane 1. XbaVXmnl
Lane 2. SacVKpnl
Lane 3. Xbal/Xhol
Lane 4. XbaMSpel
Lane 5. Pstl
Lane 6. Ncol
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Fig. 3.8: Southern blot of STIB 247 genomic DNA with a CRK4 PCR fragment
Genomic DNA was prepared from STIB 247 procyclics using the Nucleon kit. 2.5 jig of 
genomic DNA per lane was digested with enzymes for 4 hours at 37°C. Restriction digests were 
electrophoresed on a 0.8% TBE gel and blotted to Hybond-N supported nitrocellulose 
membrane (Amersham). The filter was fixed, prehybridised for 4 hours at 65°C, and probed 
with the 760 bp PCR fragment generated with OL355 and OL356 (insert from pG Ll38).
Lane 1. Notl 
Lane 2. Sail 
Lane 3. Xbal 
Lane 4. HincU 
Lane 5. HindUL 
Lane 6. BamHl 
Lane 7. Sphl 
Lane 8. Kpnl 
Lane 9. Xhol
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O L 193
GGTTTGATCGTTCCGAATTGAACGTGCATAGACAAAAACATAGAACGTTG
CCAAACTAGCAAGGCTTAACTTGCACGTATCTGTTTTTGTATCTTGCAAC
GCGAAGTGAGCTGGGCTAGTTGGCGGTTAAACAGGGGACGTGTCGAGATC
CGCTTCACTCGACCCGATCAACCGCCAATTTGTCCCCTGCACAGCTCTAG
TCACCGCCGTTTGGGGTCATTTGGGGGTAAGGAATCGACAGCCACGCTCG
AGTGGCGGCAAACCCCAGTAAACCCCCATTCCTTAGCTGTCGGTGCGAGC
TGTTTATTGTGTTCTGAGGGACTCGTTGCTCATGCTTTTTTTAATTACTC
ACAAATAACACAAGACTCCCTGAGCAACGAGTACGAAAAAAATTAATGAG
TTTTACTTAGTGTGATNTTGTACTTTTACGACTTTATCCAGTGGTAGTGT
AAAATGAATCACACTANAACATGAAAATGCTGAAATAGGTCACCATCACA
TCCTGCAGGGCATCATGTTCCCTCAATTCCGAGAACCGTCGCCAAAGACG
AGGACGTCCCGTAGTACAAGGGAGTTAAGGCTCTTGGCAGCGGTTTCTGC
AGGAAGTTTCGGATTTCTTTGGAGAAAAGTGCCCGGAAGGAAGGTTGGAA
TCCTTCAAAGCCTAAAGAAACCTCTTTTCACGGGCCTTCCTTCCAACCTT
AAGAGTTAGAGCAGTGAAGGAGAGGAATGAACCGAGGGTGTTGCATCCCC
TTCTCAATCTCGTCACTTCCTCTCCTTACTTGGCTCCCACAACGTAGGGG
OL2 0 6
CAGACTGTTCTCATTGTTTTTGGACCAGGCGATATTCCCGTTGTTGCTGC
GTCTGACAAGAGTAACAAAAACCTGGTCCGCTATAAGGGCAACAACGACG
AACATTCGGCAGAAACTACGTGTTCATACTGTAAGTCTTTTGCTGACAAA
TTGTAAGCCGTCTTTGATGCACAAGTATGACATTCAGAAAACGACTGTTT
O L 144
CTTATTGAATCACCCGCCCTCCCCTTTTACATCCTCCTGACCCTCTTCGT
GAATAACTTAGTGGGCGGGAGGGGAAAATGTAGGAGGACTGGGAGAAGCA
ATGTTACTCAACTACAGTTGTATCAATTGTGAACCAAAATACCAAGGACT
TACAATGAGTTGATGTCAACATAGTTAACACTTGGTTTTATGGTTCCTGA
TAAAGTGTAGAAAAACGATCAGAGAGTATAGAAACAAACACGTGCGTGTT
ATTTCACATCTTTTTGCTAGTCTCTCATATCTTTGTTTGTGCACGCACAA
CGTAGGGAAAGAAAACGTCTGTGTCGAACTTAGAGATCGAAGGGGATACG
GCATCCCTTTCTTTTGCAGACACAGCTTGAATCTCTAGCTTCCCCTATGC
ATAACCTGGACAAATACAACGAGTGGGGGATATAATCAAACCTCGTAAAT
TATTGGACCTGTTTATGTTGCTCACCCCCTATATTAGTTTGGAGCATTTA
H i n d i  H i n c I I  H i n d i  11  OL3 55
GTCAACTGTCAACAGACTGCAATGCATTGGAAAGCTTGGCGAAGGAACCT
CAGTTGACAGTTGTCTGACGTTACGTAACCTTTCGAACCGCTTCCTTGGA
M S T V N R L Q C I G K L G E G T
ATGGAGTGGTGTACAAGGCGAGGGAGTTGGCCACCGGTCAGATTGTTGCG
TACCTCACCACATGTTCCGCTCCCTCAACCGGTGGCCAGTCTAACAACGC
Y G V V Y K A R E L A T G Q I V A
99
OL92
8 51  TATAAACGCATTATCGTCGGCAGTGAGGATGATGGTGCACCATCGACCGC
ATATTTGCGTAATAGCAGCCGTCACTCCTACTACCACGTGGTAGCTGGCG 
Y K R I  I V G S E D D G A P S T
O L 351
9 01  CATACGGGAGATTGCGCTTCTTAAGGTTCTAAAGCATAATAATATCGTGC
GTATGCCCTCTAACGCGAAGAATTCCAAGATTTCGTATTATTATAGCACG
A I R E I A L L K V L K H N N I V
9 5 1  GACTCTATGACGTGCTTTTCGAGCCGCCAAAACTTACTCTTATTTTTGAG 
CTGAGATACTGCACGAAAAGCTCGGCGGTTTTGAATGAGAATAAAAACTC 
R L Y D V L F E P P K L T L I F E
S a u 3A I
1 0 0 1  TACTGCGAATATGATCTTAGGAGATTCATGCACAAACACGCCTCCAGAGT 
ATGACGCTTATACTAGAATCCTCTAAGTACGTGTTTGTGCGGAGGTCTCA 
Y C E Y D L R R F M H K H A S R
10  51  GCGCGCACAGGTTAAGGAAATTCTCAAACAAGTCCTCCTGGGCCTTCGGT
CGCGCGTGTCCAATTCCTTTAAGAGTTTGTTCAGGAGGACCCGGAAGCCA
V R A Q V K E I L K Q V L L G L R
O L 348
1 1 0 1  ACATGCATCAGCGGAGTGTCGTGCATCGAGACTTGAAACCAGACAACATT 
TGTACGTAGTCGCCTCACAGCACGTAGCTCTGAACTTTGGTCTGTTGTAA 
Y M H Q R S V V H R D L K P D N  I
H i n c I I
1 1 5 1  TTTGTTAGGGTTGACGGAATATCAGGGTCTGAGGGCAGTGAAATGTCAGT 
AAACAATCCCAACTGCCTTATAGTCCCAGACTCCCGTCACTTTACAGTCA 
F V R V D G I  S G S E G S E M S
O L 350
12 01  CTCTAGTAGGGAAACGGAAGTAGTTAATACGCGAGGGCACTGGGACGACA 
GAGATCATCCCTTTGCCTTCATCAATTATGCGCTCCCGTGACCCTGCTGT
V S S R E T E V V N T R G H W D D
12 5 1  GTGATGGGGCAGCCAACTGCCCCAAGAATGCGAACCCCACCGAAAACCCT
CACTACCCCGTCGGTTGACGGGGTTCTTACGCTTGGGGTGGCTTTTGGGA
S D G A A N C P K N A N P T E N P
S a u 3 A I
13 01  AACGCCAGGATCGCTTCGGAGGACCATGGAGCCGATGGTACTGTCCCCTC
TTGCGGTCCTAGCGAAGCCTCCTGGTACCTCGGCTACCATGACAGGGGAG
N A R I A S E D H G A D G T V P
13 51 TGGCTCAACCACTCCGACTTCACAGTTGGTAATTAAGTTGGGTGATTATG
ACCGAGTTGGTGAGGCTGAAGTGTCAACCATTAATTCAACCCACTAATAC
S G S T T P T S Q L V I K L G D Y
H a e l l l  O L 349
14 01  GGATGGCCCGTATAGAGAGTATCCCAGTAAAAAAGTACTCTCACGACGTG
CCTACCGGGCATATCTCTCATAGGGTCATTTTTTCATGAGAGTGCTGCAC 
G M A R I E S  I  P V K K Y S H D V
100
S a u 3 A I
14  51  GCATCCCTCTGGTATCGTAGCCCTGATGCGCTGCTGGGATCTGCAATGTA 
CGTAGGGAGACCATAGCATCGGGACTACGCGACGACCCTAGACGTTACAT 
A S L W Y R S P D A L L G S A M
H i n c I I  O L 356
1 5 0 1  CGGTTTCGCCGTTGACCTGTGGTCGGTTGGCTGTATCTTCGCAGAAATGG 
GCCAAAGCGGCAACTGGACACCAGCCAACCGACATAGAAGCGTCTTTACC 
Y G F A V D L W S V G C  I  F A E M
S a u 3 A I
1 5 5 1  TTACGGGCGCCCCATTAATACGCGGAAATACCGATGTAGATCAGTTGCTC 
AATGCCCGCGGGGTAATTATGCGCCTTTATGGCTACATCTAGTCAACGAG 
V T G A P L I  R G N T D V D Q L L
1 6 0 1  AAGACGTTCAAGCTGCTTGGCACGCCCACACCTGAGACGTGGCCATCTAT 
TTCTGCAAGTTCGACGAACCGTGCGGGTGTGGACTCTGCACCGGTAGATA 
K T F K L L G T P T P E T W P S
16  51  GAAAAATTGCCCCAAGGCCGTACAACTTCTCAAGGCTGCAGCCGAATTGG
CTTTTTAACGGGGTTCCGGCATGTTGAAGAGTTCCGACGTCGGCTTAACC
M K N C P K A V Q L L K A A A E L
OL90
17 01  CCAGGGGGGAACCTGCAGAAAATGGAAAAAAAACAAAGAATTCACGGGGT
GGTCCCCCCTTGGACGTCTTTTACCTTTTTTTTGTTTCTTAAGTGCCCCA
A R G E P A E N G K K T K N S R G
O L89
17  51  GTCCAAAAACAGCACGAGAGGAATCTCCCTAATGTGCAAAAAACTGCAAC
CAGGTTTTTGTCGTGCTCTCCTTAGAGGGATTACACGTTTTTTGACGTTG
V Q K Q H E R L N P N V Q K T A
18  01  AGGCACCTCACACCTTTCCGCCGTAATGCGTGTAGGTATTGATGGAGAGA
TCCGTGGAGTGTGGAAAGGCGGCATTACGCACATCCATAACTACCTCTCT
T G T S H L S A V M R V G I D G E
18  51  GTGGTTGTGTTGCGGACCCCAGGGACGAGCTGTATCATTTCCCGCCGGAG
CACCAACACAACGCCTGGGGTCCCTGCTCGACATAGTAAAGGGCGGCCTC
S G C V A D P R D E L Y H F P P E
19  01  TTGTGTTTTCCATCCGCATTCGATGAGTATGTGAAAGCATCCGGCTTCCA
AACACAAAAGGTAGGCGTAAGCTACTCATACACTTTCGTAGGCCGAAGGT
L C F P S A F D E Y V K A S G F
O L91
1 9 5 1  GGGACGCGTGGGTGTTGAAGGTACTGATTTTCTACGGAGGCTGATCCGTT 
CCCTGCGCACCCACAACTTCCATGACTAAAAGATGCCTCCGACTAGGCAA 
Q G R V G V E G T D F L R R L I R
2 0 0 1  ATGAGCCGTCACAGAGGATGTCGGTTCAGGAGGCGCTGTCCCATCCTTTT 
TACTCGGCAGTGTCTCCTACAGCCAAGTCCTCCGCGACAGGGTAGGAAAA 
Y E P S Q R M S V Q E A L S H P F
No t l
2 0 5 1  GTCAGTAACACAGTGGCACTAATGCAGCGGCCGCTTGATGTCATGGCTTC 
CAGTCATTGTGTCACCGTGATTACGTCGCCGGCGAACTACAGTACCGAAG 
V S N T V A L M Q R P L D V M A
101
2 1 0 1  CATGTTACGCCAATCACTTCGAGAACACAGTGTATATCCGTAATATATAT 
GTACAATGCGGTTAGTGAAGCTCTTGTGTCACATATAGGCATTATATATA 
S M L R Q S L R E H S V Y P *
2 1 5 1  ATATATATATATATATATCTACGATTATTTGTTTTGGAAGTGCAGGGGTG 
TATATATATATATATATAGATGCTAATAAACAAAACCTTCACGTCCCCAC
2 2  01  TGGCTTCCTCATTATTGGAAAATAGGCAGTTCTTACAATGTAGTTGTTAC 
ACCGAAGGAGTAATAACCTTTTATCCGTCAAGAATGTTACATCAACAATG
2 2  51  ACTTACAGGGATGTCTTCAACATAGTATAATTACGGATGATCCACAGCGG 
TGAATGTCCCTACAGAAGTTGTATCATATTAATGCCTACTAGGTGTCGCC
O L 143
2 3 01  TGGTCCCGGCAGCATTCATCGCATTTAGCGTTCTCTATCTTGCTACTTTC 
ACCAGGGCCGTCGTAAGTAGCGTAAATCGCAAGAGATAGAACGATGAAAG
H i n d i I I
2 3 51  CTTCTTTCAAGTGCATAAGCTTTCTTTACTCCCTTCTATATTTTCAAAGC 
GAAGAAAGTTCACGTATTCGAAAGAAATGAGGGAAGATATAAAAGTTTCG
2 4 01  AGACAGAACGTCACCAATCAAATATCGTAGTCCCCCCCTCTATTGTTTTT 
TCTGTCTTGCAGTGGTTAGTTTATAGCATCAGGGGGGGAGATAACAAAAA
2 4  51  GAATCTTCTCACTACTGTTTTTATTAGCGTTTTCCTCCATGACAGTTTCT 
CTTAGAAGAGTGATGACAAAAATAATCGCAAAAGGAGGTACTGTCAAAGA
K p n l
2 5 01  TTCGCATCAATTGGAGTTACGTACCCCTGCCGTTGGATGTTGGTACCCAA 
AAGCGTAGTTAACCTCAATGCATGGGGACGGCAACCTACAACCATGGGTT
2 5 51  TTCSCCCTATAGTGAGTCGTATTACGCGCGCTCACTGGCCGTCGTTTTAC 
AAGSGGGATATCACTCAGCATAATGCGCGCGAGTGACCGGCAGCAAAATG
2 6 0 1  AACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCA 
TTGCAGCACTGACCCTTTTGGGACCGCAATGGGTTGAATTAGCGGAACGT
2 6 5 1  GCACATCCCCCTTTCGCCAGCTGGCGT 
CGTGTAGGGGGAAAGCGGTCGACCGCA
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Fig. 3.9: The CRK4 gene and flanking sequences
The complete ORF and flanking sequences with relevant restriction sites, primers and 
translation of the ORF is shown. Primer sequences are highlighted in red, on the upper strand 
(sense primers) and the lower strand (antisense primers). Only the restriction sites relevant to 
the formation of the lambda library, Southern blot data and subcloning of gene fragments have 
been shown. The protein translation (blue) shows the presence of the two insert domains 
(purple).
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-------------------------------------- MSTVNRLQCIGKLGEGTYGW 21
-------------------------------------- MSTLGRYRHWKLGEGTY GMV 21
 MGSRYERLQKIGEGSYGW 19
MQVQVQEGQTACDGSLRPLPSAGPASFVPRSLRPAPLRGTSTPDRYSRIEKVGEG: YGIV 60
 MTMLGALTGRQLSSGLKDQFDRYNRMDILGEGTYGW 3 7
 MSGELANYKRLEKVGEGTYGW 22
II III IV
YKARELATG--- QIVAYKRIIVGSEDDGAPSTAIREIALLKVLKHNNIVRLYDVLFEPP- 77
YKGTEIQTG--- RWAFKRMWTSDDEGIPGAAIREICLLKELRHNNWELFEVLFDPP- 77
FRARDVTTG--- TIVAVKRIRLEKEEEGVPCTAIREISILKELRHENIVRLLDVCHSEK- 7 5
YKCHDNFTG--- RTVAMKRIPLIVNDGGVPSTAVREVSLLRELNHPYWRLLDWLHEA- 116
YRAVDRATG--- QIVALKKVRLDRTDEGIPQTALREVSILQEIHHPNIVNLLDVICADG- 93
YKALDLRPGQGQRWALKKIRLESEDEGVPSTAIREISLLKELKDDNIVRLYDIVHSDAH 82
V Via VIb
KLTLIFEYCEYDLRRFMHKHASRVR-- AQVKEILKQVLLGLRYMHQRSWHRDLKPDNI 134
KITMIFELCDCDLKRYMESRPQRLLDANTEMRPILKQIFLGLEYLHGRCWHRDMKPQNI 137 
RLTLVFECMEMDLKKYMDHVGGDLDAG--TIQEFMRSLLSGVRFCHERNVLHRDLKPPNL 133 
KLLLIFEYMEQDLQGMLK--QRNTAFVGGKLRRIMFQLLLGLHECHSRRFVHRDIKPSNI 174 
KLYLIFEYVDHDLKKALE--KRGGAFTGTTLKKIIYQLLEGLSFCHRHRIVHRDLKPANI 151 
KLYLVFEFLDLDLKRYMEGIPKDQPLGADIVKKFMMQLCKGIAYCHSHRILHRDLKPQNL 142 
• ••■** . ★ ★ . . . . . . . ★ . ★ .
FVRVDGISGSEGSEMSVSSRETEWNTRGHWDDSDGAANCPKNANPTENPNARIASEDHG 194
FVNVRGPDFAAMTALPSSPQQSMRVPHAGGTNGEAGRA--- S-ANGNEHAPRPTAAEGSV 193
LISREK--------------------------------------------------  140
LIDRKES-------------------------------------------------  181
LVTTDN--------------------------------------------------  157
LINKDG--------------------------------------------------  14 8
VII VIII
ADGTVPSGSTTPTSQLVIKLGDYGMARIESIPVKKYSHDVASLWYRSPDALLGSAMYGFA 2 54 
SPWEEAANTKDAPNQLIIKIGDFGLARVEEIPVKKYSHEWTLWYRSPDVLMSSALYSYP 253
--------------- ELKLADFGLGRAFGIPVKKF QEWTLWYRSPDVLLGSTQYGTP 183
--------------- WKLADFGLGRAFRVPLQTYTTEVMTLWYRAPEVLLGDKQYLPA 22 5
--------------- SVKIADFGLARAFQIPMHTYY HEWTLWYRAPEILLGEKHYTPA 201
--------------- NLKLGDFGLARAFGVPLRAYTHEIVTLWYRAPEVLLGGKQYSTG 192
IX X
VDLWSVGCIFAEMVTGAPLIRGNTDVDQLLKTFKLLGTPTPET--WPSMKNCPKAVQLLK 312 
VDIWSMGAIFFEMATSKVLFSGRNEDEQLLRMFWLLGSPTKET--WPSMMTYTGTMERLE 311 
VDIWSVGCIFAEMAIGAPLFTGKNDADQLLRIFQFLGTPNRQV--WPSMDTYPNSSNMLS 241 
VDVWSMGCVFAELARRRSLFAGDTAINQLFSIFQLLGTPTEAT--WRGVTSLPHHNVNFP 283 
VDMWSIGCIFAELARGKVLFRGDSEIGQLFEIFQVLGTPMDAEGSWLGVSSLPDYRDVFP 261 
VDTWSIGCIFAEMCNRKPIFSGDSEIDQIFKIFRVLGTPNEAI--WPDIVYLPDFKPSFP 250
- -AAAELARGEPAENGKKTKNSRGVQKQHER NLPNVQKTATGTSHLSAVMR 3 61
RSSRAAAERQDLTVNGDVYVQQQQLQAQQQQPQQGSSPSHSSSRAPDLLTQLAHKRFYHS 3 71
----------------------------------------------------------- 243
-----------------------------------------------------------  284
 262
----------------------------------------------------------- 251
XI
VGIDGESGCVADPRDELYHFPPELCFP-SAFDEYVKASGFQGRVGVEGTDFLRRLIRYEP 420 
ESAMQQRRESASSAANSYRLPVELWFDRPLFKEYMAATRCDVSVSPEGIDLLRRCLMYEP 431
 RPEFQQTLAATCEEQFQTNPAYAKLGPQGIDLLRWLLRYEP 282
 RWTAKPLRTAVPALDDDGVDLLRRMLCYNP 313
 KWSGKPLTQVLPTLDGDAVDLLSQMLRYNP 2 91
 QWRRKDLSQWPSLDPRGIDLLDKLLAYDP 2 80
SQRM VQEALSHPFVSNTVALMQRPLDVMASMLRQSLREHSVYP 4 64 
NQRI AAEAVHHPYLERVPVPTAGSLDVLISSLMQTMETIHLL- 474
SERL AAQALEHPYFSVEF------------------------ 3 01
RERI AYEALQHSYFDEVREEEVEKLMRFNGA------------ 345
AERI. AKAALQHPWFSDAMF------------------------ 311
INRIYARRAAIHPYFQES-------------------------- 298
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Fig. 3.10: Multiple alignment of CRK4 with CRKs
Multiple alignment of the sequences shown was done with the ClustalW application at the EBI 
website. As there were several spurious alignments of several amino acids for tbCRKl-3 and 
CDC28 within the insert domains of tbCRK4 and cfCRK, these have been manually corrected. 
Two underlying dots represents similar residues (conservative substitutions); an underlying star 
represents invariantly conserved residues. Dashes indicate spaces introduced to maximise 
alignment. Residues highlighted in red correspond to the PSTAIRE sequence motif of hsCDKl; 
residues highlighted in blue correspond to the DSEI sequence motif of hsCDKl; residues 
highlighted in green represent residues in conserved positions relative to residues in hsCDKl 
that are known to be phosphorylated.
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Fig. 3.11: Hydropathy plots of tbCRK4 and cfCRK
Hydropathy plots of the tbCRK4 and cfCRK4 proteins were produced by the method of Hopp 
& Woods, using the ProSite tool at the ExPasy website. A) tbCRK4: The first insert domain 
covers residues 140-210 (red line), the second insert domain covers residues 312-390 (green 
line). B) cfCRK: The first insert domain covers residues 144-210 (red line), the second insert 
domain covers residues 311-400 (green line). In both cases the X axis represents the sequence 
of residues, the Y axis represents the relative polarity of those residues. Hopp and Woods plots 
are essentially hydrophilicity plots, with polar amino acids assigned a positive value and 
hydrophobic amino acids assigned a negative value. Consequently, in both plots, hydrophilic 
regions have positive values and hydrophobic regions have negative values.
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Fig. 3.12: GST fusion expression construct pGL134
The construct for the expression o f recombinant GST-CRK4 was generated by excision of the 
sequence encoding Insert Domain 1 (244 bp) from pGLl 19 with Hincll-Haelll digestion. The 
244 bp fragment was cloned into the Smal site of pGEX-5X-2 vector, and screened for 
orientation by PCR. The ligation junction between the GST and CRK4 fragments was 
sequenced for one positive, pGL134, before it was transformed to BL21 E. coli for pilot 
expression. The GST fragment is approximately 26 kDa.
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Fig. 3.13: Pilot expression of GST-CRK4
20 ml of LB medium was inoculated at 1:100 with a saturated overnight culture of 
BL21pGL134 E. coli and grown, with shaking, at 37°C to an OD at 600 nm o f 0.8. A sample 
was taken to represent the uninduced control. IPTG was added to a final concentration of 2 mM 
and induced samples were withdrawn hourly. Crude whole cell lysates of the samples were 
prepared and electrophoresed on a 12.5% Lammeli gel, stained with Coomassie blue and dried 
in an EasyBreeze gel dryer (Hoeffer).
Lane 1. Low Range nonprestained markers (BioRad)
Lane 2. T=0 (uninduced)
Lane 3. T=1 hour 
Lane 4. T=2 hours 
Lane 5. T=3 hours 
Lane 6. T=4 hours
Lane 7. Rainbow prestained markers (BioRad)
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Fig. 3.14: Solubility of recombinant GST-CRK4
Pellets o f BL21pGL134 E. coli that had been induced for four hours with 2 mM IPTG and 
subsequently and frozen at -20°C were thawed and resuspended in sonication buffer. Cells were 
lysed by lysozyme treatment and freeze/thaw cycles, and centrifuged at maximum speed in a 
bench microfuge for 20 minutes at 4°C to pellet cellular debris. Soluble protein and insoluble 
protein samples were prepared and electrophoresed on a 12.5% Lammeli gel, stained with 
Coomassie blue and dried.
Lane 1. Low Range nonprestained markers (BioRad)
Lane 2. Insoluble protein 
Lane 3. Soluble protein
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Fig. 3.15: Purification of GST-CRK4
Four flasks each containing 500 ml LB medium with 100 jug ml'1 ampicillin were inoculated at 
1:100 from a saturated overnight culture o f pGL134 in BL21 E. coli and grown to an optical 
density at 600 nm of 0.8. IPTG was added to a final concentration o f 0.5 mM and the cultures 
grown for a further 4 hours before harvesting. Cell pellets were resuspended to 100 ml in lx  
PBS pH 7.2 and sonicated using a button tip at 40% amplitude for ten 10 second bursts with an 
on/off pulse of 1 second, and 2 minutes cooling on ice between bursts. TritonX-100 was added 
to 1% and the suspension centrifuged at 12 OOOg for 10 minutes at 4°C. The supernatant was 
passed through a 2 ml bed volume column of GS4B matrix, washed extensively with PBS and 
eluted with 10 mM reduced glutathione. Eluate fractions were dialysed overnight against a 
large volume of PBS at 4°C. Samples were electrophoresed on a 12.5% Lammeli gel, stained 
with Coomassie blue and dried.
Lane 1. Low Range nonprestained markers (BioRad)
Lane 2. Crude soluble protein 
Lane 3. Column flow-through 
Lane 4. First wash fraction 
Lane 5. Pool 1 
Lane 6. Pool 2
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Fig. 3.16: Western blot with partially purified anti-CRK4 antibodies
15 pi per lane of T. b. brucei STIB 247 long slender bloodstream, short stumpy bloodstream 
and procyclic form lysates were electrophoresed on a 12.5% Lammeli gel and transblotted to 
PVDF membrane at 30 mA overnight at 4°C. Soluble (S-100), insoluble and total protein 
lysates were made as described in chapter 2.3.4. The anti-CRK4/B antiserum was partially 
purified by passing an aliquot through an immobilised GST-Sepharose column to remove anti- 
GST antibodies. After brief staining with Ponceau S the filter was re wetted, blocked and 
probed with partially purified anti-CRK4 antiserum at a titre of 1:1000. An aliquot of partially 
purified antiserum was preblocked with 100 pg of purified GST-CRK4 overnight at 4°C. 
Secondary antibody was anti-rabbit HRP-conjugate (Promega) at a titre of 1:2500, and the blot 
developed with Supersignal ECL reagents (Pierce). Lanes 1-8 were probed with partially 
purified anti-CRK4/B antiserum, lanes 9-16 were probed with partially purified anti-CRK4/B 
antiserum preblocked with fusion protein. As the concentration of protein in the lysates was not 
known, protein loading between lanes is not equivalent. Markers were the Low Range 
nonprestained markers (BioRad) and Rainbow prestained markers (BioRad).
Lanes 1, 9. STIB 247 long slender bloodstream form soluble protein 
Lanes 2, 10. STIB 247 long slender bloodstream form insoluble protein 
Lanes 3, 11. STIB 247 short stumpy bloodstream form soluble protein 
Lanes 4, 12. STIB 247 short stumpy bloodstream form insoluble protein 
Lanes 5, 13. STIB 247 procyclic form total protein 
Lanes 6, 14. STIB 247 procyclic form soluble protein
Lanes l , \5 .T .b .  rhodesiense TREU 869 long slender bloodstream form soluble protein 
Lanes 8, 16. T. b. rhodesiense TREU 869 long slender bloodstream form insoluble protein
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Fig. 3.17: Western blot with purified anti-CRK4 antibodies and soluble fraction protein
Soluble fraction (S-100) protein lysates of T. b. brucei STIB 247 long slender bloodstream, 
short stumpy bloodstream and procyclic forms were made from freshly harvested cells, as 
described in chapter 2.3.4. 5x 106 cells per lane were electrophoresed on a 12.5% Lammeli gel 
and transblotted to PVDF membrane at 250 mA for 3 hours at 4°C. The partially purified anti- 
CRK4/B antibodies were further purified by passing an aliquot through an immobilised GST- 
CRK4 column to specifically purify anti-CRK4 antibodies. Lanes 1-3 were probed with the 
purified anti-CRK4 antibodies at a titre o f 1:50, lanes 4-6 were probed with the purified anti- 
CRK4 antibodies at a titre of 1:50 that had been preblocked with 100 pg purified GST-CRK4. 
Secondary antibody was anti-rabbit HRP-conjugate (Promega) at a titre of 1:2500, and the blot 
developed with Supersignal ECL reagents (Pierce). Markers were the Low Range 
nonprestained markers (BioRad) and Rainbow prestained markers (BioRad).
Lanes 1, 4. Long slender bloodstream form soluble protein 
Lanes 2, 5. Short stumpy bloodstream form soluble protein 
Lanes 3, 6. Procyclic form soluble protein
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Fig. 3.18: Modified Western blot with anti-CRK4 antibodies
5x 106 cells per lane were electrophoresed on a 12.5% Lammeli gel and transblotted to PVDF 
membrane at 30 mA overnight at 4°C. Soluble (S-100) protein lysates were made as detailed in 
chapter 2.3.4. The filters were blocked for 8 hours at room temperature on a rolling platform, 
then probed overnight at 4°C with the purified anti-CRK4 antibodies at a titre of 1:100 (lanes 3 
and 4) and 1:500 (lanes 1 and 2), or the purified anti-CRK4 antibodies at a titre of 1:100 and 
1:500 that was preblocked with 100 pg GST-CRK4 fusion protein (lanes 7 and 8, and lanes 5 
and 6, respectively). Filters were washed extensively with TBST, probed with anti-rabbit HRP- 
conjugate at a titre of 1:2500 for 45 minutes at room temperature, and again washed extensively 
with TBST before being developed with a 1:10 dilution of SuperSignal reagents (Pierce). Lanes 
1-4 probed with purified anti-CRK4 antibodies, lanes 5-8 probed with the purified anti-CRK4 
antibodies preblocked with fusion protein. Markers were the Low Range nonprestained markers 
(BioRad) and Rainbow prestained markers (BioRad).
Lanes 1, 3, 5, 7. T. b. brucei STIB 247 short stumpy bloodstream form soluble protein 
Lanes 2, 4, 6, 8. T. b. brucei STIB 247 procyclic form soluble protein
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Fig. 3.19: Testing CRK4 binding to recombinant p l2  and pl3
S-100 STIB 247 procyclic extracts were selected using beads that were aminolinked to either
p l / p  1 O I T/'-'  1
TRIS (control beads), purified recombinant p l2  or purified recombinant p l3 . Beads 
were preincubated in minicolumns with BSA to block nonspecific binding sites and washed in 
lysis buffer before 100 p,l extracts were added to each aliquot of beads (originally, 40 pi of a 
50% slurry) and incubated for 3 hours with agitation at 4°C. Columns were extensively washed 
with lysis solution with glycerol [LSG], high salt lysis solution [HSLS] and lysis solution [LS] 
before being resuspended in 100 pi SDS-PAGE sample buffer and heated to 100°C for 5 
minutes to release bound protein. 10 pi aliquots were electrophoresed on Lammeli gels, 
transblotted to PVDF membrane and probed with purified anti-CRK4 antibodies or purified 
anti-CRK4 antibodies preblocked with 140 pg GST-CRK4 fusion protein, both at a titre of 
1:50, with the secondary anti-rabbit HRP-conjugate at 1:2500. Blots were developed with 
Supersignal ECL reagents (Pierce). Lanes 1-6 was a 12.5% Lammeli gel, lanes 7-12 was a 7.5% 
Lammeli gel.
Lanes 1, 4, 7, and 10 were control beads 
Lanes 2, 5, 8, and 11 were p l2CICS1 beads 
Lanes 3, 6, 9, and 12, were p l3 sucl beads 
Lanes 1-3, 7-9. Purified anti-CRK4 antibodies
Lanes 4-6, 10-12. Purified anti-CRK4 antibodies preblocked with 140 pg GST-CRK4 fusion 
protein
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Fig. 3.20: Immunoprecipitation-linked kinase assay with anti-CRK4 antibodies
The purified anti-CRK4 antibodies were used to immunoprecipitate from an S-100 lysate of 
inidlog STIB 247 procyclics (20 pi anti-CRK4/250 pi extract per sample). After binding to 
protein A-Sepharose beads (100 pi o f a 50% slurry per minicolumn) for 2 hours at 4°C on a 
rolling platform, columns were drained and washed extensively with lysis solution [LS], high 
salt lysis solution [HSLS] and kinase assay buffer [KAB]. Beads were resuspended in KAB, 
transferred to eppendorfs and centrifuged briefly to pellet the beads, then resuspended in 20 pi 
kinase assay mix [KAM] representing 5 pg of substrate protein per reaction, and incubated for 
20 minutes at 30°C. Reactions were stopped by addition of 20 pi o f TSB and heating to 100°C 
for 5 minutes. 20 pi o f each reaction was electrophoresed on a 12.5% Lammeli gel, which was 
stained with Coomassie blue, dried and exposed to autoradiography film. Protein substrate was 
phosvitin. Markers were the Rainbow prestained markers (BioRad).
Lane 1. Anti-CRK4 preimmune serum 
Lane 2. Purified anti-CRK4 antibodies
Lane 3. Purified anti-CRK4 antibodies preblocked with 50 pg GST-CRK4 fusion protein
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Fig. 3.21: Substrate range kinase assay with anti-CRK4 antibodies
The purified anti-CRK4 antibodies were used to immunoprecipitate from an S-100 lysate of 
midlog STIB 247 procyclics (50 pi anti-CRK4/100 pi extract per sample). After binding to 
protein A-Sepharose beads and extensive washing with lysis solution [LS], high salt lysis 
solution [HSLS] and kinase assay buffer [KAB], beads were resuspended in KAB, transferred 
to eppendorfs and centrifuged briefly to pellet the beads. The beads were then resuspended in 
20 pi kinase assay mix [KAM] per sample, representing 5 pg of substrate protein per reaction, 
for 20 minutes at 30°C. Reactions were stopped by addition of 20 pi of TSB and heating to 
100°C for 5 minutes. 20 pi of each reaction was electrophoresed on a 12.5% Lammeli gel, 
which was stained with Coomassie blue, dried and exposed to autoradiography film. Lanes 1-7 
were immunoprecipitates using the purified anti-CRK4 antibodies, lanes 8-14 were 
immunoprecipitates using the purified anti-CRK4 antibodies preblocked with 50 pg GST- 
CRK4 fusion protein. Markers were the Rainbow prestained markers (BioRad).
Lanes 1,8. Phosvitin 
Lanes 2, 9. Protamine 
Lanes 3, 10. a-casein (batch 1)
Lanes 4, 11. a-casein (batch 2)
Lanes 5, 12. |3-casein (batch 1)
Lanes 6, 13. P-casein (batch 2)
Lanes 7, 14. Histone mix
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CHAPTER 4: INVESTIGATION OF GENETIC AND BIOCHEMICAL FUNCTION OF 
THE tbCYCl GENE AND tbCY Cl PROTEIN
4.1: Introduction
The Trypanosoma brucei CYC1 gene was the first cyclin-like gene to be identified from 
trypanosomatids (Affranchino et al., 1993). It was initially isolated by PCR using two primers. 
Firstly, a degenerate oligonucleotide corresponding to one of the most conserved regions of 
amino acid sequence from a range of cyclins (Minshull et al., 1990) taking into account 
trypanosome codon bias to limit the redundancy, and secondly a sense primer corresponding to 
the mini-exon splice leader sequence (Boothroyd and Cross, 1982). PCR using these primers on 
procyclic cDNA of T. brucei consistently gave an amplification product of 500 bp. Using this 
fragment as a probe, the full length gene was isolated from a A,gtlO-cDNA library prepared from 
T. brucei procyclic poly[A]+ RNA (Affranchino et al., 1993).
Sequence analysis showed the encoded protein, CYC1, to have the highest level of 
sequence identity to the mitotic-type cyclins (A and B types) and to possess a motif for ubiquitin 
modification characteristic of such cyclins, called the destruction box (Glotzer et al., 1991). 
Initial investigation reported that CYC1 could rescue a fission yeast CDC13* mutant, suggesting 
a functional role in mitosis control in trypanosomes (Affranchino et al., 1993). Furthermore, 
immunoprecipitations using a specific anti-CYC 1 antiserum coprecipitated a 34 kDa 
polypeptide reactive to an anti-PSTAIRE monoclonal antibody, and this immunoprecipitated 
complex displayed kinase activity towards histone HI. In a separate study it was demonstrated 
that there is a 3- to 5-fold increase in transcript levels of CYC1 during differentiation from the 
short stumpy bloodstream form to the procyclic form, suggesting a specific role for tbCYCl 
during the differentiation process (Hua et al., 1996).
In this chapter an analysis of the CYC1 gene and of the CYC1 protein was carried out to 
attempt to delineate the function of the gene and protein in the procyclic form. A full length 
clone of CYC1 was kindly supplied by Dr. K. Matthews (University of Manchester). The gene 
had been amplified by PCR from T. b. brucei STIB 427 genomic DNA and cloned into the 
EcoKM site of pBluescript (SK+) vector (plasmid pGL106; Fig. 4.1).
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4.2: Results
4.2.1: Production of recombinant CYC1
The full-length CYC1 gene was released from pGL106 by digestion with BamHl and 
Clal, and cloned into the BamHl and Smal sites of the pQE32 vector (Qiagen) to give pGL107. 
As Clal does not generate blunt ends, pGL106 was treated with the Klenow fragment of E. coli 
DNA Polymerase I after digestion with Clal to generate a blunt end before the gene was 
released by BamHl digestion. After cloning to pQE32 the ligation joins were then sequenced to 
confirm the identity and orientation of the insert and to check that the reading frame of the gene 
was correct with respect to the vector’s ATG start codon and the six histidine fusion tag. This 
construct creates a translational fusion putatively encoding the CYC1 protein with an N- 
terminal hexahistidine tag.
Plasmid pGL107 was transformed to M15[pREP4] E. coli and a series of test inductions 
and purifications were carried out. Initially, a small-scale pilot native purification was 
performed as per the manufacturer’s protocol, using 1 mM IPTG induction for 2 hours (for full 
details see chapter 2.3.3). Samples electrophoresed on 12.5% Lammeli gels showed no protein 
at the predicted size of 36-37 kDa being specifically eluted from the matrix. Poor gel resolution 
due to an abundance of cellular debris made it difficult to visualise any difference between 
crude whole-cell lysates of uninduced and induced cultures of M15[pREP4]pGL107, therefore 
precluding clear identification of CYClHis (data not shown).
A pilot purification geared towards determining subcellular localisation of the fusion 
protein was carried out, again following the manufacturer’s protocol (for details see chapter 
2.3.3). The result was unambiguous (Fig. 4.2); no induced protein was seen in the soluble 
fraction (lane 3) or the periplasmic fraction (lane 2), whereas an induced protein of 
approximately 36 kDa was seen in the insoluble fraction (lane 4). This indicated that the 
CYClHis was most likely forming an inclusion body within the E. coli, possibly due to over­
expression, incorrect folding, or both. The level of expression in this pilot was high; subsequent 
expression levels for large scale inductions were always much lower, for reasons that remain 
unclear.
Following subcellular localisation a set of varying conditions were tested, to attempt to 
increase the levels of soluble protein to make a native purification attempt feasible. Various 
combinations of lysozyme treatment and sonication were tested with extraction with TritonX- 
100, extraction with Tween-20 and EGTA, induction with lower concentrations of IPTG and 
induction at lower temperatures. All failed to achieve any solubilisation of CYClHis (data not 
shown). It was decided from these results that it would not be possible to isolate soluble native 
CYClHis so a denaturing purification would be necessary.
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A pilot denaturing purification to determine the elution conditions of the recombinant 
protein was therefore carried out; an induced culture was split, pelleted and one pellet 
resuspended in QLAexpress buffer A [6 M guanidine hydrochloride, 100 mM sodium phosphate, 
10 mM TRIS pH 8.0], the other in QIAexpress buffer B [8 M urea, 100 mM sodium phosphate, 
10 mM TRIS pH 8.0]. Following lysis by sonication the samples were centrifuged at 4 OOOg at 
4°C for 10 minutes and the supernatants were applied to Ni-NTA columns pre-equilibrated with 
the same buffers as used for resuspension of the cell pellet. Columns were then washed with 
buffer A or buffer B, as appropriate, until the absorbance of the flow-through at 280 nm was 
negligible. All columns were then washed with QIAexpress buffer C [same composition as 
buffer B, pH 6.3] until the absorbance at 280 nm was negligible. The columns were then eluted, 
either in a stepwise manner with QIAexpress buffers D, E [Both: same composition as buffer B, 
pH 5.9 and 4.5, respectively] and finally with QIAexpress buffer F [6 M guanidine 
hydrochloride, 200 mM acetic acid] or with buffer C containing 200 mM imidazole. Samples of 
all wash and eluate fractions were electrophoresed on 12.5% Lammeli gels, and the gels stained 
with Coomassie blue to determine the elution profile of CYClHis (data not shown). This 
denaturing pilot (for full details see chapter 2.3.3) showed the recombinant protein to have 
bound the column very efficiently, as only trace amounts eluted in the buffer C wash; this likely 
represented protein that had only partially bound the column, possibly as a result of partial 
proteolytic degradation. No CYClHis was observed to be eluted in the buffer D and E elution 
steps, but a protein of about 36 kDa was seen to elute in the first two wash fractions of the 
buffer F wash. Little if any protein was observed in further fractions of this wash, therefore it 
was clear that the bulk of recombinant, non-degraded CYClHis was eluting in the first two 
eluate fractions. A 36 kDa protein was also observed to elute with the buffer C plus 200 mM 
imidazole elution fractions, but the protein appeared to elute over a larger number of fraction 
than observed for the buffer F elution step. Consequently, a larger-scale induction and 
purification based on denaturing conditions and elution by protonation was adopted.
Larger-scale inductions and purifications were carried out, using a culture volume of 
400 ml and a final concentration of 2 mM IPTG for three hours for induction. After harvesting 
the cell pellets were processed as described (for full protocol see chapter 2.3.3). Following 
elution, the first two eluate fractions were dialysed; the recombinant protein always precipitated 
rapidly, and upon resuspension was diluted and assayed. Typically, the final concentration was 
between 1-3 mg ml'1. Samples of two purified, dialysed CYClHis pools were electrophoresed 
on a 12.5% Lammeli gel (Fig. 4.3). This showed a smear of protein centred on the 36 kDa mark, 
indicating that some of the protein was aggregating in some manner as well as some protein 
being degraded.
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4.2.2: Production of anti-CYCl antiserum and primary testing by Western blotting
A single New Zealand white rabbit was immunised with recombinant protein. 
Aggregated purified protein in phosphate sonication buffer [50 mM sodium phosphate pH 7.8, 
300 mM NaCl] was briefly sonicated prior to immunisation to break up the aggregates, and 
primary immunisation was done with 200 pg protein homogenised with incomplete Freund’s 
reagent to a final volume of 200 pi. Secondary immunisation was performed six weeks later, 
again with 200 pg protein homogenised with incomplete Freund’s reagent to a final volume of 
200 pi. Booster immunisation was performed with 20 pg protein homogenised with PBS by 
vortexing to a final volume of 200 pi.
The first anti-CYCl antiserum test bleed, which was taken prior to the first boost, was 
assessed for cross-reactivity to both purified recombinant CYClHis protein and CYClHis 
expressed in M15[pREP4] E. coli (Fig. 4.4). The anti-CYCl antiserum from the first bleed 
produced a strong signal when reacted against purified recombinant CYClHis (lane 1); the 
almost complete abrogation of this signal upon preincubation of the antiserum with an excess of 
purified CYClHis (lane 4) demonstrated that the antiserum was specific. Furthermore, the 
smearing of the signal corroborated the Coomassie stained Lammeli gel (Fig. 4.3), which 
showed the purified protein to be aggregating. The antiserum also recognised proteins in the 
whole cell lysate of the M15[pREP4] E. coli strain with three major proteins, of approximately 
15 kDa, 20 kDa and 35 kDa (lane 2); however, preincubation of the antiserum with CYClHis 
did not compete out any of these three proteins (lane 5), thus showing them to be nonspecific 
cross-reactions. The anti-CYCl antiserum detected a protein at about 36 kDa in the induced 
whole cell lysate of M15[pREP4]pGL107, the same size as recombinant purified protein (lane 
3). This signal was largely competed out with preblocking of the antiserum with purified 
CYClHis (lane 6). In addition, the antiserum detected a large, strong smeary signal stretching 
from the top of the gel down to 36 kDa (lane 3); this too was largely abrogated by preblocking 
of the antiserum, confirming the aggregation of the precipitated recombinant protein (lane 6). 
Interestingly, the antiserum also detected a protein at around 25 kDa (lane 3) that was competed 
out by preblocking of the antiserum (lane 6), suggesting that at least some of the induced 
CYClHis was being proteolysed in a specific manner. Furthermore, as this 25 kDa protein did 
not appear in purified recombinant protein (lane 1) it can be speculated that the degradation 
occurred at the N-terminus, possibly by a specific endoproteolytic action that cleaved off the 
histidine tag on a fragment of approximately 10 kDa.
The first bleed antiserum was tested against total protein lysates for STIB 247 
procyclics and T. b. rhodesiense TREU 869 long slender bloodstream form (Fig. 4.5 and 4.6). 
The antiserum detected a protein of approximately 36 kDa in the STIB 247 procyclic extract 
(Fig. 4.5, lane 2), that was competed by preincubating the antiserum with purified recombinant
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CYClHis (Fig. 4.5, lane 3). Large molecular weight proteins detected by the antiserum were not 
specific as they were not competed by the fusion protein. Preimmune serum did not cross-react 
with any protein in the procyclic lysate (Fig. 4.5, lane 1). As a control for the quality of the cell 
extracts and the exact protocol used, anti-CRKl antiserum was used to probe duplicate filters 
(Fig. 4.5, lanes 4 and 5). The 33 kDa CRK1 protein was detected (Fig. 4.5, lane 4) and was 
competed by preincubation of the anti-CRKl antiserum with CLEHPY peptide (Fig. 4.5, lane 
5).
A protein of about 36 kDa was detected in the TREU 869 long slender bloodstream 
form cell extracts by the anti-CYCl antiserum (Fig. 4.6, lane 2) which was blocked by 
preincubating the antiserum with purified recombinant CYClHis (Fig. 4.6, lane 3). In addition 
there was a protein of 32 kDa that was competed with fusion protein. The pattern of large 
molecular weight proteins detected was very similar to those detected for the procyclic extract, 
and were also shown to be nonspecific as they were not competed by the fusion protein. The 
preimmune serum cross-reacted with a single protein of about 65-70 kDa (Fig. 4.6, lane 1) that 
was also detected by the antiserum (Fig. 4.6, lane 2). As a control, a duplicate filter was probed 
with the anti-CRKl antiserum (Fig. 4.6, lanes 4 and 5). The 33 kDa CRK1 was detected (Fig. 
4.6, lane 4) and was competed by preincubation of the anti-CRKl antiserum with CLEHPY 
peptide (Fig. 4.6, lane 5).
4.2.3: Western blot analysis with anti-CYCl antiserum
After booster immunisation and exsanguination of the rabbit the bleedout anti-CYCl 
antiserum was tested against protein lysates of all three trypanosome life cycle stages studied, 
STIB 247 procyclic, long slender bloodstream and short stumpy bloodstream forms, to assess 
the stage-specific regulation of CYC1 expression. As a putative mitotic-type cyclin the 
supposition was that CYC1 would be expressed in the proliferative procyclic and long slender 
bloodstream forms, but not the cell cycle arrested short stumpy bloodstream form.
The anti-CYCl antiserum was tested against insoluble and soluble protein lysate 
fractions of the procyclic and long slender bloodstream forms, and total protein, insoluble and 
soluble protein lysate fractions of the short stumpy bloodstream form (Fig. 4.7). Total protein 
lysates and insoluble protein lysates were made as described in chapter 2.3.2, using bench 
microcentrifugation to obtain the insoluble fraction. Soluble lysates were made by centrifuging 
whole cell lysates at 100 OOOg at 4°C for 45 minutes in a Beckman ultracentrifuge and aspirating 
the supernatant, as described in chapter 2.3.2. As previously, preblocking of the anti-CYCl 
antiserum was effected by preincubation with an excess of purified recombinant protein 
(typically, an equivalent volume of purified CYClHis diluted to 1 mg m l1).
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In the procyclic soluble lysate two specific proteins were detected (lane 8) at about 36 
kDa and 40 kDa, that were competed by preincubation of the antiserum with purified 
recombinant CYClHis (lane 12). In addition there was a protein at 30 kDa (lane 8) that was not 
competed with fusion protein (lane 12). Only one protein was detected in the insoluble procyclic 
lysate (lane 7) at 140 kDa, but this was not specific as it was not competed with fusion protein 
(lane 11). The preimmune serum did not cross-react to any proteins in either of the procyclic 
lysates (lanes 3 and 4).
The pattern of proteins detected in the short stumpy bloodstream form lysates was very 
similar to those detected in the procyclic lysates. In the short stumpy bloodstream soluble lysate 
two specific proteins were detected (lane 18) at about 36 kDa and 40 kDa, that were competed 
by preincubation of the anti-CYCl antiserum with purified recombinant CYClHis (lane 21). An 
additional protein at 30 kDa and two proteins at 60 and 75 kDa (lane 18) were not specific as 
they were not competed with fusion protein (lane 21). Only one protein was detected in the 
insoluble short stumpy bloodstream lysate (lane 17) at 140 kDa, and this was not competed by 
fusion protein (lane 20). The preimmune serum did not cross-react to any proteins in any of the 
short stumpy bloodstream lysates (lanes 13, 14 and 15).
The long slender bloodstream lysates produced a different result compared to the 
procyclic and short stumpy bloodstream lysates. In the long slender bloodstream soluble lysate 
two proteins were detected (lane 6) at 30 kDa and 75 kDa, although these were not specific as 
they were not competed with fusion protein (lane 10). Two proteins were detected in the long 
slender bloodstream insoluble lysate (lane 5), one at 140 kDa and one very large molecular 
weight protein. Again, these were not competed with fusion protein (lane 9). The preimmune 
serum did not cross-react to any proteins in either of the long slender bloodstream fractions 
(lanes 1 and 2). This is contrary to what was seen with the TREU 869 long slender bloodstream 
lysates (Fig. 4.6) where the 36 kDa CYC1 protein was detected along with another specific 
protein at 32 kDa. As well as the fact that T. b. rhodesiense and T. b. brucei are arguably 
different subspecies, TREU 869 long slender bloodstream form differs from STIB 247 in that it 
is a long-term culture-adapted monomorphic isolate, incapable of differentiation.
To try and improve the specificity of the anti-CYCl antiserum and to attempt to remove 
nonspecific cross-reactions as well as to lower the background signal, the antibodies were 
purified on a Protein A/G column. An aliquot of anti-CYCl was diluted 1:1 with Immunopure 
IgG Binding Buffer (Pierce), applied to a protein A/G column pre-equilibrated with the same 
buffer, and allowed to flow completely into the gel matrix. The column was washed with 
binding buffer until the absorbance of the flow-through at 280 nm was negligible, then the 
antibodies eluted with Immunopure Elution Buffer (Pierce). The eluate fractions were assessed 
spectrophotometrically at 280 nm and those showing the greatest absorbance were pooled and 
desalted by dialysis against a large excess of 30 mM sodium borate pH 7.0 overnight at 4°C. The
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purified antibodies were tested against total protein lysates of all three life cycle stages of STIB 
247 and the TREU 869 long slender bloodstream form (Fig. 4.8). This showed little 
improvement in the signal quality. The 36 kDa protein was not detected in the STIB 247 long 
slender bloodstream lysate either with the nonpurified anti-CYCl antiserum (lane 1) or the A/G 
purified antiserum (lane 13). CYC1 was very faintly detected in the TREU 869 long slender 
bloodstream lysate by the nonpurified antiserum (lane 2) and was detected more strongly by the 
purified antiserum (lane 14). CYC1 was detected by the nonpurified antiserum in the STEB 247 
short stumpy bloodstream lysate (lane 3) and the STIB 247 procyclic lysate (lane 4), and by the 
purified antiserum (short stumpy bloodstream lysate, lane 15; procyclic lysate, lane 16). No 
specific proteins were detected in any of the lysates by the column flow-though (lanes 5-8) or by 
the column wash (lanes 9-12).
4.2.4: Immunoprecipitation with anti-CYCl antiserum
To try to demonstrate association of CYC1 with a CRK protein, and thus corroborate 
the function of CYC1 as a cyclin homologue, attempts were made to immunoprecipitate CYC1 
with the protein A/G purified anti-CYCl antiserum. Soluble fraction lysates were made from 
midlog STIB 247 procyclic cells (for full details see chapter 2.3.5). Aliquots of purified anti- 
CYCl antiserum were mixed with S-100 procyclic soluble fraction lysates to bind CYC1; this 
mix was then added to Sepharose-protein A beads that had been preblocked with BSA, and 
mixed to allow the protein A to bind the Fc portion of the antibodies. The beads were then 
extensively washed with lysis solution [LS], high salt lysis solution [HSLS] and low salt lysis 
solution [LSLS] before being eluted by addition of FSB and heating to 100°C for 5 minutes. 
Samples were electrophoresed on 12.5% Lammeli gels, transblotted to PVDF membranes and 
probed with anti-CRKl, anti-CRK2 ( purified EVREE antibodies, see chapter 5.2.1), and anti- 
CRK3 antisera (data not shown). None of the three CRKs could be detected in 
immunoprecipitates of CYC1. However, as the anti-CYCl antiserum did not detect CYC1 in the 
immunoprecipitates it was thought likely that the antibodies were not precipitating CYC1 and 
therefore could not coprecipitate CRKs. This experiment was repeated several times with 
identical results.
In order to test if CYC1 was associated with an active kinase subunit in STIB 247 
procyclic cells, immunoprecipitations were linked to kinase assays (see chapter 2.3.5). Procyclic 
S-100 soluble lysates were mixed with aliquots of purified anti-CYCl antiserum; after an 
incubation period the lysate-antibody mix was added to Sepharose-protein A beads that had 
been preblocked with BSA, and incubated with mixing to allow the protein A to bind the Fc 
portion of the antibodies. The beads were then extensively washed with LS, HSLS and kinase
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assay buffer [KAB]. Beads were resuspended in a small volume of KAB, transferred to 
eppendorfs and briefly centrifuged to pellet the beads. The KAB was aspirated and 20 pi of 
kinase assay mix [KAM] added, mixed in and incubated for 20 minutes at 30°C, before the 
reaction was stopped by adding an equivalent volume of FSB and heating to 100°C for 5 
minutes. The protein substrate in the KAM was varied between experiments, but per reaction 
represented approximately 5 pg substrate protein. 20 pi samples were electrophoresed on 12.5% 
Lammeli gels. Gels were stained with Coomassie blue to check for the presence of the antibody 
chains (to check the binding of antibodies to Sepharose-protein A), dried down and exposed to 
autoradiography film (DuPont) in hypercassettes (Amersham).
Initial kinase assays for a CYC 1-associated kinase activity were promising; the purified 
antiserum precipitated an activity towards both histone HI and an a/(3-casein mix (Fig. 4.9). A 
negative control containing no serum gave no signal for both substrates (a/|3-casein, lane 1; 
histone HI, lane 4). The preimmune serum gave a small signal for both substrates (a/P-casein, 
lane 2; histone HI, lane 5) and the purified anti-CYCl antiserum a much stronger signal in both 
cases (ot/p-casein, lane 3; histone HI, lane 6). However, as the preimmune serum had not been 
purified on a protein A/G column it was not possible to compare the kinase activity between the 
two samples as the concentration of anti-CYCl antibodies was diluted in the protein A/G 
purified antiserum.
The crucial control to assess CYC 1-associated kinase activity was competition of 
activity by preblocking of the anti-CYCl antiserum with purified CYClHis. The initial attempt 
at preblocking of the anti-CYCl antiserum by preincubation with an excess of recombinant 
CYClHis attenuated the signal by approximately 50% (as judged by scintillation counting) but 
could not abrogate it (data not shown). Further assays were problematic, as the reproducibility 
between assays was discovered to be poor. A number of explanations could account for the lack 
of a clearly demonstrable CYC 1-associated kinase activity:
(1) The antibodies, although recognising the denatured protein on Western blots, did not 
cross-react with the native conformation of the protein and therefore did not precipitate the 
cyclin.
(2) The antibodies precipitated CYC1 in complex with a CRK, but the substrates used to 
test for activity, histone HI and a/P-casein, were not suitable substrates for the complex.
(3) CYC1 was precipitated, but it did not associate with a CRK and was not a real
cyclin.
One further attempt to resolve these options was made, to try to detect a difference in 
CYC 1-associated kinase activity between midlog procyclics and procyclics at the same cell 
density that had been artificially cell cycle arrested by serum depletion (Fig. 4.10). If CYC1 was 
a cyclin involved in cell cycle control, then a comparison of rapidly cycling midlog cells and 
quiescent cells would be expected to show a relative decrease in CYC 1-associated kinase
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activity in the latter. The signal for preimmune serum was low for midlog cells (lane 1) and 
stationary cells (lane 2), and although a strong signal was obtained with the anti-CYCl 
antiserum for midlog cells (lane 3) there was also a strong signal for stationary cells (lane 4). 
Various alterations to the general protocol, including modifications of the lysis buffers and wash 
buffers to include 0.5% sodium deoxycholate and 0.01% SDS to increase stringency of binding, 
and varying incubation times and protein substrate all failed to solve the problems of poor 
reproducibility, low signal and high background. In general, more stringent regimens of washing 
resulted in lower signal but the proportional difference in signal between preimmune serum and 
immune antiserum did not change. The conclusion drawn was that no significant kinase activity 
was associated with anti-CYCl immunoprecipitates.
4.2.5: Selection using recombinant p l2  and pl3
Active kinase complexes bind to pl2/pl3, and if CYC1 could be shown to bind in 
association with a CRK this would provide evidence that it is a cyclin. This is an alternative 
method of precipitation based on binding by associated proteins rather than antibodies (Mottram 
and Grant, 1996). Recombinant Leishmania p l2CKS1 and yeast p l3 sucl were expressed, purified 
and coupled to beads by aminolinkage as described (Mottram and Grant, 1996). T. b. brucei 
CRK1, CRK2 and CRK3 have all been shown to bind p l2  beads, although CRK1 and CRK2 do 
not bind p i3 beads and CRK3 binds only weakly (Van Hellemond and Mottram, unpublished). 
To investigate whether CYC1 is associated with CRK1, 2 or 3, indeed with an as yet 
unidentified CRK, pl2/pl3 binding assays from procyclic S-100 extracts were performed. 40 pi 
aliquots of a 50% slurry of control beads, p l2  beads or pl3 beads were dispensed to 
minicolumns, washed and preincubated with a saturating quantity of BSA to block nonspecific 
binding sites; columns were drained, washed with lysis solution [LS] and 100 pi of extract 
added per column. After incubation for 3 hours at 4°C columns were drained and washed 
extensively with lysis solution with glycerol [LSG], high salt lysis solution [HSLS] and LS. 
Beads were resuspended in 100 pi of FSB and heated to 100°C for 5 minutes to release bound 
protein. 10 pi samples were electrophoresed on 12.5% Lammeli gels, transblotted to PVDF and 
the membranes probed with the anti-CYCl antiserum, anti-CRK2 (EVREE) antiserum and anti- 
CRKl antiserum (Fig. 4.11).
No proteins were detected with the anti-CYCl preimmune serum (lanes 1-3); the 
purified anti-CYCl antiserum did not detect any protein on the control beads (lane 4) or the pl3 
beads (lane 6). A single protein was detected for p l2  beads (lane 5) at approximately 12 kDa, 
that was specific as it was competed with fusion protein (lane 8). This protein likely represents 
pl2 that was present at large quantities, as a 12 kDa protein was visible when the membrane was
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stained with Ponceau S, and which forced a spurious cross-reaction. As a control, duplicate 
filters were probed with anti-CRK2 and anti-CRKl antisera. The purified EVREE antibodies 
detected the 39 kDa CRK2 on the p l2  beads (lane 11) that was competed with peptide (lane 14), 
but no CRK2 was detected on the pl3 beads (lane 12). No proteins were detected on the control 
beads. The anti-CRKl antiserum detected the 33 kDa CRK1 on p l2  beads (lane 17) that was 
competed with peptide (lane 20), but no CRK1 was detected on the pl3  beads (lane 18). No 
proteins were detected on the control beads. The control blot was not very clean, suggesting that 
stringency of washing could have been higher.
4.2.6: Targeted disruption of CYC1
Targeted gene disruption is a useful method in the analysis of the function of a gene in 
any particular life cycle stage. It is also useful in defining if a gene has an essential function; a 
gene may be designated essential, with certain provisos, if viable null mutants for the gene 
cannot be isolated following targeted disruption to delete both wild-type alleles. If the gene is 
not essential such nulls can be isolated and the function of the encoded protein studied by 
analysis comparing the resulting null phenotype to the wild-type phenotype. To gain more 
information on the role of CYC1 in STIB 247 procyclics, gene targeting constructs were 
developed based on those designed for CRK2 (pGL108 and pGLllO, Fig. 5.8). These constructs 
exploit antibiotic resistance marker genes flanked by the 5’ and 3’ processing signals of the 
PARP gene, which is constitutively expressed in procyclics. Sequences specific to the target 
gene are cloned to flank the PARP processing signals, and the knockout cassette introduced to 
procyclics by electroporation; homologous recombination occurs between the target gene 
specific sequences of the cassette and the gene itself, and transgenic cells are selected by 
application of the appropriate antibiotic.
The CYC1 open reading frame is 1005 bp long, including the TGA stop codon, coding 
for 334 residues. Primers were designed and used in PCR to amplify a 380 bp fragment 
corresponding to the 5’ end of the gene, and a 240 bp fragment corresponding to the 3’ end of 
the gene. The 5’ fragment represented the first codon after the ATG start codon to codon 129, 
the 3’ fragment represented the last 80 codons, ending at (and including) the stop codon.
Primers 5’5’ and 5’3’ were used in PCR from STIB 247 genomic DNA to amplify the 5’ 340 bp 
fragment, primers 3’5’ and 3’3’ were used in PCR from STIB 247 genomic DNA to amplify the 
3’ 240 bp fragment. Both PCR fragments were cloned into pTAG vector and sequenced to 
confirm their identity using the pTAG vector-specific pTAG5’ and pTAG3’ primers.
The pUC\S/PARP-BLE/CRK2 5’3’ and the pUC 18/PARP-PAC/CRK2 5*3* constructs, 
intermediaries in the generation of the CRK2 targeted disruption constructs pGL108 and
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pGLl 10, were used to make the CYC1 constructs (Fig. 4.12). The 3’ CRK2 sequence was 
excised by KpnVEcoRl cleavage and replaced with the CYC1 3’ fragment. Bacterial colony 
screening by PCR identified positives, and one of these for each marker was used in the second 
replacement, in which the 5’ CRK2 sequence was released by SphVXbal cleavage and replaced 
with the CYC1 5’ fragment. Owing to the presence of an internal HindUl site in the constructs, 
both had to be cloned into the //mdlH-ZscoRI sites of pBluescript in order to gain unique 
restriction sites bounding the construct that could be used to release the entire cassette for 
transfection. Accordingly, digestion with //mdIII/£'cc?RI released the 745 bp 5’ fragment and the 
1.0 kb (BLE) or 1.2 kb (PAC) 3’ fragment. The 3’ fragment was cloned into the HindUl-EcoRl 
sites of pBluescript. Subsequently, the 5’ fragment was cloned to the HindUl site and bacterial 
colony screening by PCR identified positives in which the fragment had inserted in the correct 
orientation (the CYC1 5’ sequence flanked by the vector’s Sacl site, the PARP sequence ligating 
adjacent to the start of the resistance marker) to give the targeted disruption constructs pGLl 11 
(BLE) and pGLl 12 (PAC). The entire cassettes were excised for transfection by SacVXhol 
digestion. Typically, 100 pg of DNA was digested to completion, with the extent of digestion 
followed by electrophoresing small aliquots on 0.8% TAE minigels. Once digestion was 
complete the DNA was purified by phenol-chloroform extraction and ethanol precipitation. 
Purified DNA was resuspended to 2 mg ml'1 in distilled water and frozen as 25 pg aliquots at - 
20°C until use. Typically, between 25-50 pg of DNA was used in each transfection.
Transfection of STIB 247 procyclics was carried out with the SacVXhol cassettes from 
pGLl 11 and pGLl 12, both singly and together. Individual phleomycin or puromycin resistant 
cultures were recovered, however nothing was recovered from the double-transfection culture. 
The original culture transfected with the pGLl 12 SacVXhol cassette (PAC resistance marker), 
was cloned by the semisolid plate method. Efficacy of cloning was very low, with only two 
clones surviving the procedure (WUMP 833 and WUMP 834). Both of these clones were judged 
from PCR to have the replacement cassette successfully integrated at the correct locus (Fig.
4.13) and therefore to be single allele replacements, Acycl::PAC/CYCl. WUMP 833 was then 
transfected with the SacVXhol pGLl 11 cassette (BLE resistance marker). Twenty hours after 
transfection this was split between five flasks, and after these had grown to midlog all five were 
cloned on semisolid plates. Again, cloning efficiency was poor and the emerging clones were of 
two types; large, diffuse and ‘wet-looking’, and small, tight and ‘dry-looking’, suggesting 
uneven distribution of moisture on the surface of the plates. Three clones survived transfer to 
liquid medium (WUMP 878, WUMP 879, WUMP 880). DNA was prepared from these three 
clones as well as from wild-type STIB 247. DNA was digested with HindUl, electrophoresed on 
a 0.8% TBE agarose gel, transferred to a supported nitrocellulose membrane and probed with 
the full length CYC1 gene (Fig. 4.14).
Two strongly hybridising fragments of 2.7 kb and 3.8 kb were detected in wild-type
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DNA as expected, as CYC1 has a single internal Hindlll site. The 2.7 kb and 3.8 kb DNA 
fragments were also detected in the phleomycin-puromycin doubly resistant clones WUMP 878, 
879 and 880, indicating that at least one wild-type copy of the gene was present in all three 
clones. In WUMP 878 and 879 two additional weakly hybridising fragments at approximately 
1.9 kb and 3.25 kb were detected. WUMP 880 differed from WUMP 878 and 879 in that the 
additional weakly hybridising fragments were at approximately 2.0 kb and 3.4 kb.
4.3: Discussion
The aims of the experiments in this section were to analyse the stage-specific expression 
of CYC1, to analyse CYC1 function by investigating if CYC1 associated with a CRK to give a 
kinase activity, and to determine whether the gene is essential to the procyclic form of T. b. 
brucei.
Expression of the full-length gene as a fusion protein using the Qiagen histidine-tag 
system was successful in that expression of CYC1 with an N-terminal six-histidine tag was 
achieved (Fig. 4.2). However, the fusion protein formed inclusion bodies and attempts to 
solubilise enough CYC 1 His to make a native purification feasible were not successful. 
Consequently, a denaturing purification strategy had to be adopted, and while this allowed 
purification of CYC 1 His (Fig. 4.3) it proved problematic in that the purified protein precipitated 
when the urea was removed upon dialysis. Western blotting using first bleed anti-CYC 1 
antiserum from a New Zealand white rabbit that had been immunised with the precipitated 
protein showed that the antiserum was specific as it recognised the purified fusion protein (Fig. 
4.4).
Western blotting of the first bleed anti-CYC 1 antiserum against T. brucei protein lysates 
detected a protein at the predicted size of 36 kDa (Fig. 4.5, 4.6) that was specific as it could be 
competed by preincubation of the antiserum with a saturating amount of purified fusion protein. 
Initial expectations that CYC1 would be expressed in proliferative life cycle stages of the 
parasite - if it was a functional cyclin homologue involved in the mitotic aspect of cell cycle 
control - were bolstered by the presence of the 36 kDa protein in STIB 247 procyclics and 
TREU 869 long slender bloodstream form. However, after booster immunisation and 
exsanguination the anti-CYC 1 antiserum was tested against lysates of procyclic, long slender 
bloodstream and short stumpy bloodstream forms of STIB 247 (Fig. 4.7). This clearly showed 
that CYC1 is expressed in the short stumpy bloodstream form and in procyclics, but not in the 
long slender bloodstream form. It has been demonstrated (Hua et al., 1996) that levels of CYC1 
transcript and CYC1 protein rise 3- to 5-fold between the short stumpy bloodstream and 
procyclic form T. b. brucei STIB 427, and that this rise in expression correlates closely with the
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disappearance of variable surface glycoprotein (VSG) and the appearance of procyclic acidic 
repetitive protein (PARP). The hypothesis developed was therefore that CYC1 plays a role in 
the differentiation between the two life cycle stages and is not involved in mitosis in 
trypanosomes. The pattern of expression of CYC1 observed would support this, at least for 
STIB 247; as previously mentioned, TREU 869 long slender bloodstream form is a long-term 
culture-adapted monomorphic isolate that is not capable of differentiation and therefore patterns 
of gene expression may differ between pleomorphic and monomorphic cell lines.
Key to proving that CYC1 is a functional cyclin is the demonstration of association with 
a CDK homologue (CRK protein in the case of trypanosomes). Immunoprecipitations with 
purified anti-CYCl antiserum from procyclic soluble (S-100) lysates were probed with an anti- 
CRK1 antiserum and purified EVREE antibodies; in the absence of an anti-tbCRK3 antiserum 
an anti-lmmCRK3 antiserum was used. None of these antisera detected any specific proteins. 
Indeed, probing the filters with the anti-CYCl antiserum did not detect the 36 kDa CYC1 either. 
The antiserum may contain antibodies to linear peptide sequence and spurious conformational 
epitopes corresponding to portions of the protein’s interior, rather than to native conformational 
epitopes on the protein’s exterior. It is therefore not surprising that such an antiserum would 
prove good for detecting denatured protein in the context of a Western blot but could be poor at 
binding native protein for immunoprecipitation.
To further investigate the possible association of CYC1 with a CRK, the recombinant
p j / n j  C T I f ’ lproteins pl2 and pl3  were used to specifically select CRKs and associated proteins from 
midlog STIB 247 procyclic S-100 extracts. After selection and extensive washing, bound 
protein was eluted and used in Western blots that were probed with the anti-CYCl antiserum 
(Fig. 4.11). No CYC1 was found to bind to p l2  or pl3. CRKs 1-3 have been shown to bind pl2, 
and CRK3 only has been shown to weakly bind pl3 (Van Hellemond and Mottram, 
unpublished), therefore if CYC1 was associated with any of these CRKs in procyclics it should 
have been detected. The fact that it was not, along with the fact that duplicate filters probed with 
anti-CRKl and anti-CRK2 antisera clearly showed CRK1 and CRK2 binding, shows that CYC1 
does not associate with CRK1, CRK2 or CRK3 in the procyclic form of STIB 247.
Immunoprecipitations linked to kinase assays initially gave indications that a 
precipitated activity towards a/|3-casein and histone HI was present (Fig. 4.9). However, as was 
noted previously the preimmune serum and purified anti-CYCl antiserum were not directly 
comparable. Accordingly, the best criterion for a specific associated kinase activity was 
competition of precipitable activity by preblocking of the antiserum with a saturating quantity of 
purified CYClHis fusion protein. Although some attenuation of precipitable activity was seen, 
this effect was not large and varied considerably between individual assays. The overall 
conclusion from these experiments was that no significant histone HI or a/(3-casein kinase 
activity was associated with the immunoprecipitates.
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The interpretation of this data is problematic, chiefly due to the poor ability of the anti- 
CYCl antiserum to immunoprecipitate CYC1. Western blotting showed the protein to be 
present in the short stumpy bloodstream form and procyclic form but not the long slender 
bloodstream form, consistent with the hypothesis that CYC1 functions in the differentiation 
process from short stumpy bloodstream form to procyclic form (Hua et al., 1996). This argues 
against (though does not disprove) a role for CYC1 in mitosis in proliferative life cycle stages of 
the parasite. Selection experiments showed that CYC1 is not associated with CRK1, CRK2 or 
CRK3 in the procyclic form, but does not preclude association of CYC1 with any of these CRKs 
in the short stumpy bloodstream form or during the differentiation process, although persistence 
of gene expression and protein production in the procyclic is then puzzling if it is not 
meaningfully functional after the differentiation process is complete. An alternative explanation 
is that CYC1 binds an as yet unidentified CRK that has a novel biological activity and does not 
bind the Leishmania p l2  protein. A third interpretation is that CYC1 is not a cyclin homologue 
and that it has a non-cyclin function during the differentiation from short stumpy bloodstream 
form to procyclic form. Unfortunately, in the absence of further data, no firm conclusions can be 
drawn.
The genetic experiments may suggest that CYC1 is an essential gene in the procyclic 
form, by the criteria that a gene can be deemed essential if it is not possible to delete both wild- 
type alleles and obtain viable null mutants. It was possible to delete one of the two wild-type 
alleles (Fig. 4.13) as judged by PCR; however, the primers used sat within the disruption 
construct. Although viable cells were obtained from transfection to delete the remaining wild- 
type allele, Southern blotting showed that a wild-type allele was present in all double-resistant 
clones isolated (Fig. 4.14). Interpretation of this blot is difficult; CYC1 contains a single HindUl 
site at position 721 (from the ATG start codon) and the blot showed hybridising bands of 
approximately 2.7 kb and 3.8 kb in wild-type STIB 247. The HindUl site in the disruption 
constructs is at position 745 from the ATG start codon, which is the beginning of the 
replacement cassette, therefore the difference between the 5’ fragments produced on HindUl 
digestion of wild-type genomic DNA as compared to WUMP 878, 879 and 880 genomic DNA 
would be only 24 bp, too small to be resolved on a Southern blot. However, the size difference 
between the 3’ fragments of these internal HindUl sites was calculated to be 721 bp (BLE) and 
921 bp (FAQ from the wild-type, therefore a mobility shift of one of the two hybridising 
fragments produced from wild-type by these sizes was expected. This was not what was 
observed, as the extra hybridising fragments seen for WUMP 878, 879 and 880 are all smaller 
then wild-type. Furthermore, WUMP 880 showed a different pattern of hybridising fragments 
from WUMP 878 and 879. An explanation for these results is difficult, but it is possible that the 
clones isolated were those in which the cassettes integrated at a locus or loci other than the 
CYC1 locus. Regardless of what has occurred, the key point is that all double-resistant clones
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still contain a wild-type copy of CYC1. However, an important consideration is the lack of 
information concerning the CYC1 locus. The PARP promoter is powerful, and without 
knowledge of the locus downstream of tbCYCl it is not possible to say that the failure to delete 
both alleles was due to a requirement for tbCYCl i.e. transcriptional read-through could provide 
abnormal expression of a nearby gene that is deleterious to the procyclic-stage cells. Assurance 
of tbCYCl as an essential gene would require demonstration that the disruption constructs did 
not directly alter the expression of any nearby gene, and rescue of phenotype by ectopic 
expression to demonstrate the specificity of the effect (in this case, if tbCYCl wild-type alleles 
could be deleted with ectopic expression of tbCYCl). In retrospect, disruption of tbCYCl in the 
long slender bloodstream stage of STIB 247 would have been a better approach, as tbCYCl is 
not detected in STIB 247 long slender form cells; in addition, this would have provided an 
opportunity to analyse the function of tbCYCl in the transformation form bloodstream to 
procyclic-form cells.
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Fig. 4.1: The T. brucei CYC1 gene
Schematic representation of the CYC1 gene showing relevant restriction sites and primers. The 
HindUl restriction site was used to digest DNA for Southern blotting of transgenic clones. The 
primer combinations of CYC 1K 055 with CYC 1K 053 and CYC 1K 035 with CYC 1K 033 were 
used to amplify fragments corresponding to the 5 ’ and 3 ’ end of the gene, respectively, for the 
generation of targeted disruption constructs.
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F ig. 4.2: Assessment of the subcellular distribution of CYClHis in E. coli
12.5 % Lammeli gel stained with Coomassie blue, showing distribution of CYClHis in different 
subcellular compartments. The control samples were the M15[pREP4]pGL107 culture 
immediately prior to induction by the addition o f 2 mM IPTG (uninduced control) and a sample 
of the same culture after induction, immediately prior to harvesting (induced control). The 
M15[pREP4]pGL107 culture was grown to an OD at 600 nm of 0.8 before addition of IPTG, 
and left to grow for a further two hours before harvesting.
Lane 1. Low Range nonprestained markers (BioRad)
Lane 2. Periplasmic fraction 
Lane 3. Soluble fraction 
Lane 4. Insoluble fraction
Lane 5. Low Range nonprestained markers (BioRad)
Lane 6. Uninduced control
Lane 7. Induced control
Lane 8. Periplasmic wash fraction
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Fig. 4.3: Purified recombinant CYClHis
Samples o f two different pools of purified, dialysed recombinant fusion protein, 
electrophoresed on a 12.5% Lammeli gel and stained with Coomassie blue.
Lane 1. Pool A (approximately 15 pg CYC lH is)
Lane 2. Rainbow markers (Amersham)
Lane 3. Pool B (approximately 20 pg C YC lH is)
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Fig. 4.4: W estern blot with first bleed anti-CY Cl antiserum
Crude whole-cell E. coli lysates and purified recombinant CYClHis (approximately 5 pg) were 
electrophoresed on a 12.5% Lammeli gel, blotted to PVDF membrane at 25 mA overnight at 
4°C, and the Filter probed with first bleed anti-CYCl antiserum at a titre of 1:100 (lanes 1-3). 
Duplicate lanes were probed with the first bleed anti-CYCl antiserum that had been 
preincubated with an equivalent volume of 1 mg m l1 purified fusion protein (lanes 4-6). 
Secondary anti-rabbit HRP-conjugate (Promega) was used at 1:2500, and the blot developed 
with Supersignal ECL reagents (Pierce). Markers were the Kalidescope prestained markers 
(Amersham) and Low Range nonprestained markers (BioRad).
Lanes 1, 4. Purified CYClHis (approximately 5 pg
Lanes 2, 5. M15[pREP4] E. coli, grown for 2 hours with 1 mM IPTG
Lanes 3, 6. M15[pREP4]pGL107 E coli, grown for 2 hours with 1 mM IPTG
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Fig. 4.5: Western blot of STIB 247 procyclic total protein lysate with first bleed anti-CYCl 
antiserum
5x 106 cells per lane of T. b. brucei STIB 247 procyclic total protein lysate was electrophoresed 
on a 12.5% Lammeli gel at 130 V at room temperature. Protein was transblotted to PVDF 
membrane using a wet-blot tank (BioRad) at 25 mA overnight at 4°C. The first bleed anti-CYCl 
antiserum was used at a titre o f 1:2500, the anti-CRKl antiserum at 1:100. Secondary anti-rabbit 
HRP-conjugate (Promega) was used at 1:2500, and the blot developed with Supersignal ECL 
reagents (Pierce). Markers were the Kalidescope prestained markers (Amersham) and Low 
Range nonprestained markers (BioRad).
Lane 1. Preimmune serum
Lane 2. First bleed anti-CYCl antiserum
Lane 3. First bleed anti-CYCl antiserum preblocked with 1 mg m l1 CYClHis 
Lane 4. Anti-CRKl antiserum
Lane 5. Anti-CRKl antiserum preblocked with 1 mg m l1 CLEHPY peptide
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Fig. 4.6: Western blot of TREU 869 long slender bloodstream form total protein lysate 
with first bleed anti-CYCl antiserum
5x 1()6 cells per lane o f T. b. rhodesiense TRUE 869 long slender bloodstream form total protein 
lysate per lane was electrophoresed on a 12.5% Lammeli gel at 130 V at room temperature. 
Protein was transblotted to PVDF membrane using a wet-blot tank (BioRad) at 25 mA overnight 
at 4°C. The first bleed anti-CYCl antiserum was used at a titre of 1:2500,. Secondary anti-rabbit 
HRP-conjugate (Promega) was used at 1:2500, the anti-CRKl antiserum at 1:100, and the blot 
developed with Supersignal ECL reagents (Pierce). Markers were the Kalidescope prestained 
markers (Amersham) and Low Range nonprestained markers (BioRad).
Lane 1. Preimmune serum
Lane 2. First bleed anti-CYCl antiserum
Lane 3. First bleed anti-CYCl antiserum preblocked with 1 mg ml'1 CYClHis 
Lane 4. Anti-CRKl antiserum
Lane 5. Anti-CRKl antiserum preblocked with 1 mg ml'1 CLEHPY peptide
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Fig. 4.7: Western blot of STIB 247 procyclic, long slender and short stumpy bloodstream 
form lysates with anti-CYCl antiserum
5x 106 cells per lane of T. b. brucei STIB 247 procyclic, long slender and short stumpy 
bloodstream form lysates per lane were electrophoresed on a 12.5% Lammeli gel and the protein 
transblotted to PVDF membrane by wet-blotting at 250 mA for 3 hours at 4°C. The membranes 
were probed with final bleed anti-CYCl antiserum at a titre of 1:100, and secondary anti-rabbit 
HRP-conjugate at 1:2500, and the blot developed with Supersignal ECL reagents (Pierce). 
Markers were the Kalidescope prestained markers (Amersham) and Low Range nonprestained 
markers (BioRad).
Lanes 1-4 and 13-15. Preimmune serum 
Lanes 5-8 and 16-18. Anti-CYCl antiserum
Lanes 9-12 and 19-21. Anti-CYCl antiserum preblocked with 1 mg ml'1 CYClHis 
The protein lysates used in the lanes were as follows.
Lanes 1, 5 and 9. Long slender bloodstream insoluble fraction
Lanes 2, 6 and 10. Long slender bloodstream soluble fraction
Lanes 3, 7 and 11. Procyclic insoluble fraction
Lanes 4, 8 and 12. Procyclic soluble fraction
Lanes 13, 16 and 19. Short stumpy bloodstream total protein
Lanes 14, 17 and 20. Short stumpy bloodstream insoluble fraction
Lanes 15, 18 and 21. Short stumpy bloodstream soluble fraction
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Fig. 4.8: Western blot with protein A/G purified anti-CYCl antiserum
5x 106 cells per lane of T. b. brucei STIB 247 procyclic, long slender and short stumpy
bloodstream form lysates and T. b. rhodesiense TREU 869 long slender bloodstream form lysate
per lane were run on a 12.5% Lammeli gel, and the protein transblotted to PVDF membrane by
wet-blotting at 50 mA at 4°C overnight. The anti-CYCl antiserum was partially purified by
passing through a recombinant protein A/G column (see chapter 2.3.4). The filters were probed
with the anti-CYCl antiserum, the A/G column flow-through, the A/G column wash and the
A/G column eluate, all at a titre of 1:50. Secondary anti-rabbit HRP-conjugate was used at a titre
of 1:2500, and the blot developed with Supersignal ECL reagents (Pierce). Markers were the
Kalidescope prestained markers (Amersham) and Low Range nonprestained markers (BioRad).
Lanes 1-4. Anti-CYCl antiserum
Lanes 5-8: A/G column flow-through
Lanes 9-12. A/G column wash
Lanes 13-16. A/G column eluate
The protein lysates used in the lanes were as follows.
Lanes 1, 5, 9, 13. STIB 247 long slender bloodstream total protein lysate 
Lanes 2, 6, 10, 14. TREU 869 long slender bloodstream total protein lysate 
Lanes 3, 7, 11, 15. STIB 247 short stumpy bloodstream total protein lysate 
Lanes 4, 8, 12, 16. STIB 247 procyclic total protein lysate
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Fig. 4.9: Immunoprecipitation-linked kinase assay with anti-CYCl antiserum
The protein A/G purified anti-CYCl antiserum was used to immunoprecipitate from an S-100 
lysate of midlog STIB 247 procyclics (20 pi anti-CYC 1/200 pi extract per sample). After 
binding to Sepharose-protein A and extensive washing each sample was incubated with 20 pi 
KAM, that included 5 pg o f substrate protein per reaction, for 20 minutes at 30°C. Reactions 
were stopped by addition o f 20 pi o f FSB and heating to 100°C for 5 minutes. 20 pi o f each 
reaction was electrophoresed on a 12.5% Lammeli gel, which was stained with Coomassie blue, 
dried and exposed to autoradiography film. The substrate in lanes 1-3 was an equal mix o f a/(3- 
casein, and in lanes 4-6 was histone HI. Markers were the Low Range nonprestained markers 
(BioRad).
Lanes 1, 4. No serum 
Lanes 2, 5. Preimmune serum
Lanes 3, 6. Protein A/G purified anti-CYCl antiserum
mmm-
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Fig. 4.10: Immunoprecipitation-linked kinase assay comparing midlog and cell cycle 
arrested cells
The protein A/G purified anti-CYCl antiserum was used to immunoprecipitate from S-100 
lysates of midlog STIB 247 procyclics (cell density of 6x 106 cells ml'1) and STIB 247 
procyclics that had been artificially cell cycle arrested by serum depletion. The 
immunoprecipitation and kinase assay protocols were as described in chapter 2.3.5, with 20 pi 
anti-CYC 1/200 jliI extract per sample and 5 pg substrate protein per reaction. The substrate was 
a mix of cx/fl-casein (2.5 pg o f each casein per reaction ). Markers were the Low Range 
nonprestained markers (BioRad).
Lanes 1, 2. Preimmune serum
Lanes 3, 4. Protein A/G purified anti-CYCl antiserum.
Lanes 1, 3. Midlog procyclics
Lanes 2, 4. Cell cycle arrested procyclics
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Fig. 4.11: Selection of CRK complexes from STIB 247 procyclics using recombinant pl2  
and pl3
S-100 STIB 247 procyclic extracts were selected using beads that were aminolinked to either 
TRIS (control beads), purified recombinant p l2 CKS1 or purified recombinant p l3sucl. 10 pi 
aliquots of selected samples were electrophoresed on 12.5% Lammeli gels, transblotted to 
PVDF membrane and probed with antisera at a titre of 1:100, with the secondary anti-rabbit 
HRP-conjugate at 1:2500; the blot was developed with Supersignal ECL reagents (Pierce). 
Markers were the Kalidescope prestained markers (Amersham) and Low Range nonprestained 
markers (BioRad).
Lanes 1, 4, 7, 10, 13, 16 and 19 were control beads.
Lanes 2, 5, 8, 11, 14, 17 and 20 were p l2 CKS1 beads.
Lanes 3, 6, 9, 12, 15, 18 and 21 were p l3 sucl beads.
Lanes 1-3. Anti-CYCl preimmune serum 
Lanes 4-6. Anti-CYCl antiserum
Lanes 7-9. Anti-CYCl antiserum preblocked with 100 pg CYClHis fusion protein 
Lanes 10-12: Purified EVREE antibodies
Lanes 13-15: Purified EVREE antibodies preblocked with 50 pg EVREE peptide 
Lanes 16-18. Anti-CRKl antiserum
Lanes 19-21. Anti-CRKl antiserum preblocked with 50 pg CLEHPY peptide
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Fig. 4.12: Generation of CYC1 gene disruption constructs
The CYC1 5 ’ and 3’ sequence fragments were amplified from STIB 247 genomic DNA by PCR 
and cloned into pTAG as described. The 5 ’ and 3 ’ fragments were released from pTAG using 
the restriction sites shown and used to replace the CRK2 5 ’ and 3’ sequences in the intermediary 
constructs pUC 18 f? ARP-BLE/CRK2[5'-3’ 1 and pUC18/PARP-PAC/CRK2[5’-3’]. After specific 
fragment replacement the CYC1 disruption cassettes were shuttled to pBluescript, using the 
EcoRl and Hindlll sites shown, to generate the CYC1 disruption constructs pGLl 11 (BLE) and 
pGLl 12 (PAC). The cassettes was released for transfection using the pBluescript polylinker 
sites Sacl and Xhol, which are not present within the disruption cassettes.
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Fig. 4.13: PCR from Acycl::PAC/CYCl clones genomic DNA
PCR was performed using genomic DNA in 10 pi reactions with 50 pg each o f primers 5 ’5 ’ and 
3’3 \  DNA was diluted 1:10 in distilled water and 1 pi o f this dilution used per reaction. 
Annealing temperature was 50°C, and the PCR end-point reactions were electrophoresed on a 
1% TAE gel, and visualised by staining with 0.5 pg m l1 ethidium bromide.
Lane 1. 1 kb ladder markers (GibcoBRL)
Lane 2. STIB 247 wild-type 
Lane 3. WUMP 834 
Lane 4. WUMP 833
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Fig. 4.14: Southern blot of putative Acycl::PAC/Acycl::BLE clones genomic DNA
2.5 (ig o f genomic DNA was digested with Hindlll and electrophoresed on a 0.8% TBE agarose 
gel, blotted to supported nitrocellulose membrane by the capillary method and probed with full- 
length C Y C l. Markers were the 1 kb ladder (GibcoBRL).
Lane 1. STIB 247 wild-type 
Lane 2. WUMP 878 
Lane 3. WUMP 879 
Lane 4. WUMP 880
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CHAPTER 5: ANALYSIS OF THE BIOCHEMICAL AND GENETIC FUNCTION OF 
THE tbCRK2 GENE AND tbCRK2 PROTEIN
5.1: Introduction
The CRK2 gene was initially isolated as two overlapping clones from an EMBL4 X 
library of T. b. brucei genomic DNA using a low-stringency hybridisation screen with the 
ImmCRKl gene (Mottram and Smith, 1995). A fragment was subcloned from each to 
pBluescript(+) vector, to give two subclones that overlapped by approximately 200 bp. Subclone 
pPH2 (pGLl 16) contained the 5’ end of the gene, from the internal HindUl site at position 675 
(relative to the ATG start codon) plus approximately 2 kb of upstream sequence. Subclone 
pGBl (pGLl 17) contained the majority of the gene, from the internal BamHl site at position 
229 (relative to the ATG start codon) to a BamHl site approximately 1 kb downstream of the 
TAA stop codon. The complete open reading frame (ORF) was sequenced plus some 5’ and 3’ 
flanking sequence (Fig. 5.1), a schematic is shown along with the relevant primers and 
restriction sites. CRK2 differs from other CDK homologues from other organisms, as it codes 
for a 41 amino acid N-terminal leader sequence; only CRK3 has a similar although shorter 
extension, of 19 amino acids (Mottram and Smith, 1995), which has no significant homology to 
the CRK2 N-terminal leader. The function of these leaders, if any, is unknown. Phylogenetic 
analysis does not place CRK2 in strong association with any of the other trypanosomatid CRKs, 
nor with any of the CDKs from other eukaryotes (Mottram and Smith, 1995), therefore little 
may be inferred about its role in vivo. The aims of the experiments described in this chapter 
were: 1) To identify CRK2 in different life cycle stages of T. brucei by Western blotting with 
anti-CRK2 antisera. 2) To use immunoprecipitations linked to kinase assays to demonstrate 
CRK2-associated kinase activity. 3) To use targeted gene disruption to generate null mutants 
and observe any phenotypic changes. 4) To use inducible systems to overexpress CRK2 and 
epitope-tagged CRK2 in vivo to study phenotypic changes, examine coprecipitating proteins and 
demonstrate kinase activity.
5.2: Results
5.2.1: Western blot analysis with anti-CRK2 peptide antisera
To attempt to raise specific antisera to CRK2 for use in Western blotting and 
immunoprecipitations linked to kinase assays, rabbits were immunised with a number of
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different peptides deduced from the gene sequence. Two of these peptides were 16-mers and the 
third an 11-mer. The sequences of the peptides was as follows:-
1) NE-V-R-E-E-E-V-E-L-K-M-R-F-N-G-Ac ‘EVREE’ peptide
2) nG-G-V-P-S-T-A-V-R-E-V-S-L-L-R-Ec ‘PSTAVR’ peptide
3) nC-V-E-L-K-M-R-F-N-G-Ac ‘CVELK’ peptide
‘EVREE’ corresponds to the C-terminal 16 amino acids. ‘PSTAVR’ corresponds to the 
16 amino acid region of tbCRK2 that is the homologue of the hsCDKl motif known as the 
PSTAIRE box (EGVPSTAIREISLLKE); the PSTAIRE box homologue in CRK2 is degenerate, 
with four amino acid substitutions (GGVPSTAVREVSLLRE) as compared to hsCDKl 
(Mottram and Smith, 1995). The third represents the C-terminal 11 amino acids. All three were 
conjugated to keyhole limpet haemocyanin (KLH) as a carrier protein, and the immunisation 
schedule followed was as described in chapter 2.3.4, with exsanguination of the animals after 
the second booster immunisation. Antisera were stored in aliquots at -20°C.
‘EVREE’ antiserum was purified in a two-step process; firstly, an aliquot of the 
antiserum was purified on a Protein A/G column (for full details see chapter 2.3.4) to remove 
contaminating serum proteins and specifically purify the IgG fraction of the antibodies. The 
EVREE peptide (not conjugated to KLH) was used to make an Sulfolink column as described in 
chapter 2.3.4, and an aliquot of the partially purified antiserum was passed through this column, 
thus specifically purifying only antibodies that recognised the peptide. The purified EVREE 
antibodies were tested against insoluble, soluble (S-100) and total protein lysates of T. b. brucei 
STIB 247 procyclic, long slender and short stumpy bloodstream forms. A number of proteins 
were detected in all three life cycle stages (Fig. 5.2). For each life cycle stage the pattern of 
proteins was identical between the soluble and total protein lysates; the purified EVREE 
antibodies did not detect any proteins in the insoluble lysates (lanes 2, 8, 14). In the procyclic 
form lysates a protein of approximately 46 kDa was detected, and another protein of 38 kDa was 
detected more weakly (lanes 1, 3), both of which were competed with peptide (lanes 4, 6). The 
38 kDa protein was a doublet. Two proteins were detected weakly at approximately 66 kDa and 
90 kDa (lanes 1, 3) that were not competed with peptide (lanes 4, 6). A similar pattern of pattern 
of proteins were detected in the short stumpy bloodstream and long slender bloodstream form 
lysates. These proteins were identical to those detected in the procyclic lysates except that the 
doublet of 38 kDa in procyclics (lanes 1, 3) was a single protein in the short stumpy bloodstream 
(lanes 7, 9) and long slender bloodstream (lanes 13, 15) form lysates. In the long slender 
bloodstream form lysates a protein of approximately 60 kDa (lanes 13, 15) was also detected
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and could be competed with peptide (lanes 16, 18). The size of CRK2, as predicted from the 
open reading frame, is 39 kDa, therefore the 38 kDa protein detected in all three life cycle stages 
lysates was a good candidate for CRK2.
‘PSTAVR’ antiserum was purified in a two-step process in the same manner as the 
‘EVREE’ antiserum. Partial purification on a protein A/G column of an aliquot of ‘PSTAVR’ 
was followed by affinity purification on a Sulfolink PSTAVR peptide column. The purified 
PSTAVR antibodies were then tested by Western blotting against insoluble, soluble (S-100) and 
total protein lysates of T. b. brucei STIB 247 procyclic, long slender and short stumpy 
bloodstream forms (Fig. 5.3). A similar pattern of proteins was observed in all three life cycle 
stages. A protein of between 50-60 kDa was detected very strongly in the total cell extracts from 
the three life cycle stages (lanes 1,7, 13) and insoluble lysates (lanes 2, 8, 14) that was 
competed with peptide (lanes 4, 5, 10, 11, 16, 17). Another protein was detected as a diffuse 
signal of approximately 65-70 kDa that was present in the total (lane 1,7, 13) and insoluble 
(lane 2, 8, 14) lysates and was competed with peptide (lanes 4, 5, 10, 11, 16, 17). A protein was 
also detected at approximately 43 kDa in the total (lane 1) and soluble (lane 3) procyclic lysates 
that was nonspecific as it could not be competed with peptide (lanes 4, 6). In the long slender 
bloodstream form total (lane 13) and soluble (lane 15) lysates a protein of approximately 41 kDa 
was detected weakly and was competed with peptide (lanes 16, 18).
The results from the two purified 16-mer antibodies were largely irreconcilable; both 
detected a number of proteins, but the proteins recognised differed between the two antibodies. 
As the size of CRK2, as predicted from the gene sequence, is 39 kDa it was most likely that the 
38 kDa band detected by the EVREE antibodies was CRK2. In addition, this 38 kDa protein was 
located in the soluble fraction lysates. The proteins recognised by PSTAVR were of the wrong 
size and located in the insoluble fraction lysates, with the exception of the 41 kDa protein 
located in the soluble lysate of the long slender bloodstream form. At this juncture, this protein 
could not be ruled out as CRK2.
The 11-mer peptide representing the C-terminal 11 amino acids was conjugated to KLH 
and used to immunise two rabbits (see chapter 2.3.4). The exsanguination antisera obtained, 
labelled ‘CVELK’ (R421) and ‘CVELK’ (R507), were tested in Western blots against soluble 
(S-100), insoluble and total protein lysates of T. b. brucei STIB 247 procyclic, long slender and 
short stumpy bloodstream forms. Neither antiserum detected any proteins in any of the lysates of 
the three life cycle stages. Consequently, these antisera were abandoned for use in CRK2 
analysis. It was unclear why the 11-mer peptide failed to provoke a useful immune response, as 
an 11-mer corresponding to the C-terminal 11 amino acids of CRK1 was conjugated to KLH 
and used in the immunisation of two rabbits, producing two antisera that both clearly and 
specifically recognised the 34 kDa CRK1 (data not shown). Therefore the short size of the 
peptide is unlikely to have been the reason a priori.
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5.2.2: Production of recombinant CRK2
As the approach to raising antisera using peptides deduced from the gene sequence had 
not produced sufficiently specific antibodies, it was decided to attempt to use bacterial 
expression systems to produce recombinant CRK2 for immunisation. The vector chosen was 
pQE60, which adds a C-terminal hexahistidine tag (Qiagen). Full-length CRK2 was generated 
by PCR using primers that engineered the appropriate restriction sites for the vector’s polylinker 
(Ncol at the 5’ end of the amplified CRK2, and BglTL at the 3’ end) and cloned to pQE60 to 
generate pGL217 (construct generated by G. Smith). Following transformation to the 
M15[pREP4] E. coli cell line, pilot inductions were performed using standard protocols with 
varying concentrations of IPTG to induce expression. No induced protein of the expected size of 
40 kDa was detected (data not shown). A second pilot followed a time-course of induction over 
four hours for three different cultures also failed to produce a detectable 40 kDa protein. In an 
attempt to determine if any significant induction of CRK2His was taking place, a small-scale 
pilot denaturing purification was carried out as previously described (chapter 2.3.3). However, 
no purified 40 kDa CRK2His was detected (not shown). The conclusion from these experiments 
was that CRK2His was not expressed to any significant level. Poor expression is often the result 
of the recombinant protein being toxic to the bacteria, but this usually results in slow growth 
and cell death and the induced cultures of M15[pREP4]pGL217 appeared to grow normally. As 
the gene was not sequenced after PCR and cloning it is possible that a premature stop codon was 
generated by the amplification process. To test this theory, crude whole cell lysates of 
uninduced and induced M15[pREP4]pGL217 were prepared and electrophoresed on a 12.5% 
Lammeli gel, and transblotted to nitrocellulose membrane, which was then probed with the 
purified EVREE and PSTAVR antibodies (Fig. 5.4). The PSTAVR antibodies detected a protein 
at approximately 40 kDa in both the uninduced (lane 5) and induced (lane 6) lysates that was 
competed with PSTAVR peptide (lanes 7, 8). There was no difference in the strength of the 
signal between the uninduced (lane 5) and induced (lane 6) lysates. The EVREE antibodies 
detected a protein of approximately 40-42 kDa in both the uninduced (lane 1) and induced (lane 
2) lysates that was competed with EVREE peptide (lanes 3,4). There was no difference in the 
strength of the signal between the uninduced and induced lysates. In addition, the EVREE 
antibodies detected a small molecular weight protein in both lysates (lanes 1, 2) that was 
competed with peptide (lanes 3,4) and a protein of approximately 60 kDa was weakly detected 
in both lysates (lanes 1, 2) that was competed with peptide (lanes 3,4). The conclusion was that 
full-length CRK2His was expressed only to a very low level, for whatever reason, that was 
sufficient to be detected on a Western blot but not by Coomassie staining. Construct pGL217, 
therefore, was not used to express and purify CRK2His. This experiment also showed that both 
EVREE and PSTAVR antibodies recognised CRK2, but that the EVREE antibodies had a
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higher affinity for CRK2 in the context of a Western blot. As pGL217 could not be made to 
express significant levels of recombinant protein in E. coli, use of the Qiagen histidine tag 
system was abandoned and a new approach taken using a yeast system.
The yeast system Pichia pastoris was used to attempt to produce recombinant full- 
length CRK2. Pichia pastoris is a methylotrophic yeast that can use methanol as a sole carbon 
source, although this is not the preferred source. Methanol utilisation is based upon induction of 
the alcohol oxidase genes A 0X1 and A 0X2, in a process of derepression (lack of glucose in the 
culture medium) and specific induction (presence of methanol). A0X1 accounts for the vast 
majority of transcript produced in methanol-grown cells and this can be as much as 5% of 
poly [A] + RNA, corresponding to 30% total soluble protein. The strong, highly-inducible PAOxi 
promoter is used for heterologous expression of the gene of interest, either by gene replacement 
or gene insertion to one of the two yeast strains, using a vector that contains the AOXI promoter 
and 3’ sequences. The particular vector used in this case was pPIC9, which contains the a-factor 
secretion signal immediately upstream of the polylinker. This expression system was tested 
because it has advantages over bacterial systems, including a greater likelihood of correct 
protein folding and post-translational modification, low levels of native protein secretion, and a 
tendency not to hyperglycosylate secreted proteins all combined with high expression of the 
cloned gene of interest.
A full-length copy of CRK2 with the appropriate restriction sites for cloning to the 
pPIC9 vector was produced by PCR and cloned to pPIC9. Following sequencing to ensure that 
the gene was in-frame with respect to the a-factor secretion signal sequence, the construct was 
transformed to the yeast strains involved, selected, integration checked by PCR and pilot 
expressions carried out. Transformation, selection, PCR and pilot expressions were performed 
by Dr. P. Neuville. No expression of CRK2 was observed, either intracellular or secreted. For 
this reason this expression system was also abandoned.
5.2.3: Expression of CRK2 in T. b. brucei A nTatl.l procyclics
As heterologous expression of CRK2 had been a failure in both E. coli and yeast, it was 
decided to use the Clayton expression vector pHD430 (Wirtz and Clayton, 1995) to express 
CRK2 in T. b. brucei AnTat 1.1 procyclics. This should allow a determination of the 
biochemical identity of CRK2 in Western blots and provide a phenotype for overexpression of 
CRK2. The AnTat 1.1 cell line used was kindly provided by Prof. C Clayton and was termed 
‘360’. It contained the cassette from construct pHD360 stably integrated at the repetitive a(3- 
tubulin locus, to give constitutive expression of the tetracycline repressor protein (Wirtz and 
Clayton, 1995).
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The vector pHD430 contains a cassette with the luciferase (LUC) gene under the control 
of a modified PARP promoter that contains the operator sequence from the E. coli tetracycline 
resistance operon. Downstream of the luciferase gene and the PARP 3’ processing elements a 
bleomycin (BLE) resistance marker, flanked by the aldolase 5’ and 3’ processing elements, 
provides selection for transgenic cells by transcriptional read-through from the LUC gene. The 
construct contains a segment of the ribosomal DNA (rDNA) intergenic spacer, with a unique 
Notl site in the middle of this region being used for linearisation of the construct for 
transfection. The cassette is orientated with respect to the rDNA sequence such that integration 
at the rDNA spacer by homologous recombination results in the cassette orientated in a reverse 
(nonsense) orientation with respect to the 18S rRNA locus (Wirtz and Clayton, 1995). As the 
rDNA spacer is transcriptionally silent and the cassette integrates in a reverse orientation, there 
can be no transcriptional read-through from the 18S rRNA genes. Control of expression is 
therefore as shown (Fig. 5.5). The pHD430 construct integrates at the rDNA locus and the E. 
coli repressor protein binds to the operator sequence in the modified promoter, preventing 
transcription. Addition of as little as 5 ng ml'1 of tetracycline results in the repressor protein 
becoming bound to the tetracycline, causing a conformational change that precludes binding to 
the operator, and allowing transcription of the LUC and BLE genes. Addition of tetracycline and 
phleomycin to the recovery culture medium following transfection therefore selects for 
transgenic cells with stably integrated pHD430 cassettes.
As there was no full-length CRK2 available on one subclone, the full-length CRK2 
required was generated by exploiting the 200 bp overlap of pGLl 16 and pGLl 17, and the fact 
that there were Accl sites approximately 150 bp upstream of the ATG start codon in pGLl 16, 
and at approximately 55 bp downstream of the TAA stop codon in pGLl 17. Accl cleavage of 
pGLl 16 and pGLl 17 was followed by Klenow treatment to fill in the 3’ recessed ends left by 
the enzyme cleavage. Subsequently, HindUl cleavage liberated a 0.58 kb fragment from pGLl 16 
that contained some 5’ flank sequence, the ATG start codon and 5’ gene sequence to the internal 
HindlQ. site at position 675, and from pGLl 17 a 0.65 kb fragment that contained the 3’ gene 
sequence from the internal HindUl site at position 675 to the TAA stop codon and a small 
amount of 3’ flank sequence. These two contiguous fragments were cloned at the same time to 
the EcoKV site of pBluescript (pGL130; schematic, Fig. 5.1).
The LUC gene was excised from pHD430 by BamHUHindUl cleavage and Klenow 
treated to fill in the 3’ recessed termini and created blunt ends. The vector was then treated with 
CIP to dephosphorylate the termini. Full-length CRK2 was released from pG Ll30 by ClallSmal 
cleavage, and was subsequently Klenow treated to fill in the 3’ recessed end left by Clal 
cleavage. The vector and gene were then ligated and transformants screened by restriction 
mapping and PCR. A clone with the CRK2 gene ligated in the correct orientation, plasmid 
pGLl 15, was linearised for transfection by cleavage with Notl. The 360 cell line was transfected
158
with approximately 25 jug of the purified linearised construct (for full details see chapter 2.1.2) 
and recovered in 10 ml of complete SDM-79 medium with 10 p,g ml"1 phleomycin and 10 ng 
ml'1 tetracycline, to give the nonclonal population WUMP 827. The concentration of 
tetracycline used was sufficient to induce maximal expression of the cloned CRK2 gene from 
the pHD430 cassette. Once the transfected culture had grown to midlog (approximately 6x 106 
cell ml"1), a total protein lysate was made and compared on Western blots with wild-type STIB 
247 procyclic total protein lysate made from a midlog culture. Purified EVREE antibodies and 
nonpurified EVREE antiserum were tested first (Fig. 5.6). The crude EVREE antiserum 
detected a 25 kDa protein in the STIB 247 lysate (lane 1), a protein of the predicted size of 38- 
39 kDa (lane 1) as well as several other proteins. All of these proteins except the high and low 
molecular weight proteins were competed with EVREE peptide (lane 3). A similar pattern of 
proteins was detected for WUMP 827 (lane 2). The 38-39 kDa protein (lane 2) that was 
competed with peptide (lane 4) gave a much stronger signal than from STIB 247 (lane 1), 
showing overexpression of CRK2 in the transgenic cell population. The equivalence in signal 
from the 25 kDa protein between the two lysates shows equivalence of loading of protein 
between the lysates, therefore providing an additional control validating the difference in signal 
strength for the 38-39 kDa protein. The purified EVREE antibodies also gave a far stronger 
signal for the 38-39 kDa protein (lane 5) that was competed with peptide (lane 6). This was the 
expected result as maximal expression from the pHD430 cassette has resulted in significant 
overexpression of CRK2. Therefore, the EVREE antiserum and purified antibodies recognise 
endogenous CRK2 in wild-type cells and in cells overexpressing CRK2 to abnormal cellular 
levels (WUMP 827). Purified PSTAVR antibodies gave the same result, but the signal was 
much weaker (data not shown). As well as confirming the biochemical identity of CRK2 by 
Western blotting this experiment also provided the preliminary indications that large 
overexpression of CRK2 was neither deleterious to the cell cycle progression of T. brucei 
procyclics nor did it accelerate progress through the cell cycle. Wild-type STIB 247 and WUMP 
827 both appeared by visual inspection to have similar cell morphologies and growth rates, 
although detailed analyses were not performed.
5.2.4: Immunoprecipitation with anti-CRK2 antisera
The failure of the peptide approach to produce specific antisera and the failure of the 
expression systems to produce recombinant protein meant that immunoprecipitations to profile 
CRK2 expression and activity would be difficult to perform and interpret. A pilot 
immunoprecipitation-linked kinase assay, however, was carried out from a STIB 247 procyclic 
soluble (S-100) lysate using both purified EVREE and PSTAVR antibodies, and the 11-mer
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polyclonal CVELK (R421) antiserum, with histone HI as the substrate (Fig. 5.7). For the 
purified EVREE antibodies, little difference was observed between the preimmune serum (lane
1) and the purified antibodies (lane 2). The signal could not be competed with peptide (lane 3). 
The purified PSTAVR antibodies (lane 5) gave a slightly stronger signal than the preimmune 
serum (lane 4), and this appeared to be slightly competed with peptide (lane 6) but the 
difference was marginal. The preimmune serum (lane 7) and immune (lane 8) CVELK (R421) 
antiserum gave equivalent signals, with some competition with peptide observed (lane 9); 
however, as there was no difference between the preimmune serum and immune CVELK 
(R421) antiserum this was not a specific effect. These results confirmed the unsuitability of all 
the antisera for analysis to detect CRK2 histone HI kinase activity.
5.2.5: Targeted disruption of CRK2
To investigate the role of the gene in vivo a regimen of targeted gene disruption was 
followed, to determine if the gene was essential and to analyse any resultant phenotype on 
deleting both chromosomal copies of CRK2. Three constructs were developed for this, identical 
except for the resistance markers employed. For this analysis only the procyclic form was used.
Primers CRK2N5’ and CRK2N3’ were designed for use in PCR to amplify the 5’ end of 
the gene as a fragment of approximately 490 bp, corresponding to approximately 250 bp coding 
sequence and 240 bp flanking (Fig. 5.1). Primers CRK2C5’ and CRK2C3’ were designed to for 
use in PCR to amplify the 3’ end of the gene as a fragment of approximately 525 bp, 
corresponding to approximately 300 bp of coding sequence and 225 bp of flanking sequence 
(Fig. 5.1). The primers engineered the following restriction sites on to the ends of the 
amplification products: CRK2N5’ - Sphl- CRK2N3’ -Xbal; CRK2C5’ - Kpnl; CRK2C3’ - 
EcoRI. PCR was performed using these two primer combinations on pGLl 16 (CRK2N5’ and 
CRK2N3’) and pGLl 17 (CRK2C5’ and CRK2C3’). The PCR amplification products were 
digested after amplification with the relevant enzyme pair, electrophoresed on 1% TAE agarose 
gels, excised and gel purified using either the SpinX minicolumns (Costar) or the QIA Gel 
Extraction kit (Qiagen) before being cloned to the disruption constructs.
The starting construct was based on the vector pJB44 (Sherman et al., 1991) and 
consisted of the BLE gene cloned into pBluescript and flanked by the PARP promoter, splice 
acceptor and 3’ expression sequences. The whole cassette was excised by BamHl-Kpnl cleavage 
and cloned into pUC18 vector. The PCR products were digested with the enzymes 
corresponding to the engineered sites and cloned into the relevant sites in the pUC18/PARP- 
BLE construct polylinker. The complete cassette was then shuttled into pBluescript in two 
stages, firstly the HindJR-EcoRl fragment (containing the BLE gene, the PARP 3' expression
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sequences and the tbCRK2 3' sequence), then the Hindlll-HindUI fragment (containing the 
tbCRK2 5' sequence and the PARP promoter), to generate pGL108 (Fig. 5.8). Excision of the 
cassette for transfection was effected by Sacl-Xhol cleavage.
The puromycin acetyltransferase (PAC) gene was excised from a construct designed for 
use in Leishmania mexicana by BamHVSpel cleavage. Klenow treatment of the gene generated 
blunt ends and the gene was then cloned to the EcoKV site of pBluescript (SK-). Positive clones 
were screened by PCR for those that contained the PAC gene orientated such that the 5’ end lay 
adjacent to the HindUl site in the vector’s poly linker. The EcoRI site lying between the 
poly linker Pstl site and the 3’ end of the PAC gene was then destroyed by cutting with EcoRI, 
Klenow treating the termini and religating. The gene was then excised by HindUUPstl cleavage 
and cloned to the pB/PARP-BLZs starting construct in place of the BLE gene. The CZ?K2-specific 
sequences were cloned to flank the PARP-ZMC cassette and the finished construct shuttled into 
pBluescript in two stages, exactly as for pGL108, to give pGLl 10 (Fig. 5.8).
The streptathricin acetyltransferase (SAT) gene was excised from a construct designed 
for use in Leishmania mexicana by BamHVSpel cleavage and cloned in precisely the same way 
as the PAC cassette pGLllO to give pGL109 (Fig. 5.8).
Primary transfection was carried out as described (chapter 2.1.2) to STIB 247 wild-type 
procyclics using the SacVXhoI insert from pGL108, and selected using phleomycin at 20 pg ml'1 
in liquid culture. Two nonclonal populations of cells resistant to the antibiotic grew up, WUMP 
563 and WUMP 564. Genomic DNA was isolated from both cell populations and a Southern 
blot was performed to assess integration of the BLE resistance cassette (Fig. 5.9). Genomic 
DNA was digested with BamHl, as the position of this site around the CRK2 locus had been 
mapped. The blot was probed with full-length CRK2, released from pG Ll30 by XbaUXhol 
cleavage. Given the position of two BamHl sites within the gene and a further BamHl site 3’ to 
the gene, wild-type genomic DNA was expected to give two hybridising fragments of 
approximately 0.28 kb and 1.8 kb. The BLE resistance cassette contains two BamHl sites and so 
hybridising fragments of approximately 0.22 kb, 1.8 kb and 2.45 kb were expected. The smallest 
fragment ran off the end of the gel, but the two larger fragments were clearly present in both 
WUMP 563 (lane 3) and WUMP 564 (lane 2), with a diminished signal from the 1.8 kb 
fragment as compared to wild-type consistent with replacement of one of the wild-type alleles. 
Wild-type STIB 247 (lane 4) and wild-type EATRO 795 (lane 1) genomic DNA showed only 
the 1.8 kb wild-type hybridising fragment. Both WUMP 563 and WUMP 564 had a normal 
morphology and growth rates equivalent to wild-types. FACs analysis comparing both these 
nonclonal cell populations with wild-type STIB 247 showed no difference in DNA content (data 
not shown).
WUMP 563 and WUMP 564 were transfected with the SacVXhoI insert from pGLl 10 
to attempt to generate null mutants, and selected with puromycin and phleomycin. WUMP 563
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was also transfected with the SacVXhoI insert from pGLl 10 and selected with puromycin alone. 
Three healthy populations of cells grew, genomic DNA was isolated from each as well as from 
WUMP 563, and PCR was performed using primers CRK2N5’ and CRK2C3’ to assess the 
integration of the resistance cassettes, with predicted PCR product fragments of approximately
1.5 kb for the wild-type gene, approximately 2.1 kb for the BLE resistance cassette and 2.3 kb 
for the PAC resistance cassette (Fig. 5.10). Wild-type STIB 247 DNA showed only a 1.5 kb 
fragment representing wild-type allele (lane 5). WUMP 563 showed the 1.5 kb wild-type allele 
amplification product and a fragment at approximately 2.1 kb, the predicted size of the 
amplification product from the BLE resistance cassette integrated at the CRK2 locus (lane 4). 
WUMP 563 transfected and selected with puromycin only showed the wild-type 1.5 kb and a 
band of approximately 2.3 kb, the predicted size of the amplification product from the PAC 
resistance cassette integrated at the CRK2 locus (lane 2). Given the selection applied this was 
consistent with replacement of the BLE resistance cassette with the PAC resistance cassette. 
WUMP 563 and WUMP 564 transfected and selected with phleomycin and puromycin showed 
the 2.1 kb BLE resistance cassette and the 2.3 kb PAC resistance cassette, but also the 1.5 kb 
wild-type allele amplification product. As CRK2 is a single-copy gene the simplest explanation 
of this anomalous result was that there had been a change in ploidy as a result of the transfection 
with the SacVXhoI insert from pGLl 10, possibly due to cell-cell fusion promoted by 
electroporation. In Leishmania, ploidy changes resulting from targeted disruption of an essential 
gene have been observed (Cruz et al., 1993). FACs analysis was therefore carried out on the two 
nonclonal Acrk2::BLE/Acrk2::PAC/CRK2 populations. This showed no change in cell ploidy 
between the STIB 247 parent wild-type isolate and the Acrk2::BLE/Acrk2::PAC/CRK2 
populations (data not shown); the possibility that the presence of the wild-type allele was due to 
a change in ploidy (as was seen for the ImmCRKl gene; Mottram et al., 1996) could therefore be 
discounted, although duplication of a single chromosome could not be discounted. Initial 
Southern blotting of these two nonclonal Acrk2::BLE/Acrk2::PAC/CRK2 populations genomic 
DNA gave poor results, but seemed to show that the wild-type allele present in the correct locus 
and that both the BLE resistance and PAC resistance cassettes were present at the CRK2 locus 
(data not shown). However, as these populations were nonclonal this analysis was discontinued 
pending the establishment of clonal isolates. Transfection of the PAC resistance cassette to 
WUMP 564 was repeated, and the transfected culture cloned as soon as was feasible by the 
semisolid plate method. As more than one specific type of recombination event may have been 
taking place, it was possible that any null mutants being generated could have been outgrown by 
incorrect integrants, especially if CRK2 was involved in some aspect of cell cycle progression 
and deletion of the gene compromised the cell cycle. Therefore immediate cloning following 
transfection would result in emergent clones accurately reflecting the genetic arrangement at the 
CRK2 locus as a result of secondary transfection with the PAC resistance cassette. Cloning by
162
the semisolid plate method was found to be very inefficient for the procyclic form of T. brucei, 
and several attempts were required to isolate four putative Acrk2::BLEIAcrk2::PAC clones, 
WUMP 837, WUMP 838, WUMP 839 and WUMP 840. In retrospect, a limiting dilution 
method would have been a better approach to cloning transfectants. Genomic DNA was 
prepared from the four clones and used in PCR with primers CRK2N5’ and CRK2C3’ to assess 
the genetic organisation at the CRK2 locus (Fig. 5.11). The control showed the 1.5 kb wild-type 
allele amplification product (lane 1). WUMP 837, WUMP 839 and WUMP 840 showed the 2.1 
kb BLE resistance cassette and the 2.3 kb PAC resistance cassette, and also the 1.5 kb wild-type 
allele band (lanes 5, 3, 2). WUMP 838 showed only the 1.5 kb wild-type allele fragment and the
2.1 kb BLE resistance cassette, but not the 2.3 kb PAC resistance cassette (lane 4). To 
corroborate this data a Southern blot was performed (Fig. 5.12). Genomic DNA was digested 
with BamHl and probed with full-length CRK2 released from pG Ll30 by XbaUXhol cleavage 
(Fig. 5.8). The STIB 247 wild-type control showed only the 1.8 kb fragment corresponding to 
the wild-type CRK2 allele (lane 2). WUMP 838 (lane 5) showed the 1.8 kb fragment 
corresponding to the wild-type CRK2 allele and a hybridising fragment at approximately 2.4 kb 
representing the BLE resistance cassette integrated at the CRK2 locus. WUMP 837 (lane 6), 
WUMP 839 (lane 4) and WUMP 840 (lane 3) showed the 1.8 kb wild-type allele fragment, as 
well as a fragment at approximately 2.4 kb representing the BLE resistance cassette integrated at 
the CRK2 locus, and a fragment at approximately 2.6 kb representing the PAC resistance 
cassette integrated at the CRK2 locus. The supposition for WUMP 838 was that nuclease 
activity had degraded the CRK2 sequences at the termini of the PAC resistance cassette, thus 
facilitating integration at an erroneous locus, most likely the PARP locus due to the PARP- 
specific 5’ and 3’ processing elements flanking the PAC gene. This type of recombination event 
has been observed to occur in transfection experiments, although it is a low-frequency event 
(Blundell et a l, 1996). The data for WUMP 837, WUMP 839 and WUMP 840 showed three 
genetic elements apparently occupying only two physically discrete, though identical, 
homologous loci. In Leishmania species, strategies to avoid the deletion of essential genes 
include changes in ploidy (Cruz et a l,  1993) and the translocation of tens of kilobases of DNA 
bounding the locus in question to elsewhere on the same chromosome, or even on another 
nonhomologous chromosome (Dumas et a l, 1997). Although this kind of genetic event has not 
been demonstrated in trypanosomes, to investigate the possibility that a similar event had 
occurred, Southern blotting of WUMP 837, WUMP 839 and WUMP 840 was performed, using 
a variety of enzymes to digest the genomic DNA and probed with full-length CRK2 released 
from pG Ll30 by XbaUXhol cleavage. No differences between the three clones and STIB 247 
wild-type genomic DNA was observed (data not shown) and further analysis was not performed. 
FACs analysis of the four clones as compared to STIB 247 wild-type showed no differences.
Another possibility regarding the curious genetic arrangement at the CRK2 locus in
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WUMP 837, WUMP 839 and WUMP 840 was that STIB 247 is trisomic at the chromosome 
containing CRK2. Such partial trisomy would give the observed results by PCR and Southern 
blotting, and would not show on FACs analysis or Southern blotting. To test this possibility, 
WUMP 837 was transfected with the SAT resistance cassette (insert from pGL109). The 
transfection culture was split between five flasks and selected with 20 pg ml'1 phleomycin, 10 
pg ml’1 puromycin and 40 pg ml'1 nourseothricin, and each flask cloned by the semisolid plate 
method. Only one clone was isolated, WUMP 877, genomic DNA was prepared and PCR 
reactions using CRK2N5’ and CRK2C3’ was performed. Although the results were difficult to 
interpret (data not shown) and varied between reactions, the 1.5 kb wild-type allele was always 
shown to be present. The implications are that regardless of the mechanisms involved, repeated 
transfection to attempt to delete wild-type CRK2 was not successful and that T. brucei retains a 
wild-type copy of the gene.
5.2.6: Targeted disruption of CRK2 in AnTat 1.1 procyclics expressing CRK2
The in vivo function of CRK2 was addressed by utilisation of the tetracycline-inducible 
system developed by Wirtz and Clayton (1995). Deletion of CRK2 had been shown to be not 
possible (section 5.2.5), therefore deletion of wild-type CRK2 alleles in a background of 
inducible expressed CRK2 should be possible and provide a tool for subsequent manipulation of 
cellular levels of CRK2, leading to analysis of phenotype on downregulation or overexpression 
of CRK2 as compared to wild-type.
AnTat 1.1 '360' cell line procyclics were cotransfected with pGLl 15 (the inducible 
CRK2 expression construct, see section 5.2.3) and the SAT resistance cassette released from 
pGLl09 by digestion with SacVXhoI (Fig. 5.8). Approximately 50 pg of each transfection 
construct was used, and under selection with tetracycline, phleomycin and nourseothricin a 
population of resistant cells was obtained. These were cloned by the semisolid plate method as 
described in chapter 2.1.2, and two clones isolated, WUMP 835 and WUMP 836. Each clone 
was transfected with approximately 50 pg of the PAC resistance cassette (insert from pGLl 10; 
Fig. 5.8), and the transfected cultures cloned by the semisolid method. Four clones were 
isolated, genomic DNA prepared and PCR using primers CRK2N5’ and CRK2C3’ performed to 
assess the state of the CRK2 locus. Neither of the resistance cassettes were detected in any of 
the clones, only wild-type CRK2 (data not shown). Southern blot analysis of the WUMP 835 
and WUMP 836 (which have the predicted genotype Acrk2::SAT/CRK2/pHD430-CRK2) 
showed the characteristic hybridising fragments of the wild-type allele (Fig. 5.13, lane 2) but not 
the expected fragment of approximately 2.6 kb corresponding to integration of the SAT cassette. 
Instead, they both showed an identical pattern of hybridising fragments: 1.6 kb, 0.9 kb and a
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weakly hybridising fragment at approximately 5.0 kb (lanes 3 and 4). PCR on genomic DNA of 
WUMP 835 and WUMP 836 with primer combination SAT5' and SAT3' demonstrated the 
presence in both of the SAT gene, but primer combinations CRK2N5’ and SAT3’, or CRK2C3’ 
and SAT5’, did not give any reaction (data not shown), thus confirming that the SAT cassette 
had not integrated correctly at the CRK2 locus in either clone. Protein samples were prepared 
from both clones as well as wild-type STIB 247 and equivalent loadings electrophoresed on a 
gel that was blotted and probed with protein A/G partially purified anti-EVREE antibodies (Fig.
5.14). CRK2 was detected in the wild-type sample (lane 1) and at elevated levels in the samples 
of WUMP 835 and WUMP 836 (lanes 2 and 3). In all three lanes CRK2 was competed with 
peptide (lanes 4-6); therefore both WUMP 835 and WUMP 836 displayed ectopic expression of 
CRK2 from the rRNA locus.
5.2.7: Expression in vivo of histidine-tagged CRK2
Histidine-tagged CRK2 was generated by digestion of pGL217 with HindUl to release 
the histidine-tagged 3’ end of the gene on a fragment of approximately 630 bp, which was 
cloned into the HindUl site in pBluescript. Screening by PCR identified a clone with the 
fragment orientated with the tag adjacent to the Xbal site in the vector’s polylinker. This 
intermediary pB/630 plasmid was then digested with Sphl and Xbal, releasing the 3’ end of the 
gene and the tag sequence on a small fragment of approximately 150 bp. The 150 bp fragment 
was gel purified and ligated with pG Ll30, which had been digested with Sphl and Xbal and gel 
purified. Transformants were screened by PCR and one positive - which represented reformed, 
full-length CRK2 with a hexahistidine C-terminal tag (pGL233) - was sequenced over the last 
200 bp at the 3’ end. This was because the copy of CRK2 in pGL217 was generated by PCR and 
had not been sequenced subsequently, therefore the portion of sequence of the pGL233 insert 
that was derived from pGL217 had to be sequenced to ensure that there had been no PCR- 
generated mutations. Once the sequence was confirmed, CRK2His was released from pGL233 
by digestion with Bsp\20\ and Notl, and cloned into the BspllO l site in the poly linker of 
expression plasmid pHD675 (Biebinger et al., 1997) to give pGL234. Construct pGL234 was 
linearised by digestion with Notl, purified and transfected to the STIB 427 MiTat 1.1 strain 
containing the stably integrated pHD449 (‘449’ cell line) as described (chapter 2.1.2), with 
selection under phleomycin and hygromycin.
A nonclonal population of doubly-resistant cells were recovered (WUMP 1163) and 
tested for induction of CRK2His with 0.2 ng ml'1, 1.0 ng ml'1 and 10.0 ng ml'1 of tetracycline. 10 
mis of each induced culture were harvested, resuspended in LSGI and S-100 extracts made. 
Specific selection of CRK2His was as described (Fig. 5.15) and Western blotting performed
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using purified EVREE antibodies. The hexahistidine tag binds efficiently to the nickel ions in 
the charged NTA resin; minimal washing removes most contaminating endogenous prokaryotic 
proteins. Relatively little induction of CRK2His was seen with 0.2 ng ml'1 and 1.0 ng ml'1 (lanes 
1 and 2) as compared to the induction that was observed with 10.0 ng ml'1 tetracycline (lane 3). 
A very weak signal for CRK2 was seen for the column flow-through of all three (lanes 4, 5, 6) 
and was presumably endogenous non-tagged CRK2. Significant CRK2His was found to have 
bound the Ni-NTA resin from the extract induced with 10.0 ng ml'1 (lane9), in contrast to the 
extracts induced with 1.0 ng ml'1 (lane 8) and 0.2 ng ml'1 (lane 7). Preblocking of the antibodies 
with EVREE peptide partially abrogated the signal from CRK2His but did not abolish it entirely 
(lanes 11-19; compare lanes 1-3 with 11-13, and lane 9 with lane 19). The multiplicity of bands 
in lanes 1-3 and 11-13 are a result of the primary antibody being used at too high a 
concentration.
As a follow-up experiment, S-100 extracts were made from midlog STIB 247, WUMP 
1163 grown in the absence of tetracycline for several subpassages, and WUMP 1163 grown in 
10 ng ml"1 tetracycline. CRK2His was selected on Ni-NTA beads and aliquots used for protein 
samples and kinase assay (Fig. 5.16). The Western blot (Fig. 5.16A) showed that nothing was 
specifically purified from STIB 247 wild-type (Fig. 5.16A, lane 1) and that a small but 
significant amount of CRK2His was purified from WUMP 1163 grown in the absence of 
tetracycline (Fig. 5.16A, lane 2). A very strong signal was obtained from the WUMP 1163 
eluate grown in the presence of 10.0 ng ml'1 tetracycline (Fig. 5.16A, lane 3), indicating that 
relatively large amounts of CRK2His had been selected on the Ni-NTA. The histone HI kinase 
assay, however (Fig. 5.16B) showed little difference between the three samples. A slightly 
stronger signal was obtained from WUMP 1163 grown in the presence of 10.0 ng ml'1 
tetracycline (Fig. 5.16B, lane 3) but a strong signal was obtained from 247 wild-type (Fig.
5.16B, lane 1) indicating that background in this experiment was too high for the results to be 
significant.
5.3: Discussion
The initial attempts to raise specific antisera to CRK2 by immunising rabbits with short 
peptides deduced from the gene sequence proved more complicated than anticipated. The 11- 
mer corresponding to the C-terminal 11 amino acids (CVELK peptide) produced an antiserum 
(CVELK antiserum) that detected no proteins by Western blotting in trypanosome lysates. The 
16-mer corresponding to the C-terminal 16 amino acids (EVREE peptide) raised an antiserum 
(EVREE antiserum) that was affinity purified and used to detect a number of proteins by 
Western blotting in the soluble fraction of lysates from procyclic, long slender and short stumpy
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bloodstream forms (Fig. 5.2). The 16-mer corresponding to the CRK2 PSTAIRE box homologue 
(PSTAVR peptide) raised an antiserum (PSTAVR antiserum) that was also affinity purified and 
used to detect two proteins that gave strong signals by Western blotting in the insoluble fraction 
lysates from procyclic, long slender and short stumpy bloodstream forms (Fig. 5.3). In addition, 
a protein was detected in the procyclic soluble fraction lysate and another in the long slender 
bloodstream form soluble fraction lysate. The size of CRK2, as deduced from the open reading 
frame, is predicted to be approximately 39 kDa. Therefore although the 38 kDa protein detected 
by the EVREE antibodies was a good candidate for CRK2, the 41 kDa protein detected only in 
the long slender bloodstream form by the PSTAVR antibodies could not be discounted.
Further evidence that both sets of antibodies were capable of detecting CRK2 on a 
Western blot came from attempts to express CRK2 in E. coli as a hexahistidine-tagged fusion 
protein. Pilot inductions and purifications suggested that CRK2His was not expressed.
However, a Western blot of induced and uninduced M15[pREP4]pGL217 showed a protein of 
about 40 kDa detected by both EVREE and PSTAVR antibodies, in both the induced and 
uninduced lysates, that was competed with peptide (Fig. 5.4). This suggested that transcriptional 
control of pGL217 in E. coli was slightly leaky, leading to a basal level of CRK2His expression, 
but that relief of transcriptional repression did not result in any increase in CRK2His 
expression. The reason for this is unclear as M15[pREP4]pGL217 E. coli showed no difference 
in growth kinetics in the presence or absence of the inducer IPTG, as would be expected if the 
fusion protein was highly toxic to the cells. Whatever the reason, it was clear that the pQE 
system was not a viable approach to the expression of CRK2 as a fusion protein. However, these 
experiments did demonstrate that both EVREE and PSTAVR antibodies could detect CRK2 on 
a Western blot, thus confusing the issue of why the two sets of antibodies did not detect a 
protein in common in T. brucei protein lysates. As the EVREE antibodies gave a stronger signal 
(Fig. 5.4) it was possible that these antibodies have a higher affinity for CRK2; thus if CRK2 is 
present at very low cellular levels in T. brucei it is possible that EVREE antibodies can detect it 
but PSTAVR antibodies cannot. The P. pastoris yeast system was used for the attempted 
expression of CRK2, on the basis that yeast can sometimes cope better with ectopic expression 
of eukaryotic proteins than prokaryotes, with a greater chance of correct folding of the 
expressed protein and a lower chance of hyperglycosylation. However, no detectable expression 
of CRK2 was found and the yeast expression studies were abandoned.
Conclusive proof for the biochemical identity of CRK2 came from the expression of a 
cloned copy of CRK2 in T. brucei using the pHD430 vector system (chapter 5.2.3). EVREE 
antibodies detected specifically a protein of about 38-39 kDa in a total protein lysate of STIB 
247 wild-type that was more abundant in a WUMP 827 total protein lysate (Fig. 5.6). WUMP 
827 had been grown in 10 ng ml'1 tetracycline before being harvested to make the lysate. This 
level of tetracycline was sufficient to have induced maximal expression of the cloned copy of
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CRK2, therefore the difference in signal strength for the same protein between the two cell lines 
(coupled with the fact that none of the other proteins detected differed in signal strength 
between the two) demonstrated that the 38-39 kDa protein initially detected by the purified 
EVREE antibodies (Fig. 5.2) was CRK2. Overexpression of CRK2 did not interfere with normal 
cell cycle progression, as WUMP 827 appeared to have the same morphology and growth 
kinetics as STIB 247 wild-type, thus cell cycle progression was neither accelerated nor retarded.
The purified EVREE and PSTAVR antibodies, as well as one of the nonpurified 11-mer 
anti-CRK2 antisera (R421) were tested in a pilot immunoprecipitation-linked kinase assay 
(chapter 5.2.4; Fig. 5.7). However, no specifically precipitated histone HI kinase activity was 
detected. There are a number of possible interpretations for this. Firstly, it is possible that 
although the antibodies reacted to denatured CRK2 on a Western blot they were not capable of 
recognising native protein, and thus did not precipitate native CRK2. Secondly, the PSTAIRE 
box of CDKs is involved in cyclin binding (Ducommun et al., 1991; Endicott et al., 1994; 
Jeffrey et al., 1995). Therefore the PSTAVR box is likely to be involved in cyclin binding, so it 
is possible that the PSTAVR box was occluded by a cyclin partner and thus the PSTAVR 
antibodies could not precipitate CRK2. Likewise, the C-terminus of CRK2 may not be available 
for binding in the native protein, therefore the EVREE antibodies and CVELK (R421) 
antiserum could not precipitate CRK2. A third possibility regards the substrate specificities of 
CDKs.
The 'consensus sequence' for CDK phosphorylation (S/T-P-X-K/R) was largely 
determined by comparison of the sites phosphorylated in vitro by CDK1 on various candidate 
substrates (Nigg, 1993). There is no shortage of such candidates, including nuclear lamins, 
histone HI and H3, some transcription factors, non-receptor tyrosine kinases and structural 
proteins (Nigg, 1992; Bradbury, 1992; Nigg, 1993). The initial assumption was that this 
'consensus sequence' would hold for all CDKs. However, this is not necessarily the case, for the 
following reasons.
1) Some CDK1 substrates can be phosphorylated in vitro on the same residues by 
other kinases, like MAPKs (Litchfield et al., 1991; Drewes et al., 1992; Peter et al., 
1992). Therefore, it is difficult to tell which might be the relevant kinase in vivo.
2) Activity is modified by cofactor (cyclin) binding. For example, CDK 1-cyclin B and 
CDKl-cyclin A phosphorylate different sites on histone HI; CDK2-cyclin A but not 
CDK2-cyclin B can phosphorylate the retinoblastoma-related protein pl07; CDK2- 
cyclin A but not CDK2-cyclin E can phosphorylate DPI (Schulman et al., 1998). 
Although cyclin binding to CDKs modifies the active site it does not remodel it for 
a particular substrate (Homes and Solomon, 1996). Rather, the cyclin partner seems 
to direct CDK activity by binding substrates, for example, cyclin D binds pRB 
directly and so directs CDK4 activity to pRB (Sherr, 1993). The cyclin D motif
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involved in binding is conserved in cyclin E, presumably directing CDK2 activity to 
pRB.
3) There is a temporal aspect involved. For example, CDK 1-cyclin B phosphorylates 
pRB very efficiently (Lin et al., 1991; Lees et al., 1991) but cyclin B is not 
expressed until late G1 and does not begin to associate with CDK1 until S phase, 
therefore pRB is not a relevant substrate in vivo. Conversely, CDK4/6 are active in 
mid-Gl and phosphorylate pRB, but cannot efficiently phosphorylate histone HI 
(Matsushime et al., 1994; Ewen et al., 1993; Kato et al., 1993), a protein which is 
regarded as the 'canonical' CDK substrate.
4) Sequestration may influence substrate specificity. The CDK7-cyclin H dimer or 
'free' CDK7-cyclin H-MAT1 trimer has a strong preference for CDK2 as a substrate, 
but if recruited (via MAT1) to the basal transcription factor TFIIH it has a strong 
preference for the C-terminal domain of RNA pol II and CDK2 is no longer a 
substrate (Rossignol et al., 1997).
If any of the antibodies did precipitate CRK2, therefore, failure to phosphorylate histone 
HI could be attributable to several different reasons. It could be that histone HI is simply not a 
substrate, in vivo or in vitro, for CRK2, in the same manner that histone HI is not a substrate for 
CDK4/6. A second possibility is that CRK2 is capable of phosphorylating histone HI in other 
life cycle stages, but that in procyclics it is inactive, or possibly complexed to a cyclin that 
directs its activity to other substrates. The 'consensus sequences' for CDK1 phosphorylation may 
be divergent between organisms separated by large phylogenetic distances, so mammalian 
histone HI is not a CRK substrate. Alternatively, it is possible that in procyclics CRK2 is 
recruited to a complex that modifies its activity, by analogy to CDK7 recruitment to TFIIH.
Targeted disruption of the CRK2 gene was carried out in the hope of isolating null 
mutants with a phenotype that would provide information on the function of CRK2 in the cell 
cycle of T. brucei. Targeted gene disruption to identify 'essential' genes i.e. ones that cannot be 
deleted, has been a popular approach to the identification of potential drug targets in parasites, 
particularly considering the ease with which this can be done with procyclic and bloodstream 
form trypanosomes. However, trypanosomatid genetic plasticity (considered a criterion for 
'essential' genes; Cruz et al., 1993; Mottram et al., 1996; Dumas et al., 1997) has meant that 
characterisation of essential genes has proven difficult, and it is important to remember that 
failure to delete a gene means only that it serves an essential function in the particular life cycle 
stage studied under the culture conditions used. In addition, as the different life cycle stages 
require specific temperatures for growth and survival, isolation of temperature-sensitive 
conditional mutants has proven impossible. Moreover, attention has recently been drawn to the 
shortcomings of targeted gene disruption as a validation of viable drug targets (Barrett et al., 
1999). Genes that cannot be deleted do not always represent valid drug targets (Eisenthal and
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Comish-Bowden, 1998), and conversely some genes that can be deleted - at least in some life 
cycle stages - have proven to be valid drug targets (Li et al., 1996; Li et al., 1998; Wiese, 1998). 
Trypanosome CRKs are likely to be valid targets as it has not proven possible to isolate null 
mutants for the Leishmania CRK1 and CRK3 (Mottram et al., 1996; Hassan, 1999).
Furthermore, if CRKs are functional CDK homologues involved in cell cycle progression, they 
are likely to be essential in many of the proliferative stages of the trypanosomatid parasites, and 
therefore to fulfil one important criterion for a possible drug target.
Primary transfection of STIB 247 wild-type procyclics was successful in disruption of 
one of the alleles of CRK2 (Fig. 5.9), showing that the BLE resistance cassette integrated 
correctly. Transfection of the single allele BLE replacement (WUMP 563) with the PAC cassette 
and selected with puromycin alone showed replacement of the BLE cassette with the PAC 
cassette (Fig. 5.10, lane 2), showing that the PAC cassette functions. Under the selection 
conditions this is consistent with the preservation of a wild-type allele that has an essential 
function in procyclics. There would be no selective pressure for maintenance of a wild-type 
copy of CRK2 if it were nonessential in procyclics, therefore if integration was random some 
null mutants should have been obtained. Secondary transfection of a single allele BLE 
replacement (WUMP 564) with the PAC cassette and selection with both phleomycin and 
puromycin yielded four clones, WUMP 837-840. Analysis of the CRK2 locus by PCR (Fig.
5.11) and Southern blotting (Fig. 5.12) showed that at least two different events had occurred. 
WUMP 838 was demonstrated to possess the wild-type allele and the BLE cassette at the correct 
locus, and the PAC cassette not present at the CRK2 locus. An explanation for this result is that 
nuclease activity had degraded the CRK2-specific termini of the PAC cassette, permitting 
integration at the PARP locus due to the PARP-specific 5’ and 3’ elements. This type of event 
has been demonstrated to occur at a low frequency (Blundell et al., 1996). WUMP 837, WUMP 
839 and WUMP 840 all showed the same genotype; the presence of a wild-type allele as well as 
both the BLE and PAC cassettes correctly integrated at the CRK2 locus. There were several 
possibilities that could explain this curious genetic arrangement. Firstly, that there had been a 
change in DNA content of these clones, possibly resulting in triploid or tetraploid cells. Triploid 
cells are frequently found after mating and are viable (Tait and Turner, 1990). In Leishmania 
species, triploid or tetraploid cells are frequently found after attempts to delete an essential gene 
(Cruz et al., 1993; Mottram et al., 1996; Hassan, 1999). Indeed, chromosome plasticity in 
Leishmania following attempted gene disruption has been proposed as a marker of essential 
gene function (Cruz et al., 1993; Mottram et al., 1996; Dumas et al., 1997). However, FACs 
analysis of WUMP 837, WUMP 839 and WUMP 840 disproved this as all three clones were 
found to have the same DNA content as wild-type STIB 247. A second possibility was that 
STIB 247 is trisomic at the chromosome containing CRK2. This was judged to be unlikely, as 
CRK2 has been used as a syntenic marker for molecular karyotyping of T. brucei (Melville et
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al., 1998). Alternatively, these clones may have become trisomic following transfection. To 
address these possibilities WUMP 837 was transfected with the SAT resistance cassette and 
cloned. PCR analysis of the single clone isolated (WUMP 877) demonstrated wild-type allele to 
be present, although the SAT resistance cassette was not detected at the CRK2 locus (data not 
shown). If WUMP 837 was or had become trisomic, WUMP 877 may be an example of the low- 
frequency event of incorrect integration due to the processing elements in the construct 
(Blundell et al., 1996). In this case, the culture conditions would have selected only for those 
clones in which the SAT cassette had integrated incorrectly. A third possibility was that a large 
section of DNA around the CRK2 locus had been transposed to another chromosome; this has 
been demonstrated to occur in Leishmania (Dumas et al., 1997) but has not yet been proven to 
occur in T. brucei. Regardless of the mechanisms involved, deletion of CRK2 to generate nulls 
was not possible, which may suggest that CRK2 is an essential gene. This is the case for 
procyclics, however it may also be the case for the bloodstream forms too, as Western blotting 
has shown that CRK2 is present in the long slender and short stumpy bloodstream forms (Fig. 
5.2). However, as transfection of the long slender bloodstream form was not performed, the 
possibility remains that there is stage-specific expression of another CRK or other kinase that 
can replace the loss of CRK2 in these life cycle stages.
To investigate the possibility that a strict gene dosage requirement operates on CRK2, 
and to demonstrate the specificity of the effect for the failure of targeted disruption to delete 
CRK2, attempts were made to delete the wild-type alleles in a background of ectopic expression 
of CRK2 (chapter 5.2.6). The tetracycline-inducible system was used (Wirtz and Clayton, 1995). 
The particular vector used, pHD430, was reported to achieve induction over four levels of 
magnitude within 6 hours of induction with 50 ng ml'1 tetracycline, and that intermediate levels 
of induction were achieved with lower concentrations of tetracycline (Wirtz and Clayton, 1995). 
Cotransfection of the AnTat 1.1 '360' cell line with the SAT cassette and pGLl 15 (see section 
5.2.3) followed by immediate cloning yielded two independent clones, WUMP 835 and WUMP 
836, which were transfected with the PAC cassette. Four clones were isolated; however, PCR 
demonstrated the only the wild-type allele was present at the CRK2 locus. Reinvestigation of 
WUMP 835 and WUMP 836 by Southern blotting demonstrated the presence of the wild-type 
allele and confirmed that in neither clone had the SAT cassette integrated correctly at the CRK2 
locus (Fig. 5.13), although PCR showed the SAT gene to be present in both clones, and both 
were resistant to nourseothricin. Again, an explanation of this is that both clones represented the 
low-frequency event of incorrect integration due to the processing elements in the construct 
(Blundell et al., 1996), although the reason why it was not possible to isolate clones with the 
SAT cassette integrated at the CRK2 locus is not known. The failure to isolate clones with the 
PAC cassette integrated at the CRK2 locus following transfection with the insert from pGLl 10 
is equally puzzling, since disruption of CRK2 with the PAC cassette was demonstrated to be
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possible in STIB 247. The reason why the wild-type alleles could not be disrupted in the AnTat
1.1 '360' cell line is not clear. Successful deletion of CRK2 wild-type alleles with ectopic 
expression of CRK2 would be a requirement to demonstrate that CRK2 is an essential gene in 
the procyclic-stage cell i.e. that the failure of the targeted gene disruption approach was 
specifically due to loss of CRK2. The lack of success in deleting wild-type alleles in a 
background of ectopic expression precludes designation of tbCRK2 as an essential gene.
As an alternative approach to assess the kinase activity of CRK2, instead of 
immunoprecipitation with antibodies, histidine-tagged CRK2 was expressed from the rRNA 
spacer using the pHD675 construct (Biebinger et al., 1997). Expression of CRK2His in the '449' 
cell line (Biebinger et al., 1997) should allow affinity purification of CRK2His by Ni-NTA resin 
selection; such an approach has been used successfully in Leishmania (Mottram et al., 1996; 
Grant et al., 1998). As the resistance marker in this construct is constitutively expressed and 
independent of the cloned copy of CRK2His, selection was performed without induction of the 
cloned CRK2His (chapter 5.2.7). Induction of the heterogeneous population that arose (WUMP 
1163) with different amounts of tetracycline showed relatively little CRK2His induced with 0.2 
ng ml'1 or 1.0 ng ml'1 tetracycline, but much larger quantities induced with 10.0 ng ml'1 (Fig.
5.15). The level of induction achieved with this system depends on the particular gene used 
(Biebinger et al., 1997), and in this case appeared to require relatively large amounts of 
tetracycline to get reasonable expression. A comparison of STIB 247 with WUMP 1163 grown 
with and without tetracycline was carried out, with selection on Ni-NTA resin. EVREE 
antibodies detected no endogenous CRK2 purified from STIB 247, as was expected as no 
CRK2His is present in this cell line. A small but significant amount of CRK2His was purified 
from WUMP 1163 grown in the absence of tetracycline, suggesting that transcriptional control 
of the pHD675 construct was not total, and a large amount of CRK2His was detected from 
WUMP 1163 grown in the presence of 10 ng ml'1 tetracycline. Curiously, the purified CRK2His 
demonstrated by Western blotting could not be visualised by silver staining, suggesting that 
CRK2 is present at very low cellular levels. No kinase activity was detected with purified 
CRK2His with histone HI as a substrate, which may be due to the potential problems with 
substrate choice mentioned previously. Alternatively, the hexahistidine tag may interfere with 
the kinase activity of CRK2. However, the successful expression and purification of CRK2His 
in T. brucei has promise for the future biochemical characterisation of tbCRK2.
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Fig. 5.1: The T. brucei CRK2 gene
Schematic showing the open reading frame of CRK2 with respect to the relevant primers and 
restriction endonuclease sites. The Acc\ sites and the HindlU site were used in the generation of 
a cloned copy of full-length CRK2. The BomWl sites were used as diagnostic sites for the correct 
integration of resistance cassettes, and the HindUl and Sphl sites were used in the generation of 
histidine-tagged CRK2. Primer combination CRK2N5’ with CRK2N3’, and CRK2C5’ with 
CRK2C3’ were used to amplify fragments of DNA corresponding to the 5’ and 3 ’ ends of the 
gene, respectively, for use in the generation of the disruption resistance cassettes. Primer 
combination CRK2N5’ with CRK2C3’ was frequently used as a diagnostic for correct 
integration of the resistance cassettes.
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Fig. 5.2: Western blot with EVREE antibodies and STIB 247 procyclic, short stumpy and 
long slender bloodstream form protein lysates
For each lane 5x 106 T. b. brucei STIB 247 procyclic, long slender and short stumpy 
bloodstream form lysates were electrophoresed on a 12.5% Lammeli gel at 130 V at room 
temperature. The protein was transblotted to PVDF membrane by wet-blotting at 250 mA for 3 
hours at 4°C. The membranes were probed with purified EVREE antibodies at a titre of 1:250, 
and secondary anti-rabbit HRP-conjugate at 1:2500. The blot was developed with ECL luminol 
reagents (Amersham). Markers were the Low Range nonprestained markers (BioRad).
Lanes 1-3, 7-9, 13-15. Purified EVREE antibodies
Lanes 4-6, 10-12, 16-18. Purified EVREE antibodies with 10 pg EVREE peptide
Lanes 1, 4. STIB 247 procyclic total protein lysate
Lanes 2, 5. STIB 247 procyclic insoluble protein lysate
Lanes 3, 6. STIB 247 procyclic soluble protein lysate
Lanes 7, 10. STIB 247 short stumpy bloodstream form total protein lysate
Lanes 8, 11. STIB 247 short stumpy bloodstream form insoluble protein lysate
Lanes 9, 12. STIB 247 short stumpy bloodstream form soluble protein lysate
Lanes 13, 16. STIB 247 long slender bloodstream form total protein lysate
Lanes 14, 17. STIB 247 long slender bloodstream form insoluble protein lysate
Lanes 15, 18. STIB 247 long slender bloodstream form soluble protein lysate
175
K D a 1 2 3 4 5 6
81. 2
P r o c y c l i c
4 1 . 5
31. 8
k D a
81. 2
Sh o r t
s t u m p y
b l o o d s t r e a m
f or m 4 1  5
31. 8
k D a
8 1 . 2
L o n g
s l e n d e r
b l o o d s t r e a m
f o r m 4 1 . 5
31.8
P S T A V R  P S T A V R  + p e p
7 8  9  1 0  11 1 2
P S T A V R  P S T A V R  + p e p
1 3  1 4  1 5  1 6  1 7  1 8
I
P S T A V R  P S T A V R  + p e p
176
Fig. 5.3: Western blot with PSTAVR antibodies and STIB 247 procyclic, short stumpy and 
long slender bloodstream form protein lysates
For each lane 5x 106 T. b. brucei STIB 247 procyclic, long slender and short stumpy 
bloodstream form lysates were electrophoresed on a 12.5% Lammeli gel at 130 V at room 
temperature. The protein was transblotted to PVDF membrane by wet-blotting at 250 mA for 3 
hours at 4°C. The membranes were probed with affinity purified PSTAVR antiserum at a titre of 
1:250, and secondary anti-rabbit HRP-conjugate at 1:2500. The blot was developed with ECL 
luminol reagents (Amersham). Markers were the Kalidescope prestained markers (Amersham). 
Lanes 1-3, 7-9, 13-15. Purified PSTAVR antibodies
Lanes 4-6, 10-12, 16-18. Purified PSTAVR antibodies with 10 pg PSTAVR peptide
Lanes 1, 4. STIB 247 procyclic total protein lysate
Lanes 2, 5. STIB 247 procyclic insoluble protein lysate
Lanes 3, 6. STIB 247 procyclic soluble protein lysate
Lanes 7, 10. STIB 247 short stumpy bloodstream form total protein lysate
Lanes 8, 11. STIB 247 short stumpy bloodstream form insoluble protein lysate
Lanes 9, 12. STIB 247 short stumpy bloodstream form soluble protein lysate
Lanes 13, 16. STIB 247 long slender bloodstream form total protein lysate
Lanes 14, 17. STIB 247 long slender bloodstream form insoluble protein lysate
Lanes 15, 18. STIB 247 long slender bloodstream form soluble protein lysate
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Fig. 5.4: Western blot with 16-mer peptide anti-CRK2 antibodies and 
M15[pREP4]pGL217
1 ml of a saturated overnight culture of M15[pREP4]pGL217 was used to inoculate each o f 2x 
10 ml LB. When the OD at 600 nm reached 0.9, one o f the cultures was induced by addition of 
IPTG to a final concentration o f 2 mM, and the cultures grown for a further 4 hours. 1 ml of 
each culture was harvested by centrifugation, whole cell lysates prepared and aliquots of the 
samples were electrophoresed on a 12.5% Lammeli gel and the protein blotted to PVDF 
membrane at 250 mA for 2 hours at 4°C. The filter was then probed with purified EVREE and 
PSTAVR antibodies at a titre of 1:250, detected with secondary anti-rabbit HRP-conjugate at 
1:2500 and the blot developed with ECL reagents (Amersham). Markers were the Kalidescope 
prestained markers (Amersham).
Lanes 1, 3, 5, 7. Uninduced M15[pREP4]pGL217 
Lanes 2, 4, 6, 8. Induced M15[pREP4]pGL217 
Lanes 1, 2. EVREE antibodies
Lanes 3, 4. EVREE antibodies with 10 pg EVREE peptide 
Lanes 5, 6. PSTAVR antibodies
Lanes 7, 8. PSTAVR antibodies with 10 pg PSTAVR peptide
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Fig. 5.5: The pHD430 tetracycline induction system
Schematic of the tetracycline-inducible pHD system. A) pHD360 vector is integrated at the 
repetitive a(3-tubulin locus. The TEI* gene is constitutively expressed, as is the HYG gene due 
to transcriptional read-through. B) pHD430 vector is integrated at the rRNA intergenic spacer 
(represented by the dark green boxes) in a reverse orientation to transcription of the 18S rRNA 
gene. TETR protein binds to the modified PARP promoter (red box), inhibiting transcription of 
LUC. Tetracycline binds to the TETR protein causing conformational change that prevents its 
binding to the modified PARP promoter, thus allowing transcription of LUC and BLE. The 5 ’ 
and 3’ processing elements are derived from the aldolase gene (pale blue boxes) and the actin 
gene array (dark blue boxes).
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Fig. 5.6: Western blot comparison of STIB 247 wild-type procyclic and WUMP 827 
procyclic total protein lysates with EVREE antibodies
STIB 247 wild-type procyclics were grown to midlog, WUMP 827 procyclics were grown to 
midlog in the presence of 10 ng ml'1 tetracycline. Cells were harvested with thorough washing in 
PBS, cell pellets resuspended in LSI/TSB, syringed through G25 needles and heated to 100°C 
for 5 minutes. Approximately lx  107 cells per lane of STIB 247 and WUMP 827 total protein 
lysates were electrophoresed on 12.5% Lammeli gels at 125 V at room temperature. Protein was 
transblotted to PVDF membranes at 30 mA overnight at 4°C. The filters were probed with 
preimmune and crude EVREE antiserum at a titre of 1:500, and purified EVREE antibodies at a 
titre of 1:50. Secondary anti-rabbit HRP-conjugate was used at 1:2000, and the blots were 
developed with Supersignal reagents (Pierce). Markers were the Low Range nonprestained 
markers (BioRad).
Lanes 1, 3, 5, 7. STIB 247 procyclic total protein lysate 
Lanes 2, 4, 6, 8. WUMP 827 procyclic total protein lysate 
Lanes 1, 2. Crude EVREE antiserum
Lanes 3, 4. Crude EVREE antiserum with 10 pg EVREE peptide 
Lanes 5, 6. Purified EVREE antibodies
Lanes 7, 8. Purified EVREE antibodies with 10 pg EVREE peptide
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Fig. 5.7: Immunoprecipitation-linked histone HI kinase assay with anti-CRK2 antisera
STEB 247 procyclics were grown to midlog and a total of 4.5x 108 cells harvested with extensive 
washing with PBS, resuspended in 2 ml LSI and an S-100 lysate made. 200 pi of lysate (extract 
from 4.5x 107 cells) was added to 50 pi aliquots of purified EVREE antibodies, purified 
PSTAVR antibodies, and crude anti-CRK2 (R421) antiserum, and incubated at 4°C for 3 hours. 
Antisera-lysate mixes were then added to minicolumns containing 80 pi of a 50% slurry of 
Sepharose-protein A that had been preblocked with a saturating quantity of BSA in LSI, and 
were left to incubate overnight at 4°C. Columns were drained, washed extensively with LS, 
HSLS and KAB, the resin aliquots pelleted and resuspended in 20 pi KAM containing 5 pg 
histone HI as substrate and incubated at 30°C for 20 minutes. Reactions were stopped by 
addition of 20 pi of TSB and heating to 100°C for 5 minutes, 20 pi samples were run on a 
12.5% Lammeli gel, the gel stained with Coomassie blue and dried on an slab dryer (BioRad) 
and exposed to autoradiography film.
Lane 1. EVREE preimmune serum 
Lane 2. Purified EVREE antibodies
Lane 3. Purified EVREE antibodies with 40 mg EVREE peptide 
Lane 4. PSTAVR preimmune serum 
Lane 5. Purified PSTAVR antibodies
Lane 6. Purified PSTAVR antibodies with 40 mg PSTAVR peptide
Lane 7. R421 preimmune serum
Lane 8. Crude anti-CRK2 (R421) antiserum
Lane 9. Crude anti-CRK2 (R421) antiserum with 50 pg CVELK peptide
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Fig. 5.8: Constructs for targeted disruption of CRK2
The three CRK2 targeted disruption constructs, pGL108 (BLE), pGL109 (SAT) and pGLl 10 
(.PAC)\ the plasmid backbone in each case is pBluescript and is not shown. The constructs were 
generated as described (chapter 5.2.5). The resistance cassettes were released for transfection by 
SaclJXhol cleavage and the DNA purified as described (chapter 2.2.3).
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Fig. 5.9: Southern blot comparison of WUMP 563 and WUMP 564 with STIB 247 
wild-type
Genomic DNA was prepared from procyclic form cells of STIB 247 wild-type, WUMP 563, 
WUMP 564 and EATRO 795 wild-type were prepared using the Nucleon kit (for details see 
chapter 2.2.7). 2.5 pg of genomic DNA for each was digested with approximately 20 U of 
BamHI for 2 hours at 37°C, followed by the addition of a further 10 U of BamHI and incubation 
at 37°C for a further 2 hours. Samples were electrophoresed on a 0.8% TBE gel at 30 V at room 
temperature overnight. The gel was stained with 0.5 pg ml'1 ethidium bromide and a photograph 
taken (B), before being processed (see chapter 2.3.7), although here the DNA was transferred to 
Hybond-N supported nitrocellulose (Amersham) using the Stratagene Posiblot apparatus, with a 
pressure of 70 mm Hg for 60 minutes. The filter was air-dried and UV fixed, prehybridised at 
65°C for 1 hour, and hybridised at 65°C overnight with full-length CRK2 as the probe, prepared 
as described in chapter 2.2.3.5. The filter was washed as described in chapter 2.2.3.4 and 
exposed overnight to autoradiography film (A).
Lane 1. EATRO 795 wild-type
Lane 2. WUMP 564 (Acrk2::BLE/CRK2 nonclonal population)
Lane 3. WUMP 563 (Acrk2::BLE/CRK2 nonclonal population)
Lane 4. STIB 247 wild-type
186
1 2 3 4 5
P A C  K O  -►  
B L E  K O  -►
C R K 2  ►
Kb
3.0
-  2 .0
1. 6
1.0
187
Fig. 5.10: PCR from genomic DNA of nonclonal double allele CRK2 replacement STIB 247 
procyclic populations
Genomic DNA was prepared from STIB 247 wild-type procyclics, single allele CRK2 
replacement and double allele CRK2 replacement nonclonal populations using the Nucleon kit, 
as described in chapter 2.2.7. 10 j l i I  PCR reactions using 1 p i  of resuspended genomic DNA per 
reaction (representing genomic DNA from 2x 106 cells per reaction) were performed using 
primers CRK2N5’ and CRK2C3’, with a prehold of 4 minutes at 94°C, 1 minute annealing at 
50°C and 1 minute extension at 72°C, for 25 cycles. Reactions were electrophoresed at 70 V on 
a 1% TAE minigel, and DNA visualised by staining with 1 pg ml'1 ethidium bromide. The 
Acrk2::BLE/Acrk2::PAC population A arose from transfection of WUMP 563 with the PAC 
cassette, the Acrk2::BLEIAcrk2::PAC population B from transfection of WUMP 564 with the 
PAC cassette. The reactions in lanes 1, 2 and 3 had DMSO added to a final concentration of 5%, 
to allow amplification of the GC-rich PAC cassette.
Lane 1. WUMP 564 transfected with the cassette from pGLl 10 and selected with 
phleomycin and puromycin 
Lane 2. WUMP 563 transfected with the cassette from pGLl 10 and selected with 
puromycin
Lane 3. WUMP 563 transfected with the cassette from pGLl 10 and selected with 
phleomycin and puromycin 
Lane 4. WUMP 563 
Lane 5. STIB 247 wild-type
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Fig. 5.11: PCR from genomic DNA of Acrk2::BLE/Acrk2::PAC clones
Genomic DNA was prepared from WUMP 837, WUMP 838, WUMP 839, WUMP 840 and 
STIB 247 wild-type procyclics with the Nucleon kit, as described in chapter 2.2.7. 10 pi PCR 
reactions using 1 pi of resuspended genomic DNA per reaction (representing genomic DNA 
from 2x 106 cells per reaction) were performed using primers CRK2N5’ and CRK2C3’, with a 
prehold of 4 minutes at 94°C, 1 minute annealing at 50°C and 1 minute extension at 72°C, for 25 
cycles. Each reaction also contained 5% DMSO, to allow amplification o f the GC-rich PAC 
gene.
Lane 1. STIB 247 wild-type 
Lane 2: WUMP 840 
Lane 3. WUMP 839 
Lane 4. WUMP 838 
Lane 5. WUMP 837
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Fig. 5.12: Southern blot of genomic DNA of Acrk2::BLE/Acrk2::PAC clones
Genomic DNA was prepared from WUMP 837, WUMP 838, WUMP 839, WUMP 840 and 
STIB 247 wild-type procyclics with the Nucleon kit. 2.5 pg o f each were digested with BamHI 
and electrophoresed on a 0.8% TBE agarose gel at 50 V, and the DNA transferred to Hybond-N 
supported nitrocellulose (Amersham) by the capillary method. The membrane was probed with 
full-length CRK2, released from pGL130 by XbaVXhol cleavage, and exposed to 
autoradiography film (DuPont).
Lanes 1, 6. 1 kb ladder markers (GibcoBRL)
Lane 2. STIB 247 wild-type 
Lane 3: WUMP 840 
Lane 4. WUMP 839 
Lane 5. WUMP 838 
Lane 6. WUMP 837
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Fig. 5.13: Southern blot of WUMP 835 and WUMP 836
Approximately 2.5 \xg of genomic DNA was digested with BamHI and electrophoresed on a 
0.8% TBE agarose gel. DNA was blotted to supported nitrocellulose membrane by the capillary 
method and probed with full-length CRK2. Markers were the 1 kb ladder markers (GibcoBRL). 
Lane 1. STIB 247 wild-type 
Lane 2. WUMP 835 
Lane 3. WUMP 836
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Fig. 5.14: Western blot comparing STIB 247 with WUMP 835 and WUMP 836
For each lane 5x 106 T. b. brucei STIB 247 wild-type, WUMP 835 and WUMP 836 procyclic 
lysates were electrophoresed on a 12.5% Lammeli gel at 130 V at room temperature. The 
protein was transblotted to PVDF membrane by wet-blotting at 250 mA for 3 hours at 4°C. The 
membranes were probed with partially purified EVREE antibodies (protein A/G purified) at a 
titre of 1:50, and secondary anti-rabbit HRP-conjugate at 1:2500. The blot was developed with 
ECL luminol reagents (Amersham). Markers were the Low Range nonprestained markers 
(BioRad).
Lanes 1-3. EVREE antibodies
Lanes 4-6. EVREE antibodies with 5 pg EVREE peptide 
Lane 1, 4. STIB 247 wild-type 
Lanes 2, 5. WUMP 835 
Lanes 3, 6. WUMP 836
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Fig. 5.15: Western blot of WUMP 1163 with purified EVREE antibodies
10 ml midlog cultures of WUMP 1163 were induced with 0.2, 1.0 and 10.0 ng ml'1 tetracycline 
overnight. Cells were harvested, resuspended in 500 pi LSGI and S-100 lysates made. 200 pi of 
each lysate was added to minicolumns containing 100 pi Ni-NTA resin (prewashed with LSGI) 
and incubated with agitation for 60 mins at 4°C. Columns were drained and washed with LSG, 
HSLS and LS-T, the beads collected and resuspended in 100 pi of a 1:2 mixture of LS-T:TSB to 
represent eluate (specifically purified) protein. Samples were electrophoresed on a 12.5% 
Lammeli gel at 120 V at room temperature. Protein was transblotted to PVDF membrane at for 
at 4°C. The membrane was probed with purified EVREE antibodies at a titre of 1:50, and 
secondary anti-rabbit HRP-conjugate at 1:2500. The blot was developed with ECL luminol 
reagents (Amersham). Markers were the Low Range nonprestained markers (BioRad).
Lanes 1-10. EVREE antibodies
Lanes 11-20. EVREE antibodies with 10 pg EVREE peptide
Lanes 1-3, 11-13. Induced S-100 lysate
Lanes 4-6, 14-16. Column flow-through
Lanes 7-9, 17-19. Eluate protein from Ni-NTA resin
Lanes 10, 20. Low Range markers.
Lanes 1, 4, 7, 11, 14, 17. WUMP 1163 induced with 0.2 ng m l1 tetracycline
Lanes 2, 5, 8, 12, 15, 18. WUMP 1163 induced with 1.0 ng m l1 tetracycline
Lanes 3, 6, 9, 13, 16, 19. WUMP 1163 induced with 10.0 ng ml'1 tetracycline
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Fig. 5.16: Western blot and kinase assay comparing STIB 247 wild-type with WUMP 1163 
procyclics
10 ml midlog cultures of STIB 247 wild-type, WUMP 1163 grown without tetracycline and 
WUMP 1163 grown in the presence of 10.0 ng ml'1 tetracycline were harvested, resuspended in 
500 pi LSGI and S-100 lysates made. Extracts were added to minicolumns containing 80 pi of 
Ni-NTA resin (prewashed with LSGI) and incubated with agitation for 60 mins at 4°C. Columns 
were washed with LSG, HSLS and KAB, beads collected. (A) For the Western blot, beads were 
resuspended in 100 pi of sample buffer, electrophoresed on a 12.5% Lammeli gel and 
transblotted to PVDF membrane at 25 mA at 4°C overnight; the membrane was probed with 
purified EVREE antibodies at a titre of 1:50, with secondary anti-rabbit HRP-conjugate at 
1:2500. The blot was developed with ECL luminol reagents (Amersham). Markers were the 
prestained Rainbow markers (BioRad). (B) For the kinase assay, beads were resuspended in 20 
pi of histone HI KAM, incubated at 30°C for 20 mins and reactions stopped by addition of 20 pi 
sample buffer. Samples were electrophoresed on a 12.5% Lammeli gel and stained with 
Coomassie blue, dried on a slab dryer (BioRad) and exposed overnight to autoradiography film 
(DuPont).
A) Western blot: Lane 1. STIB 247 wild-type
Lane 2. WUMP 1163, no tetracycline 
Lane 3. WUMP 1163, 10.0 ng ml'1 tetracycline
B) Kinase assay: Lane 1. STIB 247 wild-type
Lane 2. WUMP 1163, no tetracycline 
Lane 3. WUMP 1163, 10.0 ng ml'1 tetracycline
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CHAPTER 6: GENERAL DISCUSSION
6.1: Gene disruption of tbCRK2 and tbCYCl
Targeted gene disruption of tbCRK2 and tbCYCl was carried out to determine 
whether either gene played an essential role in procyclic form T. b. brucei STIB 247 in 
vitro growth. The constructs used were based upon expression of BLE, SAT and PAC 
resistance genes under the constitutive expression of a PARP promoter and PARP 3’ 
elements, flanked by sequences corresponding to the 5’ and 3’ ends of the tbCRK2 and 
tbCYCl genes.
In the case of both genes, targeted disruption of one allele was successful. PCR 
showed one allele of tbCYCl replaced by the tbCYCl-PAC cassette (Fig. 4.13) although 
the primers used sat within the targeted disruption construct, and Southern blotting was 
not performed; Southern blotting and PCR showed one allele of tbCRK2 replaced by the 
tbCRKl-BLE cassette or the tbCRK2-PAC cassette (Fig. 5.9, 5.10). Cell morphology 
and growth kinetics were comparable with wild-type STIB 247 in both cases, therefore 
neither single allele disruption was deleterious to the normal cell cycle progression of 
the procyclic form.
Attempts to generate null mutants for tbCRK2 and tbCYCl were not successful. 
In both cases, transfection to disrupt the remaining wild-type allele yielded clones that 
contained wild-type tbCRK2 or wild-type tbCYCl (Fig. 5.11 and 4.14, respectively). For 
tbCRK2, two genotypes were observed (Fig. 5.11, 5.12). Firstly, the correct integration 
of one resistance marker but the incorrect integration of the second marker (WUMP 
838), and secondly, the apparently correct integration of both markers at the tbCRK2 
locus but with the maintenance of a wild-type copy of tbCRK2 (WUMP 837, 839, 840). 
For the former, an explanation is that the selection conditions used allowed the isolation 
of a clone in which the second marker (PAC) had integrated at the PARP locus due to 
nuclease degradation of the tbCRK2-specific termini of the PAC cassette. For the latter, 
an explanation is more difficult. FACs analysis demonstrated that WUMP 837, 839 and 
840 had the same DNA content as wild-type STIB 247, therefore there had been no 
change in ploidy of these clones. The possibility that STIB 247 was trisomic at the 
chromosome containing tbCRK2 was considered unlikely as genetic analysis has shown 
STIB 247 to be diploid (Melville et al., 1998), although it was possible that they had 
become trisomic following transfection. Tertiary transfection of WUMP 837 with the 
tbCRK2-SATcassette yielded a single clone in which a wild-type allele was present. For
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tbCYCl, two genotypes were observed after attempted disruption of the remaining wild- 
type tbCYCl allele. The data is difficult to interpret, with none of the clones apparently 
showing correct integration of either resistance cassette at the tbCYCl locus. However, 
wild-type tbCYCl was clearly present in all clones isolated.
Under the criteria accepted for the definition of essential genes in 
trypanosomatids - that an essential gene cannot be deleted and attempts to do so lead to 
genomic changes (Cruz et al., 1993; Mottram et al., 1996; Dumas et al., 1997) - the data 
may suggest, but does not prove, that tbCRK2 and tbCYCl are essential to the procyclic 
from of STIB 247. It is important to note that it was not possible to delete tbCRK2 wild- 
type alleles with ectopic expression of tbCRK2, which is a control required to show that 
failure to isolate null mutants for the wild-type alleles was specifically due to loss of 
tbCRK2. As the locus around the tbCYCl open reading frame was not characterised, it 
cannot be said that failure to delete wild-type alleles was specific, in that the promoter 
elements from the disruption constructs may have been interfering with normal 
expression of nearby genes.
6.2: Biochemical characterisation of tbCRK2 and tbCYCl
It proved difficult to raise sufficiently specific antibodies to tbCRK2 to perform 
detailed biochemical characterisation. Conformation of the 39 kDa protein recognised 
by the EVREE antibodies as tbCRK2 by ectopic expression of a cloned copy of tbCRK2 
also confirmed that the 38-39 kDa protein recognised in the procyclic, long slender and 
short stumpy bloodstream stages is tbCRK2. The gene is therefore expressed and 
protein present in all three life cycle stages studied. The ectopic expression of tbCRK2 
also showed that abnormally elevated levels of tbCRK2 was not deleterious to the 
parasite. This would be consistent with activation of tbCRK2 by binding of a cyclin 
partner, in that the level of tbCRK2-associated activity could be determined by 
expression and cellular levels of the cyclin partner, not tbCRK2. However, although 
tbCRK2 was demonstrated to be expressed in the procyclic form, no precipitable 
histone HI kinase activity was detected despite the fact that tbCRK2 is shown to bind
pi/p | CKS1pl2 . Leishmanial CRK3 has been shown to bind p 12 and to possess a histone 
HI kinase activity (Grant et al., 1998). Explanations for this data includes the 
possibility that histone HI is not an substrate for tbCRK2, that tbCRK2 is expressed but 
not active in procyclics, or that it is part of a multimeric complex in procyclics that 
modify its activity with regards to substrate specificity.
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The antibodies raised to purified recombinant tbCYClHis protein showed that 
tbCYCl protein is present in the short stumpy bloodstream and procyclic forms of STIB 
247, but not in the long slender bloodstream form. This is consistent with the 
observations that tbCYCl may be involved in the transformation from the bloodstream 
to procyclic form (Hua et al., 1997). Proof the tbCYCl is a functional cyclin homologue 
requires the demonstration of association with a CDK homologue (CRK protein) but 
this has not been achieved. Immunoprecipitations using the anti-CYC 1 antibodies 
coupled to Western blots using antibodies to tbCRKl, tbCRK2 and tbCRK3 did not 
detect any coprecipitated tbCRKs, although the validity of the result is in question, as it 
appeared that the anti-CYC 1 antibodies may not be capable of immunoprecipitating
Cl T/~* 1 p i/P  l
tbCYC1. Selection experiments using recombinant p 13 and p 12 did not show
association of tbCYCl with either protein. As tbCRKl-3 have been shown to bind 
p l2CKS1 (Van Hellemond and Mottram, unpublished) the inference is that tbCYCl does 
not functionally associate with tbCRKl-3 in procyclics. Immunoprecipitation-linked 
kinase assays demonstrated no significant precipitated kinase activity, although these 
assays may have failed for the reason that the antibodies could not precipitate tbCYCl. 
Taken together, these data indicate that tbCYCl either associates with an as yet 
unidentified tbCRK that does not bind the leishmanial p l2  protein, or that it does not 
associate with tbCRK 1-3 in the procyclic form (but possibly does in the short stumpy 
bloodstream form or other life cycle stages), or that it is not a cyclin homologue and 
performs a non-cyclin function in the bloodstream form to procyclic transformation.
6.3: Analysis of tbCRK4
The full sequence of the tbCRK4 gene was deduced from fragments derived 
from genomic DNA, isolated from a AFIXII library screen, and fragments produced by 
PCR from first-strand cDNA. The two genomic subclone fragments that were isolated 
represented contiguous sequence meeting at a Sau3AI site internal to the gene at 
position 560 (relative to the A of ATG start), confirmed by the sequence of the 760 bp 
gene-internal fragment generated by PCR, which overlapped both genomic subclones at 
this site (Fig. 3.1, 3.9). The full sequence showed tbCRK4 to have high identity to the 
other trypanosomatid CRKs (Fig. 3.10). The deduced protein sequence showed the 
presence of all 11 conserved kinase domains common to all protein kinases, as well as 
the conserved features of members of the CDK family. The PSTAIRE box motif which 
has been shown to be important for cyclin binding (Jeffrey et al., 1995) is present
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though degenerate, with five substitutions (GAPPSTAIREIALLKV) as compared to 
human CDK1 (EGVPSTAIREISLLKE). Another conserved motif, the DSEI box of 
CDK1 is present though highly degenerate, with four substitutions (GNTDVDQ) as 
compared to human CDK1 (GDSEIDQ). Residues important for the regulation of CDK 
activity are conserved, including the Thr and Tyr in the ATP binding pocket (Thrl7 and 
Tyrl8, in tbCRK4), and the conserved Thr 161 equivalent (a serine in tbCRK4, at 
position 231). The tbCRK4 protein is most homologous to the Crithidia fasciculata 
cfCRK protein (Brown et al., 1992), both having large inserts of approximately 70 and 
80 amino acids between kinase catalysis domains VIb and VII, and X and XI, 
respectively. These insert domains showed no homology to each other, and neither of 
the insert domains of tbCRK4 showed significant homology to either of the insert 
domains of cfCRK, although hydropathy plotting showed the insert domains of both 
proteins to be highly hydrophilic. It is therefore possible that there is a homologous 
structure/function between the insert domains of the two proteins despite a lack of 
primary sequence homology.
Specific antibodies raised to tbCRK4 demonstrated that the protein is present in 
the short stumpy bloodstream and procyclic forms, but not in the long slender 
bloodstream form of T. b. brucei STIB 247, confirming the predicted size tbCRK4 of 
approximately 52kDa. This data, along with the conserved CDK features, suggested that 
control of tbCRK4 activity is achieved by a combination of stage-specific 
transcriptional control and post-translational modification. However, no tbCRK4- 
associated kinase activity could be immunoprecipitated from procyclics using the anti- 
tbCRK4 antibodies. This could conceivably be due to incorrect folding of the tbCRK4 
portion of the fusion protein used to raise the antibodies, so that the resulting antibodies 
could not recognise native tbCRK4. Alternatively, as the antibodies were raised to the 
peptide sequence of the first insert domain, it is possible that this insert domain has an 
in vivo function in association with other protein(s), thereby precluding antibody 
binding to native protein. Other possibilities are that tbCRK4 is present but not active in 
the procyclic, or that it is not active against any of the substrate proteins assayed or 
under the conditions used. The failure of tbCRK4 to bind the leishmanial protein 
p l2CKS1 suggests that it may have a novel biological function that distinguishes it from 
tbCRK 1-3. Given the lack of success in demonstrating tbCRK4-associated kinase 
activity or p l2CKS1 binding, demonstration of cyclin binding would appear to be one 
prerequisite for classification of tbCRK4 as a functional CDK homologue.
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6.4: Future analysis
The tradition reverse genetic approach of targeted gene disruption may be a 
useful tool for the demonstration of a gene’s essential nature in any particular life cycle 
stage in vitro, but due to the genomic plasticity little can be deduced about the gene 
function in the trypanosome as an observable phenotype often cannot be obtained. For 
this reason other approaches must be taken. The development of inducible in vivo 
expression systems (Biebinger et al., 1997) should facilitate the examination of CDK 
and cyclin homologue function in T. brucei. To generate phenotypes for CRK genes, 
such systems can be used for the ectopic expression of mutant catalytically inactive 
forms of CRKs in the bloodstream and procyclic forms, which should allow the 
investigation of CRK function in the trypanosome cell cycle. In addition, some of the 
inducible vectors allow tolerable control of expression in both life cycle stages, and 
therefore may allow the investigation of CRK function in the transformation from 
bloodstream to procyclic form. For cyclin genes this approach has promise with the 
expression of forms that are ultrastable due to mutations that disrupt the ubiquitination 
‘destruction box’ sequence, or the expression of truncated forms of the protein. 
Alternatively, the ectopic expression of antisense RNA to remove cyclin protein could 
provide insights into cyclin function in T. brucei. In particular, given the data that 
suggests a role for tbCYCl in the bloodstream to procyclic transformation, these 
methods could provide a viable approach to determining tbCYCl function.
From a biochemical perspective, the problems associated with the study of 
trypanosome CRKs or cyclins has been the difficulty in obtaining sufficiently specific 
antisera for detailed characterisation. The in vivo inducible expression in both 
bloodstream and procyclic forms of epitope-tagged CRKs and cyclins holds promise for 
the analysis of the biochemical properties of these proteins, providing that such tags do 
not destabilise the proteins or interfere with their function. Epitope tagging of CRKs 
would allow characterisation of kinase activity between life cycle stages, and temporal 
characterisation of activity in semisynchronous populations of T. brucei. Tagging of 
cyclins would allow characterisation of protein expression between life cycle stages, 
and possibly protein oscillation through the cell cycle, if trypanosome cyclins behave 
like mammalian cyclins. The tagging of both CRKs and cyclins should allow the 
definition of functional CRK-cyclin pairs in both bloodstream and procyclic stages, 
together with use of yeast two-hybrid systems and coprecipitation experiments. Epitope 
tagging may also provide a good tool for characterisation of the subcellular localisation
201
of these proteins by immunofluorescence, and for analysis of tagged CRK or cyclin 
function in a null mutant background.
In general, trypanosome CRKs and cyclins are an interesting area of research 
that may have important implications for the development of therapeutics. Now that a 
number of CRKs have been identified in both Trypanosoma and Leishmania, and three 
putative cyclins isolated in T. brucei, the challenge is to attempt to define their function 
as regards cell cycle and life cycle progression in the trypanosomatid parasites.
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